学术周报 · IF≥10 或专科旗舰刊
肿瘤领域文献阅读汇编
2026年第46周 (2026-11-13) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选: IF≥10 或专科旗舰刊 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Cancer cell | 17 | IF 56.1 |
| Cancer letters | 12 | IF 11.8 |
| ACS nano | 11 | IF 17.3 |
| Science advances | 8 | IF 13.9 |
| MedComm | 8 | IF 14.1 |
| Neuro-oncology | 6 | IF 13.1 |
| Immunity | 6 | IF 30.6 |
| Signal transduction and targeted therapy | 5 | IF 81.2 |
| Cancer discovery | 5 | IF 29.5 |
| ESMO open | 5 | IF 10.6 |
1肿瘤免疫/微环境 (51篇)
临床研究 (9篇)
Enfortumab vedotin (EV), an anti-nectin-4 antibody-drug conjugate, alone and with pembrolizumab (EV plus pembrolizumab [EV/P]), has transformed the treatment of locally advanced/metastatic urothelial carcinoma (la/mUC), yet remains biomarker agnostic. We prospectively evaluated [68Ga]Ga-DOTA-N188 PET/CT ([68Ga]-N188 PET/CT) as a whole-body alternative for nectin-4 imaging, with [18F]-FDG PET/CT as an active comparator and conventional computed tomography as the reference standard for staging la/mUC in 25 patients planned for EV/P. [18F]-FDG PET/CT showed a higher maximum standardized uptake value and tumor-to-background ratio than [68Ga]-N188 PET/CT across most lesion types (primary tumor, visceral, and osseous), except for lymph nodes. The overall tracer correlation was weak (Spearman r = 0.196), strongest in lymph nodes (r = 0.657), and absent in primary tumors and bone lesions. For primary tumor detection, [68Ga]-N188 PET/CT had higher specificity (86% vs 57%) and positive predictive value (92% vs 83%) than FDG, which had higher sensitivity (88% vs 67%). Nodal staging performance was similar in the tracers. For distant metastases, both achieved 100% sensitivity and negative predictive value, with [68Ga]-N188 PET/CT showing marginally higher specificity. [68Ga]-N188 PET/CT is feasible for whole-body nectin-4 assessment in la/mUC and supports a distinct biodistribution from FDG, suggesting complementary rather than interchangeable roles. Further prospective evaluation with treatment-outcome correlation is warranted before its use as a biomarker to guide EV-based therapy selection.
中文摘要:恩福妥单抗维多汀(EV)是一种抗nectin-4抗体药物偶联物,单药或与帕博利珠单抗联合使用(EV/P)已改变了局部晚期或转移性尿路上皮癌(la/mUC)的治疗格局,但其疗效预测仍缺乏生物标志物指导。我们前瞻性评估了[68Ga]Ga-DOTA-N188 PET/CT([68Ga]-N188 PET/CT)作为全身nectin-4成像的替代方案,以[18F]-FDG PET/CT作为活性对照,并以常规计算机断层扫描为分期参考标准,对25例计划接受EV/P治疗的患者进行了研究。在大多数病灶类型(原发肿瘤、内脏和骨病灶)中,除淋巴结外,[18F]-FDG PET/CT显示出比[68Ga]-N188 PET/CT更高的最大标准化摄取值和肿瘤背景比。整体示踪剂相关性较弱(Spearman r=0.196),在淋巴结中最强(r=0.657),在原发肿瘤和骨病灶中则无相关性。对于原发肿瘤检测,[68Ga]-N188 PET/CT的特异性(86% vs 57%)和阳性预测值(92% vs 83%)高于FDG,而FDG的敏感性更高(88% vs 67%)。两种示踪剂在淋巴结分期方面的表现相似。对于远处转移,两者均达到100%的敏感性和阴性预测值,[68Ga]-N188 PET/CT的特异性略高。[68Ga]-N188 PET/CT可用于la/mUC的全身nectin-4评估,并支持与FDG不同的生物分布特征,提示二者具有互补而非可互换的作用。在将其作为指导EV为基础的治疗选择的生物标志物之前,需要进一步的前瞻性评估以关联治疗结局。
Venous thromboembolism (VTE) provoked by transient risk factors is generally considered low risk, supporting short-term anticoagulation. However, this paradigm is based on heterogeneous definitions of provoking factors. In this prospective cohort study, we evaluated recurrence risk using the International Society on Thrombosis and Haemostasis classification of major and minor transient risk factors. Patients with symptomatic deep vein thrombosis and/or pulmonary embolism who completed ≥3 months of anticoagulation were followed after treatment discontinuation. Patients with cancer, major thrombophilia, pregnancy-associated VTE, or indication for extended anticoagulation were excluded. The primary outcome was symptomatic recurrent VTE. Cumulative incidence was estimated by Kaplan-Meier analysis. The study was terminated early due to unexpectedly high recurrence risk among patients with major provoking factors. Between 2019 and 2025, 242 patients were followed for a median of 23.9 months; 72 had major and 170 had minor transient risk factors. Recurrent VTE occurred in 13 patients with major and 7 with minor risk factors. At 24 months, recurrence risk was 9.5% (95% confidence interval [CI], 6.0-14.0) overall and 19.7% (11.0-30.2) after major and 5.0% (2.2-9.5) after minor risk factors. No recurrence occurred in 81 women with hormone-associated VTE; after their exclusion, the recurrence risk among patients with other minor risk factors increased to 9.1% (95% CI, 4.0-17.0). Recurrence after provoked VTE is not uniformly low and varies substantially by the type of transient risk factor. These findings challenge current treatment paradigms and support individualized decisions regarding anticoagulation duration.
中文摘要:由短暂危险因素诱发的静脉血栓栓塞(VTE)通常被认为风险较低,从而支持短期抗凝治疗。然而,这一范式基于对诱发因素异质性定义。在这项前瞻性队列研究中,我们利用国际血栓与止血学会关于主要和次要短暂危险因素的分类评估了复发风险。对完成至少3个月抗凝治疗的有症状深静脉血栓和/或肺栓塞患者,在停止治疗后进行随访。排除患有癌症、主要血栓形成倾向、妊娠相关VTE或有延长抗凝指征的患者。主要结局为有症状的复发性VTE。通过Kaplan-Meier分析估算累积发病率。由于主要诱发因素患者中复发风险意外高,研究提前终止。2019年至2025年间,随访了242名患者,中位随访时间为23.9个月;其中72例具有主要短暂危险因素,170例具有次要短暂危险因素。13例具有主要危险因素和7例具有次要危险因素的患者的VTE复发。在24个月时,总体复发风险为9.5%(95%置信区间[CI],6.0-14.0),主要危险因素后为19.7%(11.0-30.2),次要危险因素后为5.0%(2.2-9.5)。81名激素相关VTE女性患者中无复发;排除她们后,其他次要危险因素患者的复发风险增加至9.1%(95% CI,4.0-17.0)。诱发性VTE后的复发并非普遍较低,且随短暂危险因素类型的不同而存在显著差异。这些发现挑战了当前的治疗范式,并支持关于抗凝时长的个体化决策。
Immune-related hepatitis (IRH) and pneumonitis (IRP) occur more frequently in East Asian versus European patients receiving immune checkpoint inhibitors (ICIs). Human leukocyte antigen (HLA) allelic variations, which differ substantially between ancestries, have been associated with immune-related adverse events (irAEs) risk and ICI efficacy in European cohorts, but large-scale validation in Asian populations is lacking. Clarifying these ancestry-specific biomarkers is critical for advancing precision immunotherapy. We conducted a single-center retrospective study of 3261 East Asian patients with lung cancer treated with ICIs (2018–2023). Of these, 380 patients developed IRH and 248 developed IRP. Each case group was randomly matched 1:3 with controls without that irAE (IRH: 1,140; IRP: 744), resulting in 1793 patients for HLA genotyping. Time-varying Cox models and landmark analyses assessed irAE-overall survival (OS) associations, adjusting for immortal time bias and clinical covariates. Sample weighted Cox-proportional hazard models were conducted to estimate the associations of HLA alleles with the occurrence of irAE and survival. With a median follow-up of 24.9 months (range 0.2–90 months), we identified two independent predictive factors: (1) Mild IRH (grade 1–2) was significantly associated with prolonged OS (p=0.004), with a median onset time of 2.17 months. This association remained consistent across landmark analyses at 3, 6, 9, 12 months and median onset time, supporting its predictive value. (2) HLA-DQB1*06:01 was independently associated with poorer OS (p=0.0004, false discovery rate: 0.03), an effect observed regardless of IRH occurrence. Notably, HLA-DQB1*06:01 frequency in our cohort (8.5%) was substantially higher than reported in European ancestry (0.7%), consistent with known ethnic differences in HLA architecture. In contrast, we found no significant associations between HLA variants and the risk of developing IRH or IRP, suggesting that HLA’s predictive impact operates through mechanisms distinct from irAE susceptibility. This study provides the first large-scale evidence that mild IRH is an early favorable predictive indicator and HLA-DQB1*06:01 identifies a high-risk subgroup, collectively enabling actionable risk stratification in ICI-treated East Asian patients. The observed ethnic differences in HLA allele frequencies and their distinct associations with survival outcomes underscore the critical need for ancestry-informed precision oncology approaches in cancer immunotherapy.
中文摘要:免疫检查点抑制剂治疗中,东亚患者发生免疫相关肝炎和肺炎的频率高于欧洲患者。人类白细胞抗原等位基因变异在祖先群体间存在显著差异,且与欧洲队列中的免疫相关不良事件风险及免疫检查点抑制剂疗效相关,但缺乏针对亚洲人群的大规模验证。明确这些具有祖先特异性的生物标志物对于推进精准免疫治疗至关重要。本研究开展了一项单中心回顾性研究,纳入2018年至2023年间接受免疫检查点抑制剂治疗的3261名东亚肺癌患者。其中380例发生免疫相关肝炎,248例发生免疫相关肺炎。每个病例组均按1:3比例与未发生相应不良事件的对照组进行随机匹配(免疫相关肝炎对照组1140例,免疫相关肺炎对照组744例),共1793名患者进行人类白细胞抗原基因分型。采用时间依赖性Cox模型和地标分析评估免疫相关不良事件与总生存期的关联,并校正 immortal time bias 及临床协变量。通过样本加权Cox比例风险模型估算人类白细胞抗原等位基因与免疫相关不良事件发生及生存的关系。中位随访时间为24.9个月(范围0.2至90个月),我们确定了两个独立的预测因素:其一,轻度免疫相关肝炎(1-2级)与总生存期延长显著相关(p=0.004),中位发病时间为2.17个月。该关联在3、6、9、12个月及中位发病时间的地标分析中保持一致,支持其预测价值。其二,HLA-DQB1*06:01与较差的总生存期独立相关(p=0.0004,错误发现率0.03),无论是否发生免疫相关肝炎均观察到该效应。值得注意的是,本队列中HLA-DQB1*06:01的频率(8.5%)显著高于欧洲祖先群体报道的水平(0.7%),这与已知的人类白细胞抗原结构种族差异一致。相比之下,未发现人类白细胞抗原变异与发生免疫相关肝炎或肺炎风险之间存在显著关联,表明人类白细胞抗原的预测作用通过区别于免疫相关不良事件易感性的机制发挥作用。本研究提供了首个大规模证据,表明轻度免疫相关肝炎是早期的有利预测指标,而HLA-DQB1*06:01可识别高危亚群,从而在免疫检查点抑制剂治疗的东亚患者中实现可行的风险分层。人类白细胞抗原等位基因频率的种族差异及其与生存结局的不同关联,强调了癌症免疫治疗中采用基于祖先信息的精准肿瘤学方法的重要性。
CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC). Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) followed by chemoimmunotherapy (CIMT): six cycles of standard mFOLFOX6 and nivolumab at 240 mg. We defined a novel primary endpoint, combining pathological complete response (pCR) rate among operated patients and long-term (≥12 months) clinical complete response (cCR) rate for those electing watchful waiting, into a composite endpoint of modified pCR (mpCR) rate. Between April 2019 and March 2024, 29 patients were enrolled, median age 53 years, 72.4% male; 96.6% of tumors were cT3 or cT4, 69.0% cN+, and 96.6% microsatellite stable. Median distance from the anal verge was 7 cm; 51.7% of patients had grade ≥3 adverse events (AEs) during CIMT, including one fatality (mesenteric inflammation), attributed most likely to CRT's unresolved toxicity. Immune-mediated AEs occurred in four patients (13.8%): grade 3 diabetes mellitus (1) and grade 1 hepatitis (3), including one with asymptomatic hyper/hypothyroidism. Twenty-eight patients (96.6%) are assessable for mpCR: 6 of the 15 operated achieved pCR, and 13 were not operated with cCR ≥12 months, leading to a 67.9% mpCR rate. With a median follow-up of 43.5 months (range 25.0-84.1+), all 28 assessable pts are alive with no evidence of disease. The estimated 3-year disease-free survival and 5-year overall survival rates of the entire group are 93% [95% confidence interval (CI) 84-100] and 97% (95% CI 90-100), respectively. The addition of nivolumab to standard TNT in LARC seems safe and may enhance its effectiveness, with encouraging mpCR and survival rates. A multicenter randomized trial, further evaluating this strategy, is ongoing.
中文摘要:CA209-8M4是一项前瞻性II期试验,评估在局部晚期直肠癌(LARC)患者中总新辅助治疗(TNT)联合纳武利尤单抗的效果。入组患者为距肛缘12 cm以内的LARC(T3-4Nany或TanyN1),接受标准放化疗(CRT)后行化疗免疫治疗(CIMT):6个周期标准mFOLFOX6联合240 mg纳武利尤单抗。我们定义了一个新的主要终点,将手术患者的病理完全缓解(pCR)率与选择等待观察者的长期(≥12个月)临床完全缓解(cCR)率结合,形成改良pCR(mpCR)率复合终点。2019年4月至2024年3月间入组29例患者,中位年龄53岁,男性占72.4%;96.6%为cT3或cT4期,69.0%为cN+,96.6%为微卫星稳定。距肛缘中位距离为7 cm;CIMT期间51.7%患者发生≥3级不良事件(AE),包括1例死亡(肠系膜炎症),最可能归因于CRT未解决的毒性。免疫介导的AE见于4例患者(13.8%):3级糖尿病1例,1级肝炎3例,其中1例伴有无症状的高/甲状腺功能减退。28例患者(96.6%)可评估mpCR:15例手术患者中有6例达到pCR,13例未手术患者cCR≥12个月,mpCR率达67.9%。中位随访43.5个月(范围25.0-84.1+),所有28例可评估患者均存活且无疾病证据。全组估计3年无病生存率和5年总生存率分别为93% [95%置信区间(CI)84-100]和97%(95% CI 90-100)。在LARC中,标准TNT联合纳武利尤单抗似乎安全且可能提高疗效,mpCR和生存率令人鼓舞。一项进一步评估该策略的多中心随机试验正在进行中。
Metastatic clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous clinical outcomes, and limited biomarkers are available to predict response to targeted therapies. This study evaluated cell compartment-specific transcriptional biomarkers predicting clinical response to the tyrosine kinase inhibitor (TKI) sunitinib. In this phase 2 clinical trial (NCT00715442), 46 patients with metastatic ccRCC received sunitinib pre- and post-cytoreductive nephrectomy, with a primary endpoint of time-to-progression (TTP) and secondary endpoints of overall survival (OS) and sunitinib toxicity. To investigate spatial dynamics of therapeutic response to sunitinib, we applied whole-transcriptome digital spatial profiling (DSP) to tumor tissue from responders and non-responders. For 46 trial patients, median TTP was 8.2 months (95% CI: 6.1-19.3) and OS 36.3 months (95% CI: 19.7-70.5). Responders displayed a tumor microenvironment enriched in pro-inflammatory/immunostimulatory programs, while non-responders displayed enrichment of immunosuppressive programs with elevated PD-L1 expression in myeloid cells and exhausted CD8 + T-cell signatures. Sunitinib resistance mechanisms involving VEGF-dependent and independent angiogenic pathways were identified, revealing potential therapeutic targets. DSP-based machine learning models showed strong prognostic and predictive performance in sunitinib-treated patients in an external JAVELIN Renal 101 cohort, but attenuated performance in the avelumab plus axitinib cohort, indicating treatment-context specificity. Our findings highlight immune regulation as a key determinant of sunitinib response in metastatic ccRCC. Spatial profiling revealed potentially targetable mechanisms of TKI resistance involving SPP1-associated myeloid programs, CD8 + T-cell exhaustion, and angiogenic signaling, highlighting interactions between angiogenesis, lipid metabolism, and tumor immunity as determinants of therapeutic outcome.
中文摘要:转移性透明细胞肾细胞癌(ccRCC)临床表现异质性显著,且缺乏预测靶向治疗反应的生物标志物。本研究评估了预测酪氨酸激酶抑制剂(TKI)舒尼替尼临床反应的细胞区室特异性转录生物标志物。在该II期临床试验(NCT00715442)中,46例转移性ccRCC患者在减瘤性肾切除术前和术后接受舒尼替尼治疗,主要终点为无进展生存期(TTP),次要终点为总生存期(OS)和舒尼替尼毒性。为探究舒尼替尼治疗反应的空间动态,我们对响应者和非响应者的肿瘤组织应用了全转录组数字空间分析(DSP)。在46名试验患者中,中位TTP为8.2个月(95% CI: 6.1-19.3),OS为36.3个月(95% CI: 19.7-70.5)。响应者肿瘤微环境富含促炎/免疫刺激程序,而非响应者则显示免疫抑制程序富集,髓系细胞中PD-L1表达升高且CD8+ T细胞呈现耗竭特征。研究鉴定了涉及VEGF依赖性和非依赖性血管生成通路的舒尼替尼耐药机制,揭示了潜在的治疗靶点。基于DSP的机器学习模型在外部JAVELIN Renal 101队列的舒尼替尼治疗患者中显示出强大的预后和预测性能,但在阿维鲁单抗联合阿昔替尼队列中性能减弱,表明治疗背景特异性。研究结果强调免疫调节是转移性ccRCC中舒尼替尼反应的关键决定因素。空间分析揭示了潜在的TKI耐药机制,涉及SPP1相关的髓系程序、CD8+ T细胞耗竭和血管生成信号传导,突出了血管生成、脂质代谢与肿瘤免疫之间的相互作用作为治疗结局的决定因素。
Cutaneous squamous cell carcinoma (cSCC) is a common skin malignancy whose incidence has risen sharply over the past decade. During this period, significant progress in cSCC management has also occurred, which has evolved from an almost purely surgically based approach to a more complex multidisciplinary management. Prognostic assessment now integrates clinicopathologic factors and has enabled more precise and individualized risk models, and gene expression profiling has also emerged as potentially useful in specific clinical scenarios. Imaging has become increasingly utilized in clinical practice given its increasingly recognized impact on management decisions. Evidence supports complete surgical margin assessment as the standard for high-risk (T2b/T3-BWH) cSCC and has helped refine optimal selection for the use of adjuvant radiotherapy, but most evidence is based on retrospective cohort studies. Immune checkpoint inhibitors have transformed systemic treatment: cemiplimab, pembrolizumab, and cosibelimab are approved for locally advanced or metastatic disease, and cemiplimab is also approved in the adjuvant setting. Neoadjuvant immunotherapy can also produce deep responses, raising the possibility of treatment de-escalation. Secondary prevention is also growing, particularly among high-risk populations, with oral nicotinamide, acitretin, and topical field-directed therapies showing potential utility, but sometimes lacking strong evidence. Collectively, these developments are redefining cSCC management across the disease continuum, enabling diagnostic, therapeutic, surveillance, and preventive strategies to be increasingly tailored to individual risk and clinical context, but there is still a need for generating new data and stronger evidence at some points.
中文摘要:皮肤鳞状细胞癌(cSCC)是一种常见的皮肤恶性肿瘤,其发病率在过去十年中急剧上升。在此期间,cSCC的管理取得了显著进展,从几乎完全基于手术的方法演变为更复杂的多学科管理。预后评估现在整合了临床病理因素,并实现了更精确和个性化的风险模型,基因表达谱分析也在特定临床场景中显示出潜在价值。鉴于其对管理决策日益重要的影响,影像学在临床实践中的应用越来越多。证据支持将完整的手术切缘评估作为高危(T2b/T3-BWH)cSCC的标准,并有助于优化辅助放疗的选择,但大多数证据基于回顾性队列研究。免疫检查点抑制剂改变了全身治疗:西米普利单抗、帕博利珠单抗和科西比利单抗已获批用于局部晚期或转移性疾病,西米普利单抗也获批用于辅助治疗环境。新辅助免疫治疗也能产生深度缓解,带来了治疗降级可能性。二级预防也在增长,特别是在高危人群中,口服烟酰胺、阿维A酸和外向场导向疗法显示出潜在效用,但有时缺乏强有力的证据。总体而言,这些发展正在重新定义疾病连续体中的cSCC管理,使诊断、治疗、监测和预防策略能够越来越个体化地适应个人风险和临床背景,但在某些方面仍需生成新数据和更强有力的证据。
The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunotherapy are expanding, this issue represents a global challenge in oncology. Here, we paint an updated and comprehensive landscape of antibiotic exposure in immuno-oncology, provide actionable clinical recommendations, and envision future avenues for improvement. First, we describe the biological mechanisms by which antibiotic-induced dysbiosis contributes to ICI resistance. Next, through an updated meta-analysis of 116 cohorts and 97,850 cancer patients treated with ICI, we found a significant association between antibiotic exposure and survival outcomes (overall survival, hazard ratio [HR]: 1.49, 95% confidence interval [CI]: 1.34-1.65; progression-free survival, HR: 1.44, 95% CI: 1.31-1.58). Finally, we discuss antibiotics stewardship and microbiome-centered strategies to prevent, diagnose, and/or repair dysbiosis.
中文摘要:肠道微生物群是调节免疫检查点抑制剂(ICI)反应的可变决定因素,将抗生素暴露定位为免疫肿瘤学中导致生存结局恶化的关键但被低估的风险因素。由于近30%接受ICI治疗的患者使用抗生素且癌症免疫治疗的适应症正在扩展,该问题已成为全球肿瘤学挑战。本文描绘了免疫肿瘤学中抗生素暴露的最新全面图景,提供了可操作的临床建议,并展望了未来的改进方向。首先,我们描述了抗生素诱导的菌群失调导致ICI抵抗的生物学机制。其次,通过对116个队列和97,850名接受ICI治疗的癌症患者的更新荟萃分析,我们发现抗生素暴露与生存结局之间存在显著关联(总生存期风险比[HR]:1.49,95%置信区间[CI]:1.34-1.65;无进展生存期HR:1.44,95% CI:1.31-1.58)。最后,我们讨论了抗生素管理和以微生物群为中心的策略,用于预防、诊断和/或修复菌群失调。
Biologics and immune checkpoint inhibitors have transformed the treatment of autoimmune conditions and cancers. However, safety data regarding use during pregnancy are limited. Clinicians are left to weigh the potential benefits of treatment with frequently unknown risks to the pregnant patient and developing fetus. These therapies do not cross the placenta during the first trimester; thus, they are unlikely to cause teratogenicity. Use later in pregnancy has the potential to immunosuppress the neonate, which could lead to infection and inadequate vaccine response. These large molecules are minimally transferred into breastmilk and are mostly compatible with nursing.
中文摘要:生物制剂和免疫检查点抑制剂已彻底改变了自身免疫性疾病和癌症的治疗。然而,关于孕期使用的安全性数据仍然有限。临床医生不得不权衡治疗对孕妇及发育中胎儿的潜在益处与未知的风险。这些疗法在妊娠早期不通过胎盘,因此不太可能导致致畸性。妊娠后期使用可能会使新生儿免疫抑制,从而导致感染和疫苗反应不足。这些大分子进入乳汁的量极少,大多与哺乳兼容。
Early endpoints as surrogates for long-term outcomes are essential for treatment efficacy evaluation. In this issue of Cancer Cell, Conforti et al. report that CPS + EG and Neo-Bioscore scores predict long-term outcomes at the patient level but not at the trial level, highlighting the need for better early endpoints that reliably capture efficacy across trials.
中文摘要:早期终点作为长期结果的替代指标对于评估治疗效果至关重要。在本期《癌症细胞》杂志中,Conforti等人的研究指出,CPS+EG和Neo-Bioscore评分能够在患者层面预测长期结果,但在试验层面却无法做到这一点,这凸显了开发能够可靠捕捉跨试验疗效的更好早期终点的必要性。
基础研究 (42篇)
Cancer immunotherapy has transformed the treatment of multiple malignancies, yet primary and acquired resistance remain major barriers to attaining durable clinical benefit. Increasing evidence indicates that immunotherapy failure rarely results from a single mechanism but instead emerges from dynamic interactions within the tumor microenvironment (TME). Recent advances in single-cell, spatial multiomics, and longitudinal profiling have revealed the complex organization of TME-mediated resistance, which can be conceptualized within three interconnected suppressive modules: the tumor-cell-intrinsic module, myeloid-suppressive networks, and stromal barriers. The relative dominance of these modules varies across spatial niches, metastatic sites, disease stages, and treatment phases, leading to profound spatiotemporal heterogeneity and dynamic reorganization of dominant resistance axes. In this Review, we propose a spatiotemporal and systems-level framework for understanding TME-mediated immunotherapy resistance. We discuss how the tumor-cell-intrinsic module contributes to immune escape, how myeloid-suppressive networks and stromal barriers sustain and amplify immunosuppression, and how reciprocal crosstalk among these modules generates feed-forward loops that stabilize resistant states. We also review clinical strategies for remodeling the TME to increase the efficacy of immunotherapeutic approaches. Additionally, we discuss the opportunities and challenges associated with TME remodeling, including safety considerations, emerging biomarkers, and rational combination strategies. We propose that future TME-targeted therapies should transition from component-oriented interventions to dynamic and mechanism-matched strategies guided by dominant resistance axes. This approach aims to facilitate the development of more precise and durable cancer immunotherapies.
中文摘要:癌症免疫疗法已改变了多种恶性肿瘤的治疗方式,但原发性和获得性耐药仍是实现持久临床获益的主要障碍。越来越多的证据表明,免疫治疗失败很少由单一机制引起,而是源于肿瘤微环境中的动态相互作用。单细胞、空间多组学和纵向谱系分析的最新进展揭示了肿瘤微环境介导的抵抗力的复杂组织结构,可将其概念化为三个相互关联的抑制模块:肿瘤细胞内在模块、髓系抑制网络和基质屏障。这些模块的相对优势在不同空间生态位、转移部位、疾病阶段和治疗阶段各不相同,导致主导抵抗轴的空间时间异质性和动态重组。在本综述中,我们提出了一个用于理解肿瘤微环境介导的免疫治疗抵抗力的空间时间和系统水平框架。我们讨论了肿瘤细胞内在模块如何促进免疫逃逸,髓系抑制网络和基质屏障如何维持和放大免疫抑制,以及这些模块之间的相互串扰如何产生稳定耐药状态的反馈回路。我们还回顾了重塑肿瘤微环境以提高免疫治疗方法疗效的临床策略。此外,我们讨论了与肿瘤微环境重塑相关的机遇和挑战,包括安全性考虑、新兴生物标志物和合理的联合策略。我们提出,未来的肿瘤微环境靶向治疗应从基于成分的干预措施转变为以主导抵抗轴为指导的动态和机制匹配策略。该方法旨在促进更精准和持久的癌症免疫疗法的发展。
Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has achieved durable remissions in patients with relapsed or refractory haematological malignancies. However, its broader clinical adoption remains constrained by patient-specific ex vivo manufacturing, substantial treatment-related toxicities and limited efficacy in solid tumours. In vivo CAR immunotherapy enables endogenous immune cells to be genetically reprogrammed directly within the body, bypassing leukapheresis, ex vivo expansion and individualized cell manufacturing. This Review focuses specifically on in vivo CAR immune cell engineering for cancer therapy, encompassing haematological malignancies and solid tumours; applications in non-malignant diseases, including autoimmune disorders, are outside its scope. We examine emerging technologies for generating CAR immune cells in vivo and discuss how viral vectors, non-viral nanocarriers and biomimetic delivery systems could improve the precision, scalability and controllability of cancer immunotherapy. We further highlight immune effectors beyond CAR T cells, including CAR macrophages and CAR natural killer cells, whose distinct cytotoxic, phagocytic and immunomodulatory functions may offer complementary approaches to treating solid tumours. We discuss strategies involving tumour-microenvironment remodelling, metabolic adaptation and precision genome engineering to improve immune-cell persistence, mitigate functional exhaustion, enhance tumour infiltration and limit antigen escape. Emerging clinical studies in haematological malignancies provide initial proof of concept that functional CAR cells can be generated in patients, although long-term safety, durability and reproducibility remain to be established. A central challenge is to generate these cells with sufficient cellular and spatial precision while maintaining control over their activity over time. We discuss how cell-subset-specific delivery, programmable CAR circuits, multicellular engineering, intelligent biomaterials and artificial intelligence could support the development of in vivo CAR immunotherapy as a scalable, controllable and potentially repeatable cancer treatment.
中文摘要:过去十年中,嵌合抗原受体T细胞疗法在复发或难治性血液恶性肿瘤患者中实现了持久缓解。然而,其更广泛的临床应用仍受限于个体化的体外制造、显著的治疗相关毒性以及在实体瘤中的疗效有限。体内CAR免疫治疗能够直接在体内对内源性免疫细胞进行基因重编程,从而绕过白细胞分离、体外扩增和个性化细胞制造过程。本综述专门聚焦于用于癌症治疗的体内CAR免疫细胞工程,涵盖血液恶性肿瘤和实体瘤;非恶性疾病(包括自身免疫性疾病)的应用不在其范围内。我们考察了在体内生成CAR免疫细胞的新兴技术,并讨论了病毒载体、非病毒纳米载体和仿生递送系统如何改善癌症免疫治疗的精确性、可扩展性和可控性。我们进一步强调了除CAR T细胞之外的其他免疫效应细胞,包括CAR巨噬细胞和CAR自然杀伤细胞,其独特的细胞毒性、吞噬作用和免疫调节功能可能为治疗实体瘤提供互补策略。我们讨论了涉及肿瘤微环境重塑、代谢适应和精准基因组工程的策略,以改善免疫细胞的持久性、减轻功能耗竭、增强肿瘤浸润并限制抗原逃逸。血液恶性肿瘤中的新兴临床研究提供了初步的概念验证,证明可以在患者体内生成功能性CAR细胞,尽管长期安全性、持久性和可重复性仍有待确立。一个核心挑战是在保持对其活性随时间可控的同时,以足够的细胞和空间精度生成这些细胞。我们讨论了细胞亚群特异性递送、可编程CAR回路、多细胞工程、智能生物材料和人工智能如何支持将体内CAR免疫治疗发展为一种可扩展、可控且潜在可重复的癌症治疗方法。
Cancer-associated sarcopenia is a key determinant of treatment toxicity and mortality. Recent data indicate that insulin-like growth factor binding protein 1 and insulin-like growth factor binding protein 2 may be endocrine mediators connecting tumor-derived signals, hepatic reprogramming, and defective muscle regeneration. Furthermore, aging may contribute to susceptibility to cancer-associated muscle loss through alterations in the insulin-like growth factor (IGF)/insulin-like growth factor binding protein (IGFBP) axis and decreased muscle's anabolic and regenerative capacity. Recent mechanistic studies have identified the IGF/IGFBP axis as a promising source of biomarkers and potential therapeutic targets in cancer-associated muscle wasting.
中文摘要:癌症相关性肌少症是影响治疗毒性和死亡率的关键决定因素。最新数据表明,胰岛素样生长因子结合蛋白1和胰岛素样生长因子结合蛋白2可能是连接肿瘤衍生信号、肝脏重编程和肌肉再生缺陷的内分泌介质。此外,衰老可能通过改变胰岛素样生长因子胰岛素样生长因子结合蛋白轴以及降低肌肉的合成与再生能力,导致对癌症相关性肌肉流失的易感性增加。近期的机制研究已将胰岛素样生长因子胰岛素样生长因子结合蛋白轴确定为癌症相关性肌肉 wasting 中生物标志物和潜在治疗靶点的有前景来源。
Combining PD-1/PD-L1 blockade with anti-angiogenic therapy has transformed treatment for advanced HCC, yet durable responses remain limited. Tumor-associated endothelial cells (TECs) shape the tumor microenvironment, and contribute to immune exclusion and immunotherapy resistance. Nevertheless, TEC subsets and molecular features of immunotherapy failure in HCC are poorly defined. This study aims to identify specific TEC subsets and elucidate their functional roles underlying immunotherapy failure in HCC. We performed integrative analysis of single-cell RNA-sequencing (scRNA-seq) data from anti-PD-1-treated HCC to characterize intratumoral cellular heterogeneity and identify TEC subsets associated with treatment response. Cell-cell communication networks were inferred using CellChat. Functional studies were conducted in HUVECs and HLSECs to assess migration, tube formation, and hypoxia responses. Single-cell profiling revealed an expansion of TECs and immunosuppressive myeloid populations in nonresponders to anti-PD-1 therapy. Reclustering of endothelial cells identified a carbonic anhydrase 2 positive (CA2⁺) TEC subset enriched in nonresponders and distinguished by a hypoxia-adapted, proangiogenic, and immune-cold transcriptional program. A CA2⁺ TEC signature derived from the top subtype-specific markers predicted poor progression-free survival and nonresponse in the IMbrave150 and GO30140 cohorts. In HUVECs and HLSECs, CA2 promoted endothelial migration and tube formation and was transcriptionally induced by hypoxia via HIF-1α. Cell‒cell communication analysis showed that CA2⁺ TECs exhibited enhanced outgoing signaling toward TREM2⁺ macrophages, with the APP-CD74 axis emerging as a dominant pathway. TREM2⁺ macrophages upregulate CCL18 expression, thereby potentially limiting both the infiltration and cytotoxic function of CD8⁺ T cells. In vivo, pharmacologic CA2 blockade reprogrammed the TME, reduced immunosuppressive myeloid infiltration, and synergized with anti-PD-1 therapy to suppress tumor growth. Our study identifies CA2⁺ TECs as a distinct subset contributing to immunotherapy resistance in HCC through pro-angiogenic and immunosuppressive mechanisms. Targeting CA2 presents a promising approach to enhance the efficacy of PD-1 blockade in patients with HCC.
中文摘要:PD-1/PD-L1阻断联合抗血管生成治疗已改变晚期肝细胞癌(HCC)的治疗格局,但持久缓解仍有限。肿瘤相关内皮细胞(TECs)塑造肿瘤微环境并导致免疫排斥及免疫治疗耐药。然而,HCC中TEC亚群及其在免疫治疗失败中的分子特征尚不明确。本研究旨在鉴定特定TEC亚群并阐明其在免疫治疗失败中的功能作用。通过对接受抗PD-1治疗的HCC单细胞RNA测序(scRNA-seq)数据进行整合分析,表征肿瘤内细胞异质性并鉴定与治疗反应相关的TEC亚群。利用CellChat推断细胞间通讯网络。在HUVECs和HLSECs中进行功能研究以评估迁移、管形成及缺氧反应。单细胞谱系分析显示,抗PD-1治疗无响应者中TECs和免疫抑制性髓系细胞群扩增。内皮细胞的重新聚类鉴定出一种富集于无响应者的碳酸酐酶2阳性(CA2⁺)TEC亚群,其特征为缺氧适应、促血管生成及免疫冷转录程序。源自主要亚型特异性标志物的CA2⁺TEC特征谱预测了IMbrave150和GO30140队列中较差的无进展生存期和无响应率。在HUVECs和HLSECs中,CA2促进内皮迁移和管形成,并通过HIF-1α受缺氧转录诱导。细胞间通讯分析显示,CA2⁺TECs向TREM2⁺巨噬细胞的传出信号增强,APP-CD74轴成为主导通路。TREM2⁺巨噬细胞上调CCL18表达,从而限制CD8⁺T细胞的浸润和细胞毒性功能。体内实验表明,药理学CA2阻断重塑了肿瘤微环境,减少了免疫抑制性髓系浸润,并与抗PD-1治疗协同抑制肿瘤生长。本研究鉴定CA2⁺TECs为HCC中通过促血管生成和免疫抑制机制导致免疫治疗耐药的一个独特亚群。靶向CA2是增强HCC患者PD-1阻断疗效的有前景的策略。
Many tumors remain poorly responsive to immune checkpoint blockade. The metabolic microenvironment in tumors can mediate immunosuppression by failing to sustain productive cytotoxic lymphocyte function. Here, we showed that a coordinated ketogenic-fasting (KF) regimen sensitized immune-refractory tumors to PD-1 blockade by integrating distinct metabolic and microbial effects of ketogenic diet (KD) and intermittent fasting (IF). The KF combination established a distinct immunometabolic state that could not be fully recapitulated by either KD or IF intervention alone. KF induced systemic glucose restriction while preserving intratumoral glutamine availability and selectively upregulating the glutamine transporters SLC38A1 and SLC38A2 in tumor-infiltrating CD8+ T cells and NK cells, fueling interferon-STAT1 signaling and effector activity. Single-cell transcriptomic analysis identified KF-associated cytotoxic lymphocyte states characterized by enhanced nutrient access signatures, increased effector function, and reduced terminal dysfunction. Microbiota depletion attenuated KF-mediated tumor control without abolishing intratumoral glutamine enrichment. Fecal microbiota transfer and monocolonization identified Odoribacter splanchnicus as sufficient to restore tumor control and cytotoxic T-cell activity in microbiota-depleted hosts. Mechanistically, O. splanchnicus was linked to host polyamine remodeling and indole-3-lactic acid, which supported durable CD8+ T-cell functions distinct from the glutamine-driven effector arm. KF enhanced anti-PD-1 efficacy in immune-cold tumor models, and public human datasets showed concordant associations between glutamine context, Odoribacter abundance, and immunotherapy response. Together, these findings identify a diet-responsive host-microbiota metabolic mechanism that stimulates antitumor immunity and sensitizes immune-cold tumors to immunotherapy.
中文摘要:许多肿瘤对免疫检查点阻断治疗反应不佳。肿瘤内的代谢微环境可能因无法维持有效的细胞毒性淋巴细胞功能而导致免疫抑制。本研究显示,协同的酮症禁食方案通过整合生酮饮食与间歇性禁食的独特代谢及微生物效应,使免疫难治性肿瘤对PD-1阻断治疗敏感。该联合方案建立了独特的免疫代谢状态,单一的生酮饮食或间歇性禁食干预均无法完全重现此状态。KF诱导全身性葡萄糖限制,同时保留肿瘤内谷氨酰胺的可利用性,并选择性上调肿瘤浸润CD8+ T细胞和NK细胞中的谷氨酰胺转运蛋白SLC38A1和SLC38A2,从而促进干扰素-STAT1信号通路及效应功能。单细胞转录组分析鉴定出KF相关的细胞毒性淋巴细胞状态,其特征为营养获取标志增强、效应功能增加以及终末功能障碍减少。微生物耗竭削弱了KF介导的肿瘤控制效果,但未消除肿瘤内谷氨酰胺的富集。粪便微生物移植和单菌定植实验发现Odoribacter splanchnicus足以在微生物耗竭宿主中恢复肿瘤控制和细胞毒性T细胞活性。机制上,O. splanchnicus与宿主多胺重塑及吲哚-3-乳酸相关,后者支持了区别于谷氨酰胺驱动效应通路的持久CD8+ T细胞功能。KF增强了免疫冷肿瘤模型中抗PD-1的疗效,公共人类数据集显示谷氨酰胺背景、Odoribacter丰度与免疫治疗反应之间存在一致的相关性。综上所述,这些发现揭示了一种饮食响应的宿主-微生物代谢机制,该机制可刺激抗肿瘤免疫并使免疫冷肿瘤对免疫治疗敏感。
Disconnects between in vitro and in vivo results in experimental biology have long been recognized as potential hurdles to understanding health and disease. A prototypical example of such a disconnect is the NLRP3 inflammasome, which mediates inflammation in diverse settings of disease and protective immunity1,2. Activation of the NLRP3 inflammasome in vitro requires two signals: (1) priming by pathogen-associated molecular patterns such as bacterial lipopolysaccharides and (2) activation by molecules that disrupt cellular homeostasis1,3. By contrast, the NLRP3 inflammasome in vivo is activated by lipopolysaccharide alone. The mechanisms that underlie the difference between in vitro and in vivo activation of the NLRP3 inflammasome are undefined. Here we report that extracellular matrix (ECM) stiffness is a determinant of NLRP3 activities and that in vitro systems using physiological ECM stiffness enable one-signal in vivo-like NLRP3 activities to occur in human and mouse phagocytes. Physiological ECM stiffness induced expression of the transcription factor NRF2, which was found to be necessary for one-signal NLRP3 activation. Mechanistically, we identify Panx1 as an NRF2-regulated gene that promotes NLRP3 activity. Macrophages derived from the stiff matrix of the bone-osteoclasts-had reduced NRF2 levels and impaired NLRP3 activity. Moreover, alveolar macrophages from patients with pulmonary fibrosis displayed reduced NRF2 activity. Finally, NRF2 was required for antitumour immunity induced by cancer vaccines consisting of NLRP3 agonistic adjuvants. These findings indicate that NRF2 may be a transcriptional checkpoint that controls NLRP3 inflammasome activity.
中文摘要:体外与体内实验结果之间的差异长期被视为理解健康与疾病的潜在障碍。NLRP3炎症小体是此类差异的典型例子,它在多种疾病和保护性免疫中介导炎症。在体外环境中,NLRP3炎症小体的激活需要两个信号:一是由细菌脂多糖等病原体相关分子模式引发的启动;二是由破坏细胞稳态的分子触发的激活。相比之下,体内NLRP3炎症小体仅由脂多糖激活即可。目前关于NLRP3炎症小体在体外与体内激活差异背后的机制尚不明确。本研究报道了细胞外基质硬度是决定NLRP3活性的关键因素,使用生理性细胞外基质硬度的体外系统能够让人类和小鼠吞噬细胞发生类似体内的单信号NLRP3活性。生理性细胞外基质硬度诱导了转录因子NRF2的表达,研究发现NRF2对于单信号NLRP3激活是必需的。在机制上,我们鉴定出Panx1是一个受NRF2调控并促进NLRP3活性的基因。源自骨-破骨细胞硬基质的巨噬细胞表现出NRF2水平降低和NLRP3活性受损。此外,肺纤维化患者的肺泡巨噬细胞也显示出NLR2活性降低。最后,NRF2对于由包含NLRP3激动剂佐剂的癌症疫苗诱导的抗肿瘤免疫是必需的。这些发现表明NRF2可能是控制NLRP3炎症小体活性的转录检查点。
Tumor metabolism and immune regulation are traditionally interpreted through global metabolic reprogramming and canonical, membrane-bound immunosuppression. Emerging evidence, however, indicates that metabolic components and immune checkpoints frequently undergo subcellular spatial redistribution, generating highly localized microdomains of accumulation and specific depletion zones within tumor cells. These compartmentalized events drive noncanonical molecular functions that extend far beyond their classical roles. By reshaping epigenetic regulation, oncogenic signaling, and local protein-interaction networks, these spatial shifts influence malignant phenotypes, immune evasion, and therapeutic responses. In this review, we highlight the subcellular compartmentalization of metabolic and immune checkpoint components, alongside their corresponding localized enrichment and depletion states, and discuss their intricate interplay. We illustrate how these spatially restricted dynamics establish a highly organized layer of tumor immunometabolic crosstalk.
中文摘要:肿瘤代谢与免疫调节传统上通过全局代谢重编程及经典的膜结合免疫抑制机制进行解读。然而,新证据表明代谢成分与免疫检查点分子常发生亚细胞空间重分布,在肿瘤细胞内形成高度局部的积累微域及特异性耗竭区。这些区室化事件驱动了远超其经典功能的非经典分子作用。通过重塑表观遗传调控、致癌信号通路及局部蛋白质相互作用网络,这些空间移位影响恶性表型、免疫逃逸及治疗反应。本综述重点阐述代谢与免疫检查点成分的亚细胞区室化及其对应的局部富集与耗竭状态,并探讨其复杂相互作用。我们阐释了这些空间受限的动态过程如何建立高度有序的肿瘤免疫代谢串扰层级。
Regulatory T cells (Tregs) are critical mediators of immunosuppression in clear cell renal cell carcinoma (ccRCC), yet the tumor-intrinsic signals that drive Tregs activation and immune escape remain poorly understood. This study aimed to identify key drivers of epithelial-Tregs communication and elucidate their clinical and therapeutic relevance. We analyzed single-cell RNA sequencing data using CellChat to map epithelial-Treg interactions. Candidate genes were prioritized through survival analyses and subsequently validated across bulk transcriptomic datasets, immunotherapy cohorts, and a prospective institutional ccRCC cohort. Immune infiltration, pathway enrichment, and genomic alterations were systematically characterized. Spatial associations were examined by multiplex immunofluorescence, while functional roles were evaluated using in vitro assays and an in vivo syngeneic mouse model treated with anti-programmed cell death protein 1 (PD-1). Among epithelia-Tregs signaling candidates, midkine (MDK) emerged as a core ligand with strong prognostic relevance. MDK was markedly upregulated in ccRCC and associated with advanced tumor stage, aggressive histologic features, and unfavorable survival. High MDK expression defined a distinct immunogenomic phenotype characterized by increased Treg infiltration and altered mutation patterns. Elevated MDK expression was associated with poorer outcomes with PD-1 monotherapy and tyrosine kinase inhibitor monotherapy and showed a similar adverse trend with immune checkpoint inhibitor-based anti-angiogenic combination therapy. Spatial analyses confirmed co-localization of MDK-expressing tumor cells with forkhead box P3+ Tregs. Functionally, MDK promoted tumor cell proliferation and migration and was associated with poorer tumor control during PD-1 blockade in vivo. High MDK expression defines a Treg-enriched, immune-evasive ccRCC phenotype associated with aggressive tumor biology and unfavorable outcomes across both immunotherapy and targeted therapy settings. MDK may serve as a biomarker of adverse disease biology and a potential therapeutic target, although its predictive value for treatment selection requires further validation.
中文摘要:调节性T细胞(Tregs)是透明细胞肾细胞癌(ccRCC)中免疫抑制的关键介质,但驱动Treg激活和免疫逃逸的肿瘤内在信号仍不清楚。本研究旨在鉴定上皮细胞与Treg通讯的关键驱动因素并阐明其临床及治疗相关性。我们利用CellChat分析单细胞RNA测序数据以绘制上皮细胞与Treg的相互作用图谱。候选基因通过生存分析进行优先级排序,随后在批量转录组数据集、免疫治疗队列和前瞻性机构ccRCC队列中进行验证。系统表征了免疫浸润、通路富集和基因组改变。通过多重免疫荧光检查空间关联,并使用体外实验及接受抗程序性死亡蛋白1(PD-1)治疗的同系小鼠模型评估功能作用。在上皮细胞与Treg信号候选物中,Midkine(MDK)作为具有强预后相关性的核心配体脱颖而出。MDK在ccRCC中显著上调,并与晚期肿瘤分期、侵袭性组织学特征及不良生存率相关。高MDK表达定义了一种独特的免疫基因组表型,其特征为Treg浸润增加和突变模式改变。高MDK表达与PD-1单药治疗和酪氨酸激酶抑制剂单药治疗的较差预后相关,并在基于免疫检查点抑制剂的抗血管生成联合治疗中显示类似的不良趋势。空间分析证实表达MDK的肿瘤细胞与forkhead box P3+ Treg共定位。在功能上,MDK促进肿瘤细胞增殖和迁移,并与体内PD-1阻断期间较差的肿瘤控制相关。高MDK表达定义了一种富含Treg且具有免疫逃逸特征的ccRCC表型,该表型与侵袭性肿瘤生物学行为及不良预后相关,涵盖免疫治疗和靶向治疗场景。MDK可能作为疾病生物学不良的标志物及潜在的治疗靶点,尽管其对于治疗选择的预测价值仍需进一步验证。
Three‑dimensional (3D) bioprinting has rapidly emerged as a powerful strategy for engineering physiologically relevant tumor microenvironment (TME) models that overcome the limitations of traditional 2D cultures and animal systems. The TME is a highly dynamic and heterogeneous ecosystem composed of malignant, stromal, immune, and vascular cells embedded within a biochemically and mechanically complex extracellular matrix (ECM). These components collectively regulate tumor progression, immune evasion, metastasis, and therapeutic resistance. Conventional preclinical models fail to capture this complexity, contributing to poor clinical translation of oncology therapeutics. Advances in extrusion‑based, inkjet, laser‑assisted, and stereolithographic bioprinting now enable spatially organized, multicellular constructs with tunable biochemical and biophysical cues that more accurately recapitulate TME architecture and function. Complementary innovations in biomaterials, microfluidics, and computational modeling further expand the capabilities of bioprinted systems for drug screening, mechanistic studies, and personalized medicine. This review summarizes the cellular and acellular components of the TME, outlines major bioprinting technologies and biomaterial strategies, and highlights emerging applications in cancer modeling. We also identify key research gaps and opportunities that must be addressed to advance bioprinted TME platforms toward robust, standardized, and clinically meaningful tools for precision oncology.
中文摘要:三维生物打印已迅速成为构建具有生理相关性的肿瘤微环境模型的强大策略,旨在克服传统二维培养和动物系统的局限性。肿瘤微环境是一个高度动态且异质的生态系统,由嵌入在生化及机械复杂性细胞外基质中的恶性、间质、免疫和血管细胞组成。这些组分共同调控肿瘤进展、免疫逃逸、转移和治疗耐药性。传统的临床前模型无法捕捉这种复杂性,导致肿瘤学药物的临床转化效果不佳。挤出式、喷墨式、激光辅助式和立体光固化生物打印技术的进步,现在能够构建空间组织化的多细胞结构,并提供可调的生化及物理线索,从而更准确地重现肿瘤微环境的结构和功能。生物材料、微流控技术和计算建模方面的互补创新进一步扩展了生物打印系统在药物筛选、机制研究和个性化医学中的应用能力。本综述总结了肿瘤微环境的细胞和无细胞组分,概述了主要的生物打印技术和生物材料策略,并强调了在癌症建模中的新兴应用。我们还指出了关键的研究空白和机遇,这些内容必须得到解决,以推动生物打印的肿瘤微环境平台成为精准肿瘤学中稳健、标准化且具有临床意义的工具。
Immunotherapy has revolutionized clinical cancer management by harnessing endogenous or engineered immune responses to eliminate tumors. However, durable and safe responses in many solid tumors remain limited by the difficulty of directing potent immunomodulation to defined tumor lesions, immune-cell interfaces, and lymphoid tissues while avoiding systemic immune-related toxicity. Bioorthogonal chemistry provides a chemical strategy to address this limitation by installing non-native reactive handles in biological systems, where they undergo selective reactions to generate covalent linkages, localized activation, or functional assembly under physiological conditions. In cancer immunotherapy, these reactions can chemically label cells and biomolecules, bridge tumor-immune interfaces, anchor or assemble therapeutic platforms within tumors, and activate immunomodulators at disease-relevant sites. In this review, we first summarize the bioorthogonal reaction principles underlying chemical tagging, covalent ligation, controlled cleavage/decaging, and in situ assembly. We then discuss how these chemistries support multiscale immune engineering, from immune-tumor interface regulation and tumor microenvironment remodeling to antigen-presenting cell programming and lymph node-targeted immune priming. Finally, we highlight current translational progress, remaining challenges, and future directions for clinical implementation of bioorthogonal strategies in cancer immunotherapy. By connecting reaction design with immune-engineering function, this Review provides a framework for understanding bioorthogonal chemistry as a site-confined and multiscale strategy for cancer immunotherapy.
中文摘要:免疫疗法通过利用内源性或工程化的免疫反应来消除肿瘤,彻底改变了临床癌症管理。然而,在许多实体瘤中,持久且安全的免疫反应仍受限于将强效免疫调节定向至特定肿瘤病灶、免疫细胞界面和淋巴组织的同时避免全身性免疫相关毒性的困难。生物正交化学提供了一种化学策略来解决这一局限,即在生物系统中安装非天然反应性官能团,使其在生理条件下发生选择性反应以生成共价连接、局部激活或功能组装。在癌症免疫治疗中,这些反应可用于化学标记细胞和生物分子,桥接肿瘤与免疫界面,锚定或组装肿瘤内的治疗平台,并在疾病相关位点激活免疫调节剂。本综述首先总结了用于化学标记、共价连接、可控裂解脱保护和原位组装的生物正交反应原理。随后讨论了这些化学方法如何支持多尺度免疫工程,从免疫肿瘤界面调控和肿瘤微环境重塑到抗原呈递细胞编程及淋巴结靶向免疫启动。最后,我们强调了生物正交策略在癌症免疫治疗中临床转化的当前进展、剩余挑战及未来方向。通过将反应设计与免疫工程功能相联系,本综述为理解生物正交化学作为癌症免疫治疗的位点特异性及多尺度策略提供了框架。
Comprehensive profiling of peripheral immune cells has shown prognostic and disease-monitoring value across multiple cancers, but its clinical relevance in hepatocellular carcinoma (HCC), particularly unresectable HCC, remains insufficiently defined. To address this gap, we performed integrated peripheral immunoprofiling combining T-cell receptor (TCR) repertoire sequencing, flow cytometry-based T-cell phenotyping, bulk RNA sequencing, and public single-cell RNA-seq analysis in healthy donors, resectable HCC patients, and unresectable HCC patients. This design enabled characterization of HCC-associated and stage-associated peripheral immune alterations and identification of immunotherapy-relevant features in unresectable HCC. Single-cell analysis and flow cytometry revealed remodeling of circulating T-cell states in unresectable HCC, including reduced naïve-like compartments, enrichment of Treg-like cells, and increased memory/effector differentiation. TCR repertoire analysis showed reduced diversity, increased clonal dominance, altered V-J gene usage, decreased interindividual sharing, and convergent motif-level alterations, with early CD4+ TCR perturbations in resectable HCC and more pronounced CD8+ repertoire restriction in unresectable disease. Exploratory GLIPH-based motif analysis, HLA inference, and peptide-HLA binding prediction suggested candidate motif-HLA antigen associations involving hepatitis virus-derived antigens and recurrent HCC mutation-derived candidate neoantigens, although experimental validation is required. Bulk RNA-seq of peripheral CD8+ T cells revealed higher Activation/Effector function, Exhaustion, and Anergy signature scores in both resectable and unresectable HCC than in HDs, with no significant differences between the two HCC groups, whereas the Chemokine/Chemokine receptor signature was specifically increased in unresectable HCC. The overall IFN-response signature did not differ significantly among the three groups. Integrative machine-learning models were then developed using 818 peripheral immune-related features. Among them, the random forest (RF) model effectively distinguished healthy donors, resectable HCC patients, and unresectable HCC patients, with consistently high sensitivity and area under the curve (AUC) in both cross-validation and an independent validation cohort. In unresectable HCC patients receiving immunotherapy, four features derived from TCR-seq and T-cell subset profiling discriminated responders (CR/PR) from non-responders (SD/PD) in univariate analyses, while multivariate prioritization further highlighted ULBP1 as a consistently prioritized response-associated feature that requires validation in an independent cohort. Overall, this study supports comprehensive peripheral immune profiling as an exploratory framework for identifying stage-associated immune alterations and candidate biomarkers to inform personalized immunotherapy strategies in HCC.
中文摘要:外周免疫细胞的全面谱系分析在多种癌症中显示出预后和疾病监测价值,但在肝细胞癌特别是不可切除肝细胞癌中的临床相关性仍定义不足。为填补这一空白,我们在健康供体、可切除肝细胞癌患者和不可切除肝细胞癌患者中进行了整合的外周免疫谱系分析,结合T细胞受体库测序、基于流式细胞术的T细胞表型分析、批量RNA测序以及公共单细胞RNA测序数据。该设计使得能够表征与肝细胞癌相关及分期相关的外周免疫改变,并识别不可切除肝细胞癌中与免疫治疗相关的特征。单细胞分析和流式细胞术揭示了不可切除肝细胞癌中循环T细胞状态的重组,包括初始样区室减少、调节性T细胞样细胞富集以及记忆/效应分化增加。T细胞受体库分析显示多样性降低、克隆优势增加、V-J基因使用改变、个体间共享减少以及收敛性的基序水平改变,其中可切除肝细胞癌中CD4+ T细胞受体扰动较早出现,而不可切除疾病中CD8+库限制更为明显。探索性GLIPH基序分析、HLA推断和肽-HLA结合预测提示涉及肝炎病毒衍生抗原和复发性肝细胞癌突变衍生候选新抗原的候选基序-HLA抗原关联,但需要实验验证。外周CD8+ T细胞的批量RNA测序显示,可切除和不可切除肝细胞癌患者的激活/效应功能、耗竭和无反应性特征评分均高于健康供体,而两组肝细胞癌之间无显著差异,其中趋化因子/趋化因子受体特征在不可切除肝细胞癌中特异性增加。整体干扰素反应特征在三组间无显著差异。随后利用818个外周免疫相关特征开发了集成机器学习模型。其中,随机森林模型能有效区分健康供体、可切除肝细胞癌患者和不可切除肝细胞癌患者,在交叉验证和独立验证队列中均表现出持续的高敏感性和曲线下面积。在接受免疫治疗的不可切除肝细胞癌患者中,来自T细胞受体测序和T细胞亚群谱系分析的四个特征在一元分析中区分了响应者(完全缓解/部分缓解)与非响应者(疾病稳定/进展),而多元优先排序进一步突出了ULBP1作为一致优先的响应相关特征,该特征需要在独立队列中进行验证。总体而言,本研究支持全面的外周免疫谱系分析作为识别分期相关免疫改变和候选生物标志点的探索性框架,以指导肝细胞癌个性化免疫治疗策略。
Glycan immune checkpoints cooperate with canonical protein checkpoints to drive immune suppression at the tumor-immune interface. However, current tumor immunotherapies typically target these pathways separately, and coordinated regulation of glycan- and protein-mediated signaling remains challenging because of their spatial and functional interdependence. Here, we developed a branched tetraspecific nanobody for simultaneous protein checkpoint blockade and localized glycocalyx remodeling on both tumor cells and immune cells. Through SpyTag/SpyCatcher-mediated bioorthogonal ligation, a sialidase module, anti-CTLA-4 and anti-PD-L1 nanobodies, and a pharmacokinetic extension domain were chemically integrated into a branched four-arm macromolecular framework. This branched architecture minimizes steric interference between functional modules while maintaining their independent activities and target accessibility at the tumor-immune interface. As a result, the branched tetraspecific nanobody restores the effector functions of T cells, NK cells, and macrophages, thereby enhancing antitumor immunity. In multiple murine tumor models, including large, established tumors, this nanobody induced complete tumor regression in a subset of mice and generated a durable antitumor immune memory. These results establish branched multivalent macromolecular architectures as a strategy for coordinated glycan and protein immune checkpoint modulation and glycoimmunology reprogramming.
中文摘要:糖免疫检查点与经典蛋白检查点协同作用,在肿瘤-免疫界面驱动免疫抑制。然而,当前的肿瘤免疫疗法通常分别靶向这些通路,由于它们在空间和功能上的相互依赖性,协调调控糖介导和蛋白介导的信号仍然具有挑战性。在此,我们开发了一种分支四特异性纳米抗体,用于同时对肿瘤细胞和免疫细胞进行蛋白检查点阻断和局部糖萼重塑。通过SpyTag/SpyCatcher介导的生物正交连接,将唾液酸酶模块、抗CTLA-4和抗PD-L1纳米抗体以及药代动力学延伸结构域化学整合到一个分支四臂大分子框架中。这种分支架构最大限度地减少了功能模块之间的空间位阻干扰,同时保持了它们在肿瘤-免疫界面的独立活性和靶点可及性。结果,该分支四特异性纳米抗体恢复了T细胞、NK细胞和巨噬细胞的效应功能,从而增强抗肿瘤免疫力。在多种小鼠肿瘤模型中,包括大型已形成的肿瘤,该纳米抗体在一部分小鼠中诱导了完全的肿瘤消退并产生了持久的抗肿瘤免疫记忆。这些结果确立了分支多价大分子架构作为协调糖和蛋白免疫检查点调控及糖免疫重编程的策略。
Sepsis constitutes a life-threatening organ dysfunction caused by a dysregulated host response to infection. SESN2 (sestrin 2), an evolutionarily conserved stress-responsive protein, is a pivotal regulator of cellular homeostasis. Here, we identified TRIM13 (tripartite motif-containing 13) as a regulator that modulated the stability of SESN2 at the post-translational level. Specifically, TRIM13 promoted K63-linked ubiquitination of SESN2 with subsequent upregulation of its functional activation. Ubiquitinated SESN2 initiated a selective macroautophagic/autophagic program that facilitated the recruitment of SQSTM1/p62 (sequestosome 1/p62) to mitochondrial surfaces. The enhanced interaction between ubiquitinated SESN2 and the mitophagy receptor FUNDC1 (FUN14 domain-containing 1) at mitochondria-associated membranes (MAMs), facilitated by this modification, potentiated the mitophagic clearance of damaged mitochondria. In addition, it inhibited the interaction between FUNDC1 and RIPK3 (receptor-interacting serine-threonine kinase 3), which in turn ameliorated dysfunction and necroptosis of dendritic cells (DCs) upon sepsis. Thus, our findings establish that TRIM13 mitigates septic responses by activating SESN2-mediated mitophagy through ubiquitination, offering new insights into potential immunomodulatory strategies for sepsis.Abbreviations: AF: AlphaFold; BECN1: beclin 1, autophagy related; CLP: cecal ligation and puncture; co-IP: co-immunoprecipitation; DAMPs: danger/damageassociated molecular patterns; DCs: dendritic cells; DEGs: differentially expressed genes; FUNDC1: FUN14 domain containing 1; IL: interleukin; LPS: lipopolysaccharide; MAMs: mitochondria-associated membranes; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MHC: major histocompatibility complex; MLKL: mixed lineage kinase domain-like; Nec-1: necrostatin-1; PBMCs: peripheral blood mononuclear cells; RIPK3: receptor-interacting serine-threonine kinase 3; SESN2: sestrin 2; SIRT1: sirtuin 1; SQSTM1/p62: sequestosome 1; TEM: transmission electron microscopy; TLR: toll-like receptor; TNF: tumor necrosis factor; TRAF6: TNF receptor-associated factor 6; TRIM13: tripartite motif-containing 13; ULK1: unc-51 like kinase 1; UPR: unfolded protein response; UPS: ubiquitinproteasome system; WT: wild-type.
中文摘要:脓毒症是由宿主对感染的失调反应引起的危及生命的器官功能障碍。SESIN2(sestrin 2)是一种进化上保守的应激反应蛋白,是细胞稳态的关键调节因子。本研究鉴定出TRIM13(tripartite motif-containing 13)为在翻译后水平调节SESIN2稳定性的调节因子。具体而言,TRIM13促进SESIN2的K63连接泛素化,进而上调其功能活性。泛素化的SESIN2启动选择性巨自噬/自噬程序,促进SQSTM1/p62(sequestosome 1/p62)募集至线粒体表面。这种修饰增强了泛素化SESIN2与线粒体相关膜(MAMs)上的线粒体自噬受体FUNDC1之间的相互作用,从而增强受损线粒体的线粒体自噬清除能力。此外,它抑制了FUNDC1与RIPK3(receptor-interacting serine-threonine kinase 3)的相互作用,进而改善脓毒症状态下树突状细胞(DCs)的功能障碍和坏死性凋亡。因此,我们的研究结果表明,TRIM13通过泛素化激活SESIN2介导的线粒体自噬来减轻脓毒症反应,为脓毒症的潜在免疫调节策略提供了新见解。
Approximately 85% of colorectal cancers (CRCs) are microsatellite stable (MSS) and thus exhibit intrinsic resistance to anti-programmed death-1 (PD-1) therapy. In this study, we demonstrate that oral administration of Akkermansia muciniphila (Akk) suppresses tumorigenesis and reprograms the tumor microenvironment in MSS CRC mouse models. Akk attenuates macrophage efferocytosis through the TLR2/NF-κB pathway, an effect that leads to the accumulation of apoptotic cancer cells, which activates the cGAS-STING pathway and potentiates type I interferon production. This immunostimulatory cascade activates effector CD8+ T cells and enhances the response to anti-PD-1 therapy. We conducted a phase 1 trial (NCT06865521) combining Akk probiotics with PD-1 antibody in patients with metastatic MSS CRC after ≥1 prior line of therapy. The combination therapy was safe and achieved an objective response rate of 19%, with responders exhibiting enhanced antitumor immunity. Our multilevel investigation provides a promising strategy to overcome immunotherapy resistance in MSS CRC through targeted modulation of the gut microbiome.
中文摘要:约85%的结直肠癌为微卫星稳定型,对抗PD-1治疗存在内在耐药性。本研究显示,口服阿克曼菌可抑制小鼠模型中的肿瘤发生并重塑肿瘤微环境。该菌通过TLR2/NF-κB通路减弱巨噬细胞凋亡小体清除作用,导致癌细胞凋亡积累,进而激活cGAS-STING通路并增强I型干扰素产生。这一免疫刺激级联反应激活CD8+效应T细胞,从而增强抗PD-1治疗疗效。我们开展了一项针对既往接受过至少一线治疗的转移性微卫星稳定型结直肠癌患者的I期临床试验,联合使用阿克曼菌益生菌与PD-1抗体。联合疗法安全性良好,客观缓解率为19%,响应者表现出增强的抗肿瘤免疫反应。本研究的多层次调查为通过靶向调节肠道菌群克服微卫星稳定型结直肠癌免疫治疗耐药提供了有前景的策略。
Fibrosis and tumor innervation are two features of the tumor microenvironment (TME) that contribute directly to the lethality of pancreatic ductal adenocarcinoma (PDAC), but their potential interactions have not been explored. Moreover, although it is known that activated Schwann cells (SCs) stimulate cancer cell invasion, it remains unclear how SCs are activated. We determined how SCs are activated in the pancreatic fibrotic microenvironment. The correlation between physical features of the microenvironment and SC activation was assessed in human patient samples and in mice by SC c-Jun phosphorylation monitoring, atomic force microscopy and multiphoton live imaging. Several in vitro models in which forces were applied to SCs expressing a reporter for c-Jun phosphorylation and RNA-Seq analysis were used to decipher the cellular and molecular mechanisms of SC activation. Nerves surrounded by stiff stroma present higher SC activation. Intravital imaging shows a matrix dependent SC activation. Mechanical forces on SCs induce c-Jun phosphorylation in SCs in a non-canonical manner that involves a nuclear sensing machinery with the proinflammatory enzyme Phospholipase A2. Fibrosis enhances the protumorigenic impact of innervation by activating SCs via a mechanism in which nuclear compression triggers non-canonical activation of the AP-1 transcription factor complex. Pancreatic fibrosis alone, without cancer cells, is sufficient to activate SCs, suggesting this mechanism may be common across non-malignant pancreatic diseases. Notably, SCs are more sensitive to mechanical activation than PDAC cells. These findings reveal TME interactions that may guide future microenvironment-targeted PDAC therapies.
中文摘要:纤维化和肿瘤神经支配是胰腺导管腺癌微环境的两个特征,直接导致其高致死率,但两者的潜在相互作用尚未被探索。虽然已知活化的施万细胞能刺激癌细胞侵袭,但其活化机制仍不清楚。本研究确定了胰腺纤维化微环境中施万细胞的活化方式。通过监测施万细胞c-Jun磷酸化、原子力显微镜和多光子活体成像,在人样本和小鼠模型中评估了微环境物理特征与施万细胞活化的相关性。利用多种体外模型对表达c-Jun磷酸化报告基因的施万细胞施加力学作用,并结合RNA测序分析,阐明了施万细胞活化的细胞和分子机制。被僵硬基质包围的神经表现出更高的施万细胞活化水平。活体成像显示施万细胞的活化依赖于基质。施万细胞受到的机械力以非经典方式诱导c-Jun磷酸化,该过程涉及含有促炎酶磷脂酶A2的核感知机制。纤维化通过核压缩触发AP-1转录因子复合物的非经典激活来增强神经支配的促肿瘤影响。仅胰腺纤维化而无癌细胞足以活化施万细胞,提示该机制可能在非恶性胰腺疾病中普遍存在。值得注意的是,施万细胞对机械活化的敏感性高于胰腺导管腺癌细胞。这些发现揭示了可能指导未来靶向微环境的胰腺导管腺癌治疗策略的微环境相互作用。
Emerging evidence positions natural killer (NK) cells as key initiators of the inflammatory programs required for effective tumor immunity. Beyond direct tumor killing, NK cells trigger early immune responses by recruiting and activating dendritic cells (DCs), thereby enabling downstream T cell activation. However, in established tumors, NK cell-DC communication is often disrupted by metabolic stress and immunosuppressive pathways, leading to immune evasion. Here, we review advances in NK cell-DC cross-talk, cytokine-driven amplification loops and metabolic control of NK cell fitness. We propose that restoring these integrated immune 'circuits' may be key in converting immune-excluded tumors into immunotherapy-responsive states.
中文摘要:新兴证据表明,自然杀伤细胞是有效肿瘤免疫所需炎症程序的关键启动者。除直接杀伤肿瘤外,自然杀伤细胞还通过招募和激活树突状细胞触发早期免疫反应,从而促进下游T细胞的活化。然而,在已形成的肿瘤中,代谢应激和免疫抑制通路往往破坏了自然杀伤细胞与树突状细胞之间的通讯,导致免疫逃逸。本文综述了自然杀伤细胞与树突状细胞交叉对话、细胞因子驱动的扩增环路以及自然杀伤细胞适应性的代谢控制方面的进展。我们提出,恢复这些整合的免疫「回路」可能是将免疫排斥型肿瘤转化为对免疫治疗敏感状态的关键。
The CNS tumor classification of the WHO currently subsumes subependymomas (SE) of the supratentorial, infratentorial, and spinal compartment as one tumor type. Molecular data on SE are generally sparse, but SE are known to exhibit distinct global DNA methylation profiles according to their anatomical location. Previous studies indicate that a fraction of posterior fossa tumors exhibiting DNA methylation profiles of SE morphologically appear as ependymomas and may be prone to relapse. We assembled a cohort of ependymal tumors that best match supratentorial (n = 89), infratentorial (n = 146), or spinal (n = 45) SE DNA methylation profiles. Infratentorial tumors with an SE DNA methylation profile occurred at significantly higher ages with a male to female ratio of 4:1 and displayed two distinct subtypes. One of them (n = 49) was enriched for tumors that morphologically appear as ependymomas, carrying a loss of chromosome 6 as well as TERT promoter mutations. Respective patients showed a significantly shorter progression-free survival (p = 0.00014). Supratentorial SE frequently showed chromosome 8 loss while a small subset of tumors with a distinct DNA methylation profile and a segmentation of chromosome 6 was detected. Such chromosomal abnormalities were similarly observed in spinal SE. Based on clustering analysis and clinical features of tumors best matching a subependymoma methylation class, we postulate four subtypes of subependymomas. A fifth, previously undefined type of infratentorial ependymomas was provisionally named PFC. It showed frequent relapses but was distinct from PFA and PFB ependymomas.
中文摘要:世界卫生组织当前的中枢神经系统肿瘤分类将位于幕上、幕下和脊髓部位的室管膜下瘤归为一种肿瘤类型。关于室管膜下瘤的分子数据通常较为匮乏,但已知其根据解剖位置表现出不同的全局DNA甲基化谱。既往研究表明,部分具有室管膜下瘤DNA甲基化特征的幕下肿瘤在形态学上表现为室管膜瘤,且易复发。我们收集了一组与幕上(n=89)、幕下(n=146)或脊髓(n=45)室管膜下瘤DNA甲基化谱最匹配的室管膜来源肿瘤队列。具有室管膜下瘤DNA甲基化特征的幕下肿瘤发病年龄显著较高,男女比例为4:1,并表现出两种不同的亚型。其中一种亚型(n=49)富含形态学上表现为室管膜瘤的肿瘤,携带6号染色体缺失及TERT启动子突变。相应患者的无进展生存期显著缩短(p=0.00014)。幕上室管膜下瘤常显示8号染色体缺失,同时检测到一小部分具有不同DNA甲基化谱且6号染色体发生分割的肿瘤。脊髓室管膜下瘤中观察到类似的染色体异常。基于聚类分析及与室管膜下瘤甲基化类别最匹配的肿瘤的临床特征,我们推测室管膜下瘤存在四种亚型。第五种此前未定义的幕下室管膜瘤类型被暂命名为PFC,该类型显示频繁复发,但不同于PFA和PFB型室管膜瘤。
Combination immunotherapy targeting the coinhibitory molecules TIGIT and PD-L1 promotes non-exhausted CD8+ T cell differentiation in cancer. Because anti-TIGIT efficacy requires Fc binding, we investigated the role of Fcγ receptor (FcγR)-expressing myeloid cells in the mechanism of action. Conventional dendritic cells (cDCs) were required for therapeutic efficacy. Transcriptional profiling of intratumoral myeloid cells revealed an FcγR+ cDC type-1 (cDC1)-like activation state characterized by elevated costimulatory ligands for CD28 (CD80/CD86) and CD226 (PVR) that was enriched in Fc-active anti-TIGIT combination-treated tumors. Therapy-expanded CD8+ T cells expressed CD28 and upregulated CD226 upon treatment. Mechanistically, CD28 signaling was a prerequisite for therapy-induced CD226 expression on T cells, and cDC-derived PVR promoted CD226-mediated non-exhausted T cell differentiation. Type I interferon (IFN-I), induced through FcγR engagement, maintained and amplified the FcγR+ cDC1-like state, and exogenous IFN-I rescued anti-tumor immunity upon Fc-inert anti-TIGIT and anti-PD-L1 combination. Thus, Fc-active anti-TIGIT and anti-PD-L1 therapy promotes a sequential costimulatory cascade centered on cDCs, amplified by IFN-I signaling.
中文摘要:靶向共抑制分子TIGIT和PD-L1的联合免疫疗法可促进癌症中非耗竭性CD8+ T细胞的分化。由于抗TIGIT疗效依赖于Fc结合,我们研究了表达Fcγ受体的髓系细胞在作用机制中的角色。常规树突状细胞对治疗疗效是必需的。肿瘤内髓系细胞的转录谱分析揭示了一种FcγR阳性cDC1样激活状态,其特征为CD28(CD80/CD86)和CD226(PVR)的共刺激配体升高,该状态在Fc活性抗TIGIT联合治疗后的肿瘤中富集。治疗后扩增的CD8+ T细胞表达CD28并在治疗后上调CD226。机制上,CD28信号传导是治疗诱导T细胞上CD226表达的先决条件,而cDC来源的PVR促进了CD226介导的非耗竭性T细胞分化。通过FcγR结合诱导的I型干扰素维持并放大了FcγR阳性cDC1样状态,外源性IFN-I在Fc惰性抗TIGIT和抗PD-L1联合治疗中挽救了抗肿瘤免疫。因此,Fc活性抗TIGIT和抗PD-L1疗法促进了以cDC为中心的级联共刺激过程,并由IFN-I信号传导放大。
Melanoma treatment remains limited by drug resistance, immune-related adverse effects, and inadequate tumor-specific drug delivery. Nanoparticle (NP)-based delivery platforms have shown promise, but their clinical translation is hindered by rapid immune clearance and suboptimal biocompatibility. Current membrane-coating strategies often depend on invasive cell sources and lack patient-specific applicability. This study introduces a personalized melanoma therapy platform that integrates MnO2 NPs (MNPs) coated with urine-derived induced pluripotent stem cell (iPSC) membranes into a hydrogel-based transdermal patch. The patient-derived iPSC membrane enhances tumor targeting and immune evasion through the CXCR4/CXCL12 axis, while the MNPs facilitate pH-responsive release of cytotoxic drugs within the tumor microenvironment, maximizing therapeutic efficacy. The hydrogel transdermal patch enables direct, noninvasive delivery to skin lesions, promoting sustained drug exposure and potentially improving patient compliance. By combining autologous cell membrane coating, pH-responsive nanocarriers, and transdermal administration, this platform addresses key limitations of current melanoma therapies and supports the potential for clinical translation of personalized nanomedicine.
中文摘要:黑色素瘤的治疗仍受限于耐药性、免疫相关不良反应以及肿瘤特异性药物递送不足。基于纳米颗粒的递送平台虽展现出潜力,但其临床转化受到快速免疫清除和生物相容性不佳的阻碍。当前的膜包被策略通常依赖侵入性细胞来源且缺乏患者特异性适用性。本研究引入了一种个性化黑色素瘤治疗平台,将包裹有尿源性诱导多能干细胞膜的二氧化锰纳米颗粒整合到水凝胶透皮贴剂中。患者来源的诱导多能干细胞膜通过CXCR4/CXCL12轴增强肿瘤靶向性和免疫逃逸能力,而二氧化锰纳米颗粒则促进细胞毒性药物在肿瘤微环境中的pH响应性释放,从而最大化治疗效果。该水凝胶透皮贴剂实现了对皮肤病变的直接非侵入性递送,促进持续的药物暴露并有望提高患者依从性。通过结合自体细胞膜包被、pH响应性纳米载体和透皮给药,该平台解决了当前黑色素瘤治疗的关键局限性,支持个性化纳米医学临床转化的潜力。
Peptide supramolecular systems offer recognition and biocompatibility for precision theranostics, yet their in vivo performance is limited by insufficient structural stability, poor retention, and loss of accessible recognition interfaces under physiological perturbations. Herein, a topology-programmed supramolecular assembly strategy was developed to stabilize adaptive peptide architectures through confinement-guided organization. A β-sheet-based peptide EH, with PD-L1 (programmed death-ligand 1) targeting, favorable assembly behavior, and hydrophobic anchoring potential, was screened from an amphiphilic peptide library and integrated with immunoactivating SeAD quantum dots into PLGA (poly(lactic-co-glycolic acid)) microspheres featuring an interconnected hydrophobic channel network. This network guides channel-confined EH assembly through hydrophobic anchoring and β-sheet reinforcement, enabling ordered nanofiber alignment while preserving local conformational flexibility and exposed recognition motifs. This topology-programmed assembly converts dynamic peptide fibers into a structurally stabilized supramolecular interface, leading to prolonged tumor retention and sustained local immune checkpoint blockade. Meanwhile, ultrasound-activated SeAD induces immunogenic cell death and systemic antitumor immunity. By coupling confinement-stabilized peptide recognition with sonodynamic immune activation, EHSeAD@MS achieves durable local tumor intervention, immune microenvironment remodeling, and suppression of distant and metastatic lesions. It establishes a molecular design principle for balancing structural integrity and adaptive recognition in peptide supramolecules, providing a strategy for long-lasting peptide-based cancer immunotherapy.
中文摘要:肽超分子系统为精准诊疗提供了识别能力和生物相容性,但其体内性能受限于结构稳定性不足、滞留效果差以及在生理扰动下可及识别界面的丢失。本研究开发了一种拓扑编程的超分子组装策略,通过限制引导的组织化来稳定适应性肽架构。从两亲性肽库中筛选出具有PD-L1靶向能力、良好组装行为和疏水锚定潜力的基于β折叠的肽EH,并将其与免疫激活型SeAD量子点整合至具有互连疏水通道网络的PLGA微球中。该网络通过疏水锚定和β折叠增强引导通道受限的EH组装,实现有序纳米纤维排列,同时保留局部构象灵活性和暴露的识别基序。这种拓扑编程组装将动态肽纤维转化为结构稳定的超分子界面,从而延长肿瘤滞留并持续阻断局部免疫检查点。同时,超声激活的SeAD诱导免疫原性细胞死亡和全身抗肿瘤免疫。通过耦合限制稳定化的肽识别与声动力免疫激活,EHSeAD@MS实现了持久的局部肿瘤干预、免疫微环境重塑以及远处和转移性病灶的抑制。该研究确立了平衡肽超分子结构完整性和适应性识别的分子设计原则,为长效肽基癌症免疫治疗提供了策略。
The infiltration of CD8+ T cells into the hepatocellular carcinoma (HCC) microenvironment is a well-established determinant of immunotherapy efficacy and patient prognosis. However, the regulatory mechanisms governing this process and the therapeutic strategies capable of modulating it remain largely unexplored. Here, we identify HCC-IN-247 as a candidate compound that enhances IFNβ-driven CD8+ T cell infiltration both in vitro and in vivo. Mechanistic investigations reveal that the long noncoding RNA LINC02084 directly interacts with the transcription factor GLIS1 and facilitates its recruitment to the IFNβ promoter. HCC-IN-247 was identified through screening to target the LINC02084-GLIS1 binding interface, thereby stabilizing this RNA-protein complex. Stabilization of the complex significantly enhances IFNβ transcription, which in turn upregulates CXCL10 and CXCL11 expression and promotes CD8+ T cell infiltration. Furthermore, this study engineered a nanoparticle-based delivery system, designated Lip@RA@BSA-PD-L1/IN-247, for the codelivery of HCC-IN-247 and the anti-PD-L1 antibody atezolizumab in HCC treatment. These nanoparticles exhibited robust tumor-specific accumulation and elicited potent synergistic antitumor activity against HCC in mice. Collectively, our findings establish HCC-IN-247 as an activator of the tumor immune microenvironment and provide a preclinical basis for a combined immunotherapeutic approach to HCC.
中文摘要:CD8+ T细胞向肝细胞癌(HCC)微环境的浸润是决定免疫治疗疗效和患者预后的关键因素。然而,调控这一过程的机制及能够干预该过程的治疗策略仍知之甚少。本研究鉴定出候选化合物HCC-IN-247,能在体内外增强IFNβ驱动的CD8+ T细胞浸润。机制研究表明,长链非编码RNA LINC02084直接与转录因子GLIS1相互作用,促进其招募至IFNβ启动子区域。通过筛选发现,HCC-IN-247靶向LINC02084与GLIS1的结合界面,从而稳定该RNA蛋白复合物。复合物的稳定显著增强了IFNβ的转录,进而上调CXCL10和CXCL11的表达并促进CD8+ T细胞浸润。此外,本研究构建了一种名为Lip@RA@BSA-PD-L1/IN-247的纳米颗粒递送系统,用于在HCC治疗中共递送HCC-IN-247与抗PD-L1抗体阿替利珠单抗。该纳米颗粒表现出显著的肿瘤特异性蓄积能力,并在小鼠模型中对HCC产生了强大的协同抗肿瘤活性。综上所述,本研究确立HCC-IN-247作为肿瘤免疫微环境激活剂的作用,并为HCC的联合免疫治疗策略提供了临床前依据。
Pronounced heterogeneity and adaptability of tumors inherently curtail monotherapeutic efficacy, necessitating rationally integrated multimodal regimens that enable precise intervention, overcome resistance, and eradicate heterogeneous cell populations within the complex tumor microenvironment (TME). All-in-one mitochondria-targeted "nanomissiles" were created by emodin (Em)-Fe3+-gated, doxorubicin (DOX)-loaded PCN-600(FeIII) (denoted as DOX@ME) nanoparticles for synergistic multimodal tumor therapy integrating ferroptosis, photodynamic therapy (PDT), mild photothermal therapy (MPTT), and chemotherapy. DOX@ME achieved on-demand release of DOX in response to the TME [such as low pH, glutathione (GSH), hydrogen peroxide (H2O2), and adenosine-5'-triphosphate (ATP)] and near-infrared laser, via the disassembly of the Em-Fe3+ gating films and/or the degradation of the PCN-600(FeIII) nanocarriers. Under both 660 and 808 nm laser irradiation, DOX@ME effectively triggered apoptosis via chemotherapy, PDT, and MPTT while robustly accelerating reactive oxygen species (ROS) generation, GSH depletion, glutathione peroxidase 4 (GPX4) downregulation, and lipid peroxide (LPO) accumulation to enhance ferroptosis. Moreover, DOX@ME could alleviate thermotolerance by depleting intracellular ATP and downregulating protective heat shock protein 70 to boost the curative efficacy of MPTT. DOX@ME exhibited excellent antitumor efficacy and good biocompatibility and biosafety in A549 tumor-bearing nude mice. Collectively, DOX@ME demonstrates robust clinical translational potential for precision cancer therapy.
中文摘要:肿瘤显著的异质性和适应性固有地限制了单一疗法的疗效,因此需要合理整合的多模式治疗方案以实现精准干预、克服耐药性并清除复杂肿瘤微环境中的异质性细胞群。通过蒽醌(Em)-Fe3+门控、阿霉素(DOX)负载的PCN-600(FeIII)构建了全功能线粒体靶向纳米导弹(标记为DOX@ME),用于整合铁死亡、光动力疗法(PDT)、温和光热疗法(MPTT)和化疗的多模式协同肿瘤治疗。DOX@ME通过Em-Fe3+门控膜的解体和/或PCN-600(FeIII)纳米载体的降解,响应肿瘤微环境(如低pH、谷胱甘肽(GSH)、过氧化氢(H2O2)和三磷酸腺苷(ATP))及近红外激光,实现DOX的按需释放。在660nm和808nm激光照射下,DOX@ME通过化疗、PDT和MPTT有效诱导细胞凋亡,同时显著加速活性氧(ROS)生成、耗竭GSH、下调谷胱甘肽过氧化物酶4(GPX4)并积累脂质过氧化物(LPO)以增强铁死亡。此外,DOX@ME通过耗竭细胞内ATP和下调保护性热休克蛋白70来缓解热耐受性,从而提升MPTT的治疗疗效。在A549荷瘤裸鼠模型中,DOX@ME表现出优异的抗肿瘤疗效和良好的生物相容性与生物安全性。综上所述,DOX@ME展现出精准癌症治疗强大的临床转化潜力。
Effective glioblastoma therapy requires simultaneous solutions to poor blood-brain barrier (BBB) penetration, insufficient tumor-selective killing, and treatment-related systemic toxicity. We hypothesized that a BBB-penetrating nanoplatform capable of generating distinct H2S exposures in tumor and normal tissues could enhance antitumor efficacy while mitigating doxorubicin (DOX)-induced cardiotoxicity. Here, DOX-loaded metastable molybdenum disulfide nanoflowers functionalized with an I6P8 peptide (DOX@MSI) were developed. After BBB transport and tumor accumulation, the acidic, H2O2-rich, and GSH-rich microenvironment accelerates nanoplatform degradation, promoting GSH depletion and enhanced H2S/DOX release. High local H2S upregulates xCT, while H2S/DOX-mediated mitochondrial inhibition suppresses NADPH regeneration, synergistically triggering disulfidptosis. Meanwhile, H2S suppresses the JAK2/STAT3/IDO axis, alleviating DOX-induced immunosuppression and enhancing immunogenic cell death and T-cell-mediated antitumor immunity. In contrast, slower degradation under physiological conditions enables sustained low-level H2S release, reducing the level of oxidative stress and ERK-associated apoptosis in cardiomyocytes. Together with NIR-enhanced photothermal therapy, DOX@MSI suppresses orthotopic glioblastoma while reducing cardiac injury, thereby integrating tumor-selective multimodal therapy with active organ protection.
中文摘要:有效的胶质母细胞瘤治疗需要同时解决血脑屏障渗透性差、肿瘤选择性杀伤不足以及治疗相关全身毒性的问题。我们假设一种能够产生不同H2S暴露水平的血脑屏障穿透型纳米平台,可以在增强抗肿瘤疗效的同时减轻阿霉素诱导的心脏毒性。在此,我们开发了负载阿霉素的I6P8肽功能化亚稳态二硫化钼纳米花(DOX@MSI)。在穿过血脑屏障并积累于肿瘤后,酸性、富含H2O2和GSH的微环境加速了纳米平台的降解,促进GSH耗竭并增强H2S/阿霉素的释放。局部高浓度H2S上调xCT,而H2S/阿霉素介导的线粒体抑制抑制NADPH再生,协同触发二硫死亡。同时,H2S抑制JAK2/STAT3/IDO轴,减轻阿霉素诱导的免疫抑制并增强免疫原性细胞死亡和T细胞介导的抗肿瘤免疫。相比之下,生理条件下较慢的降解使得H2S持续低水平释放,降低心肌细胞的氧化应激水平和ERK相关凋亡。结合近红外增强的光热治疗,DOX@MSI在减少心脏损伤的同时抑制原位胶质母细胞瘤,从而将肿瘤选择性多模态治疗与主动器官保护相结合。
Modifying the lactate gradient in tumors can induce acidosis and improve the immunosuppressive microenvironment. However, the therapeutic benefit is offset by compensatory metabolic adaptations and the inability of small-molecule drugs to regulate the gradient throughout the tumor tissue. This study developed a novel nano-biocomposite (LOB@CDSH) that combines cuproptosis to damage mitochondria and cut off energy supply, thereby improving the therapeutic outcome of acidosis induction. Simultaneously, it utilizes the invasive and tumor-colonizing capabilities of engineered bacteria to efficiently reduce lactate levels within tumor tissues. The MCT4 inhibitor syrosingopine (Syro) was loaded into a reactive oxygen species-responsive copper-based metal-organic framework (Cu-DTA) and coated with hyaluronic acid (HA) to form Cu-DTA@Syro@HA (CDSH). Syro inhibits lactate efflux, leading to intracellular lactate accumulation and acidosis. This promotes mitochondrial metabolism and induces lactylation modification of methyltransferase-like 16 (METTL16), thereby upregulating the expression of ferredoxin 1 (FDX1) to enhance cuproptosis. Lactate oxidase (LOX)-engineered Escherichia coli BL21 (LOB) serves as a carrier to deliver CDSH to the tumor site, where it proliferates, disseminates, and continuously expresses LOX to deplete lactate in the tumor microenvironment, thereby alleviating lactate-mediated immunosuppression. The aforementioned nano-biocomposite provides a reciprocally modulating strategy for lactate metabolism, offering a novel approach for tumor immunotherapy.
中文摘要:调节肿瘤内的乳酸梯度可诱导酸中毒并改善免疫抑制微环境,但其治疗效益常被代偿性代谢适应所抵消,且小分子药物难以在整个肿瘤组织中调控该梯度。本研究开发了一种新型纳米生物复合材料(LOB@CDSH),结合铜死亡以损伤线粒体并切断能量供应,从而改善酸中毒诱导的治疗效果。同时,利用工程菌的侵袭和肿瘤定植能力有效降低肿瘤组织内的乳酸水平。将MCT4抑制剂西罗辛品(Syro)负载于活性氧响应型铜基金属有机框架(Cu-DTA)上,并用透明质酸(HA)包覆形成CDSH。Syro抑制乳酸外流,导致细胞内乳酸积累和酸中毒。这促进线粒体代谢并诱导甲基转移酶样16(METTL16)的乳酸化修饰,进而上调铁氧还蛋白1(FDX1)的表达以增强铜死亡。负载LOX的工程大肠杆菌BL21(LOB)作为载体将CDSH递送至肿瘤部位,在那里增殖、扩散并持续表达LOX以消耗肿瘤微环境中的乳酸,从而缓解乳酸介导的免疫抑制。该纳米生物复合材料为乳酸代谢提供了一种相互调节策略,为肿瘤免疫治疗提供了新方法。
Cells experiencing mitochondrial stress can undergo apoptosis or cell death that triggers innate immune activation. We examined the mechanisms determining these distinct outcomes in cancer. Abundant mitochondrial DNA (mtDNA) and high expression of the cGAS-STING pathway were features of KRAS-mutant cancers. In a pharmacological screen, MEK inhibitor (MEKi) effectively induced mtDNA release into the cytosol in KRAS-mutant cancer cells. However, MEKi also induced PRKN-mediated mitophagy, which limited mtDNA release by eliminating damaged mitochondria. Inhibition of mitophagy sustained mtDNA efflux and amplified cGAS-STING signaling. Mechanistically, PRKN-mediated mitophagy restrained mitochondrial outer membrane permeabilization (MOMP) to limit mtDNA efflux. The balance between mtDNA and cytochrome c (cyt.c) release defined two immunologically distinct outcomes: immunogenic cell death (ICD) and apoptosis. In preclinical models, combined inhibition of MEK and mitophagy induced robust dendritic cell (DC) activation and promoted CD8+ T cell-mediated antitumor immunity. Consistently, PRKN expression negatively correlated with immune infiltration in human cancers. Collectively, these findings provide a rationale for combination strategies targeting mitochondrial dynamics to augment antitumor immunity.
中文摘要:经历线粒体应激的细胞可发生凋亡或触发先天免疫激活的细胞死亡。我们研究了决定癌症中这些不同结果的机制。丰富的线粒体DNA(mtDNA)和cGAS-STING通路的高表达是KRAS突变型癌症的特征。在药理学筛选中,MEK抑制剂(MEKi)有效诱导KRAS突变型癌细胞中的mtDNA释放到胞质中。然而,MEKi也诱导了PRKN介导的线粒体自噬,通过消除受损线粒体限制了mtDNA的释放。抑制线粒体自噬可持续mtDNA外流并放大cGAS-STING信号。在机制上,PRKN介导的线粒体自噬限制线粒体外膜通透性(MOMP)以限制mtDNA外流。mtDNA与细胞色素c(cyt.c)释放之间的平衡定义了两种免疫学上不同的结果:免疫原性细胞死亡(ICD)和凋亡。在临床前模型中,联合抑制MEK和线粒体自噬诱导了强烈的树突状细胞(DC)激活并促进了CD8+ T细胞介导的抗肿瘤免疫。一致地,PRKN表达与人类癌症中的免疫浸润呈负相关。总之,这些发现为靶向线粒体动态以增强抗肿瘤免疫的组合策略提供了依据。
Bispecific antibodies that conditionally engage costimulatory receptors aim to enhance antitumor T cell immunity while limiting systemic toxicity. We investigated mechanisms underlying the clinical performance of a PD-L1×4-1BB bispecific antibody. Therapeutic efficacy of PD-L1×4-1BB was largely independent of PD-L1 expression on malignant cells but waned in Batf3-/- mice or upon depletion of type 1 conventional dendritic cells (cDC1s). cDC1-specific deletion of PD-L1 markedly limited tumor control. PD-L1×4-1BB enhanced proliferation of tumor-antigen-specific CD8+ T cells through mechanisms dependent on cross-presentation, the presence of interleukin (IL)-12, 4-1BB costimulation, and CD40L-mediated cDC1 licensing. PD-L1×4-1BB increased cDC1-T cell contacts, which promoted transcriptional programs associated with T cell activation and proliferation. Treated tumors exhibited increased infiltration and spatial proximity of cDC1s and activated CD8+ T cells. Accordingly, increasing dendritic-cell abundance via Flt3L further enhanced tumor control. Thus, cDC1-T cell interactions are central to PD-L1×4-1BB activity, with antigen cross-presentation, dendritic-cell licensing, and IL-12 and 4-1BB costimulation converging to promote antitumor immunity.
中文摘要:条件性共刺激受体双特异性抗体旨在增强抗肿瘤T细胞免疫同时限制全身毒性。我们研究了PD-L1×4-1BB双特异性抗体临床表现的潜在机制。PD-L1×4-1BB的治疗功效在很大程度上独立于恶性细胞的PD-L1表达,但在Batf3-/-小鼠或I型常规树突状细胞(cDC1s)耗竭时减弱。cDC1特异性敲除PD-L1显著限制了肿瘤控制。PD-L1×4-1BB通过依赖交叉呈递、白细胞介素(IL)-12存在、4-1BB共刺激以及CD40L介导的cDC1许可的机制,增强了肿瘤抗原特异性CD8+ T细胞的增殖。PD-L1×4-1BB增加了cDC1与T细胞的接触,促进了与T细胞激活和增殖相关的转录程序。治疗后的肿瘤表现出cDC1s和活化CD8+ T细胞浸润增加及空间邻近性增强。因此,通过Flt3L增加树突状细胞丰度进一步增强了肿瘤控制。综上所述,cDC1-T细胞相互作用是PD-L1×4-1BB活性的核心,抗原交叉呈递、树突状细胞许可以及IL-12和4-1BB共刺激汇聚以促进抗肿瘤免疫。
Germinal center (GC) responses generate humoral immunity through coordinated interactions between B cells and T follicular helper (TFH) and T follicular regulatory (TFR) cells. Despite high expression of PD-1 by TFH and TFR cells, the function of its ligand PD-L1 in the GC is unclear. Here, we show an immunogenic role for PD-L1 via tuning T-B collaboration to promote humoral immunity. Integrated analyses of secondary lymphoid organs (SLOs) revealed that B cell zone reticular cells (BRCs), including follicular dendritic cells (FDCs), expressed PD-L1. BRC expression of PD-L1 facilitated GC formation and enabled loss of B cell tolerance in autoantibody disease. Mechanistically, BRC-specific deletion of PD-L1 enhanced TFH cell production of Sostdc1 and TFR cell differentiation, destabilizing T-B contacts in the GC. Patient-derived tumor biopsies indicated that a tumor-infiltrating TFH SOSTDC1 signature inversely correlated with immunotherapy responsiveness. These findings reveal a non-canonical immunogenic role for PD-L1 in the GC and suggest that augmenting B cell responses could improve the efficacy of PD-L1 blockade.
中文摘要:生发中心反应通过B细胞与滤泡辅助性T细胞及滤泡调节性T细胞的协调相互作用产生体液免疫。尽管TFH和TFR细胞高表达PD-1,但其配体PD-L1在生发中心的功能尚不明确。本研究揭示了PD-L1通过调节T-B协作促进体液免疫的免疫原性作用。对次级淋巴器官的综合分析显示,B细胞区网状细胞包括滤泡树突状细胞表达PD-L1。BRC表达的PD-L1促进了生发中心的形成并导致自身抗体疾病中B细胞耐受性的丧失。在机制上,BRC特异性敲除PD-L1增强了TFH细胞产生Sostdc1和TFR细胞的分化,破坏了生发中心内T-B接触的稳定性。患者来源的肿瘤活检表明肿瘤浸润性TFH的SOSTDC1特征与免疫治疗反应呈负相关。这些发现揭示了PD-L1在生发中心的非经典免疫原性作用,并提示增强B细胞反应可能提高PD-L1阻断疗法的疗效。
T helper 9 (Th9) cells show promise for adoptive cell therapy (ACT) against solid tumors. However, clinical application faces challenges regarding their persistence in the tumor microenvironment (TME). We observed that tumor growth gradually reduced glucose concentrations in the TME, accompanied by a decline in transferred Th9 cells and their effector functions, due to Th9 cell senescence. Restoring glucose concentrations suppressed Th9 cell senescence, thereby improving their persistence. Mechanistically, glucose-deprivation-activated AMP-activated protein kinase (AMPK), triggering downstream leucine-zipper and sterile-α motif kinase (ZAK)-nuclear factor κB (NF-κB)-inducing kinase (NIK) cascades that suppressed noncanonical NF-κB signaling and interleukin (IL)-9 production, ultimately driving Th9 cell senescence. ZAK-associated chimeric antigen receptor (CAR)-T cell senescence was linked to compromised therapeutic efficacy in human cancers. Targeting ZAK rejuvenated Th9 cells and enhanced CAR-Th9 cell efficacy against solid tumors. Our study uncovers a mechanism by which nutrient deprivation promotes Th9 cell senescence to compromise persistence, highlights the potential of targeting ZAK to rejuvenate CAR-Th9 cells for solid tumor therapy.
中文摘要:Th9细胞在实体瘤的过继细胞治疗中展现出潜力,但其临床应用面临在肿瘤微环境中持久性不足的难题。我们观察到肿瘤生长逐渐降低肿瘤微环境中的葡萄糖浓度,伴随转移的Th9细胞及其效应功能的下降,这是由于Th9细胞衰老所致。恢复葡萄糖浓度可抑制Th9细胞衰老,从而改善其持久性。机制上,葡萄糖缺乏激活AMP活化蛋白激酶,触发下游亮氨酸拉链和无菌α基序激酶至核因子κB诱导激酶级联反应,抑制非经典NF-κB信号通路和白细胞介素9的产生,最终驱动Th9细胞衰老。ZAK相关的嵌合抗原受体T细胞衰老与人类癌症中治疗功效受损有关。靶向ZAK可 rejuvenate Th9细胞并增强CAR-Th9细胞对实体瘤的疗效。本研究揭示了营养剥夺促进Th9细胞衰老从而损害持久性的机制,强调了靶向ZAK以 rejuvenate CAR-Th9细胞用于实体瘤治疗的潜力。
Neutrophils represent the most abundant leukocytes in circulation and serve to protect the host from infection. Paradoxically, they also contribute to cancer by releasing extracellular traps known as neutrophil extracellular traps (NETs). These structures exert opposing effects on tumors, either promoting progression or suppressing growth, depending on the specific context. However, a comprehensive framework reconciling these dual roles is lacking. NETs can be reconceptualised as multimodal signal processors within the tumor microenvironment, with a primary focus on cancer while acknowledging relevance to certain inflammatory and autoimmune conditions. NETs function through three interconnected modalities: (1) biomechanical scaffolds that remodel tissue architecture via integrin-focal adhesion kinase (FAK) mechanotransduction; (2) immunometabolic hubs that drive glycolytic reprogramming and immune suppression; and (3) signal-integration platforms that concentrate oncogenic cues for synergistic pathway activation. This systems-level perspective, orchestrated by nodes such as hypoxia-inducible factor 1-alpha and integrin-FAK, elucidates how microenvironmental inputs dictate NET phenotypic polarity. Furthermore, therapeutic implications are addressed, including biomarker-guided stratification, optimal intervention timing during the perioperative period, dormancy phase, immunotherapy combinations, and strategies to disrupt modal crosstalk while preserving essential host defence. Future priorities include resolving NET heterogeneity and developing localised delivery systems. This roadmap enhances precision targeting of NETs in oncology and other fields.
中文摘要:中性粒细胞是循环中最丰富的白细胞,主要发挥保护宿主免受感染的作用。然而,它们通过释放细胞外陷阱(NETs)也促进癌症发展。这些结构对肿瘤具有双重作用,既可能促进进展也可能抑制生长,具体取决于特定背景。目前缺乏调和这两种矛盾作用的综合框架。本文提出将NETs重新概念化为肿瘤微环境中的多模态信号处理器,主要聚焦于癌症,同时承认其在某些炎症和自身免疫性疾病中的相关性。NETs通过三种相互关联的模式发挥作用:一是作为生物力学支架,通过整合素-局灶粘附激酶(FAK)机械转导重塑组织架构;二是作为免疫代谢枢纽,驱动糖酵解重编程和免疫抑制;三是作为信号整合平台,浓缩致癌线索以协同激活通路。由缺氧诱导因子1-alpha和整合素-FAK等节点协调的系统级视角阐明了微环境输入如何决定NET表型极性。此外,文章探讨了治疗意义,包括生物标志物指导的分层、围手术期及休眠期的最佳干预时机、免疫治疗联合策略以及破坏模态串扰同时保留宿主防御的策略。未来重点在于解决NET异质性并开发局部递送系统。这一路线图增强了在肿瘤学及其他领域对NETs的精准靶向能力。
Tissue stiffening is a predominant malignant physical alteration in cancer progression, yet its effect on specific immune subsets within the tumor microenvironment is not well defined. Here we show that elevated tissue stiffness subverts tumor-infiltrating type 1 helper T (TH1) cells to drive immunosuppression in pancreatic cancer. Mechanistically, stiffness triggers integrin-mediated mechanotransduction to activate YAP, which translocates to the nucleus and cooperates with RUNX1 to transcriptionally upregulate a set of dysfunction-associated genes. These reprogrammed TH1 cells acquire a distinct dysfunction-associated secretory phenotype, which in turn drives M2-like polarization of macrophages and amplifies local immunosuppression. Notably, inhibiting YAP expression or disrupting YAP-RUNX1 interaction reverses the dysfunctional state of TH1 cells and restores antitumor immunity. These findings delineate a mechano-immunological mechanism by which tumor stiffness subverts TH1 cell functions, indicating a possible therapeutic avenue to alleviate immunosuppression and potentiate immunotherapy efficacy in stiff tumors.
中文摘要:组织硬化是癌症进展中主要的恶性物理改变,但其在肿瘤微环境中对特定免疫亚群的影响尚不明确。本研究显示,升高的组织硬化会颠覆浸润性1型辅助T(TH1)细胞的功能,从而驱动胰腺癌中的免疫抑制。在机制上,硬化通过整合素介导的机械转导激活YAP,后者易位至细胞核并与RUNX1协同转录上调一组功能障碍相关基因。这些重编程的TH1细胞获得独特的功能障碍相关分泌表型,进而驱动巨噬细胞向M2样极化并放大局部免疫抑制。值得注意的是,抑制YAP表达或破坏YAP-RUNX1相互作用可逆转TH1细胞的功能障碍状态并恢复抗肿瘤免疫。这些发现描绘了一种机械免疫学机制,即肿瘤硬化如何颠覆TH1细胞功能,表明在硬化肿瘤中减轻免疫抑制并增强免疫治疗疗效存在潜在的治疗途径。
Immune checkpoint blockade (ICB) has revolutionized oncology for treating many cancer types including triple-negative breast cancer (TNBC). However, only a minority of patients respond, and there are no biomarkers for patient stratification and combination therapy design, particularly for metastatic disease. We profiled CD45+ immune cells by single-cell RNA sequencing (scRNA-seq) across five anatomical sites (bone marrow, blood, draining lymph nodes, lungs and mammary tumor/normal mammary tissue control) over four stages spanning tumor-free to late metastatic disease in two syngeneic orthotopic TNBC mouse models (4T1 and M6). Transcriptomic clustering and trajectory analyses were integrated with flow cytometry validation. Preclinical mouse models were designed to evaluate the combined ICB of anti-lymphocyte activation gene 3 (LAG-3) and anti-programmed cell death protein 1 (PD-1). Profound changes were observed in immune composition of the bone marrow, lymph nodes, lung and blood at the earliest timepoint, before overt metastasis. Tumors were dominated by myeloid populations and showed features consistent with T-cell dysfunction, including elevated inhibitory receptor expression on cytotoxic T lymphocytes. However, evidence of a beneficial immune response was found in lymph nodes but was clearly inactivated in tumor and lung tissues. Importantly, granulocytes were captured in the scRNA-seq atlas, revealing tumor-associated neutrophil states and highlighting increased expression of galectin-3 (LGALS3 or GAL3), a ligand for LAG-3. Targeting both LAG-3 and PD-1 showed the highest reduction in tumor size as well as metastatic burden compared with targeting PD-1 alone. A systemic, early-onset immune evasion accompanies TNBC progression. The GAL3–LAG-3 axis is a critical mechanism in the tumor microenvironment. The combined LAG-3 and PD-1 targeting strategies improve the efficacy in TNBC treatment. In addition, draining lymph nodes represent a potentially valuable source of antitumor immunity, warranting further investigation when considering the clinical practice of lymph node removal.
中文摘要:免疫检查点阻断疗法已彻底改变了包括三阴性乳腺癌在内的多种癌症的治疗格局。然而,仅有少数患者受益,且目前缺乏用于患者分层和联合治疗方案设计的生物标志物,特别是在转移性病变中。本研究通过单细胞RNA测序技术对两种原位移植三阴性乳腺癌小鼠模型(4T1和M6)在四个阶段(从无瘤状态到晚期转移)跨越五个解剖部位(骨髓、血液、引流淋巴结、肺部及乳腺肿瘤/正常乳腺组织对照)的CD45+免疫细胞进行了谱系分析。转录组聚类与轨迹分析结合流式细胞术验证显示,在出现明显转移之前,骨髓、淋巴结、肺和血液中的免疫组成已发生深刻变化。肿瘤主要由髓系细胞主导,并表现出与T细胞功能障碍一致的特征,包括细胞毒性T淋巴细胞上抑制性受体表达升高。尽管在淋巴结中发现了有益的免疫反应证据,但在肿瘤和肺组织中该反应明显被抑制。重要的是,单细胞图谱捕获了粒细胞信息,揭示了肿瘤相关中性粒细胞状态并突出了LAG-3配体半乳糖凝集素3(LGALS3或GAL3)表达的增加。与单独靶向PD-1相比,同时靶向LAG-3和PD-1显示出最大的肿瘤缩小效果和最低的转移负荷。系统性早期免疫逃逸伴随三阴性乳腺癌的进展,GAL3-LAG-3轴是肿瘤微环境中的关键机制。联合靶向LAG-3和PD-1的策略提高了三阴性乳腺癌的治疗效果。此外,引流淋巴结代表了一种潜在的抗肿瘤免疫来源,在考虑临床淋巴结切除实践时值得进一步研究。
Muscle-specific tyrosine kinase antibody-positive myasthenia gravis (MuSK-MG) is a severe autoimmune disease with limited effective treatment options. We designed an mRNA-encoded bispecific T-cell engager (MuSK×CD3 TCE) comprising the human MuSK extracellular domain and an anti-CD3 single-chain variable fragment (scFv), delivered via a lipid nanoparticles (LNPs) to the liver to enable in vivo protein synthesis, which redirects cytotoxic T cells to eliminate B cells expressing anti-MuSK B cell receptors (BCR). In vitro, the MuSK×CD3 TCE mediated dose-dependent cytotoxicity against MuSK+ target cells and induced robust T cell activation. In human PBMC-engrafted NOG mice, mRNA-LNP administration led to dose-dependent and specific inhibition of tumor growth in anti-MuSK BCR-positive tumors, with no significant impact on non-target B cells. Importantly, the TCE retained potent cytotoxic activity in the presence of physiological concentrations of MuSK autoantibodies-a key consideration for clinical translation, as patients with MuSK-MG typically harbor circulating autoantibodies. This "off-the-shelf" mRNA-LNP platform offers a precise, controllable and potent immunotherapy strategy for MuSK-MG and may be broadly applicable for other autoantibody-mediated diseases to eliminate pathogenic BCR+ B cells.
中文摘要:肌特异性酪氨酸激酶抗体阳性重症肌无力(MuSK-MG)是一种严重自身免疫性疾病,目前有效治疗手段有限。我们设计了一种编码 mRNA 的双特异性 T 细胞衔接器(MuSK×CD3 TCE),包含人 MuSK 胞外结构域和抗 CD3 单链可变区片段(scFv),通过脂质纳米颗粒(LNP)递送至肝脏以实现体内蛋白质合成,从而将细胞毒性 T 细胞重定向以清除表达抗 MuSK B 细胞受体(BCR)的 B 细胞。体外实验显示,MuSK×CD3 TCE 对 MuSK+ 靶细胞介导了剂量依赖性的细胞毒性并诱导了强烈的 T 细胞活化。在人外周血单核细胞(PBMC)植入的 NOG 小鼠模型中,mRNA-LNP 给药导致抗 MuSK BCR 阳性肿瘤生长受到剂量依赖性和特异性抑制,且对非靶标 B 细胞无显著影响。重要的是,在生理浓度的 MuSK 自身抗体存在下,该 TCE 仍保留了强大的细胞毒性活性,这是临床转化的关键考量因素,因为 MuSK-MG 患者通常携带循环自身抗体。这种「现货型」mRNA-LNP 平台为 MuSK-MG 提供了一种精准、可控且强效的免疫治疗策略,并可能广泛适用于其他自身免疫性抗体介导的疾病以清除致病性 BCR+ B 细胞。
Double-stranded RNA (dsRNA) can activate potent anti-tumor immunity, but its clinical translation remains challenging. We sought to identify clinically applicable strategies to induce endogenous dsRNA and enhance anti-tumor immune responses. Here, we integrated genome-wide CRISPR-Cas9 screening data with the Therapeutic Target Database (TTD) and identified Topoisomerase I (TOP1) as a potential inducer of dsRNA. Mechanistically, we found that TOP1 was associated with suppression of endogenous retroviruses (ERVs) in an enzyme activity-dependent manner, and this was accompanied by "viral mimicry" through the induction of dsRNA. Pharmacological inhibition of TOP1 using Irinotecan (CPT-11) triggered dsRNA accumulation across cancer models, including patient-derived organoids (PDOs), activating the RIG-I/MDA5-MAVS pathway and antiviral interferon responses (Type I/III IFNs, ISGs). scRNA-seq revealed that CPT-11 remodeled the tumor microenvironment, promoting infiltration of dendritic cells (DCs), macrophages, and T cells. Combining CPT-11 with PD-1 blockade in "cold" tumors dramatically improved survival. CPT-11 also generated a potent in situ vaccine effect, establishing immunological memory that prevented tumor rechallenge. Moreover, tumor cells pretreated with CPT-11 in vitro were also able to exert a vaccine-like effect, inhibiting the growth of subsequently inoculated tumors. Collectively, our findings support the repurposing of TOP1 inhibitors such as CPT-11 to harness dsRNA-mediated immune activation for more effective cancer therapy.
中文摘要:双链RNA可激活强效抗肿瘤免疫,但其临床转化仍面临挑战。本研究旨在寻找可诱导内源性双链RNA并增强抗肿瘤免疫反应的临床适用策略。通过整合全基因组CRISPR-Cas9筛选数据与治疗靶点数据库,我们鉴定出拓扑异构酶I作为潜在的双链RNA诱导剂。机制研究表明,TOP1以酶活性依赖的方式抑制内源性逆转录病毒,并通过诱导双链RNA实现「病毒模拟」。使用伊立替康药理学抑制TOP1可触发包括患者来源类器官在内的多种癌症模型中双链RNA的积累,激活RIG-I/MDA5-MAVS通路及抗病毒干扰素反应。单细胞测序显示伊立替康重塑了肿瘤微环境,促进树突状细胞、巨噬细胞和T细胞的浸润。在「冷」肿瘤中将伊立替康与PD-1阻断联合使用显著提高了生存率。伊立替康还产生了强效的原位疫苗效应,建立免疫记忆以预防肿瘤再挑战。此外,体外预处理的肿瘤细胞也能发挥疫苗样作用,抑制随后接种的肿瘤生长。综上所述,我们的研究支持重新利用拓扑异构酶I抑制剂如伊立替康,利用双链RNA介导的免疫激活以实现更有效的癌症治疗。
Transforming growth factor β (TGF-β) accumulation in the tumor microenvironment (TME) is a major barrier to durable antitumor immunity. We developed fibronectin extra domain B (FN-EDB)-binding peptide (FEBP)-soluble TβRII-Fc (sTβRII), an engineered inhibitor targeting the FN-EDB-rich tumor matrix for localized TGF-β blockade. In fibrotic, immune-excluded tumors, FEBP-sTβRII suppresses TGF-β/SMAD signaling to unleash T cell activation and IFN-γ production, thereby driving feedforward cancer-associated fibroblast (CAF)-myeloid reprogramming toward an antigen-presenting state. This coordinated remodeling relieves immune exclusion and converts the fibrotic TME into an antigen-visible ecosystem that sustains robust T cell infiltration and activation. Consequently, FEBP-sTβRII induces T cell-dependent tumor regression, expands effector-memory populations, and elicits long-term, cross-protective antitumor immunity, while minimizing peripheral transcriptional disturbances compared with systemic sTβRII. Together, these findings show that spatially targeted TGF-β blockade overcomes fibrotic immune exclusion to establish durable local and systemic tumor immunity.
中文摘要:肿瘤微环境中转化生长因子β(TGF-β)的积累是持久抗肿瘤免疫的主要障碍。我们开发了纤维连接蛋白额外结构域B(FN-EDB)结合肽(FEBP)与可溶性TβRII-Fc(sTβRII)的结合体,这是一种针对富含FN-EDB的肿瘤基质以实现局部TGF-β阻断的工程化抑制剂。在纤维化且免疫排斥的肿瘤中,FEBP-sTβRII抑制TGF-β/SMAD信号通路以释放T细胞激活和干扰素γ(IFN-γ)的产生,从而驱动癌症相关成纤维细胞(CAF)与髓系细胞向抗原呈递状态重新编程。这种协同重塑缓解了免疫排斥,将纤维化的肿瘤微环境转化为维持强大T细胞浸润和激活的抗原可见生态系统。因此,FEBP-sTβRII诱导T细胞依赖性的肿瘤消退,扩大效应记忆细胞群并引发长期交叉保护的抗肿瘤免疫,同时与全身性sTβRII相比最小化了外周转录干扰。综上所述,这些发现表明空间靶向的TGF-β阻断克服了纤维化免疫排斥,建立了持久的局部和全身肿瘤免疫。
Sex differences in glioblastoma (GBM) outcomes are shaped by biological, hormonal, and immune factors, but the mechanisms driving these disparities remain unclear. We identify platelet protease-activated receptor 4 (PAR4) signaling as a regulator of sex-specific anti-tumor immunity. GBM patients exhibit increased platelet reactivity driven by PAR4. In murine models, pharmacologic or genetic inhibition of PAR4 prolongs survival in females, but not males, and is estrogen dependent, persisting in hormonal females regardless of chromosomal sex. The survival advantage is mediated within the tumor microenvironment through enhanced CD8+ T cell infiltration and function. PAR4-activated platelets suppress CD8+ T cell activity, whereas CD8+ T cell depletion abolishes both tumor-induced platelet reactivity and the PAR4-dependent survival advantage. Mechanistically, PAR4 inhibition enhances CD8+ T cell signaling through interaction with estrogen receptor β (ERβ). These findings demonstrate that platelets are critical regulators of sex-specific anti-tumor immunity and identify PAR4 as a promising therapeutic target in cancer.
中文摘要:胶质母细胞瘤(GBM)患者结局存在性别差异,受生物学、激素及免疫因素影响,但其驱动机制尚不明确。本研究鉴定出血小板蛋白酶激活受体4(PAR4)信号是调节性别特异性抗肿瘤免疫的关键因子。GBM患者表现出由PAR4驱动的血小板反应性增加。在小鼠模型中,药理学或遗传学抑制PAR4可延长雌性小鼠的生存期,但对雄性无效,且该效应依赖雌激素,在激素正常的雌性小鼠中无论染色体性别如何均持续存在。这种生存优势通过肿瘤微环境内CD8+ T细胞浸润和功能的增强介导。PAR4激活的血小板抑制CD8+ T细胞活性,而CD8+ T细胞耗竭既消除了肿瘤诱导的血小板反应性,也取消了PAR4依赖的生存优势。机制上,PAR4抑制通过与雌激素受体β(ERβ)相互作用增强CD8+ T细胞信号传导。这些发现证明血小板是性别特异性抗肿瘤免疫的关键调节因子,并确定PAR4作为癌症治疗的潜在靶点。
Upregulation of PD-L1 on tumor cells is a pivotal aspect of immune evasion, leading to treatment resistance, tumor recurrence, and metastasis. Understanding the mechanisms that control PD-L1 expression in cancer cells is therefore of paramount importance. In this study, we show that deubiquitinase OTUD1 is downregulated in kidney renal clear cell carcinoma (KIRC), and its low expression is linked to a poor prognosis in patients. Analysis of a public single-cell sequencing dataset revealed that OTUD1 is enriched in specific immune cell populations, indicating its potential for immune modulation. Overexpression of OTUD1 significantly hindered KIRC progression and was associated with decreased PD-L1 expression in both KIRC patients and mouse cancer models. Further investigation uncovered that OTUD1 downregulates PD-L1 abundance and enhances tumor cell sensitivity to cytotoxicity mediated by Jurkat T cells. Mechanistically, OTUD1 interacts with and deubiquitinates the protein kinase AKT, thereby promoting the autophagosome-lysosomal degradation of PD-L1 via the AKT-mTOR-TFEB axis. Moreover, OTUD1 overexpression induced autophagy and enhanced the release or exposure of DAMPs, thereby promoting T cell infiltration into the tumor microenvironment in mice. Our study unveils a novel mechanism by which OTUD1 regulates PD-L1 degradation, highlighting its potential as a therapeutic target in KIRC cancer immunology.
中文摘要:肿瘤细胞上PD-L1的上调是免疫逃逸的关键方面,会导致治疗耐药、肿瘤复发和转移。因此,了解控制癌细胞中PD-L1表达的机制至关重要。在本研究中,我们发现去泛素化酶OTUD1在肾透明细胞癌(KIRC)中下调,其低表达与患者不良预后相关。对公共单细胞测序数据集的分析显示,OTUD1富集于特定的免疫细胞群体中,表明其具有免疫调节潜力。OTUD1的过表达显著阻碍了KIRC的进展,并与KIRC患者及小鼠癌症模型中PD-L1表达的降低相关。进一步调查揭示,OTUD1下调PD-L1丰度并增强肿瘤细胞对Jurkat T细胞介导的细胞毒性的敏感性。在机制上,OTUD1与蛋白激酶AKT相互作用并进行去泛素化,从而通过AKT-mTOR-TFEB轴促进PD-L1的自噬体-溶酶体降解。此外,OTUD1过表达诱导自噬并增强损伤相关分子模式(DAMPs)的释放或暴露,从而促进小鼠肿瘤微环境中的T细胞浸润。本研究揭示了一种OTUD1调节PD-L1降解的新机制,突出了其在KIRC癌症免疫学中的潜在治疗靶点价值。
Pyroptosis, a lytic and inflammatory form of programmed cell death, provides a promising strategy for antitumor immunotherapy. However, controllable modulation of pyroptosis using phototherapeutic agents remains challenging. In this study, we report a two-stage molecular reprogramming method to rationally design cyanine photosensitizers with tunable pyroptosis-inducing activity. We first reprogram IR808 into a novel photosensitizer T808, by integrating a tetraphenylethylene unit with IR808, which consequently enhances excited - state features related to intersystem crossing (ISC) and reactive oxygen species (ROS) generation capability, accompanied by inducing pyroptosis under irradiation. In the second process, T808 is conjugated with poly(ethylene glycol) (PEG) chains of varying lengths (M.W. 550, 1000, and 2000 Da) to finely modulate the pyroptotic efficacy. The relationship of PEG chain length with pyroptosis-inducing activity is in the order of PT550 > T808 > PT1000 >> PT2000. Cellular and in vivo studies show that T808, PT550, and PT1000 treatments suppress tumor growth and induce pyroptosis with occurrence of immunogenic cell death (ICD). Even under a lower intratumoral injection dose (25 µM), T808 and PT550 therapies exhibit remarkable antitumor efficacy with measurable pyroptosis features. This work provides a new insight into reprogramming cyanine photosensitizers into pyroptosis-active molecules, and proposes possible structural association of PEGylated cyanines with the pyroptosis activity.
中文摘要:细胞死亡是一种裂解性且具炎症性的程序性细胞死亡形式,为抗肿瘤免疫治疗提供了极具前景的策略。然而,利用光疗制剂可控地调节细胞死亡仍面临挑战。本研究报道了一种两阶段分子重编程方法,用于合理设计具有可调细胞死亡诱导活性的菁类光敏剂。首先,通过将四苯乙烯单元与IR808结合,将IR808重编程为新型光敏剂T808,从而增强与系间窜越相关的激发态特征及活性氧生成能力,并在照射下诱导细胞死亡。在第二阶段,将T808与不同分子量(550、1000和2000 Da)的聚乙二醇链偶联,以精细调节细胞死亡疗效。聚乙二醇链长度与细胞死亡诱导活性的关系顺序为PT550大于T808大于PT1000远大于PT2000。细胞及体内研究表明,T808、PT550和PT1000处理可抑制肿瘤生长并诱导细胞死亡伴随免疫原性细胞死亡的发生。即使在较低的瘤内注射剂量(25 µM)下,T808和PT550治疗仍表现出显著的抗肿瘤疗效及可测量的细胞死亡特征。这项工作为将菁类光敏剂重编程为具有细胞死亡活性的分子提供了新见解,并提出了聚乙二醇化菁类与细胞死亡活性之间可能的结构关联。
Peritoneal metastasis (PM) is characterized by an immunosuppressive tumor microenvironment (TME), therapeutic resistance, and poor clinical outcomes. However, the key mediators driving immune suppression in PM remain largely unknown. This study aimed to identify the central regulators of the immunosuppressive TME and evaluate their therapeutic potential. Integrated analyses were performed using single-cell RNA sequencing data from 19 clinical samples together with multiple bulk RNA-seq datasets to characterize the immune landscape of PM. Mechanistic studies were conducted to investigate the role of tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) in macrophage polarization and T-cell function. The therapeutic effects of PCSK9 inhibition, alone or in combination with anti- programmed cell death protein 1 (PD-1) therapy following chemotherapy, were evaluated in preclinical models. In addition, the efficacy of anti-PCSK9 therapy delivered via pressurized intraperitoneal aerosol chemotherapy (PIPAC) was validated in a rabbit model. Integrated transcriptomic analyses identified precursor-like macrophage M2 polarization as a central driver of the immunosuppressive TME in PM. Mechanistically, tumor-derived PCSK9 promoted M2 polarization of precursor-like macrophages through the nuclear factor kappa-B (NF-κB)-interleukin-10 (IL-10) signaling axis, leading to impaired T-cell function. PCSK9 inhibition reversed macrophage polarization and reprogrammed the TME toward an antitumor phenotype by enhancing T-cell activation and recruitment via the Cxcl16-Cxcr6 axis. In our exploratory preclinical experiments, sequential chemotherapy followed by combined anti-PCSK9 and anti-PD-1 therapy demonstrated schedule-dependent therapeutic benefit. Furthermore, anti-PCSK9 therapy delivered through PIPAC showed therapeutic efficacy in a rabbit model. PCSK9 is a key mediator of immune suppression in PM by promoting immunosuppressive macrophage polarization and T-cell dysfunction. Targeting PCSK9 remodels the TME and enhances antitumor immunity, supporting PCSK9 inhibition as a promising therapeutic strategy, particularly in combination with chemotherapy and immune checkpoint blockade for the treatment of PM.
中文摘要:腹膜转移以免疫抑制性肿瘤微环境、治疗抵抗和较差的临床结局为特征。然而,驱动腹膜转移中免疫抑制的关键介质仍 largely unknown。本研究旨在鉴定免疫抑制性肿瘤微环境的核心调节因子并评估其治疗潜力。利用19个临床样本的单细胞RNA测序数据与多个批量RNA-seq数据集进行整合分析,以表征腹膜转移的免疫景观。机制研究探讨了肿瘤来源的前蛋白转化酶枯草溶菌素9型(PCSK9)在巨噬细胞极化和T细胞功能中的作用。在临床前模型中评估了化疗后单独或联合抗程序性死亡蛋白1(PD-1)治疗时抑制PCSK9的治疗效果。此外,通过加压腹膜气溶胶化疗(PIPAC)递送抗PCSK9治疗的疗效在兔模型中得到验证。整合转录组分析鉴定出前体样巨噬细胞M2极化为腹膜转移中免疫抑制性肿瘤微环境的核心驱动因素。机制上,肿瘤来源的PCSK9通过核因子κB(NF-κB)-白细胞介素10(IL-10)信号轴促进前体样巨噬细胞的M2极化,导致T细胞功能受损。PCSK9抑制逆转了巨噬细胞极化,并通过Cxcl16-Cxcr6轴增强T细胞激活和招募,将肿瘤微环境重编程为抗肿瘤表型。在探索性临床前实验中,序贯化疗后联合抗PCSK9和抗PD-1治疗显示出依赖时间安排的疗效。此外,通过PIPAC递送的抗PCSK9治疗在兔模型中显示出治疗效果。PCSK9是通过促进免疫抑制性巨噬细胞极化和T细胞功能障碍来介导腹膜转移中免疫抑制的关键介质。靶向PCSK9重塑肿瘤微环境并增强抗肿瘤免疫力,支持将PCSK9抑制作为一种有前景的治疗策略,特别是在与化疗和免疫检查点阻断联合用于腹膜转移治疗时。
FOXP3-expressing regulatory T cells (Tregs) are a specialized subset of T lymphocytes that are crucial for maintaining immune homeostasis and preventing autoimmunity. However, their pervasive presence and potent immunosuppressive functions within the tumor microenvironment (TME) are a barrier to anti-tumor immunity, presenting a major challenge for cancer immunotherapy. In this review, we discuss strategies for the therapeutic modulation of Tregs. Current and emerging promising technological approaches include antibody-based approaches, small molecule inhibitors, engineered Tregs, microbiome modulation, and Treg survival manipulations. Additionally, existing and promising combinatorial therapies integrate Treg cell targeting with complementary treatment strategies. The goal of this review is to spotlight how Treg-targeted interventions can overcome immune escape and ultimately enhance immunotherapy efficacy to improve clinical outcomes in cancer patients.
中文摘要:表达FOXP3的调节性T细胞(Tregs)是维持免疫稳态和预防自身免疫的关键T淋巴细胞亚群。然而,它们在肿瘤微环境中的广泛存在及其强大的免疫抑制功能构成了抗肿瘤免疫的障碍,给癌症免疫治疗带来了重大挑战。本综述探讨了Tregs的治疗性调控策略。当前及新兴的有前景的技术方法包括基于抗体的方法、小分子抑制剂、工程化Tregs、微生物组调节以及Treg生存操纵。此外,现有的和具有前景的组合疗法将Treg细胞靶向与互补治疗策略相结合。本综述旨在突出显示针对Treg的干预措施如何克服免疫逃逸并最终增强免疫治疗疗效以改善癌症患者的临床结局。
Monitoring therapy-induced molecular changes within subcellular compartments is crucial for understanding cellular stress and providing clues to treatment response. Mitochondrial base excision repair (BER) enzymes have emerged as promising indicators of therapeutic response, yet effective tools for their on-site and dynamic monitoring remain scarce. Here, we report an endogenously gated DNA nanodevice (EGDN) capable of real-time, mitochondria-specific monitoring of flap endonuclease 1 (FEN1), a key BER enzyme, under therapeutic challenge. The EGDN remains silent during transport and is sequentially activated by the mitochondria-encoded ribosomal RNA and FEN1, thus achieving spatial control over FEN1 imaging. This conditional regulation pattern reduces nonspecific signals and sharpens the spatial resolution of FEN1 visualization within mitochondria. We further demonstrate that EGDN dynamically tracks mitochondrial FEN1 fluctuations in tumor cells undergoing chemotherapy or radiation therapy, providing a molecular readout of treatment-associated alterations. Collectively, this work establishes a robust biosensing toolbox for dissecting the BER process at the subcellular level, with broad implications for cancer early diagnosis and targeted therapy.
中文摘要:监测亚细胞区室中治疗诱导的分子变化对于理解细胞应激和提供治疗反应线索至关重要。线粒体碱基切除修复酶已成为有前景的治疗反应指标,但用于原位动态监测的有效工具仍然稀缺。本文报道了一种内源门控DNA纳米器件,能够在治疗挑战下实时、特异性地监测关键碱基切除修复酶 flap endonuclease 1。该器件在运输过程中保持沉默,并依次由线粒体编码的核糖体RNA和flap endonuclease 1激活,从而实现了对flap endonuclease 1成像的空间控制。这种条件性调控模式降低了非特异性信号,提高了线粒体内flap endonuclease 1可视化的空间分辨率。我们进一步证明该器件能够动态追踪接受化疗或放疗的肿瘤细胞中线粒体flap endonuclease 1的波动,提供了与治疗相关改变的分子读数。总体而言,这项工作建立了一个用于在亚细胞水平剖析碱基切除修复过程的稳健生物传感工具箱,对癌症早期诊断和靶向治疗具有广泛意义。
Antibody-drug conjugates (ADCs) have expanded treatment options across multiple malignancies, but their clinical benefit remains constrained by heterogeneous and sometimes serious toxicities. These toxicities rarely arise from a single component; instead, they reflect the association between target biology, molecular architecture, systemic exposure, and tissue susceptibility. We first examine the structural basis of ADC toxicity by discussing the distinct contributions of the antibody-target axis, linker, payload, drug loading, and conjugation strategy to systemic exposure and tissue toxicity. We distinguish organ-selective "on-target, off-tumor" injury from target-independent toxicity and further characterize two major off-target routes: context-dependent uptake of intact ADCs through Fcγ receptor-mediated or pinocytosis-dominant pathways, and spatially distinct exposure to released payload arising from premature systemic release or localized bystander diffusion. Furthermore, we summarize a multidisciplinary management framework, ranging from prophylactic measures to graded interventions across complex scenarios such as treatment rechallenge and combination therapy. Finally, we discuss strategies to widen the therapeutic window through exposure-response-guided dosing, next-generation molecular engineering, and emerging conjugate platforms. Artificial intelligence and computational approaches may further extend safety optimization from drug design to patient stratification and real-world surveillance. By linking molecular design, spatial exposure, and clinical management, this review provides an integrated framework to improve ADC safety while preserving antitumor efficacy.
中文摘要:抗体药物偶联物(ADC)已拓展了多种恶性肿瘤的治疗选择,但其临床获益仍受限于异质性及有时严重的毒性反应。这些毒性极少源于单一成分,而是反映了靶点生物学、分子结构、全身暴露量及组织易感性之间的关联。我们首先通过讨论抗体-靶点轴、连接子、载荷、药物负载及偶联策略对全身暴露量和组织毒性的独特贡献,剖析ADC毒性的结构基础。我们区分了器官选择性的「靶点相关、肿瘤外」损伤与靶点非依赖性毒性,并进一步表征了两条主要的脱靶途径:即通过Fcγ受体介导或胞饮作用主导的途径摄取完整ADC的上下文依赖性摄取,以及因过早全身释放或局部旁观者扩散导致的空间上不同的游离载荷暴露。此外,我们总结了多学科管理框架,涵盖从预防措施到复杂场景(如治疗再挑战及联合疗法)中的分级干预措施。最后,我们讨论了通过暴露-反应指导的给药、下一代分子工程及新兴偶联平台来扩大治疗窗的策略。人工智能和计算方法可能进一步将安全性优化从药物设计延伸至患者分层和真实世界监测。通过将分子设计、空间暴露与临床管理相联系,本综述提供了一个整合框架,旨在改善ADC安全性的同时保留抗肿瘤疗效。
Colorectal cancer liver metastases (CRC-LMs) are associated with poor survival and frequently resist immunotherapy, yet the mechanisms underlying this immune refractoriness remain incompletely defined. Here, we identify a tumor-intrinsic type I interferon (IFN-I)-high state in CRC-LMs associated with loss of the IFN-α/β receptor subunit 1 (IFNAR1) on effector T lymphocytes within immune-enriched perimetastatic niches. Reduced IFNAR1 expression stratifies patients with poor clinical outcomes. Transcriptional profiling of patient-derived organoids and complementary preclinical models revealed heterogeneous but recurrent tumor-derived IFN-I production in CRC-LMs. In IFN-Ihigh contexts, sustained signaling promoted IFNAR1 internalization on effector CD8+ T cells, impairing their persistence, survival, and effector function. Pharmacologic or genetic stabilization of IFNAR1 on cell surface restored CD8+ T cell fitness and selectively enhanced T cell receptor- and chimeric antigen receptor-based immunotherapies in IFN-Ihigh tumors. These findings define a context-dependent IFN-Ihigh / IFNAR1low axis that constrains antitumor immunity in CRC-LMs and identify IFNAR1 stabilization as a strategy to convert chronic IFN signaling from a suppressive barrier into a therapeutic vulnerability.
中文摘要:结直肠癌肝转移(CRC-LMs)与不良生存率相关且常对免疫治疗产生抵抗,但其免疫耐受机制尚未完全明确。本研究在富含免疫细胞的瘤周微环境中发现,CRC-LMs具有肿瘤内在的I型干扰素(IFN-I)高表达状态,并伴随效应T淋巴细胞上IFN-α/β受体亚基1(IFNAR1)的缺失。IFNAR1表达降低的患者临床预后较差。对患者来源类器官及互补临床前模型的转录组分析显示,CRC-LMs中存在异质性但反复出现的肿瘤源性IFN-I产生。在IFN-I高表达背景下,持续信号传导促进效应CD8+ T细胞表面IFNAR1的内吞,损害其持久性、存活率和效应功能。通过药理学或基因工程手段稳定细胞表面的IFNAR1,恢复了CD8+ T细胞的适应性,并在IFN-I高表达的肿瘤中选择性增强了基于T细胞受体和嵌合抗原受体的免疫疗法疗效。这些发现定义了一种限制抗肿瘤免疫的上下文依赖性IFN-I高/IFNAR1低轴,并将IFNAR1稳定化确定为一种将慢性IFN信号从抑制性屏障转化为治疗脆弱点的策略。
2消化系统肿瘤 (31篇)
临床研究 (5篇)
Aflatoxin B1 (AFB1) is a mycotoxin, or fungal toxin, that contaminates maize, peanuts, and tree nuts grown in warm regions of the world. It causes liver cancer and is synergistic with chronic hepatitis B virus (HBV) infection to multiplicatively increase cancer risk. Peanuts (also called groundnuts) are a major source of aflatoxin exposure in many populations worldwide. We conducted a systematic data review to examine the occurrence of AFB1 in peanut food products in 106 nations. We then conducted a dietary exposure assessment based on this occurrence dataset and consumption of peanuts in these nations, to compare trends across the time periods from 1990 to 2024. 22 nations experienced a substantial increase in aflatoxin exposure through peanut consumption, and 22 nations experienced a substantial decrease. Changes in exposure are largely driven by changes in intake levels. Many sub-Saharan African populations have alarmingly high levels of aflatoxin exposure, due to high contamination coupled with high consumption. Detection methods are shown to demonstrate recent improvements in sensitivity. These findings are important given the health risks of high aflatoxin exposure; most notably liver cancer.
中文摘要:黄曲霉毒素B1(AFB1)是一种霉菌毒素,会污染全球温暖地区种植的玉米、花生和坚果。它会导致肝癌,并与慢性乙型肝炎病毒(HBV)感染协同作用,成倍增加癌症风险。花生是全球许多人群黄曲霉毒素暴露的主要来源。我们进行了系统数据回顾,以检查106个国家花生食品中AFB1的发生情况。随后,基于该发生数据集和这些国家的花生消费量,进行了膳食暴露评估,以比较1990年至2024年不同时间段的变化趋势。22个国家通过花生消费经历的黄曲霉毒素暴露显著增加,另有22个国家显著减少。暴露水平的变化主要由摄入量的变化驱动。撒哈拉以南非洲许多人群的黄曲霉毒素暴露水平高得令人担忧,这是由于高污染与高消费量共同作用所致。检测方法的改进显示灵敏度有所提高。鉴于高黄曲霉毒素暴露的健康风险,尤其是肝癌,这些发现具有重要意义。
Despite substantial advances in digital and computational pathology over the past decade, pragmatic and systematic guidance for translating AI models from research into clinical practice remains limited. Most existing frameworks offer only high-level recommendations on validation, regulatory compliance, and implementation, often lacking pathology-specific roadmaps aligned with laboratory standards. This review first summarizes current progress in digitalization and AI in pathology, with emphasis on key applications in biomarker quantification, molecular status prediction, and multimodality integration. We then outline nine major components essential for pathology AI clinical integration, from defining clinical needs through analytical and clinical validation, workflow interoperability, to health economics, and further summarize and compare eight available frameworks. Next, we introduce the AI Development and Optimization in Pathology for Translation (ADOPT) framework, a practical, phased deployment roadmap specifically designed to align with College of American Pathologists and Clinical Laboratory Improvement Amendments (CAP/CLIA) guidelines, to facilitate safe and effective clinical integration of pathology AI tools. We conclude by discussing future perspectives of digital and computational pathology in cancer care, emphasizing widespread clinical adoption of digitized pathology, effective multidisciplinary collaboration, and optimized pathologist-AI synergy to fully realize the promise of pathology AI.
中文摘要:尽管过去十年数字病理和计算病理学取得了显著进展,但将人工智能模型从研究转化为临床实践的实用且系统的指导仍然有限。大多数现有框架仅提供关于验证、监管合规性和实施的高层建议,往往缺乏与实验室标准对齐的病理学特定路线图。本综述首先总结了当前在数字化和人工智能方面的进展,重点介绍生物标志物定量、分子状态预测和多模态整合中的关键应用。随后,我们概述了病理学人工智能临床整合所需的九个主要组成部分,从定义临床需求到分析和临床验证、工作流互操作性,再到卫生经济学,并总结比较了八个现有框架。接下来,我们介绍了用于翻译的病理学人工智能开发与优化(ADOPT)框架,这是一个实用的分阶段部署路线图,专门设计为符合美国病理学家学院和临床实验室改进修正案(CAP/CLIA)指南,以促进病理学人工智能工具的安全有效临床整合。最后,我们讨论了数字和计算病理学在癌症护理中的未来前景,强调广泛采用数字化病理学、有效的多学科合作以及优化的病理学家与人工智能协同作用,以充分实现病理学人工智能的承诺。
Although an increased risk of colorectal cancer (CRC) among patients with ulcerative colitis (UC) is well established, the magnitude and determinants of excess risk remain ambiguous. This uncertainty hampers risk stratification and evidence-based endoscopic surveillance. We empaneled a population-based cohort of incident UC cases in Scandinavia, achieved a median follow-up of 15.0 years through record linkages, designed a case-cohort study, and undertook standardized data abstraction from hospital records of 566 patients with CRC and 720 patients from a sub-cohort randomly sampled at baseline. We fitted weighted multivariable Cox proportional hazard models to estimate hazard ratios (HRs) with 95%CIs, which approximates analyzing the full cohort of 90 780 subjects. We confirmed 2-fold higher CRC risk in patients with pancolitis compared with proctitis (HR 2.3, 95%CI 1.5-3.4). We saw no association between severe macroscopic (HR 1.1, 95%CI 0.7-1.8) or microscopic (HR 1.5, 95%CI 1.0-2.3) inflammation and CRC risk. In contrast, low grade dysplasia predicted a more than 3-fold, and adenomas an almost 10-fold excess rate of CRC (HR 9.8, 95%CI 5.2-18.6). Overall, HRs did not depend on follow-up time (0-1 years, 1-8 years, and >8 years). Pharmacologic treatments with biologic drugs (HR 2.4, 95%CI 0.7-7.7) or immunomodulators (HR 1.1, 95%CI 0.7-1.7) did not significantly reduce the CRC rate. In patients with UC, mucosal abnormalities rather than disease extent and inflammation were the strongest predictive factors of CRC. Our findings do not support prevailing recommendations for endoscopic surveillance.
中文摘要:尽管溃疡性结肠炎患者患结直肠癌的风险增加已得到证实,但超额风险的程度和决定因素仍不明确。这种不确定性阻碍了风险分层和有证据支持的内镜监测。我们组建了一个基于人群的斯堪的纳维亚新发溃疡性结肠炎病例队列,通过记录链接实现了中位随访15.0年,设计了病例对照研究,并从566名结直肠癌患者和基线随机抽样的亚组中的720名患者的医院记录中进行了标准化数据提取。我们拟合了加权多变量Cox比例风险模型以估计风险比及其95%置信区间,这近似于分析包含90780名受试者的完整队列。我们证实,与直肠炎相比,全结肠炎患者的结直肠癌风险高出2倍(风险比2.3,95%置信区间1.5-3.4)。我们发现严重的宏观炎症(风险比1.1,95%置信区间0.7-1.8)或微观炎症(风险比1.5,95%置信区间1.0-2.3)与结直肠癌风险之间没有关联。相比之下,低级别发育不良预测了超过3倍的结直肠癌超额发生率,而腺瘤则预测了近10倍的超额发生率(风险比9.8,95%置信区间5.2-18.6)。总体而言,风险比不依赖于随访时间(0-1年、1-8年和>8年)。使用生物制剂(风险比2.4,95%置信区间0.7-7.7)或免疫调节剂(风险比1.1,95%置信区间0.7-1.7)的药物治疗并未显著降低结直肠癌发生率。在溃疡性结肠炎患者中,黏膜异常而非疾病范围和炎症是结直肠癌最强的预测因素。我们的发现不支持现行的内镜监测推荐意见。
Rolling circle amplification (RCA) is a simple and efficient isothermal enzymatic reaction. However, its linear amplification kinetics and unsatisfactory multiplex detection capability severely limit further improvements in detection sensitivity and application flexibility. In this work, we developed a lambda exonuclease-assisted probe signal amplification strategy termed LEPA, integrated with endonuclease-mediated exponential RCA for the sensitive detection of target nucleic acids. This system enables precise target recognition through ligase and padlock probes, which, in turn, initiate cascaded RCA for efficient signal amplification. Through a cyclic "binding-cleavage-dissociation" process between E-probes and amplification products, the system achieves dual signal amplification and single-nucleotide resolution. The LEPA-RCA system demonstrates exceptional detection sensitivity and specificity, allowing precise discrimination of alleles with a mutation frequency as low as 0.1% and supporting multiplex intracellular RNA detection. In clinical validation, this method effectively distinguished the expression levels of serum miR-16-5p and miR-92a-3p between healthy individuals and colorectal cancer (CRC) patients, showing high consistency with RT-qPCR results. Moreover, it achieved excellent diagnostic performance (AUC = 0.85). With a modular design, the LEPA-RCA system serves as a robust platform for high-precision multiplex nucleic acid detection in complex biological matrices, showing great potential for clinical translation.
中文摘要:滚环扩增(RCA)是一种简单高效的恒温酶促反应。然而,其线性扩增动力学和不理想的多重检测能力严重限制了检测灵敏度和应用灵活性的进一步提升。本研究开发了一种名为LEPA的lambda外切酶辅助探针信号放大策略,并结合内切酶介导的指数型RCA用于靶核酸的灵敏检测。该系统通过连接酶和锁状探针实现精确的靶标识别,进而启动级联RCA以实现高效的信号放大。通过E-探针与扩增产物之间的循环“结合-切割-解离”过程,该系统实现了双重信号放大和单核苷酸分辨率。LEPA-RCA系统展现出卓越的检测灵敏度和特异性,能够以低至0.1%的突变频率精确区分等位基因,并支持细胞内RNA的多重检测。在临床验证中,该方法有效区分了健康个体与结直肠癌(CRC)患者血清中miR-16-5p和miR-92a-3p的表达水平,与RT-qPCR结果具有高度一致性。此外,该方法取得了优异的诊断性能(AUC=0.85)。凭借模块化设计,LEPA-RCA系统作为高精度多重核酸检测的稳健平台,在复杂生物基质中展现出巨大的临床转化潜力。
Circulating tumor DNA (ctDNA) testing can identify molecular residual disease after radical cystectomy for muscle-invasive bladder cancer (MIBC), yet it remains unknown how clinicians have adopted it into practice. We evaluated trends in ctDNA testing and its association with adjuvant therapy. Using the Flatiron Health Research Database, we identified adults with nonmetastatic MIBC diagnosed on or after 1 January 2021, who underwent radical cystectomy and had at least 12 weeks of observable follow-up. The primary exposure was a documented postcystectomy ctDNA result (Signatera), defined by a result report 4-24 weeks after cystectomy. Logistic regression evaluated trends in documented results. Modified Poisson regression estimated adjusted risk ratios (RRs) for adjuvant therapy within 24 weeks among patients whose ctDNA result preceded the treatment decision. Among 4533 patients, the median age was 70 years, 77.4% were male, and 74.6% were White. The odds of a documented ctDNA result increased by 16% per calendar quarter [odds ratio (OR) 1.16, 95% confidence interval (CI) 1.13-1.19]. Patients with high-risk pathology were nearly twice as likely to have a documented result (9.0% versus 5.3%; RR 1.71, 95% CI 1.35-2.17). Patients with a documented result more often received adjuvant therapy than patients without (49.6% versus 33.5%; RR 1.48, 95% CI 1.32-1.66). Among 200 patients whose ctDNA result preceded the treatment decision, detectable ctDNA (n = 59) was associated with greater adjuvant therapy use in unadjusted analysis (45.8% versus 21.3%; RR 2.15, 95% CI 1.41-3.28), but this association was attenuated and no longer significant after adjustment (adjusted RR 1.34, 95% CI 0.89-2.02). High-risk pathology remained strongly associated with treatment (adjusted RR 9.45, 95% CI 3.07-29.10). Postcystectomy ctDNA testing increased rapidly, particularly among patients with high-risk pathology. Pathologic risk remained the factor most strongly associated with adjuvant treatment, whereas the association with detectable ctDNA was attenuated after adjustment, although precision was limited.
中文摘要:循环肿瘤DNA检测可识别肌层浸润性膀胱癌根治性膀胱切除术后存在的分子残留病灶,但其临床实践中的采纳情况尚不明确。本研究评估了ctDNA检测的趋势及其与辅助治疗的关系。利用Flatiron Health研究数据库,我们确定了2021年1月1日及以后诊断的非转移性肌层浸润性膀胱癌成人患者,这些患者接受了根治性膀胱切除术并至少有12周的可见随访时间。主要暴露因素为记录的术后ctDNA结果(Signatera),定义为术后4至24周出具的结果报告。逻辑回归评估了记录结果的趋势。修正泊松回归估计了ctDNA结果先于治疗决策的患者在24周内接受辅助治疗的调整风险比。在4533名患者中,中位年龄为70岁,男性占77.4%,白人占74.6%。每过一个日历季度,记录ctDNA结果的几率增加16%(比值比OR 1.16,95%置信区间CI 1.13-1.19)。高危病理特征患者的结果记录率接近两倍于低危患者(9.0%对5.3%;风险比RR 1.71,95% CI 1.35-2.17)。有记录结果的患者接受辅助治疗的比例高于无记录结果的患者(49.6%对33.5%;RR 1.48,95% CI 1.32-1.66)。在200名ctDNA结果先于治疗决策的患者中,未调整分析显示可检测到的ctDNA与更高的辅助治疗使用率相关(45.8%对21.3%;RR 2.15,95% CI 1.41-3.28),但调整后这种关联减弱且不再显著(调整RR 1.34,95% CI 0.89-2.02)。高危病理特征仍与治疗强烈相关(调整RR 9.45,95% CI 3.07-29.10)。术后ctDNA检测迅速增加,特别是在高危病理特征患者中。病理风险仍是与辅助治疗最密切相关的因素,而可检测ctDNA的关联在调整后减弱,尽管精确度有限。
基础研究 (26篇)
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, highlighting the need for strategies that selectively deliver cytotoxic agents to tumor cells. Trophoblast cell-surface antigen 2 (TROP2) has been proposed as a candidate therapeutic target in PDAC, but non-antibody-based delivery formats remain underexplored. Using protein-SELEX, we identified T17, a high-affinity aptamer that specifically binds to TROP2, and conjugated it to monomethyl auristatin E through an MC-Val-Cit-PAB linker to generate the aptamer-drug conjugate T17-M. Preclinical evaluation in cellular and animal models showed that T17-M retained TROP2-dependent binding, underwent clathrin-mediated internalization and lysosomal processing, and suppressed tumor growth in cell-line-derived and patient-derived xenografts. T17-M also reduced liver metastasis and induced calreticulin exposure, ATP release, and HMGB1 secretion, consistent with immunogenic cell death. In immunocompetent models, T17-M promoted dendritic-cell activation and CD8+ T cell infiltration, while its combination with PD-1 blockade further enhanced tumor control and prolonged survival. These findings provide preclinical proof-of-concept for T17-M as an alternative TROP2-targeted drug-delivery strategy for PDAC.
中文摘要:胰腺导管腺癌治疗困难,亟需能将细胞毒性药物选择性递送至肿瘤细胞的策略。滋养层细胞表面抗原2被提出作为胰腺导管腺癌的潜在治疗靶点,但非抗体类递送格式的研究仍不充分。本研究通过蛋白质SELEX技术筛选出高亲和力且特异性结合TROP2的适配体T17,并通过MC-Val-Cit-PAB连接臂将其与单甲基澳瑞他汀E偶联,生成适配体药物偶联物T17-M。在细胞和动物模型中的临床前评估显示,T17-M保留了依赖TROP2的结合能力,经历网格蛋白介导的内吞作用和溶酶体加工,并在细胞系来源及患者来源异种移植模型中抑制肿瘤生长。T17-M还减少肝转移并诱导钙网蛋白暴露、ATP释放和HMGB1分泌,符合免疫原性细胞死亡特征。在免疫健全模型中,T17-M促进树突状细胞活化和CD8+ T细胞浸润,其与PD-1阻断联合使用进一步增强了肿瘤控制效果并延长生存期。这些发现为T17-M作为胰腺导管腺癌替代的TROP2靶向药物递送策略提供了临床前概念验证。
Perineural invasion (PNI) is a prominent feature of pancreatic cancer (PDAC) and is closely associated with tumor progression and poor prognosis. However, its spatial cellular architecture and underlying mechanisms remain incompletely understood. Here, we applied high-resolution spatial transcriptomics to construct a comprehensive atlas of the PNI microenvironment across distinct anatomical regions of intra and extra-pancreas. We observed that the Basal-like tumor subtype exhibited a higher propensity for PNI compared with the Classical subtype, a finding further supported by multiplex imaging on whole-mount histopathology. Comparative spatial analysis revealed distinct immune and stromal organization between tumor subtypes, with enrichment of M2-like macrophage potentially promoting epithelial cell migration in the vicinity of Basal-like tumors. In addition, we identified myofibroblast subset may promote Schwann cell activation and PNI-associated nerve injury was further accompanied by a shift toward inflammatory fibroblast polarization and features of CD8+ T cell exhaustion within the local microenvironment. Finally, spatial profiling indicated functional heterogeneity among tumor-associated Schwann cells, which may contribute to the tumor progression. Collectively, this study provides a spatially resolved view of the cellular and molecular landscape of PNI in PDAC and offers insights into Basal-specific neurotropic behavior and microenvironmental reorganization.
中文摘要:神经周围侵犯(PNI)是胰腺导管腺癌(PDAC)的显著特征,与肿瘤进展和不良预后密切相关。然而,其空间细胞架构及潜在机制尚不完全清楚。本研究应用高分辨率空间转录组学技术,构建了涵盖胰内和胰外不同解剖区域的PNI微环境综合图谱。我们观察到,相较于经典亚型,基底样肿瘤亚型表现出更高的PNI倾向,这一发现在全切片组织病理学的多重成像中得到了进一步支持。比较空间分析揭示了不同肿瘤亚型间存在差异的免疫和基质组织结构,其中M2样巨噬细胞的富集可能促进基底样肿瘤邻近区域的上皮细胞迁移。此外,我们鉴定出肌成纤维细胞亚群可能促进施万细胞活化,而PNI相关的神经损伤进一步伴随着向炎症性成纤维细胞极化的转变以及局部微环境中CD8+ T细胞耗竭特征的出现。最后,空间谱系分析表明肿瘤相关施万细胞存在功能异质性,这可能有助于肿瘤进展。综上所述,本研究提供了PDAC中PNI细胞和分子景观的空间分辨率视图,并为基底特异性神经趋向性行为及微环境重组提供了见解。
Colorectal cancer (CRC) is a highly heterogeneous malignancy. Although surgery-based multimodal therapy provides durable benefits for a subset of patients with localized disease, a considerable proportion of patients still experience recurrence or progression post-treatment. Delineating the molecular mechanisms underlying CRC progression and chemoresistance is imperative for identifying therapeutic targets and thereby improving treatment outcomes. Using single-cell RNA sequencing (scRNA-seq), we identified C-C motif chemokine ligand 7 (CCL7) as a key mediator of intercellular communication between tumor-associated macrophages (TAMs) and CRC cells within the tumor microenvironment (TME). TAMs express and secrete high levels of CCL7, which reprograms lipid metabolism in CRC cells, induces the accumulation of lipid droplets (LDs), and markedly promotes CRC cell proliferation and chemoresistance. Elevated CCL7 expression is associated with poor prognosis in patients with CRC. Bulk RNA-seq revealed that CCL7 markedly upregulates the expression of the transcription factor BATF3. Integrating CUT&Tag profiling, HOMER de novo/known motif enrichment analysis, FIMO prediction, co-immunoprecipitation (Co-IP), and dual-luciferase reporter assays, we demonstrated that BATF3 interacts with JunD to synergistically activate the USP22 promoter, thereby upregulating USP22 expression. Furthermore, USP22 deubiquitinates and stabilizes DGAT2, thereby promoting LD accumulation and lipid metabolic reprogramming, which accelerates malignant progression and acquired chemoresistance in CRC. By dissecting the intricate crosstalk within the CRC microenvironment, we elucidated the molecular cascade through which the CCL7-dependent BATF3/USP22/DGAT2 axis drives tumor progression and chemoresistance. Targeting this axis may block lipid metabolic reprogramming and thereby curb these malignant phenotypes, highlighting a promising therapeutic strategy for CRC.
中文摘要:结直肠癌(CRC)是一种高度异质性的恶性肿瘤。尽管基于手术的 multimodal therapy 能为部分局部病变患者带来持久的获益,但相当比例的患者在治疗后仍会出现复发或进展。阐明 CRC 进展和化疗耐药背后的分子机制对于识别治疗靶点并改善治疗结果至关重要。利用单细胞 RNA 测序(scRNA-seq),我们鉴定出 C-C 基序趋化因子配体 7(CCL7)是肿瘤微环境(TME)中肿瘤相关巨噬细胞(TAMs)与 CRC 细胞之间细胞间通讯的关键介质。TAMs 表达并分泌高水平的 CCL7,后者重编程了 CRC 细胞的脂质代谢,诱导脂滴(LDs)积累,并显著促进 CRC 细胞增殖和化疗耐药。CCL7 表达升高与 CRC 患者的不良预后相关。批量 RNA-seq 显示 CCL7 显著上调转录因子 BATF3 的表达。整合 CUT&Tag 分析、HOMER de novo/已知基序富集分析、FIMO 预测、免疫共沉淀(Co-IP)和双荧光素酶报告基因实验,我们证明 BATF3 与 JunD 相互作用协同激活 USP22 启动子,从而上调 USP22 表达。此外,USP22 去泛素化并稳定 DGAT2,从而促进 LD 积累和脂质代谢重编程,加速 CRC 的恶性进展和获得性化疗耐药。通过剖析 CRC 微环境内复杂的串扰,我们阐明了 CCL7 依赖性的 BATF3/USP22/DGAT2 轴驱动肿瘤进展和化疗耐药的分子级联反应。靶向该轴可能阻断脂质代谢重编程从而遏制这些恶性表型,突显了 CRC 的一种有前景的治疗策略。
Immunoglobulin A (IgA) is the most abundant antibody isotype produced by mammals, and has a specialized role in mucosal homeostasis1. IgA is constantly secreted into the intestinal lumen and binds to commensal microorganisms to regulate their colonization and function2,3, with unclear implications for health. IgA deficiency is common in humans, but difficult to study, because of its complex aetiology and comorbidities4-8. Here we use genetically and environmentally controlled mice to show that various models of IgA deficiency result in increased susceptibility to several models of endogenous colorectal cancer. Cellular and molecular analyses revealed that, in the absence of IgA, colonic epithelial cells induce antibacterial factors and accelerate cell cycling in response to the microbiota. Oral treatment with IgA was sufficient to reduce steady-state proliferation and protect mice from tumours; however, this function was due to the structure of the antibody rather than to binding specificity. In a reductionist culture system, IgA directly suppressed epithelial growth. Co-immunoprecipitation mass spectrometry and targeted CRISPR screening identified DMBT1 as an IgA-binding epithelial surface protein that is required for IgA-mediated suppression of proliferation. Together, IgA and DMBT1 tune the normal cycling of absorptive colonocyte progenitors. In IgA-knockout mice, deleting the transmembrane and cytoplasmic signalling portions of DMBT1 was sufficient to reverse both the increased epithelial cell proliferation and the increased tumour susceptibility seen in these mice. These experiments establish a homeostatic function for IgA in tempering physiological epithelial responses to the microbiota to maintain mucosal health.
中文摘要:免疫球蛋白A(IgA)是哺乳动物产生的最丰富的抗体同种型,在黏膜稳态中发挥特殊作用。IgA不断分泌至肠腔并与共生微生物结合以调节其定植和功能,其对健康的影响尚不明确。人类IgA缺乏症很常见,但由于病因复杂且伴有合并症,难以研究。本研究利用基因和环境受控的小鼠模型,表明多种IgA缺乏模型会导致对几种内源性结直肠癌模型的易感性增加。细胞和分子分析显示,在缺乏IgA的情况下,结肠上皮细胞会诱导抗菌因子并加速细胞周期以应对微生物群。口服IgA足以降低稳态增殖并保护小鼠免受肿瘤侵害;然而,这一功能归因于抗体的结构而非结合特异性。在简化培养系统中,IgA直接抑制上皮生长。免疫共沉淀质谱分析和靶向CRISPR筛选鉴定出DMBT1为一种IgA结合的上皮表面蛋白,该蛋白是IgA介导的增殖抑制所必需的。综上所述,IgA和DMBT1共同调节吸收性结肠细胞干细胞的正常周期。在IgA敲除小鼠中,删除DMBT1的跨膜和胞质信号部分足以逆转这些小鼠中观察到的上皮细胞增殖增加和肿瘤易感性增加。这些实验确立了IgA在调节生理性上皮对微生物群反应以维持黏膜健康方面的稳态功能。
Computed tomography (CT) stages pancreatic ductal adenocarcinoma (PDAC) but does not read out the treatment-guiding tumour biology, requiring biopsy. Whether an imaging-biology relationship discovered in preclinical MRI holds independently in human CT is unknown. One pipeline was applied to two PDAC cohorts: longitudinal 9.4 T multi-parametric MRI (169 sessions; 1002 image series, 471 quantitative maps) with terminal histopathology in male C57BL/6 mice bearing orthotopic KPC-derived tumours treated with gemcitabine, a dendritic-cell vaccine, both, or neither, and abdominal CT with matched proteogenomics from CPTAC-PDA. Radiomics and frozen foundation-model embeddings were modelled under grouped cross-validation against five pre-specified paired endpoints, with no cross-species transfer of features, weights, or labels. Applied independently, the pipeline recovered four matched molecular endpoints in both species (CD8 infiltration, stromal collagen, CD8:CD68 immune balance, cytolytic activity), with areas under the receiver-operating-characteristic curve (AUROCs) of 0.938-0.960 in mice and 0.780-0.856 in humans. Survival concordance indices were 0.729 and 0.689. After adjustment for age, stage, and grade, the human imaging score remained independently prognostic (hazard ratio 1.87 per SD, 95% CI 1.32 to 2.66; p < 0.001 [Wald test]; combined concordance index 0.726 versus 0.611 for clinical covariates). Findings held in portal-venous-restricted analysis; frozen embeddings outperformed end-to-end fine-tuning in both arms. One pipeline recovered matched PDAC biology in mouse MRI and human CT, supporting preclinical imaging to nominate non-invasive CT biomarker candidates for biopsy-sparing PDAC trial stratification, pending prospective external validation. National Cancer Institute; Society of Interventional Radiology Foundation; University of California Irvine Anticancer Challenge Pilot grant.
中文摘要:计算机断层扫描(CT)用于分期胰腺导管腺癌(PDAC),但无法读取指导治疗肿瘤生物学特征,因此需要活检。在临床前MRI中发现的影像-生物学关系是否在人类CT中独立成立尚不清楚。本研究将同一分析流程应用于两个PDAC队列:一组为携带原位KPC衍生肿瘤的雄性C57BL/6小鼠,接受吉西他滨、树突状细胞疫苗、两者联合或无治疗,并进行纵向9.4T多参数MRI扫描(169个会话;1002个图像序列,471个定量图谱),最终进行组织病理学检查;另一组为来自CPTAC-PDA的腹部CT及匹配的多组学数据。在分组交叉验证下,对五个预先指定的配对终点分别建模,未进行跨物种的特征、权重或标签转移。独立应用该流程后,在两种物种中均恢复了四个匹配的分子终点(CD8浸润、间质胶原、CD8:CD68免疫平衡、细胞毒性活性),小鼠的受试者工作特征曲线下面积(AUROCs)为0.938-0.960,人类为0.780-0.856。生存一致性指数分别为0.729和0.689。在调整年龄、分期和分级后,人类影像评分仍具有独立的预后价值(每标准差风险比1.87,95%置信区间1.32至2.66;P < 0.001 [Wald检验];综合一致性指数0.726,优于临床协变量的0.611)。在门静脉期限制分析中结果依然成立;冻结嵌入模型在两个队列中均优于端到端微调。该流程在小鼠MRI和人类CT中恢复了匹配的PDAC生物学特征,支持利用临床前影像筛选非侵入性CT生物标志物候选者,用于避免活检的PDAC试验分层,但需前瞻性外部验证确认。
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy for which neoadjuvant chemotherapy with albumin-bound paclitaxel combined with gemcitabine (AG) is a standard first-line approach for borderline resectable and locally advanced disease. However, secondary resistance to this regimen is common, and its underlying mechanisms remain poorly defined. In this study, we investigated how neoadjuvant AG therapy shapes the tumor stroma in PDAC. Single-cell transcriptomics of patient tumors revealed that AG treatment induces a phenotypic switch of cancer-associated fibroblasts (CAFs) from myofibroblastic (myCAF) to inflammatory (iCAF) states and identified a previously unrecognized TMEM100+CAF subset enriched in nonresponders. Mechanistic studies showed that albumin-bound paclitaxel activates IL-2-STAT5 signaling to drive TMEM100 expression and that TMEM100+CAFs promote chemoresistance through paracrine secretion of amphiregulin (AREG) and activation of tumor EGFR signaling. Genetic ablation of TMEM100+CAFs in mouse models reversed CAF switching and enhanced the antitumor efficacy of AG therapy. These findings map chemotherapy-induced CAF plasticity, reveal a TMEM100-AREG axis of resistance, and highlight TMEM100+CAFs as a promising target to sensitize PDAC to neoadjuvant treatment.
中文摘要:胰腺导管腺癌是一种致死率极高的恶性肿瘤,对于交界可切除和局部晚期疾病,白蛋白结合型紫杉醇联合吉西他滨(AG)是新辅助化疗的标准一线方案。然而,对该方案的继发性耐药很常见,其潜在机制尚不明确。本研究探讨了新辅助 AG 治疗如何塑造胰腺导管腺癌中的肿瘤基质。患者肿瘤的单细胞转录组学分析显示,AG 治疗诱导癌症相关成纤维细胞从肌成纤维细胞状态向炎症状态发生表型转换,并鉴定出一个在无应答者中富集的先前未被认识的 TMEM100+CAF 亚群。机制研究表明,白蛋白结合型紫杉醇通过激活 IL-2-STAT5 信号通路驱动 TMEM100 的表达,而 TMEM100+CAF 通过旁分泌分泌双调蛋白并激活肿瘤 EGFR 信号通路促进化疗耐药。在小鼠模型中基因敲除 TMEM100+CAF 逆转了 CAF 的转换并增强了 AG 治疗的抗肿瘤疗效。这些发现描绘了化疗诱导的 CAF 可塑性,揭示了 TMEM100-双调蛋白轴的耐药机制,并突显了 TMEM100+CAF 作为增敏胰腺导管腺癌新辅助治疗的潜在靶点价值。
Tumor-resident bacteria establish a profound immunosuppressive microenvironment that compromises cancer immunotherapy. While ablating these microbes holds therapeutic promise, broad-spectrum antibiotics can cause systemic dysbiosis, and the Gram-negative outer membrane can restrict the entry of conventional sonosensitizers, limiting the antibacterial efficacy of sonodynamic therapy (SDT). Here, we report an ultrasound-driven, bacteria-targeted immunotherapy utilizing polyarginine-functionalized peptide-sonosensitizer conjugates to achieve the in situ pulverization of the tumor Fusobacterium nucleatum (F. nucleatum), thereby eliciting potent innate antitumor immunity. The cationic conjugates electrostatically intercalate into Gram-negative bacterial membranes, inflicting a structural predisruption. Subsequent ultrasound irradiation synergizes localized sonochemical oxidation with mechanical shear forces to thoroughly shatter the bacteria. This targeted microbial fragmentation liberates massive quantities of pathogen-associated molecular patterns (PAMPs) that, unlike tumor-derived signals from conventional SDT, decisively reprogram macrophages toward an antitumor M1 phenotype to awaken innate immunity. Synchronized with tumor-specific antigens released via conjugate-induced immunogenic cell death, the liberated PAMPs synergistically amplify antigen presentation and optimally drive dendritic cell maturation. In a bacteria-colonized murine colorectal cancer model, this localized therapy markedly suppressed primary tumor growth and elicited both a pronounced abscopal effect against distant tumors and antitumor immune memory. By repurposing complicit bacteria into potent endogenous adjuvants, this ultrasound-driven strategy reverses bacteria-mediated immunosuppression, offering a transformative paradigm for treating microbiome-colonized solid tumors.
中文摘要:肿瘤驻留细菌建立了一个深刻的免疫抑制微环境,损害了癌症免疫治疗。虽然消除这些微生物具有治疗前景,但广谱抗生素会导致全身菌群失调,且革兰氏阴性菌的外膜会限制常规声敏剂的进入,从而限制了声动力疗法(SDT)的抗菌功效。在此,我们报告了一种超声驱动、靶向细菌的免疫治疗方法,利用精氨酸功能化的肽-声敏剂偶联物实现肿瘤内具核梭杆菌(F. nucleatum)的原位粉碎,从而引发强大的先天抗肿瘤免疫。阳离子偶联物通过静电作用插入革兰氏阴性菌膜,造成结构破坏。随后的超声照射将局部声化学氧化与机械剪切力协同作用,彻底粉碎细菌。这种靶向微生物碎片化释放了大量病原体相关分子模式(PAMPs),与传统SDT产生的肿瘤来源信号不同,这些PAMPs决定性地将巨噬细胞重编程为抗肿瘤M1表型以唤醒先天免疫。与偶联物诱导的免疫原性细胞死亡释放的肿瘤特异性抗原同步,释放的PAMPs协同增强抗原呈递并最佳地驱动树突状细胞成熟。在细菌定型的鼠结直肠癌模型中,这种局部治疗显著抑制了原发肿瘤的生长,并引发了针对远处肿瘤的明显远隔效应和抗肿瘤免疫记忆。通过将共谋细菌重新利用为强效的内源性佐剂,这种超声驱动策略逆转了细菌介导的免疫抑制,为治疗微生物群定型的实体瘤提供了一种变革性的范式。
Adenosquamous carcinoma (ASC) in intrahepatic cholangiocarcinoma (iCCA) has long been considered rare (~1-2%), yet its occurrence portends lethal disease progression. Here, we identify latent squamous plasticity, a transcriptionally primed yet histology-silent state that is quantifiable by a squamous transition potential (STP) index. Approximately 20-30% of iCCA patients can be classified as STP-high and experience ASC-like dismal outcomes. Mechanistically, FOSL1 acts as a plasticity trigger, driving a temporally ordered squamous program by reshaping the chromatin landscape. Additionally, it cooperates with p63 in an enhancer-dependent manner to dysregulate PTGS2/COX-2 expression. The resulting intratumoral PGE2 accumulation drives neutrophil-mediated FOXP3-negative type 1 regulatory T-cell (Tr1) polarization and predisposes STP-high tumors to immunotherapy resistance. Through a drug-repurposing screen, we identify celecoxib as a dual-function agent that counteracts latent squamous plasticity while fostering an immune-permissive state, providing a clinically actionable strategy for squamous-biased iCCA now being evaluated in a phase Ib/II trial (NCT07632235).
中文摘要:肝内胆管癌中的腺鳞癌长期被认为罕见约占1至2但其发生预示着致命的疾病进展。我们识别出一种潜在的鳞状可塑性这是一种转录预激活但组织学沉默的状态可通过鳞状转换潜力指数进行量化。约20至30的肝内胆管癌患者被归类为高鳞状转换潜力群体并经历类似腺鳞癌的恶劣预后。在机制上FOSL1作为可塑性触发因子通过重塑染色质景观驱动时间有序的鳞状程序。此外它以增强子依赖的方式与p63协同作用导致PTGS2COX-2表达失调。由此产生的肿瘤内前列腺素E2积累驱动中性粒细胞介导的FOXP3阴性1型调节性T细胞极化并使高鳞状转换潜力肿瘤易受免疫治疗耐药的影响。通过药物重定位筛选我们确定塞来昔布为一种双重功能制剂既能对抗潜在的鳞状可塑性又能促进免疫许可状态为正在进行的IbII期临床试验NCT07632235中评估的鳞状偏向性肝内胆管癌提供了临床可操作的策略。
Bacteria are increasingly recognized as contributors to cancer, yet the underlying mechanisms remain unclear for most species. Here, we find that Gemella morbillorum (Gm) is enriched in feces and tumor tissues from patients with colorectal cancer (CRC) and reveal a multi-step host-pathogen mechanism that promotes colorectal tumorigenesis. In mouse models of CRC, Gm suppresses IL-22 production by type 3 innate lymphoid cells (ILC3s), impairing intestinal barrier function and facilitating bacterial translocation to early neoplastic lesions. At the tumor site, Gm utilizes an ANXA2-dependent, clathrin-mediated pathway to invade CRC cells. Gm induces profound lipid remodeling, characterized by the accumulation of oxidation-prone fatty acids and enhanced lipid peroxidation, which contributes to invasion-dependent DNA damage. Inhibition of lipid peroxidation attenuates Gm-induced DNA damage, functionally linking lipid oxidative stress to genotoxicity. Together, these findings identify Gm as a candidate onco-pathogen in CRC that uses multiple mechanisms to disarm the intestinal barrier and trigger genotoxicity.
中文摘要:细菌日益被认为是癌症的诱因,但大多数菌种的作用机制尚不明确。本研究发现在结直肠癌患者的粪便和肿瘤组织中富集了咽峡炎链球菌(Gm),并揭示了一种促进结直肠肿瘤发生的多步骤宿主病原体相互作用机制。在结直肠癌小鼠模型中,Gm抑制第三型先天淋巴细胞产生的IL-22,损害肠道屏障功能并促进细菌向早期病变灶转移。在肿瘤部位,Gm通过依赖ANXA2的网格蛋白介导途径侵入结直肠癌细胞。Gm诱导显著的脂质重塑,表现为易氧化脂肪酸积累和脂质过氧化增强,从而导致依赖侵袭的DNA损伤。抑制脂质过氧化可减弱Gm诱导的DNA损伤,从功能上将脂质氧化应激与基因毒性联系起来。综上所述,这些发现将Gm确定为结直肠癌中的一种候选致癌病原体,其通过多种机制削弱肠道屏障并引发基因毒性。
Truncating mutations in the adenomatous polyposis coli (APC) gene-a key driver of colorectal cancer (CRC) initiation-frequently lead to the production of a truncated APC protein (Trunc-APC). However, its post-transcriptional roles and oncogenic potential remain largely unexplored. Here, we demonstrate that Trunc-APC functions as an RNA-binding protein, directly associating with pre-mRNA via its N-terminal 1-169 amino acid region to regulate widespread alternative splicing (AS) in CRC cells. Specifically, Trunc-APC promotes exon inclusion in ARHGEF11, producing an oncogenic isoform that is associated with enhanced Bcl-xL/BAX complex formation and reduced apoptosis. Mechanistically, Trunc-APC interacts with the RNA helicase DDX21 and facilitates SF3B complex recruitment to pre-mRNA, thereby modulating splicing patterns. Notably, treatment with the splicing inhibitor Madrasin significantly reduced tumor burden in ApcMin/+ CRC mice, indicating strong antitumor efficacy. Collectively, these findings establish Trunc-APC as a novel regulator of alternative splicing and a promoter of CRC progression, and highlight the therapeutic potential of targeting the Trunc-APC/DDX21/SF3B axis in CRC.
中文摘要:腺瘤性结肠息肉病(APC)基因的截断突变作为结直肠癌(CRC)发生的关键驱动因素,常导致产生截短的APC蛋白(Trunc-APC)。然而其转录后作用及致癌潜力尚不明确。本研究证实Trunc-APC具有RNA结合蛋白功能,通过N端1至169氨基酸区域直接与前体mRNA结合,调控CRC细胞中的广泛可变剪接。具体而言,Trunc-APC促进ARHGEF11的外显子包含,产生一种致癌亚型,该亚型与增强的Bcl-xL/BAX复合物形成及凋亡减少相关。机制上,Trunc-APC与RNA解旋酶DDX21相互作用,促进SF3B复合物招募至前体mRNA,从而调节剪接模式。值得注意的是,使用剪接抑制剂Madrasin显著降低了ApcMin/+ CRC小鼠的肿瘤负荷,显示出强大的抗肿瘤功效。综上所述,这些发现确立了Trunc-APC作为可变剪接的新型调控因子及CRC进展促进者的地位,并突出了靶向Trunc-APC/DDX21/SF3B轴在CRC治疗中的潜力。
Excess cholesterol accumulates in colorectal cancer (CRC) and promotes its progression, yet systemic cholesterol-lowering has limited benefits and safety concerns. Here we show that redirecting intestinal cholesterol metabolism through the gut microbiota generates a metabolite, 4-cholesten-3-one (4-C-3), which suppresses CRC growth. A screen of microbial cholesterol metabolites showed that 4-C-3 is depleted in faecal and tumour samples from patients with CRC. 4-C-3 suppresses tumour growth in CRC cell lines, patient-derived organoids and xenografts. Mechanistically, 4-C-3 suppresses two major oncogenic drivers of CRC by inhibiting epidermal growth-factor receptor activation and stabilizing mutant oncogenic KRAS in an inactive state, thereby overcoming KRAS-driven resistance to anti-epidermal growth-factor receptor therapy. As proof of concept, restoring 4-C-3 using either Oscillibacter ruminantium, a natural 4-C-3 producer reduced in CRC, or a non-pathogenic Escherichia coli engineered to convert intestinal cholesterol into 4-C-3, lowered intratumoral cholesterol and induced tumour regression in preclinical models without overt toxicity. These findings uncover a microbiota-cholesterol metabolic pathway that can be harnessed through microbiome engineering to selectively target CRC and overcome therapy resistance.
中文摘要:过量胆固醇在结直肠癌(CRC)中积累并促进其进展,但系统性降胆固醇疗法获益有限且存在安全隐患。本研究显示,通过肠道微生物群重定向肠道胆固醇代谢可生成一种名为4-胆甾烯-3-酮(4-C-3)的代谢物,从而抑制CRC生长。对微生物胆固醇代谢产物的筛选表明,CRC患者的粪便和肿瘤样本中4-C-3含量耗竭。在CRC细胞系、患者来源类器官及异种移植模型中,4-C-3均能抑制肿瘤生长。机制上,4-C-3通过抑制表皮生长因子受体(EGFR)激活并稳定突变型致癌KRAS于非活性状态,从而抑制CRC的两大主要致癌驱动因素,进而克服KRAS驱动的抗EGFR治疗耐药性。作为概念验证,利用在CRC中减少的天然4-C-3产生菌瘤胃振荡菌或经工程改造将肠道胆固醇转化为4-C-3的非致病性大肠杆菌恢复4-C-3水平,可在无显著毒性的前提下降低肿瘤内胆固醇含量并诱导临床前模型中的肿瘤消退。这些发现揭示了一条可通过微生物组工程加以利用的微生物群-胆固醇代谢通路,以选择性靶向CRC并克服治疗耐药性。
Multi-phase contrast-enhanced CT (CECT) plays a crucial role in liver tumor diagnosis but is limited by additional radiation exposure and a restricted patient population. While virtual contrast enhancement (VCE) methods can generate virtual liver CECT images, challenges persist due to detail-deficient non-contrast CT (NCCT) images and phase-wise feature variations. In this paper, we propose phase-aware diffusion (PA-Diff), a novel model for multi-phase liver CT enhancement and contrast-agent-free liver tumor diagnosis, which combines two novel designs: 1) Phase-specific path allocation that enables precise multi-phase enhancement by combining independent diffusion paths and shared encoder and decoder; 2) Cycle re-encoding learning that enhances tumor detail by recovering target images and re-encoding them into complementary features for loss calculation during training. We also perform automatic diagnosis on the VCE CT images. Experiments on two dataset demonstrate effective multi-phase enhancement and accurate Hepatocellular Carcinoma (HCC) screening and Microvascular Invasion (MVI) diagnosis, highlighting the model's clinical value.
中文摘要:多期增强CT在肝肿瘤诊断中至关重要,但受限于额外的辐射暴露和受限的患者群体。虚拟对比增强方法虽能生成虚拟肝脏增强CT图像,但因细节缺失的非增强CT图像及分期特征差异仍面临挑战。本文提出了一种名为PA-Diff的新型模型,用于多期肝脏CT增强和无对比剂肝肿瘤诊断,该模型结合了两种新颖设计:一是分期路径分配,通过结合独立的扩散路径与共享的编码器和解码器实现精确的多期增强;二是循环重编码学习,通过在训练过程中恢复目标图像并将其重新编码为互补特征以计算损失,从而增强肿瘤细节。我们还在虚拟对比CT图像上进行了自动诊断。在两个数据集上的实验证明了有效的多期增强以及准确的肝细胞癌筛查和微血管侵犯诊断,突显了该模型的临床价值。
Redox-responsive prodrug nanodelivery systems hold immense promise in cancer therapy, offering advantages of improved pharmacokinetics, enhanced tumor selectivity, and increased safety. However, compared with standard therapeutic formulations, prodrug nanodelivery systems fail to yield superior antitumor efficacy at equivalent doses, attributable to inadequate drug activation and intratumoral accumulation. Herein, the three-in-one drug-release module, comprising an α-disulfide bond, an ethylene glycol moiety, and a short carbon chain, was covalently linked to paclitaxel (PTX) to construct three prodrug nanoassemblies (PSBA10 NPs, PSBA12 NPs, PSBA14 NPs). Notably, PSBA10 NPs, which possessed the shortest carbon chain, exhibited hypersensitive redox-responsive drug release and potentiated antitumor efficacy. Although PSBA10 NPs exhibited better safety than paclitaxel solution (Taxol) at equivalent doses, superior efficacy remained unattainable. Interestingly, a temporal-dose-regulated glutathione (GSH) gradient across the liver-blood-tumor axis increased the intratumoral accumulation of PSBA10 NPs by approximately 3-fold, resulting in pronounced antitumor efficacy superior to Taxol. This transient depletion of GSH in the liver and blood reduced the cleavage of disulfide bonds in the systemic circulation, enhancing tumor accumulation and selective activation of PSBA10 NPs. Our study highlighted a tumor treatment model based on the synergistic strategy of structural optimization and GSH gradient regulation across the liver-blood-tumor axis to boost the efficacy of chemotherapy.
中文摘要:氧化还原响应型前药纳米递送系统在癌症治疗中展现出巨大潜力,具有改善药代动力学、增强肿瘤选择性和提高安全性等优势。然而,与标准治疗制剂相比,在同等剂量下前药纳米递送系统未能产生更优的抗肿瘤疗效,这归因于药物激活不足和肿瘤内蓄积量低。本研究构建了一种三合一药物释放模块,包含α-二硫键、乙二醇部分和短碳链,并将其共价连接到紫杉醇(PTX)上,构建了三种前药纳米组装体(PSBA10 NPs、PSBA12 NPs、PSBA14 NPs)。值得注意的是,具有最短碳链的PSBA10 NPs表现出超敏感的氧化还原响应药物释放并增强了抗肿瘤疗效。尽管在同等剂量下PSBA10 NPs比紫杉醇溶液(Taxol)具有更好的安全性,但仍未能达到更优的疗效。有趣的是,通过时间剂量调节肝脏-血液-肿瘤轴上的谷胱甘肽(GSH)梯度,使PSBA10 NPs在肿瘤内的蓄积量增加了约3倍,从而产生了优于Taxol的显著抗肿瘤疗效。这种肝脏和血液中GSH的瞬时耗竭减少了全身循环中二硫键的裂解,增强了PSBA10 NPs的肿瘤蓄积和选择性激活。本研究强调了一种基于结构优化和肝脏-血液-肿瘤轴上GSH梯度调节协同策略的肿瘤治疗模型,以提高化疗疗效。
Existing treatment options for colorectal and pancreatic cancers harboring mutant p53 (p53mut) are largely ineffective and lack selectivity. Our novel therapeutic strategy for p53mut cancers with a thymidine analogue (TAS102) and a PARP inhibitor (PARPi) showed promising efficacy in a clinical trial, although the mechanisms remain not fully understood. Here, we investigated the molecular mechanisms underlying therapeutic efficacy of our approach and explored new combinations to further enhance the response. To define the contribution of each drug into the therapeutic response, we conducted an unbiased transcriptomic analysis in p53-proficient and p53mut cancer models. The biological effects were investigated in comprehensive analyses of cell proliferation, cell death, and DNA damage. The drug interactions were explored in cytotoxicity assays and efficacy was tested in patient-derived colorectal and pancreatic cancer models. We found that TAS102-PARPi treatment induces DNA breaks and long G2-arrest in p53mut cells, whereas normal cells rapidly repair their DNA and re-enter the cell cycle. Transcriptomic analysis showed that TAS102 is the major driver of the response, whereas PARPi improves selectivity of the TAS102 effects. The treatment does not block replication in p53mut cells but induces post-replicative DNA repair and represses mitosis. Delayed blockade of G2-checkpoint results in massive cell death in p53mut cells selectively. Priming TAS102-PARPi treatment in combination with delayed G2-checkpoint blockade was highly effective against cancer models and was well-tolerated in mice. Broadly, a novel two-step therapeutic strategy showed high efficacy and selectivity for p53mut cancers and low toxicity to normal tissues, demonstrating potential for clinical translation.
中文摘要:携带突变型p53(p53mut)的结直肠癌和胰腺癌现有治疗选择大多无效且缺乏选择性。我们针对p53mut癌症的新型治疗策略联合使用胸苷类似物TAS102与PARP抑制剂(PARPi),在临床试验中显示出令人鼓舞的疗效,尽管其机制尚未完全阐明。本研究旨在探究该疗法有效性的分子机制并探索新的组合以进一步增强反应。为明确每种药物在治疗反应中的贡献,我们在p53野生型和p53mut癌症模型中进行了无偏见的转录组学分析。通过综合分析细胞增殖、细胞死亡和DNA损伤来研究生物学效应。在细胞毒性测定中探讨了药物相互作用,并在患者来源的结直肠癌和胰腺癌模型中测试了疗效。我们发现TAS102联合PARPi处理在p53mut细胞中诱导DNA断裂和长期G2期阻滞,而正常细胞迅速修复其DNA并重新进入细胞周期。转录组学分析显示TAS102是反应的主要驱动因素,而PARPi提高了TAS102效应的选择性。该治疗并未阻断p53mut细胞的复制,而是诱导复制后DNA修复并抑制有丝分裂。延迟的G2检查点阻滞导致p53mut细胞发生大规模选择性死亡。在癌症模型中,将TAS102联合PARPi处理与延迟G2检查点阻滞相结合具有高度有效性且在小鼠中耐受性良好。总体而言,这种新颖的两步治疗策略对p53mut癌症显示出高效性和选择性,并对正常组织毒性较低,展示了临床转化的潜力。
Lymph node metastasis (LNM) represents a pivotal event in cancer progression and a major determinant of response to immune checkpoint blockade (ICB). Elucidation of the molecular mechanisms linking metastatic dissemination to immune suppression could identify potential therapeutic targets to improve ICB efficacy. Here, we identified the coagulation initiator tissue factor (F3) as a central regulator bridging tumor metastasis and immune evasion in gastric cancer (GC). F3 was significantly upregulated in LNM-positive tumors and correlated with impaired ICB responsiveness and poor clinical outcome. Mechanistically, the intracellular domain of F3 directly bound eEF1A1 to promote STAT3 phosphorylation and induce CCL20 expression, which selectively recruited CCR6+ regulatory T cells (Tregs) to establish an immunosuppressive microenvironment. Disruption of this F3-eEF1A1-STAT3-CCL20 axis with the clinically approved compound olsalazine disodium served as a compelling preclinical proof-of-concept to potently suppress tumor growth, abrogate Treg infiltration, and restore ICB sensitivity, all without perturbing basal coagulation. These findings redefine F3 from a canonical coagulation initiator to a tumor-intrinsic immunomodulator and reveal a druggable vulnerability that uncouples its oncogenic signaling from hemostasis.
中文摘要:淋巴结转移(LNM)是癌症进展中的关键事件,也是决定免疫检查点阻断(ICB)疗效的主要因素。阐明连接转移扩散与免疫抑制的分子机制,可能为改善 ICB 疗效提供潜在的治疗靶点。本研究在胃癌(GC)中确定了凝血启动因子组织因子(F3)作为连接肿瘤转移与免疫逃逸的核心调控因子。F3 在淋巴结转移阳性肿瘤中显著上调,并与 ICB 反应受损及不良临床预后相关。机制上,F3 的胞内结构域直接结合 eEF1A1,促进 STAT3 磷酸化并诱导 CCL20 表达,从而选择性招募 CCR6+ 调节性 T 细胞(Tregs)以建立免疫抑制微环境。使用临床批准的药物柳氮磺吡啶钠破坏这一 F3-eEF1A1-STAT3-CCL20 轴,在临床前概念验证中显示出强大的抗肿瘤生长、消除 Treg 浸润并恢复 ICB 敏感性的效果,且未干扰基础凝血功能。这些发现将 F3 从经典的凝血启动因子重新定义为肿瘤内在的免疫调节因子,并揭示了一种可靶向的脆弱环节,使其致癌信号与止血功能解偶联。
KRASG12D is a predominant driver in pancreatic cancer, yet the basis of intrinsic resistance to KRASG12D-targeted therapy remains poorly defined. Integrated genomics, transcriptomics, and proteomics profiling across 242 patient-derived organoids (PDOs) and matched tumor tissues reveals a KRASG12D-mutant subset intrinsically resistant to KRASG12D-targeted therapeutics, characterized by marked downregulation of innate immune signaling pathways. Functional validation demonstrates that suppressing interferon signaling in sensitive models induces resistance, whereas activation of interferon signaling, particularly interferon beta (IFN-β), increases sensitivity in resistant models. Combining IFN-β with KRAS inhibitors (MRTX1133, HRS-4642, and RMC-6236) exhibits synergistic antitumor effects in intrinsically resistant pancreatic cancer. Mechanistically, sustained MYC activity is associated with attenuated sensitivity to KRAS inhibition and correlates with repressed interferon signaling, suggesting a potential role in promoting intrinsic resistance. These findings identify interferon signaling as a candidate determinant of KRAS-targeted therapy response and support interferon-based combinations as a potential strategy for intrinsically resistant pancreatic cancer.
中文摘要:KRASG12D是胰腺癌的主要驱动基因,但其对KRASG12D靶向治疗产生内在抵抗的机制尚不明确。通过对242个患者来源类器官及其配对的肿瘤组织进行整合基因组学、转录组学和蛋白质组学分析,发现存在一个对KRASG12D靶向药物具有内在抵抗性的KRASG12D突变亚群,其特征是先天免疫信号通路的显著下调。功能验证表明,在敏感模型中抑制干扰素信号通路会诱导耐药性,而在耐药模型中激活干扰素信号通路(特别是干扰素β)则能提高敏感性。将IFN-β与KRAS抑制剂(MRTX1133、HRS-4642和RMC-6236)联合使用,在具有内在抵抗性的胰腺癌中表现出协同抗肿瘤作用。机制上,持续的MYC活性与对KRAS抑制的敏感性降低相关,并与干扰素信号通路的抑制相关,提示其在促进内在抵抗方面可能发挥作用。这些发现将干扰素信号通路确定为影响KRAS靶向治疗反应的关键决定因素,并支持以干扰素为基础的联合疗法作为治疗胰腺癌内在抵抗的潜在策略。
In this issue of Cancer Cell, Sadanandam et al. integrate multi-omics profiling of microsatellite-stable colorectal cancer with patient-derived models, identifying focal adhesion kinase and phosphoinositide-dependent kinase 1 as promising therapeutic targets. The study advances multi-omics discoveries toward functional precision oncology and potential treatment strategies to guide clinical translation.
中文摘要:本期《癌症细胞》杂志中,Sadanandam等人将微卫星稳定型结直肠癌的多组学谱系分析与患者来源模型相结合,鉴定出局灶性黏附激酶和磷酸肌醇依赖性激酶1作为有前景的治疗靶点。该研究推动了多组学发现向功能性精准肿瘤学和潜在治疗策略的转化,以指导临床转化。
Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted therapies. Leveraging multiomic data from ∼2,000 tumor samples (including 316MSS CRCs not previously profiled) representing ∼4,500 molecular profiles and 195,246 single cells/nuclei, we uncover complex biology and therapeutic vulnerabilities. Application of a multiomic-phenomic integrative framework, including iPhenMap (a machine-learning tool), reveals complex molecular programs, including replication stress, right-sided biology, glutaminolysis-driven metabolic reprogramming, and MYC-E2F transcriptional networks governing epigenetic remodeling and perineural invasion. Focusing on RAS-mutant MSS CRC, functional validation in state-of-the-art patient-derived tumoroid and matched xenograft models confirms focal adhesion kinase (FAK), phosphoinositide-dependent kinase (PDK)1/2, and proteasome inhibition as potential therapeutic strategies when combined with mitogen-activated protein kinase (MEK) blockade. This work underscores the power of integrated multiomic profiling and functional modeling to refine potential treatment approaches in MSS CRC patient populations.
中文摘要:微卫星稳定(MSS)结直肠癌是一种分子机制复杂且临床治疗棘手的疾病亚型,缺乏有效的靶向疗法。本研究利用来自约2,000个肿瘤样本的多组学数据(包括此前未进行图谱分析的316例MSS结直肠癌),涵盖约4,500个分子特征和195,246个单细胞或细胞核,揭示了其复杂的生物学机制和治疗脆弱性。应用包含iPhenMap(一种机器学习工具)的多组学表型整合框架,发现了复杂的分子程序,包括复制应激、右侧结肠癌生物学特征、谷氨酰胺分解驱动的代谢重编程以及调控表观遗传重塑和神经周围浸润的MYC-E2F转录网络。聚焦于RAS突变的MSS结直肠癌,在先进的患者来源类器官和匹配异种移植模型中的功能验证证实,当联合使用丝裂原活化蛋白激酶(MEK)抑制剂时,局灶性粘附激酶(FAK)、磷酸肌醇依赖性激酶(PDK)1/2以及蛋白酶体抑制可作为潜在的治疗策略。本研究强调了整合多组学图谱和功能建模在优化MSS结直肠癌患者群体潜在治疗方案中的重要作用。
Chromatin dynamics shape gastric cancer at every stage. In this issue of Cancer Cell, Wang et al. uncover a premalignant chromatin state primed for oncogenic activation alongside a pseudo-gastric subtype that hijacks acid secretion to evade antitumor immunity, revealing gastric proton pumps as a potential therapeutic target.
中文摘要:染色质动态在胃癌的每个阶段塑造其发展。在本期《癌症细胞》杂志中,Wang等人揭示了一种为致癌激活做准备的癌前染色质状态,以及一种劫持酸分泌以逃避免疫抗肿瘤反应的假胃亚型,揭示了胃质子泵作为潜在的治疗靶点。
Chromatin remodeling is prominent in cancers, yet it remains obscure how chromatin dynamics underlies stepwise tumorigenesis and informs anti-cancer therapeutics. By decoding a large-scale chromatin accessibility atlas of 650 multistage samples from 439 patients, we delineate epigenetic switches spanning multistep gastric tumorigenesis. A cancer-resembling epigenetic priming state in intestinal metaplasia licenses subsequent tumor initiation. In advanced malignancies, inter-tumoral diversity stratifies three epigenomic subtypes. The proliferative and mesenchymal-inflammatory subtypes are sensitive to neoadjuvant immunotherapy, while the pseudo-gastric subtype is intrinsically drug resistant. Mechanistically, the refractory subtype is featured by a unique gastric lineage-mimicking phenotype, governed in part by FOSL2 to up-regulate H+/K+ ATPase transporters and sculpt an acidic milieu suppressing CD8+ T cells. Inhibition of this phenotype by either FOSL2 depletion or vonoprazan, a clinically available acid blocker, sensitizes immunotherapy. Collectively, these findings highlight that chromatin accessibility dynamics facilitates sequential tumorigenesis from gastric pre-cancer and defines subtypes exploitable to guide immunotherapy and overcome drug resistance.
中文摘要:染色质重塑在癌症中十分显著,但其动力学如何支撑逐步肿瘤发生并指导抗癌治疗仍不清楚。通过解码来自439名患者的650个多阶段样本的大规模染色质可及性图谱,我们描绘了跨越多步胃癌肿瘤发生的表观遗传开关。肠化生中的类癌表观遗传启动状态许可了随后的肿瘤起始。在晚期恶性肿瘤中,瘤间多样性划分出三种表观基因组亚型。增殖性和间质炎症性亚型对新辅助免疫治疗敏感,而假胃型亚型则具有内在的药物抗性。机制上,难治性亚型以独特的胃谱系模拟表型为特征,部分由FOSL2调控上调H+/K+ ATPase转运蛋白并塑造酸性微环境以抑制CD8+ T细胞。通过FOSL2耗竭或维泊伏沙文(一种临床可用的酸抑制剂)抑制该表型可增敏免疫治疗。总之,这些发现表明染色质可及性动力学促进了从胃癌前病变到肿瘤的连续发生,并定义了可用于指导免疫治疗和克服药物抗性的亚型。
Colorectal cancer (CRC) progression and resistance to therapy are driven by complex molecular mechanisms, implying the importance of identifying biomarkers and developing treatment strategies. Whereas Src homology region 2 domain-containing phosphatase 1 (SHP1) is implicated in immune regulation, its role in tumor malignancy remains unclear. Here, we demonstrate that SHP1 is significantly upregulated in CRC tissues and correlates with poor prognosis. Mechanistically, SHP1 was found to dephosphorylate the N(6)-methyladenosine (m6A) demethylase fat mass and obesity-associated protein (FTO) at the Y475 tyrosine residue, thereby enhancing its enzymatic activity to reduce global m6A methylation levels. Integrated RNA sequencing and m6A profiling revealed that SHP1 depletion increased PTEN-induced kinase 1 (PINK1) mRNA m6A modifications, promoting its degradation and suppressing mitophagy. SHP1 inhibitor TPI-1 or siRNA-SHP1-loaded lipid nanoparticles (LNPs) attenuated CRC cell proliferation, migration, and tumor growth in xenograft models through impaired mitochondrial homeostasis. These findings establish the SHP1-FTO-m6A axis as a critical regulator of mitophagy-driven CRC progression. Clinically, our study highlights SHP1 as a prognostic biomarker and potential therapeutic target, with TPI-1 and LNP-siSHP1 offering novel strategies for CRC management.
中文摘要:结直肠癌(CRC)的进展和治疗耐药性由复杂的分子机制驱动,这凸显了识别生物标志物及开发治疗策略的重要性。Src同源区2结构域含磷酸酶1(SHP1)虽参与免疫调节,但其在肿瘤恶性进展中的作用尚不明确。本研究证实SHP1在CRC组织中显著上调且与不良预后相关。机制上,SHP1通过去磷酸化N(6)-甲基腺苷(m6A)去甲基化酶脂肪质量和肥胖相关蛋白(FTO)的Y475酪氨酸残基,增强其酶活性从而降低全局m6A甲基化水平。整合RNA测序与m6A谱分析显示,SHP1缺失增加PTEN诱导激酶1(PINK1)mRNA的m6A修饰,促进其降解并抑制线粒体自噬。在异种移植模型中,SHP1抑制剂TPI-1或负载siRNA-SHP1的脂质纳米颗粒(LNPs)通过破坏线粒体稳态减弱CRC细胞增殖、迁移及肿瘤生长。这些发现确立SHP1-FTO-m6A轴为调控线粒体自噬驱动CRC进展的关键因子。临床层面,本研究将SHP1列为预后生物标志物及潜在治疗靶点,TPI-1与LNP-siSHP1为CRC管理提供了新策略。
Single-cell transcriptomics has greatly advanced insight into hepatic immunity and immunotherapy. However, the absence of an integrated atlas spanning multiple hepatic diseases limits systematic comparisons of immune heterogeneity and dynamics. Here, we established a Pan-HEpatic single-cell Atlas of T cells (Pheat), covering 139 donors, 255 blood and liver samples spanning chronic hepatitis (chronic hepatitis B/C [CHB/CHC], alcohol-associated hepatitis, metabolic dysfunction-associated steatohepatitis), cirrhosis, hepatocellular carcinoma (HCC), and healthy controls (HC), and delineated profound population-, tissue-, and disease-level heterogeneity of 624,215 T cells, with emphasis on CD8+ exhausted T cells (Tex) and CD4+ regulatory T cells (Treg). Within Tex, intrahepatic precursor Tex (Texpre) were depleted in CHB compared with healthy controls and other hepatic diseases. Disease-specific checkpoint dominance (4-1BB in CHB, TIGIT in HCC) in Texpre was identified and experimentally validated. Panobinostat was predicted and validated to reinvigorate Texpre in CHB patients. In parallel, effector Treg (eTreg) accumulated in diseased livers and exhibited divergent IL-2-STAT5 signaling-hyperactive in CHB and HCC, suppressed in cirrhosis-indicating distinct immunosuppressive status. Lapatinib/olopatadine enhanced Treg suppressive markers in cirrhosis. Pheat provides a high-resolution atlas of hepatic T cells, revealing disease-specific immune heterogeneity and regulatory programs that inform cellular and molecular targets for potential immunotherapy.
中文摘要:单细胞转录组学极大地推进了对肝脏免疫和免疫治疗的洞察。然而,缺乏跨越多种肝脏疾病的综合图谱限制了免疫系统异质性和动态变化的系统比较。在此,我们建立了泛肝脏T细胞单细胞图谱(Pheat),涵盖139名供体、255个血液和肝脏样本,涉及慢性肝炎(慢性乙型/丙型肝炎[CHB/CHC]、酒精性肝炎、代谢功能障碍相关脂肪性肝炎)、肝硬化、肝细胞癌(HCC)和健康对照(HC)。我们描绘了624,215个T细胞在群体、组织和疾病水平的深刻异质性,重点聚焦于CD8+耗竭T细胞(Tex)和CD4+调节性T细胞(Treg)。在Tex中,与健康对照组和其他肝脏疾病相比,CHB患者肝内前体Tex(Texpre)发生耗竭。我们鉴定并实验验证了Texpre中疾病特异性的检查点优势(CHB中为4-1BB,HCC中为TIGIT)。泛丁酸钠被预测并验证可重新激活CHB患者的Texpre。同时,效应Treg(eTreg)在病变肝脏中积累,并表现出不同的IL-2-STAT5信号通路活性:在CHB和HCC中呈超激活状态,而在肝硬化中受抑制,表明存在不同的免疫抑制状态。拉帕替尼/奥洛帕定增强了肝硬化中Treg的抑制性标志物。Pheat提供了高分辨率的肝脏T细胞图谱,揭示了疾病特异性的免疫异质性和调控程序,为潜在免疫治疗的细胞和分子靶点提供了依据。
Less oxygen-independent Type-I reactive oxygen species (ROS) generated by photosensitizers offer distinct advantages for tumor photodynamic therapy (PDT). However, most conventional photosensitizers activate nonselective mixed ROS pathways, significantly hindering the advancement of PDT. In this study, we propose a synergistic molecular design strategy that integrates sulfur-atom positioning and acceptor engineering to achieve preferential Type-I ROS generation. We identified a novel near-infrared Type-I photosensitizer NS4. Combined theoretical calculations and experimental characterizations demonstrate that sulfur substitution enhances the S1-T1 intersystem crossing, while acceptor engineering promotes a pronounced twisted intramolecular charge transfer (TICT). This TICT effect lowers the energy of the S1 state and stabilizes the T1 state, thereby synergistically enabling the preferential production of Type-I ROS. Both free NS4 derivative and NS-NPs, self-assembled from NS4 and F-127, can generate substantial amounts of Type-I ROS under 660 nm laser irradiation, effectively triggering tumor cell apoptosis. In vivo assessments confirm that a single dose of NS-NPs significantly suppresses tumor growth with negligible systemic toxicity. This work establishes theoretical and structural guidelines for the rational design of high-performance Type-I photosensitizers and facilitates the further translation of PDT.
中文摘要:光敏剂产生的氧非依赖性I型活性氧(ROS)较少,为肿瘤光动力治疗(PDT)提供了独特优势。然而,大多数传统光敏剂激活非选择性的混合ROS通路,严重阻碍了PDT的发展。本研究提出了一种协同分子设计策略,整合硫原子定位和受体工程,以实现优先产生I型ROS。我们鉴定出一种新型近红外I型光敏剂NS4。结合理论计算与实验表征表明,硫取代增强了S1-T1系间窜越,而受体工程促进了显著的扭曲分子内电荷转移(TICT)。该TICT效应降低了S1态能量并稳定了T1态,从而协同实现了I型ROS的优先产生。游离NS4衍生物及由NS4与F-127自组装形成的NS-NPs在660nm激光照射下均可产生大量I型ROS,有效触发肿瘤细胞凋亡。体内评估证实,单次剂量的NS-NPs能显著抑制肿瘤生长且全身毒性可忽略不计。本研究为高性能I型光敏剂的合理设计建立了理论与结构指导原则,并促进了PDT的进一步转化应用。
Cancer-induced cachexia is a multifactorial syndrome characterized by systemic inflammation and progressive skeletal muscle and fat wasting. More than 80% pancreatic cancer patients exhibit a cachectic phenotype, which significantly contributes to the overall mortality of cancer patients. Till now, there is no FDA-approved therapy for cancer-associated cachexia that has been developed. In the present study, we have demonstrated the anti-cachectic potential of an anti-malarial compound, atovaquone. We observed that atovaquone inhibits cancer cell-conditioned media-induced myotube atrophy in a dose-dependent manner. Atovaquone treatments lead to reduced cachectic markers expression in conditioned media-treated myotubes. Further, we observed that atovaquone treatment results in reduced reactive oxygen species levels in conditioned media-treated myotubes. Mechanistically, we observed that atovaquone treatment of myotubes enhances the glycolytic capacity of conditioned-media-treated myotubes by upregulating Glut4 expression. Furthermore, we established that increased Glut4 expression is primarily driven by atovaquone-induced AMPK activation. By utilizing a syngeneic orthotopic implantation model of pancreatic cancer, we have observed that atovaquone can inhibit cachectic phenotype in tumor-bearing mice, without impacting the overall tumour growth. Overall, we have demonstrated that atovaquone exhibits anti-cachectic properties in both in vitro and in vivo model systems of pancreatic cancer-associated cachexia by modulating glycolytic capacity.
中文摘要:癌症诱导的恶病质是一种以全身性炎症和进行性骨骼肌及脂肪消耗为特征的多因素综合征。超过百分之八十的胰腺癌患者表现出恶病质表型,这显著增加了癌症患者的总体死亡率。迄今为止,尚未开发出获得美国食品药品监督管理局批准的癌症相关恶病质疗法。在本研究中,我们证明了抗疟药物阿托伐醌具有抗恶病质潜力。我们观察到阿托伐醌以剂量依赖性方式抑制癌细胞条件培养基诱导的肌管萎缩。阿托伐醌处理导致条件培养基处理的肌管中恶病质标志物表达减少。此外,我们观察到阿托伐醌处理降低了条件培养基处理的肌管中的活性氧水平。在机制上,我们发现阿托伐醌处理通过上调Glut4表达增强条件培养基处理的肌管的糖酵解能力。进一步的研究证实,Glut4表达的增加主要由阿托伐醌诱导的AMPK激活驱动。利用胰腺癌的自体同系原位植入模型,我们观察到阿托伐醌可以在不影响整体肿瘤生长的情况下抑制荷瘤小鼠的恶病质表型。总体而言,我们证明了阿托伐醌通过调节糖酵解能力在胰腺癌相关恶病质的体外和体内模型系统中表现出抗恶病质特性。
Metabolic plasticity enables tumors to adapt to fluctuating nutrient environments, yet the non-canonical functions of metabolic enzymes under stress remain largely unexplored. Here, we established a pyrimidine biosynthesis-associated gene score (PBAGS) that predicts survival in esophageal squamous cell carcinoma (ESCC) and identified dihydroorotate dehydrogenase (DHODH) as a critical driver with a context-dependent dual role. Under glucose-replete conditions, DHODH functions as a canonical oncogene, promoting pyrimidine and cysteine metabolism, alongside UDP-GlcNAc production; accordingly, its inhibition by leflunomide suppresses tumor growth. Strikingly, under glucose starvation, DHODH undergoes a functional switch to become a "molecular executioner." Mechanistically, starvation triggers the DHODH-OGT axis to maintain site-specific O-GlcNAcylation of SLC7A11 at Ser26, thereby stabilizing SLC7A11. This modification promotes excessive cystine accumulation and subsequent actin cytoskeleton collapse, ultimately triggering disulfidptosis. Accordingly, inhibition of DHODH abolishes this modification and rescues cells from starvation-induced death. Clinically, DHODH-SLC7A11 axis correlates tightly with GLUT1 expression. Mimicking glucose starvation using GLUT1 inhibitor BAY-876 significantly enhances radiosensitivity in ESCC PDX models that harbor high DHODH/SLC7A11 expression. Collectively, our findings uncover that under glucose starvation, DHODH and SLC7A11 co-dependency synergistically promotes disulfidptosis, suggesting that targeting the metabolic context offers a potent strategy to sensitize ESCC to radiotherapy.
中文摘要:代谢可塑性使肿瘤能够适应波动的营养环境,然而应激状态下代谢酶的非经典功能仍未被充分探索。本研究建立了预测食管鳞状细胞癌(ESCC)患者生存的嘧啶生物合成相关基因评分(PBAGS),并鉴定出二氢乳清酸脱氢酶(DHODH)为具有情境依赖性双重作用的关键驱动因子。在葡萄糖充足条件下,DHODH发挥经典致癌基因功能,促进嘧啶和半胱氨酸代谢及UDP-GlcNAc生成;因此,使用来氟米特抑制DHODH可抑制肿瘤生长。令人惊讶的是,在葡萄糖饥饿条件下,DHODH发生功能转换成为分子执行者。机制上,饥饿触发DHODH-OGT轴以维持SLC7A11在Ser26位点的特异性O-GlcNAc修饰,从而稳定SLC7A11。该修饰促进半胱氨酸过度积累及随后的肌动蛋白细胞骨架塌陷,最终触发二硫键死亡(disulfidptosis)。因此,抑制DHODH可消除该修饰并挽救细胞免于饥饿诱导的死亡。临床上,DHODH-SLC7A11轴与GLUT1表达紧密相关。使用GLUT1抑制剂BAY-876模拟葡萄糖饥饿状态,显著提高了高表达DHODH/SLC7A11的ESCC患者来源异种移植(PDX)模型的放射敏感性。综上所述,我们的发现揭示在葡萄糖饥饿条件下,DHODH与SLC7A11的共依赖性协同促进二硫键死亡,表明靶向代谢情境是增敏ESCC放疗的有效策略。
Cholangiocarcinoma (CCA) is characterized by a dense desmoplastic microenvironment dominated by cancer-associated fibroblasts (CAFs), which profoundly shape tumor behavior and diminish therapeutic efficacy. By integrating analyses of patient specimens with multi-omics profiling, mechanistic assays, tumor-CAF co-culture and xenograft models, and single-cell transcriptomics, we identified retinoic acid receptor γ (RARγ) as a central regulator of reciprocal communication between malignant cells and CAFs that promotes ferroptosis resistance. RARγ was markedly elevated in CAF-enriched tumors and associated with poor overall survival. Multi-omics integration revealed that RARγ increases CREB stability and reduces K33- and K48-linked polyubiquitination, thereby enhancing CREB occupancy at the AKR1C1 promoter and driving transcriptional activation. AKR1C1 subsequently reinforces the Nrf2-GPX4 antioxidant axis, elevates glutathione metabolism, and suppresses lipid peroxidation. Beyond intrinsic protection, RARγ induces LCN2 transcription and promotes exosomal packaging of LCN2, which is transferred to adjacent CAFs and triggers robust CSF3 (G-CSF) secretion. CAF-derived G-CSF feeds back to malignant cells to amplify RARγ expression and ferroptotic tolerance, forming a self-sustaining paracrine circuit. Single-cell RNA sequencing further supported coordinated interactions between RARG+ tumor subsets and CSF3+ CAFs, reinforcing the relevance of this signaling loop in human CCA. Collectively, these findings position RARγ as a master organizer of tumor-stroma crosstalk through the CREB-AKR1C1 and LCN2-CSF3 axes, establishing a ferroptosis-resistant niche and promoting CCA aggressiveness.
中文摘要:胆管癌(CCA)的特征是富含癌症相关成纤维细胞(CAFs)的致密促结缔组织增生微环境,这深刻塑造了肿瘤行为并降低了治疗疗效。通过整合患者标本分析、多组学谱系分析、机制测定、肿瘤-CAF共培养及异种移植模型以及单细胞转录组学,我们鉴定出视黄酸受体γ(RARγ)是恶性细胞与CAFs之间双向通讯的关键调节因子,该过程促进了铁死亡抵抗。在富含CAFs的肿瘤中RARγ显著升高,且与较差的总体生存期相关。多组学整合分析显示,RARγ通过增加CREB稳定性并减少K33和K48连接的聚泛素化,从而增强CREB在AKR1C1启动子上的占据率并驱动转录激活。AKR1C1随后强化Nrf2-GPX4抗氧化轴,提升谷胱甘肽代谢并抑制脂质过氧化。除了内在保护外,RARγ还诱导LCN2转录并促进其外泌体包装,LCN2被转移至邻近的CAFs并触发强烈的CSF3(G-CSF)分泌。CAF来源的G-CSF反馈至恶性细胞以放大RARγ表达和铁死亡耐受性,形成自我维持的旁分泌环路。单细胞RNA测序进一步支持了RARG+肿瘤亚群与CSF3+ CAFs之间的协调相互作用,强化了该信号环路在人类CCA中的相关性。综上所述,这些发现将RARγ定位为通过CREB-AKR1C1和LCN2-CSF3轴组织肿瘤-基质串扰的主要组织者,建立了铁死亡抵抗微环境并促进CCA的侵袭性。
3其他实体瘤 (22篇)
临床研究 (3篇)
Liquid biopsies are one of the few noninvasive procedures for probing disease at the molecular level. They represent a scalable solution to cancer detection and monitoring by capturing tumor-derived signals from circulating biomolecules such as proteins, DNA, RNA, and metabolites. However, these signals are often sparse, heterogeneous, and shaped by genetics, demographics, and comorbidities. Recent advances in artificial intelligence, especially with multimodal foundation models, have proven capable of extracting signals from noisy, high-dimensional data. Pretraining on large cohorts and integrating complementary modalities may improve sensitivity for tumor signals in blood, though significant clinical and infrastructural barriers remain. This review synthesizes advances in liquid biopsy technologies and artificial intelligence and examines how their convergence can enable enhanced cancer monitoring.
中文摘要:液体活检是少数几种在分子水平探测疾病的非侵入性手段之一。通过捕获来自循环生物分子如蛋白质、DNA、RNA和代谢物的肿瘤衍生信号,它们为癌症检测和监测提供了一种可扩展的解决方案。然而,这些信号往往稀疏且异质,并受到遗传背景、人口统计学特征及共病的影响。人工智能的最新进展,特别是多模态基础模型,已被证明能够从嘈杂的高维数据中提取信号。在大型队列上进行预训练并整合互补模态可能提高对血液中肿瘤信号的敏感性,尽管仍面临显著的临床和基础设施障碍。本综述总结了液体活检技术和人工智能方面的进展,并探讨了它们的融合如何促进癌症监测的增强。
Early-onset pancreatic neuroendocrine tumors (EO-PanNETs) exhibit distinct clinical features, but their metabolic profiles and age-related associations remain poorly understood. This study included 641 patients with PanNETs from four tertiary centers in China. EO-PanNETs were defined as PanNETs diagnosed before 50 years. 1,282 hospital-based nonmalignant controls were matched 1:2 by age and sex. Conditional logistic regression and Cox models were used to assess associations with PanNET occurrence and survival outcomes, respectively. Age-related effect modification was assessed using exposure-by-age interaction terms, with age modeled continuously using restricted cubic splines (RCS) in sensitivity analyses. Compared with late-onset cases, EO-PanNETs exhibited a higher prevalence of reduced high-density lipoprotein cholesterol (29.2% vs 17.8%, P < 0.001). Although the overall prevalence of diabetes was similar between EO-PanNETs and LO-PanNETs, the proportion of new-onset cases among patients with diabetes was higher in EO-PanNETs(71.4% vs. 44.8%, P = 0.018). In case-control analyses using matched nonmalignant controls as reference, alcohol intake (OR, 1.77 vs. 0.79; P interaction = 0.008), diabetes mellitus (OR, 9.72 vs. 3.34; P interaction = 0.048) and elevated triglycerides (OR, 1.75 vs. 1.01; P interaction = 0.023) showed stronger associations with PanNET occurrence in younger individuals. EO-PanNETs also exhibited better overall survival and progression-free survival than LO-PanNETs. RCS analyses further identified age-related differences in the associations of alcohol intake and overweight with PanNET occurrence. These findings highlight age-related differences in the associations of metabolic factors with PanNETs, providing new insights into age-related metabolic heterogeneity in this rare disease.
中文摘要:早发性胰腺神经内分泌肿瘤(EO-PanNETs)具有独特的临床特征,但其代谢谱及与年龄的关联尚不明确。本研究纳入中国四家三级医院的641例PanNET患者,并将EO-PanNETs定义为50岁前确诊的PanNET。选取1282名非恶性对照者按1:2比例进行年龄和性别匹配。采用条件Logistic回归和Cox模型分别评估与PanNET发生及生存结局的关联。通过暴露与年龄交互项评估年龄相关的效应修饰,敏感性分析中采用限制性立方样条(RCS)对年龄进行连续建模。与晚发性病例相比,EO-PanNETs患者高密度脂蛋白胆固醇降低的患病率更高(29.2% vs 17.8%,P < 0.001)。尽管EO-PanNETs与LO-PanNETs患者的糖尿病总体患病率相似,但EO-PanNETs中糖尿病新发病例的比例更高(71.4% vs 44.8%,P = 0.018)。在以匹配的非恶性对照为参照的病例对照分析中,饮酒(OR 1.77 vs 0.79;交互作用P值0.008)、糖尿病(OR 9.72 vs 3.34;交互作用P值0.048)和高甘油三酯血症(OR 1.75 vs 1.01;交互作用P值0.023)在年轻个体中与PanNET发生的关联更强。EO-PanNETs患者的总生存期和无进展生存期优于LO-PanNETs。RCS分析进一步识别出饮酒和超重与PanNET发生关联中的年龄差异。这些发现强调了代谢因素与PanNET关联中的年龄差异,为该罕见疾病的年龄相关代谢异质性提供了新见解。
Aging is a major risk factor for melanoma. However, it is unclear whether aging fuels tumor evolution by altering mutation rates, changing the microenvironmentally induced selection on drivers, or both. We analyzed 5472 melanomas, estimating how selection on individual variants changes with patient age while accounting for differing neutral mutation rates. Neutral mutation rates increased only modestly with age; ultraviolet damage remained predominant, but endogenous processes increasingly contributed to older tumors. In contrast, selection on major drivers was strongly age dependent: The advantage of BRAF V600E declined precipitously with age, whereas NRAS Q61 mutations gained advantage. TERT promoter mutations became more frequent, yet less advantageous. Aging therefore reshapes melanoma evolution primarily by altering selection, motivating age-conscious evaluation of clinical biomarkers and therapies.
中文摘要:衰老是黑色素瘤的主要风险因素。然而,尚不清楚衰老是通过改变突变率、改变微环境诱导的驱动基因选择压力,还是两者共同作用来促进肿瘤进化。我们分析了5472例黑色素瘤样本,在考虑中性突变率差异的情况下,估算了个体变异的选择优势随患者年龄的变化情况。结果显示,中性突变率仅随年龄轻微增加;紫外线损伤仍占主导地位,但内源性过程对老年肿瘤的贡献逐渐增加。相比之下,主要驱动基因的选择优势表现出强烈的年龄依赖性:BRAF V600E突变的优势随年龄增长急剧下降,而NRAS Q61突变获得优势。TERT启动子突变频率增加,但其优势减弱。因此,衰老主要通过改变选择压力来重塑黑色素瘤的进化,这促使临床生物标志物和疗法评估需考虑年龄因素。
基础研究 (19篇)
Treatment resistance in pleural mesothelioma (PM) is a clinical challenge. Cisplatin-based chemotherapy remains a cornerstone of treatment, but responses are transient as resistant tumor cells drive disease progression. The contribution of the tumor immune microenvironment to chemoresistance is poorly understood so far. Using cisplatin-resistant murine (AB12, PM27) and human (MSTO-211H) PM models combined with transcriptomics, immune profiling and functional assays, we identify a key role for the CCL5-CCR5 axis in shaping an immunosuppressive niche that supports tumor progression. Resistant cells upregulate and secrete high levels of CCL5, leading to enhanced tumor growth in vivo. Immune profiling of tumor microenvironment reveals a marked recruitment of CCR5+ macrophages displaying an immunosuppressive phenotype characterized by reduced inflammatory activity. Mechanistically, tumor-derived CCL5 promotes macrophage recruitment and polarization toward a pro-tumoral state through CCR5 signaling. Disruption of this axis, either by pharmacological inhibition of CCR5 using maraviroc or by genetic silencing of CCL5, reduces macrophage infiltration and significantly impairs tumor progression. These findings reveal microenvironment-driven mechanism of chemoresistance in PM and identify the CCL5-CCR5 axis as a key vulnerability. Targeting this pathway may therefore represent a promising therapeutic strategy to limit the progression of cisplatin-resistant mesothelioma by disrupting the tumor-supportive immune microenvironment.
中文摘要:胸膜间皮瘤的治疗耐药性是一个临床挑战。以顺铂为基础的化疗仍是治疗的核心,但肿瘤细胞耐药导致疾病进展,使得疗效短暂。目前对肿瘤免疫微环境在化疗耐药中作用的机制尚不清楚。本研究结合顺铂耐药的鼠源(AB12、PM27)和人源(MSTO-211H)间皮瘤模型,利用转录组学、免疫谱分析和功能实验,确定了CCL5-CCR5轴在塑造支持肿瘤进展的免疫抑制微环境中的关键作用。耐药细胞上调并分泌高水平的CCL5,导致体内肿瘤生长增强。对肿瘤微环境的免疫谱分析显示,CCR5阳性巨噬细胞显著浸润,呈现炎症活性降低的免疫抑制表型。机制上,肿瘤来源的CCL5通过CCR5信号通路促进巨噬细胞招募并向促肿瘤状态极化。破坏该轴(通过使用马拉维考进行药理学抑制CCR5或通过基因沉默降低CCL5表达)可减少巨噬细胞浸润并显著抑制肿瘤进展。这些发现揭示了微环境驱动的间皮瘤化疗耐药机制,并将CCL5-CCR5轴确定为关键脆弱环节。靶向该通路可能成为通过破坏肿瘤支持性免疫微环境来限制顺铂耐药间皮瘤进展的一种有前景的治疗策略。
A new genomic atlas of 667 canine tumors reveals where dog cancers mirror human disease and where their genetic underpinnings diverge. The findings could help researchers choose better canine models for cancer studies while identifying new therapeutic targets for veterinary medicine.
中文摘要:一项包含667例犬肿瘤的新基因组图谱揭示了犬类癌症在哪些方面与人类疾病相似,以及其遗传基础在哪些方面存在差异。这些发现有助于研究人员为癌症研究选择更合适的犬类模型,同时为兽医学识别新的治疗靶点。
NNMT (nicotinamide N-methyltransferase) is a pivotal metabolic-epigenetic integrator that regulates cellular methylation balance. Although its expression and function exhibit profound, context-dependent heterogeneity in metabolic diseases and cancer, its role within the vascular system, particularly in aging endothelial cells, remains elusive. We examined NNMT expression in a small, pathological, male-only cohort of older versus younger plaque-adjacent human carotid intimal donors, primary mouse aortic endothelial cells, and senescent human umbilical vein endothelial cells. Using endothelial-targeted adeno-associated virus-Tie systems, we assessed the effects of NNMT restoration and knockdown on vasodilation and arterial stiffness in aged mice. Mechanistic insights were obtained through exploratory multiomics integration. We established that NNMT expression exhibits an exploratory inverse association in a small, pathological, male-only cohort of older versus younger plaque-adjacent human carotid intimal donors, a pattern mirrored by declines observed in primary mouse aortic endothelial cells and senescent human umbilical vein endothelial cells. Functional assays demonstrated that NNMT restoration improves vasodilation and arterial stiffness in aged mice, whereas knockdown exacerbates these deficits. Mechanistically, exploratory multiomics integration, including Cleavage Under Targets and Tagmentation and transcriptomic analyses, suggests that NNMT-associated reduction in histone H3 lysine 27 trimethylation occupancy at the LMNA (lamin A/C) promoter correlates with its transcriptional maintenance, a process influenced by S-adenosylmethionine supplementation. Downstream, we identified that NNMT-induced LMNA stabilization operates in concert with HSF1 (heat shock transcription factor 1) activation and nuclear translocation, a process accompanied by enhanced binding to HSP90 and HSP70 promoters to drive their transcription. Furthermore, we demonstrated that the vascular protective effects of the natural compound Heterophyllin B are mediated, at least in part, by NNMT, as these benefits were partially attenuated after endothelial NNMT knockdown in vivo. We identify a protective, age-dependent role for NNMT in vascular endothelium. Our findings reveal that NNMT maintains endothelial homeostasis through coordinated regulation of nuclear LMNA and the downstream HSP (heat shock protein) stress response, highlighting the therapeutic potential of this pathway for addressing age-related endothelial dysfunction.
中文摘要:NNMT(烟酰胺N-甲基转移酶)是一种关键的代谢表观遗传整合剂,负责调节细胞内的甲基化平衡。尽管其在代谢性疾病和癌症中的表达与功能表现出显著且依赖背景的异质性,但其在血管系统特别是衰老内皮细胞中的作用尚不明确。我们在一个仅包含男性的小规模病理队列中比较了老年与年轻斑块邻近人类颈动脉内膜供体的NNMT表达,并在原代小鼠主动脉内皮细胞和衰老的人脐静脉内皮细胞中进行了验证。利用内皮靶向腺相关病毒Tie系统,我们评估了NNMT恢复与敲低对老年小鼠血管舒张及动脉僵硬度的影响。通过探索性多组学整合获得机制见解。我们发现NNMT表达在仅含男性的小规模病理队列中呈现探索性的负相关模式,该模式在原代小鼠主动脉内皮细胞和衰老人脐静脉内皮细胞的下降趋势中得到印证。功能实验表明,NNMT恢复改善了老年小鼠的血管舒张功能和动脉僵硬度,而敲低则加剧了这些缺陷。机制上,包括Cleavage Under Targets and Tagmentation及转录组学分析在内的探索性多组学整合显示,NNMT相关的LMNA启动子处组蛋白H3第27位赖氨酸三甲基化占有率降低与其转录维持相关,该过程受S-腺苷甲硫氨酸补充的影响。下游方面,我们发现NNMT诱导的LMNA稳定与HSF1激活及核转位协同作用,伴随其与HSP90和HSP70启动子结合增强以驱动其转录。此外,我们证明天然化合物异叶桂木素B的血管保护作用至少部分由NNMT介导,因为体内内皮NNMT敲低后这些益处部分减弱。我们确定了NNMT在血管内皮中具有保护性的年龄依赖性作用。我们的研究揭示NNMT通过协调调控核内LMNA及下游HSP应激反应来维持内皮稳态,突显了该通路在治疗年龄相关性内皮功能障碍方面的治疗潜力。
Kinase mutations can alter activity, inhibitor response and downstream phosphorylation signaling, particularly within four resistance-associated substructures: gatekeeper, G-loop, αC-helix, and A-loop. KinaseMD 2.0 (http://modinfor.com/KinaseMD/) updates the kinase-centered database in three areas. Integrating source-curated annotations with Dr. Kinase predictions expanded substructure annotations from 1162 to 13 522 and kinase coverage from 388 to 547. Updated pharmacogenomic and signaling layers contain 422 244 drug-response measurements, 1614 candidate drug-resistance evidence records, and 359 600 predicted phosphorylation-network rewiring events. The new Kinase Perturbation Evidence Mapping (KPEM) workflow combines LLM-based literature extraction from an initial collection of over 480 000 publications with standardized processing of 30 public drug-treatment phosphoproteomic datasets. It provides 23 757 kinase-level records of literature-reported evidence and 53 029 phosphoproteomic records across 5124 drug/agent categories and 1598 disease contexts, distinguishing reported phosphorylation evidence from inferred kinase-associated signaling responses. By linking resistance-associated substructures, cancer mutations, drug response, and phosphorylation signaling, KinaseMD 2.0 supports studies of drug-resistance mechanisms and kinase-inhibitor design and development.
中文摘要:激酶突变可改变激酶活性、抑制剂反应及下游磷酸化信号传导,特别是在四个与耐药性相关的亚结构中:门控区、G环、αC螺旋和A环。KinaseMD 2.0数据库在三个方面进行了更新。通过将来源注释与Dr. Kinase预测相结合,亚结构注释从1162项扩展至13522项,激酶覆盖范围从388种扩大至547种。更新的药物基因组学和信号传导层包含422244项药物反应测量数据、1614条候选药物耐药性证据记录以及359600项预测的磷酸化网络重连事件。新的激酶扰动证据映射(KPEM)工作流程结合了基于大型语言模型的文献提取技术,处理初始收集的超过48万篇出版物,并对30个公共药物处理磷蛋白组学数据集进行标准化处理。该流程提供了23757条文献报道的激酶水平记录和53029条磷蛋白组学记录,涵盖5124种药物/试剂类别和1598种疾病背景,区分了报道的磷酸化证据与推断的激酶相关信号反应。通过关联耐药性相关亚结构、癌症突变、药物反应和磷酸化信号,KinaseMD 2.0支持对药物耐药机制及激酶抑制剂设计与开发的研究。
Acute necrotizing pancreatitis (ANP) is a severe inflammatory pancreatic disease characterized by pancreatic necrosis and systemic inflammation, with complex pathogenesis, rapid progression, and poor prognosis. Mitochondrial dysfunction in pancreatic acinar cells represents a pivotal early event in ANP; however, mitophagy, a central component of mitochondrial quality control, remains poorly characterized in terms of its role, regulatory networks, and therapeutic potential in ANP. In this study, we demonstrated that BNIP3 (BCL2 interacting protein 3) expression was significantly downregulated in patients with ANP and negatively correlated with inflammatory severity. Consistently, BNIP3-mediated mitophagy was impaired in the pancreatic tissue of ANP mouse models. Notably, restoration of BNIP3 expression using a novel adeno-associated virus targeting pancreatic tissue (AAV-PAN)-Bnip3 gene therapy vector alleviated pancreatic necrosis and systemic inflammatory injury, promoted mitophagy, and inhibited mitochondrial dysfunction and oxidative stress. Mechanistically, BNIP3-dependent mitophagy facilitated the clearance of damaged mitochondria and prevented mitochondrial DNA (mtDNA) release into the cytosol, thereby suppressing AIM2 (absent in melanoma 2) inflammasome activation and subsequent acinar cell pyroptosis. Furthermore, we identified the transcription factor FOXA2 (forkhead box A2) as a direct upstream regulator that bound to the Bnip3 promoter and positively regulated its expression. FOXA2 was downregulated in ANP, whereas pancreas-specific FOXA2 overexpression activated BNIP3-mediated mitophagy and conferred protection against inflammatory injury. Together, these findings uncovered a previously unrecognized mechanism whereby the FOXA2-BNIP3-AIM2 axis mitigated pancreatic and systemic inflammatory injury in ANP by enhancing mitophagy to restrain mtDNA-dependent AIM2 inflammasome activation, highlighting the FOXA2-BNIP3-AIM2 axis as a promising target for gene therapy.Abbreviations: AAV: adeno-associated virus; AAV-PAN: adeno-associated virus targeting pancreatic tissue; AAV8: adeno-associated virus serotype 8; ACTB/β-actin: actin, beta; AIM2: absent in melanoma 2; AMY: amylase; ANOVA: analysis of variance; ANP: acute necrotizing pancreatitis; ANXA5/annexin V: annexin A5; AP: acute pancreatitis; ATP: adenosine triphosphate; BNIP3: BCL2 interacting protein 3; CASP1: caspase 1; CCK: cholecystokinin; CGAS: cyclic GMP-AMP synthase; ChIP: chromatin immunoprecipitation; CON: control; CTSI: computed tomography severity index; DAMP: danger/damage-associated molecular pattern; DAPI: 4',6-diamidino-2-phenylindole; DEGs: differentially expressed genes; DHE: dihydroethidium; DNA: deoxyribonucleic acid; dsDNA: double-stranded DNA; EGFP: enhanced green fluorescent protein; ELISA: enzyme-linked immunosorbent assay; EtBr: ethidium bromide; FITC: fluorescein isothiocyanate; FOXA2: forkhead box A2; FUNDC1: FUN14 domain containing 1; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GOT1/AST: glutamic-oxaloacetic transaminase 1, soluble; GPT/ALT: glutamic pyruvic transaminase, soluble; GSDMD: gasdermin D; H&E: hematoxylin and eosin; HC: healthy control; IgG: immunoglobulin G; IL1B/IL-1β: interleukin 1 beta; IL6/IL-6: interleukin 6; KEGG: Kyoto encyclopedia of genes and genomes; LDH: lactate dehydrogenase; LV: lentivirus; MAP: mild acute pancreatitis; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MAP1LC3B/LC3B: microtubule associated protein 1 light chain 3 beta; MDA: malondialdehyde; MPO: myeloperoxidase; mRNA: messenger RNA; MSAP: moderately severe acute pancreatitis; mtDNA: mitochondrial DNA; MUT: mutant; nc: negative control; N-GSDMD: N-terminal fragment of GSDMD; OCT: optimal cutting temperature; PBS: phosphate-buffered saline; PCR: polymerase chain reaction; PFA: paraformaldehyde; PI: propidium iodide; PINK1: PTEN induced kinase 1; PPI: protein-protein interaction; PRKN/parkin: parkin RBR E3 ubiquitin protein ligase; qPCR: quantitative polymerase chain reaction; RNA: ribonucleic acid; ROS: reactive oxygen species; SAP: severe acute pancreatitis; SD: standard deviation; siRNA: small interfering RNA; SOD: superoxide dismutase; SQSTM1/p62: sequestosome 1; STING1: stimulator of interferon response cGAMP interactor 1; TBK1: TANK binding kinase 1; TEM: transmission electron microscopy; Tert: telomerase reverse transcriptase; TNF/TNF-α: tumor necrosis factor; TOMM20/TOM20: translocase of outer mitochondrial membrane 20; vg: vector genomes; WT: wild type; ΔΨm: mitochondrial membrane potential.
中文摘要:急性坏死性胰腺炎是一种以胰腺坏死和全身炎症为特征的严重炎症性胰腺疾病,其发病机制复杂、进展迅速且预后不良。胰腺腺泡细胞中的线粒体功能障碍是急性坏死性胰腺炎的关键早期事件;然而,作为线粒体质量控制核心组成部分的线粒体自噬,其在急性坏死性胰腺炎中的作用、调控网络及治疗潜力仍不明确。本研究表明,BNIP3在急性坏死性胰腺炎患者中表达显著下调,且与炎症严重程度呈负相关。一致地,在急性坏死性胰腺炎小鼠模型胰腺组织中,BNIP3介导的线粒体自噬功能受损。值得注意的是,使用靶向胰腺组织的新腺相关病毒AAV-PAN-Bnip3基因治疗载体恢复BNIP3表达可减轻胰腺坏死和全身炎症损伤,促进线粒体自噬,并抑制线粒体功能障碍及氧化应激。机制上,BNIP3依赖的线粒体自噬促进了受损线粒体的清除,防止线粒体DNA释放至胞质,从而抑制AIM2炎症小体激活及随后的腺泡细胞焦亡。此外,我们鉴定出转录因子FOXA2为直接上游调节因子,其结合于Bnip3启动子并正向调控其表达。FOXA2在急性坏死性胰腺炎中下调,而胰腺特异性过表达FOXA2可激活BNIP3介导的线粒体自噬并对抗炎症损伤。综上所述,这些发现揭示了一种先前未被认识的机制,即FOXA2-BNIP3-AIM2轴通过增强线粒体自噬以限制线粒体DNA依赖的AIM2炎症小体激活,从而减轻急性坏死性胰腺炎中的胰腺及全身炎症损伤,突显了该轴作为基因治疗靶点的潜力。
Germ line gain-of-function (GOF) mutations in the signal transducer and activator of transcription 1 (STAT1) gene cause a dominantly inherited inborn error of immunity (IEI) characterized by chronic mucocutaneous candidiasis, autoimmunity, severe opportunistic infections, and an increased risk of malignancy. Allogeneic hematopoietic stem cell (HSC) transplantation (HSCT) is curative but is associated with increased risk of morbidity and mortality in patients with STAT1 GOF mutations compared with those with other IEIs. To develop a curative, autologous alternative to HSCT, we evaluated gene-editing strategies in STAT1 GOF model cell lines, primary T cells, and patient-derived HSCs. Universal and mutation-specific strategies using CRISPR/Cas-mediated homology-directed repair were limited by low efficacy (<25%), poor viability, and a lack of allele specificity. In contrast, adenine base editing corrected the recurrent and highly pathogenic p.T385M mutation with upwards of 90% efficiency in patient T cells and HSCs without significant unintended on- or off-target genomic aberrations. Gene editing functionally restored total STAT1 expression (P< .0217), STAT1 phosphorylation (P< .0056), interferon-stimulated gene expression (OAS1; P = .0005), and improved interleukin-17 production (P< .0001). Edited HSCs retained multilineage differentiation capacity and sustained engraftment with persistence of the corrected allele at 16 weeks in humanized immunodeficient mice. These data demonstrate efficient and precise correction of STAT1 GOF mutations by base editing, with maintenance of the correction through long-term engraftment in vivo. To our knowledge, this represents the first application of gene editing to correct a dominant GOF mutation causing immunodeficiency, with potential applicability to other genetic disorders associated with heterozygous and GOF mutations.
中文摘要:STAT1基因种系功能获得性(GOF)突变导致一种常染色体显性遗传的先天性免疫缺陷病(IEI),其特征为慢性黏膜皮肤念珠菌病、自身免疫、严重机会性感染及恶性肿瘤风险增加。异基因造血干细胞移植(HSCT)虽具治愈性,但相较于其他IEI患者,STAT1 GOF突变患者的发病率和死亡率风险更高。为开发HSCT的自体替代疗法,我们评估了STAT1 GOF模型细胞系、原代T细胞及患者来源造血干细胞(HSCs)中的基因编辑策略。基于CRISPR/Cas介导的同源定向修复的通用及突变特异性策略受限于低效率(<25%)、存活率差及缺乏等位基因特异性。相比之下,腺嘌呤碱基编辑器以超过90%的效率纠正了患者T细胞和HSCs中复发且高致病性的p.T385M突变,且无明显非预期在体或脱靶基因组异常。基因编辑功能性地恢复了总STAT1表达(P<.0217)、STAT1磷酸化(P<.0056)、干扰素刺激基因表达(OAS1; P=.0005),并改善了白细胞介素-17的产生(P<.0001)。编辑后的HSCs保留了多系分化能力,并在人源化免疫缺陷小鼠中维持长期植入,校正等位基因在16周时持续存在。这些数据证明了碱基编辑能高效精确地纠正STAT1 GOF突变,并在体内长期植入过程中维持校正效果。据我们所知,这是首次应用基因编辑纠正导致免疫缺陷的显性GOF突变,具有应用于其他与杂合及GOF突变相关的遗传性疾病的潜力。
Impaired expression of major histocompatibility complex class I (MHC-I) greatly compromises cytotoxic T-cell-mediated anticancer immunotherapy. Existing MHC-I activation strategies are greatly challenged by poor tumor specificity and off-target toxicity. Herein, we report a dual tumor-specific CRISPR/Cas9 gene editing system that can precisely knock out succinate dehydrogenase subunit C (Sdhc) to activate the MHC-I pathway via epigenetic and transcriptional regulation. A tumor-specific gene editor is first engineered via reversible shielding of sgRNA using an apurinic/apyrimidinic endonuclease 1 (APE1)-responsive, complementary ssDNA, yielding AP-sgRNA with blocked editing activity in normal cells yet completely restored activity in APE1-overexpressing tumor cells. Subsequently, tumor-targeted delivery of AP-sgRNA and Cas9 mRNA (mCas9) is achieved using dibenzocyclooctyne-decorated lipid nanoparticle (DLNP), which upon bioorthogonal click reaction can anchor cancer cells that are prelabeled with azido groups using the unnatural sugar DCL-AAM. Thus, AP-sgSdhc/mCas9@DLNP enables efficient and selective Sdhc editing in tumor cells, leading to epigenetic and transcriptional activation of MHC-antigen processing and presentation genes and thereby provoking robust antitumor efficacy in the B16-OVA melanoma model through enhanced, T cell-mediated immune responses. Moreover, it completely suppressed pulmonary metastasis after combination with aPD-L1 in the 4T1 lung metastasis model. This study provides an enlightened paradigm for precision gene editing and renders a promising mechanism for potentiating cancer immunotherapy.
中文摘要:主要组织相容性复合体I类分子(MHC-I)表达受损严重削弱了细胞毒性T细胞介导的抗癌免疫治疗。现有的MHC-I激活策略因肿瘤特异性差和脱靶毒性而面临巨大挑战。本研究报道了一种双肿瘤特异性CRISPR/Cas9基因编辑系统,该系统可精确敲除琥珀酸脱氢酶亚基C(Sdhc),通过表观遗传和转录调控激活MHC-I通路。首先,利用含AP位点的/无嘌呤/无嘧啶内切核酸酶1(APE1)响应的互补单链DNA对sgRNA进行可逆屏蔽,构建了肿瘤特异性基因编辑器,生成的AP-sgRNA在正常细胞中编辑活性被阻断,而在APE1过表达的肿瘤细胞中活性完全恢复。随后,利用修饰有二苯并环辛炔的脂质纳米颗粒(DLNP)实现AP-sgRNA和Cas9 mRNA(mCas9)的肿瘤靶向递送,该纳米颗粒通过生物正交点击反应锚定预先用非天然糖DCL-AAM标记了叠氮基团的癌细胞。因此,AP-sgSdhc/mCas9@DLNP能够在肿瘤细胞中实现高效且选择性的Sdhc编辑,导致MHC抗原加工和呈递基因的表观遗传及转录激活,从而通过增强的T细胞介导的免疫反应在B16-OVA黑色素瘤模型中引发强大的抗肿瘤疗效。此外,在4T1肺转移模型中,该疗法与抗PD-L1抗体联合使用完全抑制了肺转移。本研究为精准基因编辑提供了启发性范式,并为增强癌症免疫治疗提供了有前景的机制。
Radiation-induced heart disease (RIHD) is a life-threatening sequela for cancer survivors. A proactive preventive strategy is urgently needed but remains elusive, particularly for the vulnerable paediatric population where prospective data are scarce. To address this gap, this study aimed to evaluate the prophylactic efficacy of sacubitril/valsartan against RIHD in children through a comprehensive translational research pipeline. A prospective observational study was first conducted in 40 paediatric solid tumour patients, comparing cardiac function before and 1 week after radiotherapy, with 80 healthy controls. A juvenile rat RIHD model was then established, in which the efficacy of sacubitril/valsartan was assessed and validated through longitudinal echocardiography, cardiac magnetic resonance imaging, histopathology, bulk RNA-seq, and single-nucleus RNA-seq. Finally, a prospective clinical cohort (n = 15 sacubitril/valsartan, n = 15 control) was conducted in paediatric patients post-radiotherapy, with a 12-month follow-up for efficacy and safety. In paediatric patients, radiotherapy significantly impaired biventricular function, notably reducing left ventricular global longitudinal strain, and mean heart radiation dose was significantly correlated with cardiac function impairment. In juvenile rats, sacubitril/valsartan attenuated pathological ventricular wall thickening, myocardial fibrosis, diastolic dysfunction, and perfusion deficits. Mechanistically, it mitigated endothelial cell damage and immune cell activation, promoted a macrophage phenotypic shift from M1 to M2, suppressed fibroblast-to-myofibroblast transition, and broadly attenuated pro-fibrotic and inflammatory cell-cell communication. In the clinical cohort, sacubitril/valsartan significantly improved left ventricular global longitudinal strain and aortic compliance vs controls, with a favourable safety profile. This first-in-kind translational study demonstrates that early prophylaxis with sacubitril/valsartan is a feasible and effective strategy to mitigate radiation-induced cardiotoxicity in children. These findings, underpinned by multi-modal validation from bench to bedside, challenge the reactive management paradigm in paediatric cardio-oncology and establish a foundational evidence base for a new standard of proactive heart care in childhood cancer survivors.
中文摘要:放射性心脏病是癌症幸存者的一种危及生命的后遗症。尽管迫切需要一种主动预防策略,但在前瞻性数据稀缺的脆弱儿科人群中仍难以实现。为填补这一空白,本研究旨在通过综合转化研究管道评估沙库巴曲缬沙坦对儿童放射性心脏病的预防功效。首先开展了一项前瞻性观察性研究,纳入40名患有实体瘤的儿科患者,比较其放疗前与放疗后1周的心脏功能,并纳入80名健康对照组。随后建立幼年大鼠放射性心脏病模型,通过纵向超声心动图、心脏磁共振成像、组织病理学、批量RNA测序及单核RNA测序评估并验证沙库巴曲缬沙坦的功效。最后开展了一项前瞻性临床队列研究(沙库巴曲缬沙坦组n=15,对照组n=15),对放疗后的儿科患者进行为期12个月的有效性与安全性随访。在儿科患者中,放疗显著损害双心室功能,特别是降低左心室整体纵向应变,且平均心脏辐射剂量与心脏功能损害显著相关。在幼年大鼠中,沙库巴曲缬沙坦减轻了病理性心室壁增厚、心肌纤维化、舒张功能障碍及灌注不足。机制上,它减轻了内皮细胞损伤和免疫细胞激活,促进巨噬细胞表型从M1向M2转变,抑制成纤维细胞向肌成纤维细胞转化,并广泛减弱促纤维化和炎症的细胞间通讯。在临床队列中,与对照组相比,沙库巴曲缬沙坦显著改善了左心室整体纵向应变和主动脉顺应性,且具有较好的安全性。这项首创的转化研究表明,早期使用沙库巴曲缬沙坦进行预防是减轻儿童放射性心脏毒性的可行且有效的策略。这些基于从基础到临床多模态验证的发现,挑战了儿科心血管肿瘤学中被动管理的范式,并为儿童癌症幸存者建立主动心脏护理的新标准奠定了证据基础。
Cancer drug resistance remains a principal barrier to durable cancer control, yet it is still often interpreted through endpoint-centred models that emphasise pre-existing resistant clones, incomplete drug exposure or late-acquired mechanisms. These explanations are essential but incomplete. The question is not only why resistant cells exist, but also how residual cells remain alive long enough to become resistant. Across tumour types and therapeutic modalities, treatment reshapes residual populations while it is acting, driving transitions through non-genetic heterogeneity, stochastic cell-fate variability, reversible tolerance, stress adaptation, microenvironmental support and eventually stable resistance. This Review develops a temporal framework in which resistance is resolved into a phase-structured trajectory organised around two mechanistic transitions: entry into adaptive buffering and later stabilisation into resistance hardening. Adaptive buffering is defined operationally as a transient, support-dependent survival state in which residual tumour cells preserve viability by recruiting physiological support systems while molecular and phenotypic reorganisation proceeds. It is not a single pathway or a synonym for drug tolerance, but a functional demand-capacity state whose dependencies change over time. We distinguish adaptive buffering from drug tolerance, persister states, dormancy, minimal residual disease and established resistance and discuss how buffering can be evaluated experimentally using perturbational, single-cell, spatial, computational and functional readouts. The framework suggests that informative biomarkers should assign residual populations to adaptive phases, so that therapy can intercept transient dependencies before adaptive states become hardened and clinically entrenched.
中文摘要:癌症药物耐药性仍是实现持久癌症控制的主要障碍,然而它通常仍通过以终点为中心的模型来解释,这些模型强调预先存在的耐药克隆、药物暴露不完全或晚期获得的机制。这些解释虽然必要但不完整。问题不仅在于耐药细胞为何存在,更在于残留细胞如何存活足够长的时间以发展为耐药状态。跨多种肿瘤类型和治疗模式,治疗在发挥作用的同时重塑残留群体,驱动其通过非遗传异质性、随机细胞命运可变性、可逆耐受、应激适应、微环境支持并最终进入稳定耐药状态的转变。本综述构建了一个时间框架,将耐药性解析为围绕两个机制性转变组织的分阶段轨迹:进入适应性缓冲和随后稳定化为耐药硬化。适应性缓冲被操作性地定义为一种短暂的、依赖支持的生存状态,在此状态下残留肿瘤细胞通过招募生理支持系统来维持活力,同时分子和表型重组正在进行。它不是单一通路或药物耐受的代名词,而是一种功能性的供需状态,其依赖性随时间变化。我们将适应性缓冲与药物耐受、持久状态、休眠、微小残留病灶和已建立的耐药性区分开来,并讨论了如何利用扰动、单细胞、空间、计算和功能读数在实验上评估缓冲状态。该框架表明,信息丰富的生物标志物应将残留群体分配到适应阶段,以便在治疗转变为硬化和临床 entrenched 之前拦截其短暂依赖性。
Histopathological assessment remains the gold standard for cancer diagnosis. However, automated histopathology models can be sensitive to domain shifts arising from organ-specific morphological heterogeneity and scanner-associated acquisition variability. To investigate these complementary sources of variation, we established the Cross-Organ and Cross-Scanner Adenocarcinoma Segmentation (COSAS) 2024 Challenge, comprising separate cross-organ and cross-scanner segmentation tasks. The benchmark includes 580 pixel-level annotated histopathology patches spanning six organ sites and six scanner platforms. Thirty international teams submitted valid solutions using a range of convolutional, transformer-based, and hybrid architectures together with different training, augmentation, and inference strategies. Separately, we evaluated conventional segmentation networks and foundation-model-based baselines as organizer-run references. Performance varied substantially across domains and between the two tasks. The relative strengths of the reference models were task dependent, with no model family uniformly strongest across both settings, while the leading challenge submissions achieved competitive performance through different combinations of augmentation, multi-domain training, model design, and inference-time refinement. Overall, COSAS provides a controlled benchmark for studying cross-domain adenocarcinoma segmentation and offers practical insights into the design of AI systems that can better handle the biological and technical variability encountered in diagnostic workflows.
中文摘要:组织病理学评估仍是癌症诊断的金标准。然而,自动化组织病理学模型对由器官特异性形态异质性和扫描仪相关采集变异性引起的域偏移敏感。为研究这些互补的变异来源,我们建立了跨器官和跨扫描腺癌分割(COSAS)2024挑战赛,包含独立的跨器官和跨扫描分割任务。基准数据集包括580个像素级标注的组织病理学切片,涵盖六个器官部位和六个扫描仪平台。三十支国际团队提交了有效解决方案,使用了多种卷积、基于Transformer及混合架构,并结合不同的训练、增强和推理策略。此外,我们评估了传统分割网络和基础模型基线作为主办方运行的参考标准。性能在不同域之间以及两项任务之间存在显著差异。参考模型的相对优势取决于具体任务,没有任何一种模型家族在两种设置下均表现最强,而领先的挑战赛提交方案通过不同的增强组合、多域训练、模型设计和推理时优化实现了具有竞争力的性能。总体而言,COSAS提供了一个受控基准,用于研究跨域腺癌分割,并为设计能更好处理诊断工作流程中遇到的生物和技术变异性的AI系统提供了实用见解。
Metabolites are small molecules produced by biochemical reactions in living organisms and serve as the material foundation for life activities. Conventionally, metabolites have been regarded primarily as energy substrates and biosynthetic precursors for macromolecules. Beyond these roles, accumulating evidence has shown that metabolites also function as key regulators of diverse signaling events through noncanonical mechanisms, including epigenetic regulation, post-translational modifications, and intercellular communication. Importantly, aberrant alterations in metabolites are closely linked to the onset and progression of various diseases, such as neurodegenerative diseases, cancer, and autoimmune disorders, where metabolic reprogramming drives pathological remodeling of the tissue microenvironment. On this basis, researchers have developed various therapeutic strategies to target metabolic disturbances and restore metabolic balance, including lifestyle interventions, bioactive compound supplementation, and pharmacological treatments. Accordingly, this review systematically discusses the network architecture and interconnections of the three core metabolic pathways, highlights the roles of specific metabolites in disease pathogenesis, and offers insights into potential therapeutic approaches.
中文摘要:代谢物是生物体内生化反应产生的小分子,是生命活动的物质基础。传统上,代谢物主要被视为能量底物和生物大分子的合成前体。除这些作用外,越来越多的证据表明,代谢物还通过表观遗传调控、翻译后修饰和细胞间通讯等非经典机制,作为多种信号事件的关键调节因子。重要的是,代谢物的异常改变与神经退行性疾病、癌症和自身免疫性疾病等多种疾病的发病及进展密切相关,其中代谢重编程驱动了组织微环境的病理重塑。在此基础上,研究人员开发了多种针对代谢紊乱并恢复代谢平衡的治疗策略,包括生活方式干预、生物活性化合物补充和药物治疗。因此,本综述系统讨论了三大核心代谢通路的网络架构及其相互联系,强调了特定代谢物在疾病发病机制中的作用,并对潜在的治疗方法提供了见解。
Differentiated thyroid carcinoma (DTC) has one of the most favorable prognoses among all human malignant tumors. However, distant metastases significantly reduce patient survival rates, causing the 5-year survival rate to plummet from over 98% for primary tumors to below 50%. Therefore, elucidating the mechanisms driving DTC metastasis is crucial. This study integrated single-cell and spatial transcriptomic techniques to analyze patient-derived samples from the primary lesion and multiple metastatic lesions (including lymph node, bone, and brain metastases), constructing high-resolution maps of clonal evolutionary structures and the tumor microenvironment (TME). An integrated analysis of single-cell RNA sequencing and spatial transcriptomics was performed to delineate malignant cell evolution, TME heterogeneity, and metastasis-associated signaling programs in DTC. We inferred malignant cells based on copy number variation, reconstructed metastatic trajectories using pseudotime analysis, and mapped intercellular communication through ligand-receptor interaction modeling. Additionally, we validated key cellular distributions in patient tissues using multiplex immunofluorescence staining. Furthermore, we evaluated the effects of IL-1β+ tumor-associated macrophages (TAMs) on thyroid cancer cell proliferation, migration, and invasion in vitro, together with arachidonic acid-related programs, using peripheral blood mononuclear cell-derived macrophage polarization, transwell co-culture and conditioned-medium assays with thyroid cancer cells, and aspirin intervention. Through analysis, we identified metastasis-specific copy number variation evolutionary trajectories and revealed extensive TME heterogeneity. Furthermore, the research uncovered a complex intercellular communication network. Notably, we identified a distinct subset of IL-1β+ TAMs that exhibited significantly stronger pro-inflammatory activity compared with conventional M2-like TAMs. These IL-1β+ TAMs were selectively enriched in lymph node metastases and exhibited activation of arachidonic acid metabolism, accompanied by increased expression of pro-inflammatory and epithelial-mesenchymal transition-associated factors. In vitro functional assays further demonstrated that IL-1β+ macrophages promoted thyroid cancer cell proliferation, migration, and invasion more strongly than M2 macrophages. Importantly, aspirin intervention significantly attenuated these IL-1β+macrophage-mediated effects in vitro. Collectively, this study provides the first comprehensive characterization of transcriptomic heterogeneity features and microenvironmental dynamics during the multi-organ metastasis process of thyroid cancer. Furthermore, our in vitro findings suggest that aspirin may attenuate IL-1β+macrophage-mediated tumor-promoting effects, supporting further investigation of this pathway in preclinical models of thyroid cancer metastasis.
中文摘要:分化型甲状腺癌(DTC)在所有人类恶性肿瘤中预后最为良好,但远处转移会显著降低患者生存率,使原发灶超过98%的5年生存率骤降至50%以下,因此阐明驱动DTC转移的机制至关重要。本研究整合单细胞与空间转录组技术,分析来自原发病灶及多个转移病灶(包括淋巴结、骨和脑转移)的患者样本,构建克隆进化结构与肿瘤微环境的高分辨率图谱。通过整合单细胞RNA测序与空间转录组学分析,描绘DTC中恶性细胞的进化、肿瘤微环境的异质性以及转移相关的信号程序。我们基于拷贝数变异推断恶性细胞,利用伪时间分析重建转移轨迹,并通过配体-受体相互作用模型绘制细胞间通讯网络。此外,我们使用多重免疫荧光染色在患者组织中验证了关键细胞的分布。进一步地,我们评估了IL-1β+肿瘤相关巨噬细胞(TAMs)与花生四烯酸相关程序对甲状腺癌细胞增殖、迁移和侵袭的影响,采用外周血单核细胞来源的巨噬细胞极化、Transwell共培养及条件培养基实验,并结合阿司匹林干预。分析结果显示,我们鉴定出转移特异性的拷贝数变异进化轨迹并揭示了广泛的肿瘤微环境异质性,同时发现了一个复杂的细胞间通讯网络。值得注意的是,我们发现了一类独特的IL-1β+ TAMs亚群,其促炎活性显著强于传统的M2样TAMs。这些IL-1β+ TAMs在淋巴结转移灶中选择性富集,表现出花生四烯酸代谢的激活,并伴随促炎因子和上皮-间质转化相关因子表达的增加。体外功能实验进一步证实,与M2巨噬细胞相比,IL-1β+巨噬细胞更强地促进甲状腺癌细胞的增殖、迁移和侵袭。重要的是,阿司匹林干预显著减弱了这些IL-1β+巨噬细胞介导的效应。综上所述,本研究首次全面表征了甲状腺癌多器官转移过程中转录组异质性特征与微环境动态。此外,我们的体外发现表明阿司匹林可能减弱IL-1β+巨噬细胞介导的促肿瘤效应,支持在甲状腺癌转移的临床前模型中进一步研究该通路。
Tumor organoids have emerged as the most promising avatar to model cancer and to be used as drug testing platform in personalized medicine protocols. The derivation of organoids from epithelial tumors is well established, and their use has proven useful for biomarker discovery, drug screening, and clinical decision support. However, generation of organoids from sarcomas is much less developed and current protocols require further optimization to fully harness their research and clinical potential. In this study, the authors examined the challenges of generating basement membrane extract-based organoids from patient-derived sarcoma samples. Out of 19 samples, 3D structures formed in seven (37%), but none could be propagated beyond the first passage. Alternatively, the authors established expandable organoids from sarcoma xenografts. From 14 xenograft samples, seven (50%) were successfully expanded over multiple passages and biobanked. Notably, xenografts from parental and doxorubicin-resistant 143B osteosarcoma cells yielded long-term cultures suitable for studying drug resistance. Transcriptomic and functional analyses revealed that SRC signaling contributes to doxorubicin resistance in osteosarcoma. Inhibiting SRC with dasatinib restored sensitivity to doxorubicin in vitro and in vivo by downregulating cJUN-mediated ABCB1 expression. These findings support xenograft-derived organoids as a viable platform for modeling sarcoma and investigating therapeutic resistance.
中文摘要:肿瘤类器官已成为建模癌症并在个性化医疗方案中用作药物测试平台的最具前景的模型。上皮肿瘤类器官的构建已相当成熟,其在生物标志物发现、药物筛选和临床决策支持方面已被证明具有实用价值。然而,来自肉瘤的类器官构建发展较为滞后,现有方案仍需进一步优化以充分发挥其研究和临床潜力。本研究探讨了从患者来源的肉瘤样本中生成基于基底膜提取物的类器官所面临的挑战。在19个样本中,仅有7个(37%)形成了三维结构,但均无法在首次传代后继续扩增。作为替代方案,作者成功建立了来自肉瘤异种移植模型的扩增性类器官。在14个异种移植样本中,有7个(50%)成功经过多次传代扩增并建立生物库。值得注意的是,源自亲本型及多柔比星耐药型143B骨肉瘤细胞的异种移植模型产生了适用于研究药物抵抗的长期培养物。转录组学和功能性分析显示,SRC信号通路参与介导骨肉瘤的多柔比星耐药性。通过达沙替尼抑制SRC可下调cJUN介导的ABCB1表达,从而在体内外恢复对多柔比星的敏感性。这些发现支持异种移植来源的类器官作为建模肉瘤及研究治疗抵抗的可行平台。
Macroautophagy is well-characterized in blood endothelial cells but remains poorly defined in lymphatic endothelial cells (LECs). We previously showed that LEC-specific loss of Atg5 (autophagy-related 5; ATG5[LEC-KO]) impairs lymphocytes' egress from secondary lymphoid organs (SLOs) by disrupting the sphingosine-1-phosphate (S1P) gradient, phenocopying S1P lyase blockade by 4-deoxypyridoxine (DOP). Here, we examined how these interventions affect lung metastasis. Both loss of ATG5 in LECs and DOP treatment suppressed melanoma lung colonization, but through distinct mechanisms. DOP reduced lymphocyte numbers but enhanced effector T cell function, consistent with improved immunosurveillance. Conversely, LEC-autophagy loss increased pulmonary B and CD8 T cell abundance and decreased FLT4/VEGFR3 (FMS-like tyrosine kinase 4) expression in LECs, indicating structural remodeling of the lymphatic network. These findings demonstrate that disruption of S1P metabolism or LEC-autophagy constrains metastasis via divergent modulation of lymphatic and immune compartments, underscoring LEC-autophagy as a non-redundant and targetable regulator of metastatic niche formation.Abbreviations: ATG5: autophagy related 5; DOP: 4-deoxypyridoxine; FLT4/VEGFR3: FMS-like tyrosine kinase 4; ICB: immune checkpoint blockade; KO: knockout; LEC: lymphatic endothelial cell; NK: natural killer; PROX1: prospero homeobox 1; S1P: sphingosine-1-phosphate;SLO: secondary lymphoid organ; SPNS2: SPNS lysolipid transporter 2, sphingosine-1-phosphate; TdLN: tumor-draining lymph node; Teffector: effector T cell; Treg: regulatory T cell; VEGFC: vascular endothelial growth factor C; WT: wild-type.
中文摘要:巨自噬在血内皮细胞中特征明确,但在淋巴管内皮细胞(LECs)中的作用尚不明确。我们此前研究表明,特异性敲除LECs中的Atg5基因会破坏鞘氨醇-1-磷酸酯(S1P)梯度,从而阻碍淋巴细胞从次级淋巴器官(SLOs)流出,其表型模拟了4-脱氧吡啶(DOP)对S1P裂解酶的阻断作用。本研究探讨了这些干预措施对肺癌转移的影响。结果显示,LECs中ATG5的缺失和DOP治疗均能抑制黑色素瘤在肺部的定植,但机制不同。DOP减少了淋巴细胞数量,但增强了效应T细胞的功能,这与免疫监视能力的改善一致。相反,LECs自噬功能的缺失增加了肺部B细胞和CD8 T细胞的数量,并降低了LECs中FLT4/VEGFR3的表达,表明淋巴网络发生了结构重塑。这些发现表明,破坏S1P代谢或LECs自噬通过差异化调节淋巴和免疫微环境来限制转移,突显了LECs自噬作为转移生态位形成中非冗余且可靶向的调节因子的作用。
Lemongrass, drying sensitively, is widely used in food and pharmaceuticals. Advancements in drying technology improve product quality and reduce the environmental impact of pharmaceutical processes. This study evaluated a novel Smart Infrared-Hot Air Rotary Drum Dryer (SIRHRDD) for lemongrass processing, focusing on energy efficiency, essential oil quality, and bioactivity. Operating across modes (IR, Heater, and Hybrid) at 30, 40, and 50 °C, the smart-controlled system achieved up to 71.3% energy savings. IR at 30 °C minimized carbon emissions, while Hybrid at 40 °C maximized oil yield. Notably, IR at 50 °C optimized key bioactives: Neral (38.35%) and Geranial (48.13%). Preliminary biological assays indicated promising modulatory potential against human skin carcinoma cells (A-431). Molecular docking simulation showed that Geranial and Neral have favorable theoretical binding affinities for EGFR and STAT3 proteins, comparable to standard drugs. These findings demonstrate that SIRHRDD is a sustainable, high-efficiency technology for producing therapeutic-grade essential oils, offering a scalable solution for the medicinal industry.
中文摘要:香茅干燥过程敏感,广泛应用于食品和制药领域。干燥技术的进步能够提升产品质量并减少制药过程的环境影响。本研究评估了一种新型智能红外-热风旋转滚筒干燥机(SIRHRDD)在香茅加工中的应用,重点关注其能效、精油质量和生物活性。该智能控制系统在红外(IR)、加热(Heater)和混合(Hybrid)模式下,分别在30、40和50°C下运行,实现了高达71.3%的节能效果。30°C下的红外干燥使碳排放最小化,而40°C下的混合模式则使精油产量最大化。值得注意的是,50°C下的红外干燥优化了关键生物活性成分:香叶醛(Neral)含量为38.35%,橙花醛(Geranial)含量为48.13%。初步生物学实验表明,该提取物对人类皮肤癌细胞(A-431)具有潜在的调节作用。分子对接模拟显示,香叶醛和橙花醛对EGFR和STAT3蛋白具有良好的理论结合亲和力,与标准药物相当。这些发现证明SIRHRDD是一种可持续、高效的用于治疗级精油生产的技术,为医药工业提供了可扩展的解决方案。
To elucidate the genetic architecture of the DNA damage response (DDR) network, we conduct unbiased genetic interaction screens using Cas12a. We disrupt 233 DDR genes frequently mutated in cancer and other genetic diseases, either individually or in pairwise combinations, enabling us to assess the phenotypic effects induced by the loss of DDR gene pairs under unperturbed cell growth conditions. We identify high-confidence positive and negative gene-gene interactions, along with connections between previously unlinked DDR pathways. Among the identified genetic interactions, we uncover synthetic lethal interactions between genes encoding the translesion polymerase REV1-Pol ζ complex and the MCM8-MCM9-HROB DNA helicase complex, between Fanconi anemia genes and various mitotic DNA repair genes, as well as between genes encoding the DNA translocase SMARCAL1 and components of the FANCM complex, suggesting opportunities for targeted treatments in tumors carrying mutations in these genes. Collectively, our genetic map of the DDR network identifies synthetic lethal and buffering interactions with therapeutic potential.
中文摘要:为阐明DNA损伤反应(DDR)网络的遗传架构,我们利用Cas12a进行了无偏倚的遗传相互作用筛选。我们单独或成对地破坏了在癌症和其他遗传疾病中频繁突变的233个DDR基因,从而能够在未受干扰的细胞生长条件下评估DDR基因对缺失所诱导的表型效应。我们鉴定了高置信度的正负基因间相互作用,以及先前未连接的DDR通路之间的联系。在鉴定的遗传相互作用中,我们发现编码跨损伤聚合酶REV1-Pol ζ复合物的基因与编码MCM8-MCM9-HROB DNA解旋酶复合物的基因之间存在合成致死相互作用,Fanconi贫血基因与多种有丝分裂DNA修复基因之间存在相互作用,以及编码DNA易位酶SMARCAL1的基因与FANCM复合物组分之间存在相互作用,这表明针对携带这些基因突变的肿瘤存在靶向治疗的机会。总体而言,我们的DDR网络遗传图谱鉴定了具有治疗潜力的合成致死和缓冲相互作用。
Phytocannabinoids are pharmacologically diverse constituents of Cannabis sativa whose actions go beyond canonical cannabinoid receptors. Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are best characterized, while cannabigerol, cannabidivarin, tetrahydrocannabivarin, cannabichromene, cannabinol, and related compounds are emerging candidates. This review integrates molecular pharmacology, pharmacokinetics, safety, and therapeutic evidence across neurologic, neuropsychiatric, inflammatory, pain, cardiovascular and metabolic, hepatic, renal, and neoplastic disorders. The strongest evidence supports pharmaceutical-grade oral CBD as adjunctive therapy for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, and standardized THC-CBD formulations for selected patients with multiple sclerosis-associated spasticity. Emerging clinical signals in schizophrenia, pain, fibromyalgia, sleep disturbance, substance-use disorders, dermatologic conditions, sickle cell disease, and other symptom-focused indications support continued development. However, efficacy remains compound-, formulation-, exposure-, and indication-specific. In oncology, supportive-care applications must remain distinct from tumor-directed treatment, for which clinical efficacy has not been established. Preclinical studies show coherent effects on neuronal excitability, glial and immune activation, endothelial dysfunction, oxidative and nitrative stress, mitochondrial injury, fibrosis, and regulated cell death. These findings support further investigation in neurodegeneration, ischemia-reperfusion injury, diabetic cardiovascular disease, immune-mediated disorders, hepatic and renal injury, and selected cancers. Translation is constrained by product heterogeneity, variable exposure, uncertain target engagement, model differences, drug interactions, and underpowered trials. Standardized products, exposure-informed dosing, pharmacodynamic biomarkers, responder-enriched designs, and indication-specific randomized studies can address these barriers. Phytocannabinoids therefore represent a promising therapeutic platform whose potential will be best realized by matching defined compounds and formulations to biologically coherent diseases, mechanisms, treatment windows, and patient populations.
中文摘要:植物大麻素是大麻植物的药理活性成分,其作用超越经典大麻素受体。Δ9-四氢大麻酚(THC)和大麻二酚(CBD)特征最为明确,而大麻萜酚、大麻二酚变体、四氢大麻酚变体、大麻色烯、大麻酚及相关化合物是新兴候选物。本综述整合了神经精神、炎症、疼痛、心血管代谢、肝脏、肾脏及肿瘤性疾病领域的分子药理学、药代动力学、安全性和治疗证据。最强证据支持药用级口服CBD作为Dravet综合征、Lennox-Gastaut综合征和结节性硬化症相关癫痫的辅助治疗,以及标准化THC-CBD制剂用于特定多发性硬化症相关痉挛患者。精神分裂症、疼痛、纤维肌痛、睡眠障碍、物质使用障碍、皮肤病变、镰状细胞病及其他以症状为导向的适应症中的新兴临床信号支持持续开发。然而,疗效仍取决于化合物、制剂、暴露水平和适应症特异性。在肿瘤学领域,支持性护理应用必须与抗肿瘤治疗区分开来,后者尚未确立临床疗效。临床前研究显示对神经元兴奋性、胶质细胞和免疫激活、内皮功能障碍、氧化和硝化应激、线粒体损伤、纤维化和调节性细胞死亡具有连贯作用。这些发现支持进一步研究神经退行性疾病、缺血再灌注损伤、糖尿病心血管疾病、免疫介导疾病、肝肾损伤及特定癌症。转化受限于产品异质性、暴露差异、靶点结合不确定性、模型差异、药物相互作用及样本量不足的试验。标准化产品、基于暴露的剂量调整、药效学生物标志物、响应者富集设计及适应症特异性随机研究可解决这些障碍。植物大麻素因此代表了一个有前景的治疗平台,其潜力将通过将定义的化合物和制剂与生物学一致的疾病、机制、治疗窗口及患者群体相匹配而得到最佳实现。
TKIs (tyrosine kinase inhibitors) have transformed cancer therapy; however, cardiotoxicity remains a frequent adverse effect with variable susceptibility among patients. For sunitinib, a commonly prescribed TKI, the molecular programs and functional features underlying this variability are not well defined, and clinically actionable predictors of cardiotoxicity risk remain lacking. To investigate interindividual variability in sunitinib-induced cardiotoxic responses, we implemented the Cell Village platform consisting of human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from 20 healthy donors. Pooled iPSCs were differentiated into cardiomyocytes, treated with sunitinib for 72 hours, followed by harvesting for single-nucleus RNA sequencing. Donor identity was determined using single nucleotide polymorphism-based demultiplexing. Additionally, individual line-specific transcriptomic responses to sunitinib were integrated with quantitative functional phenotyping (including contractility, electrophysiology, and recovery efficacy following tocotrienol treatment) in iPSC-CMs differentiated from a subset of 10 lines. Sunitinib induced a robust global transcriptional response characterized by dysregulation of tyrosine kinase signaling, cytoskeletal organization, ion channels, and calcium-handling pathways. Although the pathway-level changes were shared, individual donor lines displayed heterogeneity in both gene expression patterns and functional impairment. Across functional parameters, relaxation velocity was the most consistently correlated with toxicity severity. Integration of each iPSC line's functional data with the corresponding transcriptomic signatures identified gene modules related to calcium handling and structural organization strongly correlated with donor-specific toxicity and recovery indices. Pharmacological validation using tocotrienol demonstrated partial, donor-dependent improvement of sunitinib-related iPSC-CM impairments. This proof-of-concept study establishes a scalable, donor-resolved platform that links pooled transcriptomic profiling with functional toxicity and recovery phenotypes in human cardiomyocytes. By linking molecular perturbations to functional outcomes across genetically diverse backgrounds, this approach provides a framework for dissecting interindividual variability in TKI-associated cardiotoxicity. More broadly, it provides a foundation for extending population-scale cardiotoxicity assessment to additional drugs and protective interventions.
中文摘要:酪氨酸激酶抑制剂(TKIs)改变了癌症治疗格局,但心脏毒性仍是常见的不良反应,且患者间易感性存在差异。对于常用的TKI舒尼替尼,其可变性背后的分子程序和功能特征尚未明确,缺乏临床可操作的毒性风险预测指标。为探究舒尼替尼诱导的心脏毒性反应的个体差异,我们构建了由20名健康供体的人诱导多能干细胞衍生心肌细胞(iPSC-CMs)组成的Cell Village平台。将混合的iPSCs分化为心肌细胞,经舒尼替尼处理72小时后进行单核RNA测序,并通过基于单核苷酸多态性的去复用技术确定供体身份。此外,将10个特定谱系iPSC-CMs对舒尼替尼的个体转录组反应与定量功能表型(包括收缩力、电生理及生育三烯酚治疗后的恢复效率)相结合进行分析。舒尼替尼诱导了以酪氨酸激酶信号、细胞骨架组织、离子通道和钙处理通路失调为特征的强全局转录反应。尽管通路水平的变化是共享的,但不同供体谱系在基因表达模式和功能损伤方面表现出异质性。在所有功能参数中,舒张速度与毒性严重程度相关性最强。将各iPSC谱系的功能数据与相应的转录组特征整合,发现与钙处理和结构组织相关的基因模块与供体特异性毒性和恢复指数高度相关。使用生育三烯酚的药理学验证表明,其对舒尼替尼相关的iPSC-CM损伤具有部分且依赖供体的改善作用。这项概念验证研究建立了一个可扩展的、供体分辨的平台,将混合转录组分析与人类心肌细胞的功能毒性和恢复表型联系起来。通过在不同遗传背景下将分子扰动与功能结果相关联,该方法为解析TKI相关心脏毒性的个体差异提供了框架。更广泛地说,它为将人群规模的心脏毒性评估扩展到其他药物和保护性干预措施奠定了基础。
Abdominal aortic aneurysms (AAAs) are a life-threatening cardiovascular disease for which there is a lack of therapy preventing aortic rupture. During AAA formation, pathological vascular remodeling is driven by an imbalance of proinflammatory and anti-inflammatory macrophage responses, and mechanisms regulating macrophage-mediated inflammation remain undefined. Recent evidence suggests that males absent on the first (MOF), a histone acetyltransferase, can play a critical role in establishing macrophage phenotype and modulating innate immune response. Single-cell RNA sequencing analysis of human AAAs and control tissues was performed to analyze MOF expression in aortic monocyte/macrophages and the inflammatory immune response. Mice underwent 2 murine AAA models: either Ang II (angiotensin II) or topical porcine pancreatic elastase. To investigate the role of MOF in AAA development, targeted inhibition was performed with MG-149 administration or in mice genetically deficient in macrophage-specific MOF (Moff/fLyz2Cre+). Finally, flow cytometry and chromatin immunoprecipitation were conducted to analyze macrophage phenotype and levels of histone (H) lysine (K) acetylation (H4K16ac) in human and murine AAA macrophages. Using single-cell RNA sequencing of human AAA tissues and multiple murine AAA models, we identified that MOF is increased in aortic monocyte/macrophages associated with upregulation of inflammatory transcriptional programs. Mechanistically, TNF-α (tumor necrosis factor alpha) signaling promotes the induction of MOF, which in turn induces NF-κB (nuclear factor kappa-light-chain-enhancer of activated B)-mediated inflammatory gene transcription by increasing the activating H4K16ac mark on gene promoters in infiltrating aortic macrophages. In vivo targeted inhibition of the MOF pathway, with myeloid-specific genetic depletion (Moff/fLyz2Cre+) or pharmacological inhibition in the elastase- and angiotensin II-induced AAA model, preserved macrophage function, decreased elastin fragmentation, attenuated aortic inflammation, and markedly reduced AAA development. Our study provides important evidence that MOF regulates macrophage phenotypic function and inflammation during human and murine AAA development. Targeting the MOF pathway affords the opportunity to prevent pathological macrophage infiltration within the aortic wall and potentially limit AAA development.
中文摘要:腹主动脉瘤(AAA)是一种危及生命的心血管疾病,目前缺乏预防主动脉破裂的治疗手段。在AAA形成过程中,病理性血管重塑由促炎和抗炎巨噬细胞反应的失衡驱动,而调节巨噬细胞介导炎症的机制尚不明确。近期证据表明,雄性缺失于第一个位点(MOF)组蛋白乙酰转移酶在建立巨噬细胞表型和调节先天免疫反应中起关键作用。本研究对人和对照组织的AAA进行了单细胞RNA测序分析,以分析主动脉单核/巨噬细胞中的MOF表达及炎症免疫反应。小鼠接受了两种AAA模型:血管紧张素II(Ang II)或局部猪胰腺弹性蛋白酶诱导。为探究MOF在AAA发展中的作用,通过给予MG-149进行靶向抑制,或在巨噬细胞特异性MOF基因缺陷小鼠(Moff/fLyz2Cre+)中进行研究。最后,采用流式细胞术和染色质免疫沉淀分析人和小鼠AAA巨噬细胞的表型及组蛋白赖氨酸乙酰化(H4K16ac)水平。利用人AAA组织的单细胞RNA测序和多种小鼠AAA模型,我们发现MOF在主动脉单核/巨噬细胞中增加,并与炎症转录程序的上调相关。机制上,TNF-α信号促进MOF的诱导,进而通过增加浸润主动脉巨噬细胞基因启动子上的激活H4K16ac标记,诱导NF-κB介导的炎症基因转录。体内对MOF通路的靶向抑制,无论是髓系特异性基因耗竭(Moff/fLyz2Cre+)还是药理学抑制,在弹性蛋白酶和血管紧张素II诱导的AAA模型中均能保留巨噬细胞功能,减少弹性蛋白碎片化,减轻主动脉炎症,并显著降低AAA的发展。本研究提供了重要证据,表明MOF调节人和小鼠AAA发展过程中巨噬细胞的表型功能和炎症。靶向MOF通路为预防主动脉壁内病理性巨噬细胞浸润并可能限制AAA发展提供了机会。
4临床/流行病学 (15篇)
临床研究 (11篇)
People with neurofibromatosis type 1 (NF1) are at risk for developing peripheral nerve sheath tumors (PNSTs) ranging from benign neurofibromas to high-grade sarcomas. PNSTs known as atypical neurofibromas are at increased risk for malignant transformation. In 2017 the term ANNUBP (atypical neurofibromatous neoplasm of uncertain biologic potential) was proposed for PNSTs at increased risk for malignant transformation based on histopathologic features. Subsequently it was recognized that PNSTs not meeting ANNUBP criteria could still have concerning clinical, imaging and molecular features. A State of the Science conference addressed how to define these pre-cancerous PNSTs and reached consensus regarding clinical management and priority areas of research. Key recommendations from this symposium include: (1) using a combination of histologic, molecular and imaging features to define pre-malignant "at-risk" PNST; (2) recognizing that people with NF1 may be divided into "higher-risk" and "average-risk" for MPNST based on features such as their germline NF1 variant, internal tumor burden and history of malignancy or radiotherapy and; (3) the need to validate consensus screening and surveillance strategies based on personal and tumor-related risk factors. These recommendations will advance the ability to standardize care, and potentially fuel research that enables early diagnosis, prevention of malignant transformation and improved outcomes.
中文摘要:1型神经纤维瘤病(NF1)患者面临从良性神经鞘瘤到高级别肉瘤的周围神经鞘肿瘤(PNST)发展风险。被称为非典型神经鞘瘤的PNST具有更高的恶变风险。2017年,基于组织病理学特征,提出了ANNUBP(生物学潜能不确定的非典型神经纤维瘤性肿瘤)这一术语用于描述具有较高恶变风险的PNST。随后认识到,不符合ANNUBP标准的PNST仍可能表现出令人担忧的临床、影像学和分子特征。一次科学状态会议探讨了如何定义这些癌前PNST,并在临床管理和研究优先领域达成共识。本次研讨会的关键建议包括:(1)结合组织学、分子和影像学特征来定义癌前「高风险」PNST;(2)认识到NF1患者可根据胚系NF1变异、内部肿瘤负荷以及恶性肿瘤或放疗史等特征分为MPNST的「高风险」和「平均风险」群体;(3)需要基于个人和肿瘤相关风险因素验证共识筛查和监测策略。这些建议将提高标准化护理的能力,并可能推动早期诊断、预防恶变和改善预后的研究。
Oral nutritional supplementation (ONS), providing supplementary oral nutrition in addition to usual food, is widely used during concurrent chemoradiotherapy (CCRT) for nasopharyngeal carcinoma (NPC), but its optimal timing and cost utility remain uncertain. To evaluate efficacy and explore cost utility of early ONS in patients with NPC undergoing CCRT. This multicenter, open-label, randomized clinical trial was conducted at 6 Chinese tertiary hospitals from July 2021 to May 2025. Eligible patients were aged 18 to 70 years with newly diagnosed stage II to IVA NPC, a Patient-Generated Subjective Global Assessment (PG-SGA) score of 0 to 8, and planned CCRT. Key exclusions included oral intake less than 60% of requirements for 3 days or longer, inability or unwillingness to receive concurrent chemotherapy, and inability to receive oral or enteral nutrition. Data were analyzed from November 2025 to March 2026. Participants were randomized 1:1 to early ONS at CCRT start or routine ONS after prespecified nutritional decline. The primary end point was the incidence of more than 5% weight loss from baseline to CCRT completion. Secondary end points included PG-SGA score, the incidence of grade 3 or higher radiation-induced oral mucositis (RIOM), quality of life (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30), and radiotherapy interruption. Cost utility measures included total cost, utility, and incremental cost utility ratio. Of 242 patients screened, 236 patients were randomized, and the prespecified modified intention-to-treat population included 216 patients (mean [SD] age, 46.62 [11.19] years; 168 [77.8%] male), with 107 receiving early ONS and 109 receiving routine ONS. More than 5% weight loss occurred in 70 participants (65.4% ) in the early ONS group, compared with 88 participants (80.7%) in the routine ONS group (relative risk [RR], 0.81; 95% CI, 0.68-0.96; P = .01). An intention-to-treat analysis including all randomized participants yielded a similar estimate (RR, 0.78; 95% CI, 0.65-0.93). In the modified intention-to-treat population, grade 3 or higher RIOM occurred in 15 participants (14.0%) in the early ONS group vs 29 participants (26.6%) in the routine ONS group (RR, 0.53; 95% CI, 0.30-0.93). Best-case costs were $9560.56 in the early ONS group vs $9685.23 in the routine ONS group, with quality-adjusted life-years of 0.1144 vs 0.1132, respectively. This randomized clinical trial found that early ONS reduced clinically meaningful weight loss during CCRT; exploratory analyses suggested potential benefits for severe RIOM and a potentially favorable short-term economic profile. ClinicalTrials.gov Identifier: NCT04823468.
中文摘要:口服营养补充(ONS)在鼻咽癌(NPC)同步放化疗(CCRT)期间广泛应用,但其最佳时机和成本效益尚不明确。本研究旨在评估早期 ONS 在 NPC 患者中的疗效并探索其成本效益。这是一项于 2021 年 7 月至 2025 年 5 月在中国 6 家三级医院开展的多中心、开放标签随机临床试验,数据于 2025 年 11 月至 2026 年 3 月进行分析。纳入标准包括年龄 18-70 岁、新诊断 II-IVA 期 NPC、患者生成主观整体评估(PG-SGA)评分 0-8 分且计划接受 CCRT。排除标准包括连续 3 天或更长时间口服摄入量低于需求量的 60%、无法或不愿接受同步化疗以及无法接受口服或肠内营养。受试者按 1:1 随机分配至在 CCRT 开始时接受早期 ONS 或在预设营养下降后接受常规 ONS。主要终点为从基线到 CCRT 完成时体重减轻超过 5% 的发生率。次要终点包括 PG-SGA 评分、3 级或以上放射性口腔黏膜炎(RIOM)发生率、生活质量(EORTC QLQ-C30)及放疗中断情况。成本效益指标包括总成本、效用值和增量成本效用比。在筛查的 242 名患者中,236 名被随机分组,预设的符合方案集人群包括 216 名患者(平均年龄 46.62 岁,男性 77.8%),其中 107 名接受早期 ONS,109 名接受常规 ONS。早期 ONS 组体重减轻超过 5% 的发生率为 65.4%(70/107),低于常规 ONS 组的 80.7%(88/109)(相对风险 [RR] 0.81;95% CI 0.68-0.96;P=.01)。包含所有随机参与者的意向性治疗分析得出相似结果(RR 0.78;95% CI 0.65-0.93)。在符合方案集人群中,早期 ONS 组 3 级或以上 RIOM 发生率为 14.0%(15/107),低于常规 ONS 组的 26.6%(29/109)(RR 0.53;95% CI 0.30-0.93)。最佳情况下,早期 ONS 组总成本为 9560.56 美元,效用值为 0.1144;常规 ONS 组总成本为 9685.23 美元,效用值为 0.1132。本随机临床试验发现,早期 ONS 可减少 CCRT 期间具有临床意义的体重减轻;探索性分析提示其对严重 RIOM 有潜在益处且短期经济前景有利。
Despite multimodal treatment, recurrence remains common in patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). Whether perioperative chemoimmunotherapy improves long-term outcomes remains uncertain. To estimate the effect of perioperative camrelizumab plus chemotherapy on event-free survival (EFS) compared with standard surgery-based treatment in patients with resectable locally advanced HNSCC. The CAMORAL trial was a multicenter, phase 2 randomized clinical trial conducted at 4 academic hospitals in China between October 2020 and March 2024, with data cutoff on April 11, 2025. Patients aged 18 to 75 years with untreated, resectable stage III to IVB HNSCC were assigned to neoadjuvant-adjuvant treatment or control. Analyses used the intention-to-treat population. Data were analyzed from May 2025 to February 2026. Patients were randomized (1:1) to receive two 21-day cycles of neoadjuvant camrelizumab, 200 mg, plus albumin-bound paclitaxel and carboplatin followed by surgery, risk-adapted adjuvant therapy, and maintenance camrelizumab for up to 15 cycles; or upfront surgery followed by standard risk-adapted adjuvant therapy. The primary end point was 2-year EFS. Secondary end points included major pathological response (MPR), pathological complete response (pCR), overall survival, 2-year distant metastasis-free survival, 2-year locoregional recurrence-free survival, and safety. Of 125 included patients, 99 (79.2%) were male, and the mean (SD) age was 56.3 (11.7) years. A total of 63 patients were assigned to the neoadjuvant-adjuvant group and 62 to the control group; the median (IQR) follow-up was 24.6 (16.8-36.5) months. A total of 103 (82.4%) had oral cavity primary tumors. Among 125 patients, the 2-year EFS rate was 77.8% (95% CI, 63.6-87.0) in the neoadjuvant-adjuvant group compared with 46.1% (95% CI, 31.3-59.6) in the control group (hazard ratio, 0.34; 95% CI, 0.17-0.68; P = .001). MPR and pCR were 47.6% (95% CI, 34.9-60.6) and 25.4% (95% CI, 15.3-37.9), respectively, in the neoadjuvant-adjuvant group, with no MPR or pCR events in the control group. The 2-year overall survival rates were 92.0% and 69.1%, respectively (hazard ratio, 0.25; 95% CI, 0.10-0.64); the hazard ratio of 2-year distant metastasis-free survival was 0.15 (95% CI, 0.03-0.68). Grade 3 or higher treatment-emergent adverse events occurred in 50 of 63 patients (79.4%) in the neoadjuvant-adjuvant group and 35 of 62 patients (56.5%) in the control group; 1 fatal treatment-emergent adverse event occurred in the control group. In this phase 2 randomized clinical trial, perioperative camrelizumab plus chemotherapy significantly improved EFS with manageable toxic effects, supporting evaluation of intensified perioperative immune priming in resectable HNSCC. ChiCTR.org.cn Identifier: ChiCTR2000037980.
中文摘要:尽管采用多模式治疗,可切除的局部晚期头颈部鳞状细胞癌(HNSCC)患者的复发仍然常见。围手术期化疗免疫治疗是否能改善长期预后尚不确定。本研究旨在评估在可切除的局部晚期 HNSCC 患者中,围手术期卡瑞利珠单抗联合化疗对比标准手术治疗对无事件生存期(EFS)的影响。CAMORAL 试验是一项在中国 4 家学术医院进行的 multicenter、2 期随机临床试验,研究时间为 2020 年 10 月至 2024 年 3 月,数据截止日为 2025 年 4 月 11 日。纳入年龄 18 至 75 岁、未经治疗且可切除的 III 至 IVB 期 HNSCC 患者,随机分配至新辅助辅助治疗组或对照组。分析采用意向性治疗人群。数据于 2025 年 5 月至 2026 年 2 月进行分析。患者按 1:1 比例随机接受两个 21 天周期的新辅助卡瑞利珠单抗(200 mg)联合白蛋白结合型紫杉醇和卡铂,随后进行手术、风险适应性辅助治疗以及最多 15 个周期的维持卡瑞利珠单抗治疗;或先行手术,随后进行标准风险适应性辅助治疗。主要终点为 2 年 EFS。次要终点包括主要病理缓解(MPR)、病理完全缓解(pCR)、总生存期、2 年无远处转移生存期、2 年局部区域复发-free 生存期及安全性。在纳入的 125 名患者中,99 名(79.2%)为男性,平均(标准差)年龄为 56.3(11.7)岁。共 63 名患者分配至新辅助辅助组,62 名分配至对照组;中位(四分位距)随访时间为 24.6(16.8-36.5)个月。共 103 名(82.4%)患者原发灶位于口腔。在 125 名患者中,新辅助辅助组的 2 年 EFS 率为 77.8%(95% CI, 63.6-87.0),对照组为 46.1%(95% CI, 31.3-59.6)(风险比 0.34;95% CI, 0.17-0.68;P = .001)。新辅助辅助组的 MPR 和 pCR 分别为 47.6%(95% CI, 34.9-60.6)和 25.4%(95% CI, 15.3-37.9),对照组无 MPR 或 pCR 事件。两组 2 年总生存率分别为 92.0% 和 69.1%(风险比 0.25;95% CI, 0.10-0.64);2 年无远处转移生存期的风险比为 0.15(95% CI, 0.03-0.68)。新辅助辅助组中有 50/63 名患者(79.4%)出现 3 级或更高治疗相关不良事件,对照组为 35/62 名患者(56.5%);对照组发生 1 例致死性治疗相关不良事件。在本项 2 期随机临床试验中,围手术期卡瑞利珠单抗联合化疗显著改善了 EFS,且毒性可控,支持在可切除 HNSCC 中进一步评估强化的围手术期免疫预处理策略。ChiCTR.org.cn 注册号:ChiCTR2000037980。
Early detection of esophageal squamous cell carcinoma (ESCC) is hindered by a lack of noninvasive biomarkers for precancerous lesions. Here, we report a circulating cell-free DNA (cfDNA) methylation approach for early esophageal neoplasia detection. In prospective community screening, the assay achieved standardized sensitivity of 78% at 79% specificity for the clinically actionable endpoint of high-grade intraepithelial neoplasia (HGIN) or ESCC, with stage-specific sensitivities of 76% for HGIN and 86% for ESCC. Genome-wide methylation profiling reveals HGIN as an early epigenetic reprogramming stage. Integrative spatial and single-cell RNA sequencing reveals pronounced remodeling of the endothelial-proximal epithelial cell population, whose methylation signatures are detected in cfDNA. Guided by these findings, we develop an 11-gene cfDNA methylation panel that shows robust discrimination of early-stage ESCC across three retrospective case-control sets and an independent screening-derived case-control set. Together, these results demonstrate that our cfDNA methylation panel has promising utility for early ESCC detection.
中文摘要:早期食管鳞状细胞癌(ESCC)的检测因缺乏癌前病变的非侵入性生物标志物而受阻。本研究报道了一种用于早期食管肿瘤检测的循环游离DNA(cfDNA)甲基化方法。在前瞻性社区筛查中,该检测方法在高级别上皮内瘤变(HGIN)或ESCC这一具有临床干预价值的终点上实现了79%特异性下的78%标准化灵敏度,其中HGIN和ESCC的分期特异性灵敏度分别为76%和86%。全基因组甲基化谱分析揭示HGIN是一个早期的表观遗传重编程阶段。整合空间转录组学和单细胞RNA测序显示内皮邻近上皮细胞群发生了显著重塑,其甲基化特征可在cfDNA中检测到。基于这些发现,我们开发了一个11基因cfDNA甲基化面板,在三个回顾性病例对照队列和一个独立的筛查衍生病例对照队列中均显示出对早期ESCC的强有力区分能力。综上所述,这些结果证明该cfDNA甲基化面板在早期ESCC检测中具有广阔的应用前景。
Spray cryotherapy (LNSC) is hypothesized to increase effectiveness of neoadjuvant chemoradiation (CRT). We aimed to determine safety of multiple cryotherapy sessions prior to and concurrent with CRT in locally advanced esophageal cancer. "3+3" phase 1 dose frequency escalation trial. Primary outcome was safety; secondary outcomes were Quality of Life (QoL) complete clinical response (cCR), survival, and immunogenic cell death (change in serum HMGB1). There was no treatment related grade 2 or 3 adverse events when LNSC was administered before or concurrent with CRT (n =13). Maximum Tolerated Dose was 3 sessions (2 prior to CRT, 1 during CRT). Mean QoL score improved from 37 at baseline to 31, 29, and 34 after the 1st, 2nd, and 3rd sessions (p-value 0.002, 0.004, and 0.4 respectively). CR with LNSC + CRT occurred in 70%. Over median follow-up of 36 months, overall survival was 40%. 38% showed >25% decrease in HMGB1 within 30 days. No patient experienced dose limiting toxicity. LNSC was safely administered during CRT, improved QoL and high cCR rates were observed. These results support proceeding with a phase 2 trial.
中文摘要:喷雾冷冻治疗(LNSC)被假设能增强新辅助放化疗(CRT)的疗效。本研究旨在评估在局部晚期食管癌患者中,于CRT前及与CRT同期进行多次冷冻治疗的安全性。这是一项采用「3+3」设计的I期剂量频率递增试验。主要终点为安全性;次要终点包括生活质量(QoL)、完全临床缓解率(cCR)、生存率以及免疫原性细胞死亡(血清HMGB1的变化)。在LNSC于CRT前或同期给药时(n=13),未发生与治疗相关的2级或3级不良事件。最大耐受剂量为3次治疗(CRT前2次,CRT期间1次)。平均QoL评分从基线的37分改善至第1、2、3次治疗后的31、29和34分(P值分别为0.002、0.004和0.4)。LNSC联合CRT的完全缓解率为70%。在中位随访36个月期间,总生存率为40%。38%的患者在30天内HMGB1下降超过25%。无患者出现剂量限制性毒性。LNSC在CRT期间给药安全,观察到QoL改善及较高的cCR率。这些结果支持开展II期临床试验。
Sex-associated differences in hepatocellular carcinoma (HCC) prognosis remain incompletely characterized across major etiologies. In this retrospective international multicenter cohort study, we included 7623 consecutive patients with newly diagnosed HCC from 41 centers in five countries and evaluated the associations of sex and four-level etiology with overall survival (OS) and the first adverse liver event (hepatic decompensation, liver failure, or liver-related death). Sex-related OS was evaluated in the full cohort, after 1:1 propensity-score matching (1351 men and 1351 women), and in a multivariable Cox model including recorded initial treatment modality; cause-specific Cox and Fine-Gray models evaluated adverse liver events. Five-year OS was 24.3% in women and 22.0% in men. Female sex was associated with lower mortality before matching (hazard ratio [HR], 0.90; 95% CI, 0.85-0.97), after matching (HR, 0.91; 95% CI, 0.84-0.99; p = 0.024), and after multivariable adjustment (HR, 0.91; 95% CI, 0.85-0.98; p = 0.010). Male sex was associated with a higher hazard of adverse liver events (cause-specific HR, 1.26; 95% CI, 1.11-1.43; subdistribution HR [sHR], 1.23; 95% CI, 1.08-1.40). Alcohol-related and metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC had higher liver-event hazards than hepatitis B virus (HBV)-related HCC. For OS, the global sex-by-etiology interaction was not significant (p = 0.866). Female sex was associated with modestly better outcomes, although the China-dominant cohort limits generalizability.
中文摘要:在主要病因中,与性别相关的肝细胞癌预后差异仍未被完全阐明。在这项回顾性国际多中心队列研究中,我们纳入了来自五个国家41个中心的7623例新诊断肝细胞癌患者,并评估了性别和四级病因与总生存期及首次不良肝脏事件(肝衰竭、肝功能衰竭或肝相关死亡)的关联。在全队列中评估了性别相关的总生存期,在1:1倾向评分匹配后(1351名男性和1351名女性),并在包含记录初始治疗方式的多元Cox模型中进行了评估;病因特异性Cox和Fine-Gray模型用于评估不良肝脏事件。女性五年总生存率为24.3%,男性为22.0%。在匹配前,女性性别与较低的死亡率相关(风险比[HR],0.90;95%置信区间[CI],0.85-0.97),匹配后(HR,0.91;95% CI,0.84-0.99;p = 0.024)和多元调整后(HR,0.91;95% CI,0.85-0.98;p = 0.010)均显示出类似趋势。男性性别与较高的不良肝脏事件风险相关(病因特异性HR,1.26;95% CI,1.11-1.43;亚分布HR [sHR],1.23;95% CI,1.08-1.40)。酒精相关和代谢功能障碍相关脂肪性肝病相关的肝细胞癌比乙型肝炎病毒相关的肝细胞癌具有更高的肝脏事件风险。对于总生存期,全球性别与病因的交互作用不显著(p = 0.866)。女性性别与略好的结果相关,尽管以中国为主导的队列限制了普遍适用性。
This phase III, randomized, double-blind study (daNIS-2) evaluated the efficacy and safety of NIS793, an anti-transforming growth factor-beta (TGF-β) monoclonal antibody, in combination with gemcitabine and nab-paclitaxel [standard of care (SOC)] versus placebo and SOC as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The study included a safety run-in (n = 21 patients enrolled) followed by a randomized part (n = 490 patients randomly assigned). Patients were assigned 1 : 1 to receive NIS793 or placebo with SOC. The primary endpoint was overall survival (OS), secondary endpoints included progression-free survival (PFS), overall response rate (ORR), safety, pharmacokinetics, and exploratory biomarker analyses. The study was terminated early following an interim analysis due to an unfavorable benefit-risk profile. Median OS was 9.2 months in the NIS793 arm versus 11.2 months in the placebo arm (hazard ratio 1.26, 95% confidence interval 1.01-1.59). The estimates of ORR and median PFS indicate a less favorable treatment effect with NIS793. Safety profiles were comparable between arms, although higher rates of anemia, epistaxis, and rash were observed with NIS793; serious adverse events were more frequent in the NIS793 arm, with most being grade ≥3. Pharmacodynamic markers such as Pro-C3 supported target engagement. However, such target engagement did not translate into clinical benefit and early circulating tumor DNA dynamics were associated with less favorable outcomes. Biomarker analyses suggested that unfavorable benefit-risk profile of NIS793 was most pronounced in patients with a low epithelial-to-mesenchymal transition signature and a classical molecular subtype. NIS793 in combination with SOC did not improve survival outcomes in first-line mPDAC and was associated with an unfavorable benefit-risk profile. Exploratory biomarker findings highlight the complexity of TGF-β signaling and underscore the need for refined patient selection strategies in future trials.
中文摘要:这项三期随机双盲研究(daNIS-2)评估了抗转化生长因子-β单克隆抗体NIS793联合吉西他滨和nab-紫杉醇作为转移性胰腺导管腺癌患者一线治疗的疗效与安全性,并与安慰剂联合标准治疗进行比较。研究包含一个安全导入期(入组21名患者),随后是随机部分(490名患者随机分配)。患者按1:1比例接受NIS793或安慰剂联合标准治疗。主要终点为总生存期,次要终点包括无进展生存期、总缓解率、安全性、药代动力学及探索性生物标志物分析。由于中期分析显示获益风险特征不利,研究提前终止。NIS793组的 Median 总生存期为9.2个月,而安慰剂组为11.2个月(风险比1.26,95%置信区间1.01-1.59)。总缓解率和无进展生存期的估计值表明NIS793的治疗效果较差。两组安全性特征相似,但NIS793组贫血、鼻出血和皮疹发生率较高;严重不良事件在NIS793组更常见,且多为3级或以上。药代动力学标志物如Pro-C3支持靶点结合,但这种靶点结合并未转化为临床获益,早期循环肿瘤DNA动态变化与较差的预后相关。生物标志物分析表明,NIS793的不利获益风险特征在具有低上皮间质转化特征和经典分子亚型的患者中最为明显。NIS793联合标准治疗未能改善转移性胰腺导管腺癌患者的一线生存结局,且伴随不利的获益风险特征。探索性生物标志物发现突显了TGF-β信号通路的复杂性,并强调了未来试验中需要优化患者选择策略。
Endoscopic papillectomy (EP) enables resection of ampullary lesions but its use is limited by piecemeal resection and high recurrence rates. To overcome these limitations, we developed endoscopic submucosal dissection including papilla (ESDIP). This study aimed to evaluate clinical outcomes and identify risk factors for local residual/recurrent tumor after ESDIP for laterally spreading ampullary tumors. This single-center retrospective study analyzed consecutive patients who underwent ESDIP between 2011 and 2024. The primary outcome was local residual/recurrent tumor after ESDIP. Risk factors for local residual/recurrent tumor were evaluated using Cox proportional hazards regression analysis. Of the 81 consecutive patients in whom ESDIP was attempted, conversion to EP or surgery was done in 3. En bloc resection was achieved in all 78 remaining patients. After excluding 23 patients based on predefined criteria, 55 were analyzed. Median tumor size was 38 mm (range 15-128 mm). Negative horizontal and vertical margins, excluding the papillary ductal margin (PDM), were achieved in 48 patients (87%), whereas negative PDM and R0 resection were achieved in 34 (62%) and 29 (53%), respectively. Median follow-up was 31 months. The 3-year cumulative incidence of residual/recurrent tumor was 33%, and all residual/recurrent tumors were confined to the papilla. Positive/indeterminate PDM was a significant risk factor for local residual/recurrent tumor (hazard ratio 8.35, 95%CI 2.35-29.64). Although ESDIP enabled en bloc resection of laterally spreading ampullary tumors, the high rate of positive/indeterminate PDM, resulting in frequent papilla-confined residual/recurrent tumors, remained its main limitation.
中文摘要:内镜乳头切除术(EP)可实现壶腹病变的切除,但其应用受限于分片切除和高复发率。为克服这些局限性,我们开发了包括乳头的内镜黏膜下剥离术(ESDIP)。本研究旨在评估ESDIP治疗侧向扩散型壶腹肿瘤的临床结局,并识别局部残留或复发性肿瘤的风险因素。这项单中心回顾性研究分析了2011年至2024年间接受ESDIP治疗的连续患者。主要结局为ESDIP后的局部残留或复发性肿瘤。使用Cox比例风险回归分析评估局部残留或复发性肿瘤的风险因素。在尝试ESDIP的81例连续患者中,3例转为EP或手术。其余78例患者均实现了整块切除。根据预设标准排除23名患者后,对55名患者进行了分析。中位肿瘤大小为38毫米(范围15至128毫米)。48名患者(87%)获得了阴性水平切缘和垂直切缘,不包括乳头导管切缘(PDM),而34名患者(62%)获得阴性PDM,29名患者(53%)实现R0切除。中位随访时间为31个月。残留或复发性肿瘤的3年累积发生率为33%,所有残留或复发性肿瘤均局限于乳头。阳性或不确定的PDM是局部残留或复发性肿瘤的显著风险因素(风险比8.35,95%CI 2.35至29.64)。尽管ESDIP实现了侧向扩散型壶腹肿瘤的整块切除,但阳性或不确定的PDM率高,导致频繁的乳头局限性残留或复发性肿瘤,这仍然是其主要局限性。
For patients with RAS-mutant metastatic colorectal cancer (mCRC), effective second-line therapies remain limited. In this multicenter, single-arm phase II trial conducted from March 2023 to November 2025, we enrolled 42 patients with RAS-mutant mCRC who had progressed after first-line therapy. All patients received fruquintinib (4 mg once daily on Days 1-21 of each 28-day cycle) combined with either FOLFIRI or FOLFOX chemotherapy based on prior treatment history. The median progression-free survival (PFS) was 8.08 months (95% CI: 6.18, 9.46), ranking among the longest reported in the second-line setting. The objective response rate (ORR) was 52.5% (95% CI: 36.13, 68.49) and the disease control (DCR) rate 97.5% (95% CI: 86.84, 99.94). Notably, this study reports the first conversion surgery outcomes in this setting, with three patients (7.14%) undergoing successful resection-a rate approaching that observed in first-line trials. The safety profile was manageable, with 7.1% of patients experiencing grade ≥ 3 adverse events including diarrhea (4.8%) and thrombocytopenia (2.4%); no treatment-related deaths occurred. Prior bevacizumab treatment did not affect the consistent efficacy of this regimen. These results support further randomized evaluation of this fruquintinib-based combination as a promising second-line option for patients with RAS-mutant mCRC.
中文摘要:对于RAS突变型转移性结直肠癌患者,有效的二线治疗仍然有限。本研究是一项于2023年3月至2025年11月开展的多中心、单臂II期临床试验,共纳入42名在一线治疗后进展的RAS突变型转移性结直肠癌患者。所有患者均接受呋喹替尼(每28天周期第1至21天每日一次4mg)联合FOLFIRI或FOLFOX化疗的方案,具体取决于既往治疗史。中位无进展生存期为8.08个月(95%置信区间:6.18至9.46),在二线治疗报道中位居前列。客观缓解率为52.5%(95%置信区间:36.13至68.49),疾病控制率达97.5%(95%置信区间:86.84至99.94)。值得注意的是,本研究首次报告了该情境下的转化手术结果,3名患者(7.14%)成功接受切除手术,这一比例接近一线临床试验中观察到的水平。安全性可控,7.1%的患者出现3级及以上不良事件,包括腹泻(4.8%)和血小板减少症(2.4%);无治疗相关死亡发生。既往贝伐珠单抗治疗未影响该方案的疗效一致性。这些结果支持进一步随机评估该呋喹替尼联合方案作为RAS突变型转移性结直肠癌患者有前景的二线选择。
Poorly differentiated thyroid cancer (PDTC) lacks a dedicated staging system, requiring use of the eighth version of the American Joint Committee on Cancer and Union for International Cancer Control TNM staging system (TNM-8) for differentiated thyroid cancer despite its distinct biology. To develop a PDTC-specific staging system. This cohort study analyzed data from the International Aggressive Thyroid Cancer Collaborative Group (IATCCG), including surgically treated patients at 91 centers in 14 countries from January 1984 to January 2026. External validation was performed using patients from the US Surveillance, Epidemiology, and End Results (SEER) database. Data were analyzed from December 2025 to June 2026. The primary end point was overall survival. With M1 disease predefined as stage IVB, the schema for stages I-IVA in patients with M0 disease were redefined. All possible TN combinations were fitted into multivariable Cox models, with the lowest Akaike information criterion defining the proposed system. Prognostic discrimination was assessed using adjusted hazard ratios (aHRs) and C statistics. Among 1010 patients in the IATCCG cohort, 610 (60.4%) were female, and the median (IQR) age at diagnosis was 58 (46-68) years; median (IQR) follow-up was 41 (15-85) months. Among 170 patients in the SEER cohort, 85 (50.0%) were female, and the median (IQR) age at diagnosis was 61 (49-72) years; median (IQR) follow-up was 92 (42-154) months. In the IATCCG cohort, level VII lymph node metastasis (LNM) was associated with lower 5-year overall survival (45.2%; 95% CI, 33.4-61.2) than level VI (73.2%; 95% CI, 64.4-83.3) or lateral neck LNM (56.7%; 95% CI, 49.4-65.0). Level VII LNM was therefore reclassified from N1a to N1c. The lowest Akaike information criterion configuration among 16 738 candidates defined stages I to IVA as follows: I, T1N0/NX/N1a or T2N0/NX; II, T1N1b/N1c, T2N1a/N1b, or T3N0/NX/N1a; III, T2N1c, T3N1b, or T4aN0/NX/N1a; IVA, T3N1c, T4aN1b/N1c, or T4b any N; and IVB, M1 disease. Compared with TNM-8, stage I disease decreased from 44.4% (448 of 1010) to 24.6% (248 of 1010) and stage IV disease increased from 18.5% (187 of 1010) to 32.4% (327 of 1010) with the proposed system. The proposed staging had a higher C statistic than TNM-8 (0.74 [95% CI, 0.71-0.76] vs 0.71 [95% CI, 0.68-0.74]; difference, 0.03; 95% CI, 0.01-0.04). Corresponding SEER C statistic values were 0.76 (95% CI, 0.71-0.81) vs 0.74 (95% CI, 0.68-0.79), respectively (difference, 0.02; 95% CI, -0.01 to 0.06). This cohort study found that this PDTC-specific staging system provides improved prognostic stratification reflecting its different biology. These data provide a strong rationale for the potential inclusion of a stand-alone American Joint Committee on Cancer staging system for PDTC.
中文摘要:分化型甲状腺癌的美国癌症联合委员会和国际抗癌联盟第八版TNM分期系统(TNM-8)缺乏针对低分化甲状腺癌(PDTC)的专用分期系统,尽管其生物学特性不同,但仍需使用该系统。本研究旨在开发PDTC专用分期系统。这项队列研究分析了来自14个国家91个中心的国际侵袭性甲状腺癌协作组(IATCCG)数据,包括1984年1月至2026年1月接受手术治疗的患者。利用美国监测、流行病学和最终结果(SEER)数据库中的患者进行了外部验证。数据分析时间为2025年12月至2026年6月。主要终点为总生存期。将M1疾病预定义为IVB期,重新定义了M0疾病患者的I至IVA期方案。将所有可能的TN组合拟合到多变量Cox模型中,最低赤池信息准则定义所提出的系统。使用调整后的风险比(aHRs)和C统计量评估预后判别能力。在IATCCG队列的1010名患者中,610名(60.4%)为女性,诊断时中位年龄(四分位距)为58(46-68)岁;中位随访时间(四分位距)为41(15-85)个月。在SEER队列的170名患者中,85名(50.0%)为女性,诊断时中位年龄(四分位距)为61(49-72)岁;中位随访时间(四分位距)为92(42-154)个月。在IATCCG队列中,VII级淋巴结转移(LNM)与较低的5年总生存率(45.2%;95% CI, 33.4-61.2)相关,低于VI级(73.2%;95% CI, 64.4-83.3)或侧颈LNM(56.7%;95% CI, 49.4-65.0)。因此,将VII级LNM从N1a重新分类为N1c。在16738个候选者中,最低赤池信息准则配置将I至IVA期定义如下:I期,T1N0/NX/N1a或T2N0/NX;II期,T1N1b/N1c、T2N1a/N1b或T3N0/NX/N1a;III期,T2N1c、T3N1b或T4aN0/NX/N1a;IVA期,T3N1c、T4aN1b/N1c或T4b任何N;IVB期,M1疾病。与TNM-8相比,所提出的分期系统将I期疾病从44.4%(1010例中的448例)减少到24.6%(1010例中的248例),将IV期疾病从18.5%(1010例中的187例)增加到32.4%(1010例中的327例)。所提出的分期系统具有比TNM-8更高的C统计量(0.74 [95% CI, 0.71-0.76] vs 0.71 [95% CI, 0.68-0.74];差异,0.03;95% CI, 0.01-0.04)。相应的SEER C统计量值分别为0.76(95% CI, 0.71-0.81)vs 0.74(95% CI, 0.68-0.79),差异为0.02;95% CI, -0.01至0.06)。这项队列研究发现,该PDTC专用分期系统提供了更好的预后分层,反映了其不同的生物学特性。这些数据为将独立的美国癌症联合委员会PDTC分期系统纳入其中提供了强有力的依据。
Preclinical rodent studies showing a dose-dependent increase in thyroid C-cell hyperplasia and neoplasia with Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs), led the United States Federal Drug Administration to require a boxed warning contraindicating GLP-1RAs for patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome. However, neither primate oncogenicity studies nor patient clinical trials showed C-cell stimulation, calling into question the relevance of rodent models to humans. Indeed, rodents have a high rate of spontaneous thyroid C-cell tumors, a higher number of thyroid C-cells and GLP-1 receptors and use a different pathway from humans in MTC oncogenesis. Although, the majority of meta-analyses of randomized clinical trials and cohort studies using administrative, electronic medical record and/or registry databases report no clear association between GLP-1RA use and thyroid cancer development, pharmacovigilance database studies do demonstrate a positive relationship; however, this association can only be inferred as a possible signal rather than causation and is likely due to notoriety or reporting bias. Additionally, analysis of the overall trends of thyroid cancer incidence in the U.S. since the release of GLP-1RAs for patient use in 2005 show an early increase, probably due to overdiagnosis of papillary carcinoma (PTC); however, the relative proportion of MTC has actually decreased. Because the preponderance of data does not support a causative relationship between GLP-1RA use and MTC (or PTC), we conclude that the need for the boxed warning about the risk of C-cell neoplasia is no longer necessary.
中文摘要:临床前啮齿类动物研究表明,胰高血糖素样肽-1受体激动剂(GLP-1RAs)会导致甲状腺C细胞增生和肿瘤发生呈剂量依赖性增加,这促使美国食品药品监督管理局要求对具有髓样甲状腺癌(MTC)个人或家族史或多发性内分泌肿瘤综合征患者禁用GLP-1RAs并添加黑框警告。然而,灵长类动物致癌性研究和患者临床试验均未显示C细胞刺激作用,从而引发了啮齿类动物模型对人类相关性的质疑。事实上,啮齿类动物自发甲状腺C细胞肿瘤的发生率高,甲状腺C细胞和GLP-1受体数量较多,且在MTC发生机制上使用的通路与人类不同。尽管大多数基于随机对照试验、队列研究以及利用行政、电子病历和/或登记数据库的荟萃分析报告称GLP-1RA使用与甲状腺癌发生之间无明显关联,但药物警戒数据库研究确实显示出正相关关系;然而,这种关联只能推断为一种可能的信号而非因果关系,且可能源于知名度或报告偏倚。此外,自2005年GLP-1RAs用于患者以来,美国甲状腺癌发病率的总体趋势分析显示早期有所增加,这可能与乳头状癌(PTC)的过度诊断有关;然而,MTC的相对比例实际上有所下降。鉴于大多数数据不支持GLP-1RA使用与MTC(或PTC)之间存在因果关系,我们得出结论,关于C细胞肿瘤风险的黑框警告已无必要。
基础研究 (4篇)
Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive malignancies of the digestive tract, making early detection critically important for improving patient survival and treatment outcomes. Biomarker detection is routinely employed as one of the primary modalities for the identification of ESCC. Despite advantages of high sensitivity and fast response, current optical fiber biosensors still face the main challenges of multi-biomarker detection to reduce false-positive results and compensation of the interference from bulk refractive index (BRI) variations for reliable measurement. Here, we report a distributed fiber-optic biosensor capable of simultaneously detecting ESCC dual biomarkers with BRI self-compensation. A step-tapered fiber (STF) sensor is designed with two distinct tapered regions for biomarker detection with BRI compensation. Optical frequency domain reflectometry is employed to simultaneously interrogate the two regions, enabling accurate and rapid detection of ESCC dual biomarkers in a single-shot distributed measurement. Simultaneous detection of both Cyfra21-1 and squamous cell carcinoma antigen (SCCA) biomarkers has been demonstrated within a short assay time of less than 30 min and with an average relative error of 13.8 and 15%, respectively, showing 4.5 times and 11.5 times accuracy improvement when compared to those without BRI compensation. Limits of detection of 0.07 and 0.1 ng/mL have been achieved for Cyfra21-1 and SCCA detection, respectively. The capability of multi-biomarker detection with BRI self-compensation would greatly reduce false-positive rates in ESCC diagnosis.
中文摘要:食管鳞状细胞癌(ESCC)是消化道中最具侵袭性的恶性肿瘤之一,早期检测对于改善患者生存率和治疗效果至关重要。生物标志物检测是识别ESCC的主要手段之一。尽管具有高灵敏度和快速响应的优势,现有光纤生物传感器仍面临多生物标志物检测以减少假阳性结果,以及补偿本体折射率(BRI)变化干扰以实现可靠测量的主要挑战。本文报道了一种具有BRI自补偿功能的分布式光纤生物传感器,能够同时检测ESCC双生物标志物。该传感器采用双阶锥形光纤(STF),设计了两个不同的锥形区域用于生物标志物检测及BRI补偿。利用光学频域反射技术同时探测这两个区域,实现了单次分布式测量中对ESCC双生物标志物的准确快速检测。在不到30分钟的短检测时间内,成功实现了Cyfra21-1和鳞状细胞癌抗原(SCCA)两种生物标志物的同步检测,平均相对误差分别为13.8%和15%,相比无BRI补偿的检测,准确率分别提高了4.5倍和11.5倍。Cyfra21-1和SCCA的检测限分别达到0.07 ng/mL和0.1 ng/mL。这种具有BRI自补偿的多生物标志物检测能力将显著降低ESCC诊断中的假阳性率。
Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.
中文摘要:乳腺癌是女性中最常见的癌症,根据基因表达模式分为管腔型和基底样型,其中后者与较差的预后相关。单细胞技术的最新进展强调了肿瘤内异质性的存在,这给癌症治疗和实现长期无病生存带来了巨大挑战。本研究对一组直接取自手术切除后的初治人类管腔型乳腺癌队列进行了广泛的表观遗传异质性分析。通过应用基于飞行时间质谱的单细胞表观遗传方法,我们在管腔型肿瘤中鉴定出一个复发的基底样细胞亚群,该亚群在不同患者间具有保守的表观遗传特征。通过对全基因组DNA甲基化模式进行反卷积分析也识别出这些基底样细胞,其特征为高表达侵袭性致癌特征和激素受体信号通路的下调。直接比较组蛋白3赖氨酸4的单甲基化和三甲基化的单细胞蛋白质组和基因组谱系分析显示,这些修饰特征是导致管腔型身份丧失的关键标志。最后,我们强调了在血液中游离核小体上同时进行单分子水平组蛋白修饰分析的潜力,将其作为一种表观遗传液体活检方法用于乳腺癌的早期诊断。此外,血液中测得的表观遗传基底特征与预后相关,能够识别疾病复发风险增加的患者。
Glioblastoma (GBM) remains an incurable disease with an extremely poor prognosis. Tumor resection represents a first-line treatment when possible, but most patients suffer tumor recurrence, the primary cause of mortality. One of the functions of connexin43 (Cx43), a gap junction-forming subunit that also has a role in channel-independent signaling, is the inhibition of Src, an oncoprotein involved in tumor progression and recurrence. We previously developed a Cx43 mimetic peptide TAT-Cx43266-283 that recapitulates the inhibition of Src and exerts antitumor effects in patient-derived and mouse in vitro and in vivo models, and here we aimed to explore its effect in GBM recurrence. Analysis of clinical datasets shows a marked increase of Src activity after the standard of care treatments, suggesting that targeting Src activity could prevent GBM recurrence. Importantly, we found that the combination of tumor resection and TAT-Cx43266-283 extended survival in two syngeneic, immunocompetent GBM resection models, which recapitulated key complementary histological features of GBM. TAT-Cx43266-283 in combination with tumor resection increased tumor cell apoptosis and decreased important hallmarks of GBM recurrence by targeting the specific dominant features in each model, such as aberrant vascularization or tumor infiltration. These effects occurred alongside the recruitment of tumor-associated macrophages and microglia (TAMs) to tumor border and their shift towards an antitumor phenotype. Our findings suggest the possible involvement of the immune system in the antitumor effects of TAT-Cx43266-283 and reveal the efficacy and safety of the intracavitary application of TAT-Cx43266-283 after tumor resection, supporting its potential in a clinical setting.
中文摘要:胶质母细胞瘤(GBM)仍是一种无法治愈且预后极差的疾病。在可行的情况下,肿瘤切除是首选治疗方法,但大多数患者面临肿瘤复发这一主要死亡原因。连接蛋白43(Cx43)作为形成缝隙连接的一个亚基,同时也参与非通道依赖性信号传导,其功能之一是抑制Src,而Src是一种参与肿瘤进展和复发的癌蛋白。我们此前开发了一种模拟Cx43作用的肽TAT-Cx43266-283,该肽重现了对Src的抑制作用,并在患者来源及小鼠的体外和体内模型中表现出抗肿瘤效果,本研究旨在探讨其在GBM复发中的作用。临床数据集分析显示,在接受标准护理治疗后Src活性显著增加,表明靶向Src活性可预防GBM复发。重要的是,我们发现将肿瘤切除与TAT-Cx43266-283联合应用,在两个模拟GBM关键互补组织学特征的免疫健全同系GBM切除模型中延长了生存期。TAT-Cx43266-283与肿瘤切除联合应用通过靶向每个模型中的特定主导特征(如异常血管生成或肿瘤浸润),增加了肿瘤细胞凋亡并降低了GBM复发的重要标志。这些效应伴随着肿瘤相关巨噬细胞和小胶质细胞(TAMs)向肿瘤边缘的募集及其向抗肿瘤表型的转变。我们的研究结果表明免疫系统可能参与TAT-Cx43266-283的抗肿瘤作用,并揭示了在肿瘤切除后腔内应用TAT-Cx43266-283的有效性和安全性,支持其在临床环境中的潜力。
Cancer-associated differentially methylated regions (DMRs) are promising biomarkers for cancer diagnosis, prognosis, and therapeutic response, but their biological significance and potential applications remain to be systematically explored across datasets. To support this, we released MethMarkerDB 2.0 (https://methmarkerdb.hzau.edu.cn/v2), which provides several improvements over the previous version: (i) Expands the data resource from 13 to 21 cancer types and from 658 to 1236 whole-genome methylome samples, comprising ∼5.6 million candidate DMRs and 6411 literature-curated biomarker records.(ii) Integrates 450K DNA methylation data from The Cancer Genome Atlas and Epigenome-Wide Association Study Atlas and transcript annotations into the "MethMarker Gene Search" module. These data provide complementary evidence from independent datasets and platforms and allow users to examine CpG-level information for individual DMRs. Additionally, cell-type-resolved reference methylation data allow users to check cellular-background methylation. (iii) Introduces four analysis modules to characterize DMR methylation patterns across age groups and spatial ecotypes, and connect DMRs with transcription factor binding evidence and cancer cell-line drug responses. Moreover, the "Methylation-Cas Designer" supports guide RNA design for methylation-sensitive restriction enzyme-Cas assays and targeted epigenome editing. In summary, MethMarkerDB 2.0 provides expanded resources, diverse functional analyses, and experimental design tools, facilitating the interpretation and application of cancer-associated DMRs.
中文摘要:癌症相关差异甲基化区域(DMRs)是癌症诊断、预后和治疗反应的潜在生物标志物,但其生物学意义和潜在应用仍需跨数据集进行系统探索。为此,我们发布了 MethMarkerDB 2.0(https://methmarkerdb.hzau.edu.cn/v2),相较于前一版本提供了多项改进:(i)将数据资源从13种癌症类型扩展至21种,全基因组甲基化样本从658个增加至1236个,包含约560万个候选DMRs和6411条文献筛选的生物标志物记录。(ii)整合了来自癌症基因组图谱(TCGA)和表观遗传广泛关联研究图谱(EWAS Atlas)的450K DNA甲基化数据及转录本注释至“MethMarker基因搜索”模块。这些数据提供了来自独立数据集和平台的互补证据,允许用户检查单个DMRs的CpG水平信息。此外,细胞类型分辨的参考甲基化数据使用户能够查看细胞背景甲基化情况。(iii)引入四个分析模块以表征不同年龄组和环境生态型中的DMR甲基化模式,并将DMRs与转录因子结合证据及癌细胞系药物反应相联系。此外,“Methylation-Cas设计器”支持用于甲基化敏感限制性内切酶Cas测定和靶向表观基因组编辑的向导RNA设计。总之,MethMarkerDB 2.0提供了扩展的资源、多样化的功能分析和实验设计工具,促进了癌症相关DMRs的解释与应用。
5乳腺癌 (15篇)
临床研究 (2篇)
Breast cancer prevention has been demonstrated using aromatase inhibitors (AIs) including exemestane, but menopause-related adverse events can limit adherence. We hypothesized that estrogens are potential biomarkers that could be measured at baseline to predict the probability of AI-related adverse events. Estrone (E1) and estradiol (E2) levels were measured from Mammary Prevention 3 trial baseline serum samples (n = 4111) using liquid chromatography with tandem mass spectrometry. Hot flashes, fatigue, and joint pain were assessed using the Common Terminology Criteria for Adverse Events v4.0. Severe toxicity (grade ≥3) and moderate toxicity (grade ≥2) were contrasted with less severe toxicity. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for each symptom (years 1 and 5) and baseline E1 and E2 levels. Women on exemestane with the highest levels of E1 or E2 at baseline were significantly more likely to develop severe hot flashes (E1: ORyr-1 = 3.8, 95% CI 1.6-10.5) and (E2: ORyr-1 = 4.2, 95% CI 1.6-13.1) compared with women in the lowest quartile, with a clear dose-response observed at year 1. Severe joint pain was associated with higher baseline E1 and E2 levels in women on exemestane at year 1 but was only statistically significant for E1 (quartiles 2 and 3). There were no significant associations in the placebo group. Women in the highest quartile of E1 or E2 were significantly more likely to discontinue protocol therapy within the first 12 months, independent of assigned treatment, compared with women in the lowest quartile. Postmenopausal women with elevated estrogen levels who initiate exemestane are at greater risk for the development of severe hot flashes and joint pain and may benefit from measures to limit early discontinuation.
中文摘要:芳香酶抑制剂(包括依西美坦)已被证明可用于乳腺癌预防,但绝经相关不良事件可能限制患者的依从性。我们假设雌激素是潜在的生物标志物,可在基线时测量以预测与芳香酶抑制剂相关的不良事件的概率。本研究利用液相色谱串联质谱法测定了Mammary Prevention 3试验基线血清样本(n=4111)中的雌酮(E1)和雌二醇(E2)水平。采用不良事件通用术语标准v4.0评估潮热、疲劳和关节疼痛。将重度毒性(≥3级)和中度毒性(≥2级)与较轻的毒性进行对比。使用逻辑回归估算每个症状(第1年和第5年)以及基线E1和E2水平的比值比(ORs)和95%置信区间(95%CIs)。与最低四分位数的女性相比,基线E1或E2水平最高的依西美坦治疗组女性出现重度潮热的可能性显著更高(E1:第1年OR=3.8,95%CI 1.6-10.5;E2:第1年OR=4.2,95%CI 1.6-13.1),并在第1年观察到明显的剂量反应关系。在第1年,接受依西美坦治疗的女性中,重度关节疼痛与较高的基线E1和E2水平相关,但仅E1具有统计学意义(第2和第3四分位数)。安慰剂组未发现显著关联。无论分配的治疗方案如何,E1或E2处于最高四分位数的女性在最初12个月内停止方案治疗的可能性均显著高于最低四分位数的女性。雌激素水平升高的绝经后女性若开始接受依西美坦治疗,出现重度潮热和关节疼痛的风险更大,可能受益于限制早期停药的措施。
Neutrophils are heterogeneous and critical components of the tumor microenvironment, yet their spatial heterogeneity and clinical implications remain poorly understood. We establish large-scale breast cancer cohorts integrating AI-powered computational pathology (n = 1,113) and single-cell spatial omics (n = 104) to investigate the clinical relevance and biological mechanisms underlying neutrophil spatial patterns. Clinical implications were greatest in triple-negative breast cancer (TNBC): neutrophil-tumor cell proximity associated with favorable prognosis, while neutrophil-immune cell proximity predicted superior immunotherapy response. Combining these patterns with established biomarkers improved TNBC stratification for prognosis and immunotherapy efficacy. Spatial omics and experimental validation demonstrated that tumor-proximal neutrophils enhanced MHC I expression on tumor cells via inflammatory crosstalk, promoting immune-mediated tumor clearance and improved prognosis. Neutrophils adjacent to immune cells exhibited an antigen-presenting phenotype, augmentable by targeting polyamine metabolism. Our study highlights the functional diversity and spatial heterogeneity of neutrophils and provides a translational strategy with routine computational pathology.
中文摘要:中性粒细胞是肿瘤微环境中异质性且至关重要的组成部分,但其空间异质性及临床意义尚不明确。我们建立了大规模乳腺癌队列,整合了基于人工智能的计算病理学数据(n=1,113)和单细胞空间组学数据(n=104),以探究中性粒细胞空间模式的临床相关性和生物学机制。在三阴性乳腺癌中临床意义最为显著:中性粒细胞与肿瘤细胞的邻近性与良好的预后相关,而中性粒细胞与免疫细胞的邻近性则预测了更优的免疫治疗反应。将这些模式与现有生物标志物相结合,改善了用于预后和免疫治疗疗效的三阴性乳腺癌分层。空间组学及实验验证表明,靠近肿瘤的炎症串扰增强了肿瘤细胞上的MHC I类分子表达,促进了免疫介导的肿瘤清除并改善预后。邻近免疫细胞的中性粒细胞表现出抗原呈递表型,可通过靶向多胺代谢进行增强。本研究突出了中性粒细胞的功能多样性和空间异质性,并提供了一种基于常规计算病理学的转化策略。
基础研究 (13篇)
Multiplexed profiling of diverse biomarkers is essential for precision diagnostics, but remains challenging for label-free sensors because signals typically scale with analyte mass. Here, we present a dynamic plasmonic imaging platform based on electromechanically driven nano-oscillators for multiplexed, label-free quantification of nucleic acids, proteins, and small molecules within a unified sensing architecture. Size-encoded nanoparticles tethered to a plasmonic surface are electrically actuated to oscillate vertically within the evanescent field and tracked by distance-resolved surface plasmon resonance imaging. Molecular binding alters the effective surface charge of each nano-oscillator, modulating the electrostatic-driven forces and changing oscillation amplitude. This charge-to-motion transduction mechanism reduces dependence on molecular mass and enhances sensitivity for low-molecular weight analytes. This platform simultaneously detects microRNAs, proteins, and small molecules spanning a ∼300-fold molecular weight range within a single field of view. We further demonstrate multiplexed profiling of tumor-associated microRNAs in pretreated supernatants from patient-derived breast cancer cells across 24 clinical samples. Dynamic plasmonic nano-oscillators provide a scalable architecture for multiplex molecular diagnostics.
中文摘要:多种生物标志物的多重分析对于精准诊断至关重要,但对于无标记传感器而言仍具挑战性,因为信号通常与分析物质量成正比。本文提出了一种基于机电驱动纳米振荡器的动态等离激元成像平台,用于在统一的传感架构中对核酸、蛋白质和小分子进行多重无标记定量。尺寸编码的纳米颗粒连接至等离激元表面,并在消逝场中通过电学驱动进行垂直振荡,随后通过距离分辨的表面等离激元共振成像进行追踪。分子结合会改变每个纳米振荡器的有效表面电荷,从而调节静电驱动力并改变振荡幅度。这种电荷到运动的转导机制降低了对分子质量的依赖,并提高了对低分子量分析物的灵敏度。该平台在单个视场内同时检测跨越约300倍分子量范围的微小RNA、蛋白质和小分子。我们进一步展示了在来自24个临床样本的患者来源乳腺癌细胞预处理上清液中肿瘤相关微小RNA的多重分析结果。动态等离激元纳米振荡器为多重分子诊断提供了可扩展的架构。
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and is characterized by a high metastatic potential and limited treatment options. TNBC frequently metastasizes to lymphatic vessels and the presence of breast cancer cells in tumor-draining lymph nodes (LNs) is an important prognostic factor. Nevertheless, the molecular and metabolic reprogramming of TNBC-associated lymphatic vasculature remains poorly understood. A comprehensive single-cell RNA sequencing analysis of 44,000 endothelial cells from human breast tumor datasets was performed. RBP1, a retinol-binding protein, was identified as a metabolic gene highly and specifically upregulated in tumor-associated lymphatic endothelial cells (LECs). Then, RBP1 expression in human TNBC biopsies was assessed, and its association with LN status and overall patient survival was investigated in a cohort of 1,474 breast cancer patients. We further evaluated the in vivo relevance of RBP1 by CRISPR/Cas9-mediated Rbp1 knockout in a pre-clinical TNBC mouse model. In vitro functional studies were performed using co-culture systems and RBP1-silencing in LECs. Finally, RBP1 mechanism of action in the lymphatic vasculature was determined by bulk-RNA sequencing and validated by applying different cellular and molecular approaches. Single-cell profiling revealed that the metabolic gene RBP1 was upregulated in LECs within the human breast tumor microenvironment. Further analysis showed that lymphatic RBP1 expression was associated with LN metastases, and correlated with poor prognosis and reduced survival in TNBC patients. In the pre-clinical TNBC mouse model, CRISPR-Cas9-mediated Rbp1 knockout reduced lymphangiogenesis, tumor growth and metastatic burden, and increased necrosis. Moreover, functional assays demonstrated that direct co-culture of LECs with TNBC cells, or exposure to their secretome, induced lymphatic RBP1 upregulation and enhanced pro-lymphangiogenic activities, whereas RBP1 silencing compromised their biological, redox and metabolic properties. Mechanistically, bulk RNA sequencing of RBP1-silenced LECs combined with experimental validation revealed that RBP1, through its retinol-binding domain, modulates the VEGFR3 and NOTCH pathways, while also involving lipid mobilization. We define lymphatic RBP1 as a key "switch" that couples LEC metabolism to molecular programs, thereby driving tumor-associated lymphangiogenesis, breast tumor growth and lymphatic dissemination in TNBC. Our findings underscore the potential of RBP1 as both a novel prognostic biomarker and a tractable therapeutic target for blocking TNBC progression and lymphatic metastasis.
中文摘要:三阴性乳腺癌是侵袭性最强的乳腺癌亚型,具有高转移潜力和治疗选择有限的特征。三阴性乳腺癌常发生淋巴管转移,且肿瘤引流淋巴结中存在癌细胞是重要的预后因素。然而,三阴性乳腺癌相关淋巴血管的分子和代谢重编程机制尚不清楚。本研究对来自人类乳腺癌数据集的44,000个内皮细胞进行了全面单细胞RNA测序分析。视黄醇结合蛋白1(RBP1)被鉴定为在肿瘤相关淋巴管内皮细胞中高表达且特异性上调的代谢基因。随后,评估了人类三阴性乳腺癌活检组织中RBP1的表达,并在1,474名乳腺癌患者队列中调查了其与前哨淋巴结状态及患者总生存期的关联。我们进一步通过临床前三阴性乳腺癌小鼠模型中的CRISPR/Cas9介导的Rbp1敲除,评估了RBP1在体内的相关性。利用共培养系统和淋巴管内皮细胞中RBP1沉默进行了体外功能研究。最后,通过批量RNA测序确定淋巴血管中RBP1的作用机制,并应用不同的细胞和分子方法进行了验证。单细胞谱系分析显示,代谢基因RBP1在人乳腺癌肿瘤微环境的淋巴管内皮细胞中上调。进一步分析表明,淋巴管RBP1表达与前哨淋巴结转移相关,并与三阴性乳腺癌患者的不良预后和生存率降低相关。在临床前三阴性乳腺癌小鼠模型中,CRISPR-Cas9介导的Rbp1敲除减少了淋巴管生成、肿瘤生长和转移负荷,并增加了坏死。此外,功能实验表明,淋巴管内皮细胞与三阴性乳腺癌细胞的直接共培养或其分泌组暴露诱导了淋巴管RBP1的上调并增强了促淋巴管生成活性,而RBP1沉默损害了其生物学、氧化还原和代谢特性。机制上,对RBP1沉默的淋巴管内皮细胞进行的批量RNA测序结合实验验证显示,RBP1通过其视黄醇结合结构域调节VEGFR3和NOTCH通路,同时涉及脂质动员。我们将淋巴管RBP1定义为关键的「开关」,将淋巴管内皮细胞代谢与分子程序偶联,从而驱动三阴性乳腺癌相关的淋巴管生成、乳腺癌肿瘤生长和淋巴转移。我们的研究结果强调了RBP1作为新型预后生物标志物和阻断三阴性乳腺癌进展及淋巴转移的可靶向治疗靶点的潜力。
Dysregulation of cell cycle control contributes to the progression and therapeutic resistance of intrahepatic cholangiocarcinoma (ICC), yet the therapeutic potential of targeting this pathway remains incompletely understood. Here, we show that the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor Dalpiciclib suppresses ICC progression, although its efficacy varies across patient-derived models. Mechanistically, Dalpiciclib inhibits CDK4-mediated phosphorylation of β-catenin at Ser675, thereby attenuating epithelial-mesenchymal transition (EMT) and metastatic phenotypes. We further identify miR-221-3p as a key post-transcriptional regulator of CDK4 signaling that modulates both ICC progression and sensitivity to dalpiciclib. Elevated miR-221-3p promotes CDKN1B downregulation, thereby relieving its inhibitory effect on CDK4, enhancing β-catenin phosphorylation, and facilitating metastatic progression. Notably, circulating miR-221-3p levels closely mirrored intratumoral miR-221-3p expression and were associated with Dalpiciclib sensitivity in corresponding patient-derived xenograft (PDX) models, suggesting its potential as a non-invasive biomarker for assessing treatment response. Collectively, these findings identify a miR-221-3p/CDKN1B/CDK4/β-catenin axis that links cell cycle regulation ICC progression and CDK4 inhibitor response, providing a mechanistic rationale for preclinical evaluation of Dalpiciclib treatment in ICC.
中文摘要:细胞周期控制失调导致肝内胆管癌(ICC)的进展和治疗耐药,但靶向该通路的治疗潜力尚不完全清楚。本研究显示,CDK4/6抑制剂Dalpiciclib可抑制ICC进展,但其疗效在不同患者来源模型中存在差异。机制上,Dalpiciclib通过抑制CDK4介导的β-catenin在Ser675位点的磷酸化,从而减弱上皮间质转化(EMT)和转移表型。我们进一步发现miR-221-3p是调控CDK4信号的关键转录后调节因子,可影响ICC进展及对Dalpiciclib的敏感性。高水平的miR-221-3p促进CDKN1B下调,从而解除其对CDK4的抑制作用,增强β-catenin磷酸化并促进转移进展。值得注意的是,循环miR-221-3p水平与肿瘤内miR-221-3p表达高度一致,并与相应患者来源异种移植(PDX)模型中Dalpiciclib的敏感性相关,提示其作为评估治疗反应的无创生物标志物的潜力。综上所述,这些发现确定了一条miR-221-3p/CDKN1B/CDK4/β-catenin轴,该轴将细胞周期调节、ICC进展与CDK4抑制剂反应联系起来,为ICC中Dalpiciclib治疗的临床前评估提供了机制依据。
Directed cell migration is central to the early stages of breast cancer metastasis, when cancer cells detach from the primary tumor and migrate toward distant sites. Here, we use magnetic fields to manipulate this process and examine directional migration and morphology. Magnetic alginate-chitosan (MAC) beads were embedded within a collagen hydrogel to create force-driven micro-topography, and we compared the migration and morphology of MDA-MB-231 breast cancer cells on these constructs. Using video microscopy, we quantified changes in cell shape, velocity, and migration direction in response to intratissue strain. The magnetically actuated cancer metastasis model (MACMM) provides a controllable platform for regulating the magnitude and direction of applied forces to mimic tumor-stroma forces. Under the field, MDA-MB-231 cells near the bead, where strain was maximal, rounded and lost directional persistence (directionality ratio 0.277 versus 0.435 with the same bead and no field), whereas migration speed was not detectably changed. A computational model was developed to map magnetic field gradients and stress-strain profiles within the system. Simulations showed that a field gradient of ∼159 T/m induces a compressive stress of ∼122.8 Pa at 850 µm, decreasing to ∼39.4 Pa at 1500 µm, a 3.11-fold difference that coincides with the transition from rounded cells near the bead to more elongated cells farther away. Magnetic actuation enables tunable control of the force applied to the ECM and generates computed strain gradients across the matrix, accompanied by polarized-light evidence of collagen compaction and alignment at the bead surface, providing insight into cancer cell responses. STATEMENT OF SIGNIFICANCE: Tumors compress and stiffen the surrounding collagen, and these mechanical cues guide invading breast cancer cells. Most laboratory models apply uniform loads or expose cells to free magnetic nanoparticles. We embedded a single magnetic alginate-chitosan bead in a collagen gel so that an external magnet loads the matrix from within while the nanoparticles stay encapsulated. One construct therefore contains a compressed, aligned zone next to the bead and a less loaded zone farther away, both mapped by a computational model of field, force, and stress. Under actuation, cells near the bead rounded and moved less persistently, without slowing down. The platform offers a calibrated way to study how graded matrix loading shapes cancer cell behavior.
中文摘要:定向细胞迁移是乳腺癌转移早期阶段的关键过程,此时癌细胞从原发肿瘤脱离并迁移至远处部位。本研究利用磁场操控该过程并考察定向迁移及形态变化。将磁性海藻酸钠-壳聚糖微球嵌入胶原水凝胶中以构建力驱动的微地形,并比较MDA-MB-231乳腺癌细胞在这些结构上的迁移和形态。通过视频显微镜量化了细胞形状、速度和迁移方向对组织内应变的响应变化。磁性驱动癌症转移模型提供了可控平台以调节施加力的大小和方向从而模拟肿瘤间质力。在磁场作用下靠近微球(应变最大处)的MDA-MB-231细胞变圆并失去定向持续性(方向性比值0.277对比无磁场时的0.435),而迁移速度无明显变化。开发了计算模型以映射系统内的磁场梯度和应力应变分布。模拟显示约159 T/m的场梯度在850 µm处诱导约122.8 Pa的压应力,在1500 µm处降至约39.4 Pa,这种3.11倍的差异与微球附近细胞变圆而远处细胞更延长的转变相吻合。磁性驱动实现了对基质施加力的可调控制并在基质中产生计算的应变梯度伴随偏振光证据显示胶原在微球表面压缩和排列从而揭示癌细胞响应机制。肿瘤会压缩并硬化周围胶原这些机械线索引导侵袭性乳腺癌细胞。大多数实验室模型施加均匀载荷或使细胞暴露于自由磁性纳米颗粒。我们将单个磁性海藻酸钠-壳聚糖微球嵌入胶原凝胶中使外部磁体从内部加载基质同时纳米颗粒保持封装。因此一个结构包含微球旁边的压缩对齐区和较远的低负载区两者均由场力和应力的计算模型映射。在驱动下微球附近的细胞变圆且迁移持续性降低但未减速。该平台提供了校准方式来研究梯度基质载荷如何塑造癌细胞行为。
Most breast cancers respond poorly to immune checkpoint blockade (ICB), and hormone receptor-positive (HR +) tumors, which constitute most diagnoses, are particularly refractory. This review synthesizes evidence on tumor-intrinsic determinants of the immune-cold phenotype in breast cancer under an operational framework designated ICE, comprising three functionally defined domains: Invisibility (failure of antigen generation, presentation, and innate sensing), Coercion (active exclusion and post-infiltration suppression of effector cells), and Exhaustion-by-Metabolism (metabolic attrition of infiltrating lymphocytes). ICE is not proposed as a newly discovered taxonomy of immune evasion; its added value lies in integrating breast-cancer subtype resolution, evidence provenance, systems-level interactions, negative clinical evidence, and mechanism-biomarker-intervention matching within a single operational framework. Four features define this framework. The domains are overlapping rather than sequential, and an explicit assignment rule places multifunctional regulators such as MYC, hypoxia-inducible factor 1α, and lactate in a primary domain while cataloguing secondary effects. Tumor-immune interaction is treated as bidirectional, positioning tumor-intrinsic programs as both causes and consequences of immune pressure. Major mechanistic and translational claims are assigned claim-specific evidence tiers. Resistance to immune-mediated killing, including death receptor loss, is classified as cross-dimensional cytoprotection rather than a recognition defect. Applying this discipline exposes an asymmetric evidence base: antigen presentation defects and metabolic suppression rest on substantial preclinical data with limited clinical validation, several widely cited mechanisms derive from non-breast models, and the translational record includes cross-cancer constraints-failure of IDO1 inhibition in a melanoma phase III trial and minimal STING-agonist monotherapy activity in early mixed-solid-tumor studies-together with breast-cancer-specific negative findings from IMpassion131 and the unfavorable benefit-risk profile of abemaciclib plus pembrolizumab. Cross-dimensional systems-level structures, including the hypoxia-adenylosuccinate lyase-fumarate-STING axis and the tumor-macrophage arginine-polyamine relay, are identified as the most instructive examples of domain interaction, and seven falsifiable predictions are advanced, each specifying a measurable biomarker and a decisive experiment.
中文摘要:大多数乳腺癌对免疫检查点阻断治疗反应不佳,其中激素受体阳性肿瘤尤为难治。本综述在名为ICE的操作框架下综合了关于乳腺癌免疫冷表型肿瘤内在决定因素的证据,该框架包含三个功能定义领域:不可见性(抗原生成、呈递和先天感知的失败)、强制作用(效应细胞的主动排除和浸润后抑制)以及代谢耗竭(浸润淋巴细胞的代谢损耗)。ICE并非提出的新免疫逃逸分类法,其价值在于将乳腺癌亚型解析、证据来源、系统水平相互作用、阴性临床证据及机制生物标志物干预匹配整合于单一操作框架中。该框架由四个特征定义:领域重叠而非顺序排列,明确分配规则将MYC、缺氧诱导因子1α和乳酸等多功能调节因子归入主要领域并列出次要效应;肿瘤免疫相互作用被视为双向的,将肿瘤内在程序定位为免疫压力的原因和结果;主要的机制和转化主张被赋予特定证据等级;对免疫介导杀伤的抵抗包括死亡受体丢失被归类为跨维度细胞保护而非识别缺陷。应用这一学科暴露出不对称的证据基础:抗原呈递缺陷和代谢抑制基于大量临床前数据但缺乏临床验证,几个广泛引用的机制源自非乳腺癌模型,转化记录包括跨癌种限制如黑色素瘤III期试验中IDO1抑制的失败以及早期混合实体瘤研究中STING激动剂单药活性的微弱,加上来自IMpassion131研究的乳腺癌特异性阴性发现以及阿贝西利联合帕博利珠单抗的不利获益风险特征。缺氧-延胡索酸合酶-延胡索酸-STING轴和肿瘤巨噬细胞精氨酸多胺接力等跨维度系统水平结构被确定为领域相互作用的最具启发性的例子,并提出了七个可证伪的预测,每个预测都指定了可测量的生物标志物和决定性实验。
Mature adipocytes within the breast tumour microenvironment contribute a significant role in malignant progression. At the invasive front of breast tumours, mature adipocytes undergo morphological and phenotypic changes and may provide metabolic support to fuel tumour growth and spread. However, investigations into mature adipocyte-breast cancer interactions have been limited by the lack of suitable in vitro models. Here, we developed an innovative 3D in vitro co-culture system allowing direct contact between patient-derived mature breast adipocytes and breast cancer cell lines, to systematically examine cell-cell interactions over 21 days. In co-culture with triple negative breast cancer cells (MDA-MB-231), mature adipocytes exhibited loss of Perilipin 1 (PLIN1) expression and were associated with reduced chemotherapy responsiveness and increased Major Vault Protein (MVP) abundance. In contrast, Luminal A (MCF7) breast cancer cells displayed increased expression of mesenchymal markers (N-cadherin and Vimentin), consistent with a partial epithelial to mesenchymal transition. The direct 3D co-culture model developed by this work provides a novel platform to study breast cancer subtype-specific interactions between mature adipocytes and cancer cells, revealing interactions associated with chemotherapy responsiveness and malignant progression.
中文摘要:乳腺肿瘤微环境中的成熟脂肪细胞在恶性进展中发挥重要作用。在乳腺肿瘤的侵袭前沿,成熟脂肪细胞发生形态和表型改变,并为肿瘤生长和扩散提供代谢支持。然而,由于缺乏合适的体外模型,对成熟脂肪细胞与乳腺癌相互作用的研究受到限制。本研究开发了一种创新的3D体外共培养系统,允许患者来源的成熟乳腺脂肪细胞与乳腺癌细胞系直接接触,以系统研究21天内的细胞间相互作用。在与三阴性乳腺癌细胞(MDA-MB-231)共培养时,成熟脂肪细胞表现出Perilipin 1(PLIN1)表达丢失,并与化疗反应性降低及Major Vault Protein(MVP)丰度增加相关。相比之下,Luminal A型(MCF7)乳腺癌细胞显示间质标志物(N-cadherin和Vimentin)表达增加,符合部分上皮间质转化特征。本研究开发的直接3D共培养模型为研究成熟脂肪细胞与癌细胞之间亚型特异性相互作用提供了新平台,揭示了与化疗反应性和恶性进展相关的相互作用。
Inflammatory breast cancer (IBC) is a highly aggressive breast cancer subtype characterized by diffuse, biologically invasive growth and poorly defined tissue boundaries, resulting in a high mortality rate even after multimodal treatment. Here, we report an intracellular polymerization-induced self-assembly (PISA) strategy that constructs mechanically active peptide nanosheets. Upon 365 nm UV irradiation, the photoinitiator Irgacure 2959 (I2959) initiates intracellular PISA of HisMAm in IBC cells. The corresponding nanosheets prepared in vitro exhibit a thickness of ∼30 nm and a wet-state apparent Young's modulus of 8.02 ± 0.43 MPa. These nanosheets act through two coordinated materials-cell interactions: (i) increasing cellular viscosity and spatially associating with the actin cytoskeleton, suppressing cell migration and invasion; and (ii) accumulating in the endoplasmic reticulum and eliciting paraptosis-like cell death. In a subcutaneous IBC xenograft model, localized fiber-assisted light activation achieves 72.2% tumor growth inhibition without overt systemic toxicity. Overall, this work establishes intracellular PISA as a spatiotemporally controlled materials strategy for localized IBC treatment.
中文摘要:炎性乳腺癌(IBC)是一种高度侵袭性的乳腺癌亚型,其特征为弥漫性、生物学侵袭性生长及组织边界不清,即使在多模态治疗后仍具有高死亡率。本研究报道了一种细胞内聚合诱导自组装(PISA)策略,用于构建具有机械活性的肽纳米片。在365 nm紫外光照射下,光引发剂Irgacure 2959(I2959)在IBC细胞中启动HisMAm的细胞内PISA过程。体外制备的相应纳米片厚度约为30 nm,湿态表观杨氏模量为8.02 ± 0.43 MPa。这些纳米片通过两种协同的材料-细胞相互作用发挥作用:(i)增加细胞粘度并与肌动蛋白细胞骨架空间关联,从而抑制细胞迁移和侵袭;(ii)在内质网中积累并引发类似浆液性坏死的细胞死亡。在皮下IBC异种移植模型中,局部光纤辅助光激活实现了72.2%的肿瘤生长抑制,且无明显全身毒性。总体而言,本研究确立了细胞内PISA作为一种时空可控的材料策略,用于局部治疗IBC。
Morphology-Tunable Nanoparticles of Aspartic Acid Paclitaxel Conjugates for Breast Cancer Treatment.
The structural morphologies of nanomaterials serve as vital determinants in their biological interactions and efficacy in vivo. Achieving programmable control over the assembly morphology solely through molecular design remains challenging. Herein, a supramolecular strategy to control the assembly morphology of prodrugs for the orchestration of drug delivery in vivo is reported. A paclitaxel prodrug (PCA) was synthesized by conjugating aspartic acid with paclitaxel through a succinyl linker. PCA can spontaneously self-assemble into nanofibers. Incorporating the diacylphosphatidylethanolamine-PEG2k (DSPE-PEG2k) induces a morphological transition from fibers to rods and ultimately to spheres. Molecular dynamics simulations show that intermolecular hydrogen bonds fall from approximately 50 in DP1 NFs to fewer than 5 in DP3 NPs, and carboxyl-related atoms in aspartic acid account for 53.24% of the total hydrogen bonds, proving that the carboxyl-mediated hydrogen-bond network dominates anisotropic assembly. Although fibrous and spherical assemblies exhibit the fastest release rate and optimized cellular delivery of paclitaxel in vitro, respectively, the rod-shaped assemblies achieve an optimal combination of prolonged blood circulation, enhanced tumor accumulation, and facilitated cellular internalization, resulting in superior antitumor efficacy in vivo, compared to fibrous and spherical counterparts and Abraxane. This study elucidates how supramolecular interactions regulate the macroscopic morphology of prodrug assemblies at the molecular level, establishing a design paradigm for engineering anisotropic nanomedicines with tailored in vivo fate.
中文摘要:纳米材料的结构形态是其体内生物相互作用和疗效的关键决定因素。仅通过分子设计实现组装形态的可编程控制仍然具有挑战性。本文报道了一种超分子策略,用于控制前药的组装形态以协调体内药物递送。通过将天冬氨酸与紫杉醇通过琥珀酰连接子偶联,合成了一种紫杉醇前药PCA。PCA可自发自组装成纳米纤维。加入二酰基磷脂酰乙醇胺PEG2k(DSPE-PEG2k)会诱导形态从纤维转变为棒状,最终变为球形。分子动力学模拟显示,DP1纳米纤维中的分子间氢键数量从约50个减少到DP3纳米颗粒中的少于5个,且天冬氨酸中羧基相关原子占总氢键的53.24%,证明羧基介导的氢键网络主导各向异性组装。尽管纤维状和球状组装体分别在体外表现出最快的释放速率和优化了紫杉醇的细胞递送效率,但棒状组装体实现了延长血液循环、增强肿瘤积累和促进细胞内吞的最佳组合,与纤维状和球状对应物以及白蛋白结合型紫杉醇相比,在体内具有更优越的抗肿瘤疗效。本研究阐明了超分子相互作用如何在分子水平上调节前药组装体的宏观形态,为设计具有定制体内命运的各向异性纳米药物建立了设计范式。
Racial disparities in the incidence of, and mortality from, aggressive breast cancers are a pressing public health issue. Many factors have been investigated in these inequities; however, the role of toxicant exposures is not well characterized. We and others have identified substantial inequities in chemical biomarker concentrations by race. The goal of this study was to test the hypothesis that exposure to these chemicals is linked to biological changes relevant to aggressive breast cancers, such as dysregulation of the Hallmarks of Cancer. We used high-throughput transcriptomic profiling of normal primary human breast epithelial cells from diverse donors (n = 6) to test the effects of 8 chemicals (cadmium, lead, arsenic, copper, PFNA, BPA, BPS, and p,p'-DDE) with documented exposure disparities by race/ethnicity across 3 concentrations (100 nM, 1 μM, and 10 μM). Across chemicals, we identified that pathways related to cell cycle regulation and protein secretion were commonly affected. Through bioinformatic estimation of cell-type proportions, we found that metals like lead and cadmium induced cell-type shifts, consistent with the dysregulated cellular plasticity cancer hallmark. Lead- and arsenic-response genes were enriched for genes associated with poor breast cancer survival in the Cancer Genome Atlas. Integrating concentration-response modeling and chemical biomonitoring data, BPA, p,p'-DDE, copper, and lead elicited expression changes at concentrations relevant to the US population. Finally, we identified substantial interindividual heterogeneity in response to chemical classes, with heavy metals producing the largest dose-responsive transcriptional effects. These findings highlight the value of high-throughput transcriptomics as a new approach methodology (NAM) in quantifying how common exposures may impact aggressive breast cancer-associated biological processes.
中文摘要:侵袭性乳腺癌的发病率及死亡率存在种族差异,这是一个紧迫的公共卫生问题。尽管已对诸多因素进行了调查,但毒物暴露的作用尚不明确。我们及其他研究者已发现不同种族间化学标志物浓度存在显著的不平等。本研究旨在验证一个假设,即这些化学物质的暴露与侵袭性乳腺癌相关的生物学改变有关,例如癌症特征的失调。我们利用来自不同供体的正常原代人乳腺上皮细胞(n=6)的高通量转录组分析,测试了8种化学物质(镉、铅、砷、铜、PFNA、BPA、BPS和p,p'-DDE)在3个浓度(100 nM、1 μM和10 μM)下的影响,这些化学物质的暴露存在种族/族裔差异。跨化学物质的分析显示,细胞周期调节和蛋白质分泌相关通路普遍受到影响。通过生物信息学估算细胞类型比例,我们发现铅和镉等金属诱导了细胞类型的转变,这与失调的细胞可塑性癌症特征一致。铅和砷响应基因在癌症基因组图谱中与不良乳腺癌生存率相关的基因富集。结合浓度反应建模和化学生物监测数据,BPA、p,p'-DDE、铜和铅在美国人群相关浓度下引发了表达变化。最后,我们发现了不同化学类别响应的显著个体间异质性,其中重金属产生了最大的剂量依赖性转录效应。这些发现强调了高通量转录组学作为新 Approach 方法论在量化常见暴露如何影响侵袭性乳腺癌相关生物学过程方面的价值。
Endotrophin (ETP), a C-terminal cleavage fragment of the collagen VI α3 chain, has emerged as a key mediator of fibroinflammation and a clinically relevant biomarker of disease progression. Accumulating evidence from both preclinical models and human studies implicates elevated ETP levels as a driver of tissue remodelling, metabolic dysfunction, inflammation and fibrosis across multiple organ systems. Increased ETP has been linked to obesity-associated adipose tissue dysfunction, steatotic liver disease, breast cancer progression, chronic kidney disease and cardiovascular disease, underscoring its broad pathological relevance. The convergence of mechanistic and clinical data positions ETP as a promising therapeutic target across a range of diseases linked by common ETP-driven dysfunction. Here we synthesize current knowledge of ETP's regulation and functions, critically evaluate its role in diverse disease contexts and outline key unanswered questions and emerging strategies for therapeutic intervention.
中文摘要:内皮生长因子(ETP)是胶原VIα3链的C端裂解片段,已成为纤维化炎症的关键介质及疾病进展的临床相关生物标志物。来自临床前模型和人类研究的累积证据表明,升高的ETP水平是驱动多器官系统组织重塑、代谢功能障碍、炎症和纤维化的因素。ETP增加与肥胖相关的脂肪组织功能障碍、脂肪性肝病、乳腺癌进展、慢性肾脏病和心血管疾病有关,强调了其广泛的病理相关性。机制数据和临床数据的汇聚将ETP定位为一系列由共同ETP驱动功能障碍相关疾病的有前景的治疗靶点。本文综合了关于ETP调节和功能的知识,批判性地评估了其在不同疾病背景下的作用,并概述了关键未解问题和治疗干预的新兴策略。
In this issue of Cancer Cell, Xu et al. combine large-scale computational pathology, spatial omics, and functional experiments to examine neutrophil organization in triple-negative breast tumors. They identify two neutrophil niches with different clinical associations: tumor-proximal neutrophils are linked to favorable prognosis, whereas neutrophils near immune cells associate with immunotherapy response.
中文摘要:本期《癌症细胞》杂志中,徐等人结合大规模计算病理学、空间组学和功能实验,研究了三阴性乳腺癌肿瘤中的中性粒细胞组织。他们鉴定出两个具有不同临床关联的中性粒细胞生态位:靠近肿瘤的中性粒细胞与良好的预后相关,而靠近免疫细胞的中性粒细胞则与免疫治疗反应相关。
Triple-negative breast cancer (TNBC) is an aggressive cancer subtype with limited treatment options. Platinum chemotherapy is incorporated into several therapeutic strategies, but its clinical benefit is constrained by resistance, toxicity, and suboptimal patient stratification. Platinum-induced DNA crosslinking remains the principal mechanism underlying antitumor activity. Recent studies indicate that Pt(IV) prodrugs, multifunctional agents, subcellularly targeted complexes, and tumor-responsive delivery systems can extend platinum pharmacology beyond conventional cytotoxicity. In parallel, studies have revealed emerging vulnerabilities, including homologous recombination deficiency, immunogenic cell death, ferroptosis, and DNA damage response dependencies, that provide new opportunities to enhance efficacy and overcome resistance. Advanced translational models and biomarker-guided stratification may help translate these opportunities into more precise therapeutic strategies. In this article, we review these developments and discuss their implications for advanced platinum therapies in TNBC.
中文摘要:三阴性乳腺癌是一种侵袭性强的癌症亚型,治疗选择有限。铂类化疗被纳入多种治疗策略,但其临床获益受限于耐药性、毒性及患者分层不足。铂诱导的DNA交联仍是其抗肿瘤作用的主要机制。近期研究表明,Pt(IV)前药、多功能制剂、亚细胞靶向复合物及肿瘤响应型递送系统可将铂类药理学拓展至传统细胞毒性之外。同时,研究揭示了同源重组缺陷、免疫原性细胞死亡、铁死亡及DNA损伤反应依赖性等新兴脆弱环节,为提高疗效和克服耐药提供了新机遇。先进的转化模型与生物标志物指导的分层策略有助于将这些机遇转化为更精准的治疗方案。本文综述了这些进展并探讨了其对三阴性乳腺癌中先进铂类治疗的影响。
Golgiphagy contributes to Golgi quality control, yet its regulatory mechanisms and physiological functions remain poorly understood. We identify the deubiquitinase USP28 as an upstream regulator of TM9SF3-dependent Golgiphagy. Nutrient deprivation and Golgi stress induce CRM1-dependent nuclear export of USP28, enabling its translocation to the Golgi, where it removes K48-linked ubiquitin chains from TM9SF3 to prevent its proteasomal degradation and promote Golgiphagy. TM9SF3-dependent Golgiphagy regulates glycosyltransferase abundance through selective degradation of cargo such as MGAT5, thereby maintaining glycosylation homeostasis. Genetic or pharmacological inhibition of the USP28-TM9SF3-Golgiphagy pathway disrupts glycosylation homeostasis and suppresses breast tumor growth. Together, these findings establish the USP28-TM9SF3 axis as a regulatory mechanism linking Golgiphagy to glycosylation homeostasis and breast cancer progression.Abbreviations: CRM1: chromosome region maintenance 1; ER: endoplasmic reticulum; LIR: LC3-interacting region; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; MGAT5: alpha-1,6-mannosylglycoprotein 6-beta-Nacetylglucosaminyltransferase; TM9SF3: transmembrane 9 superfamily member 3; USP28: ubiquitin specific peptidase 28.
中文摘要:高尔基体自噬参与高尔基体质量控制,但其调控机制和生理功能尚不清楚。我们鉴定出去泛素化酶USP28是TM9SF3依赖性高尔基体自噬的上游调节因子。营养剥夺和高尔基体应激诱导CRM1依赖性的USP28核输出,使其易位至高尔基体,在那里它去除TM9SF3上的K48连接泛素链,防止其蛋白酶体降解并促进高尔基体自噬。TM9SF3依赖性的高尔基体自噬通过选择性降解MGAT5等货物来调节糖基转移酶的丰度,从而维持糖基化稳态。遗传或药理学抑制USP28-TM9SF3-高尔基体自噬通路会破坏糖基化稳态并抑制乳腺癌肿瘤生长。总之,这些发现确立了USP28-TM9SF3轴作为连接高尔基体自噬与糖基化稳态及乳腺癌进展的调控机制。
6神经系统肿瘤 (13篇)
临床研究 (3篇)
Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake. Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds. In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.
中文摘要:大多数评估O-(2-[18F]-氟乙基)-L-酪氨酸(FET)PET用于胶质母细胞瘤进展的研究依赖于单次扫描评估,这在示踪剂摄取处于临界值时留下了诊断不确定性。我们利用连续FET PET评估胶质母细胞瘤进展过渡期间的代谢活性演变,以确定纵向参数变化是否能提高诊断确定性。回顾性评估了2016年至2026年间接受690次动态FET PET扫描(中位数3次;范围2-12次)的182名胶质母细胞瘤患者。符合条件的病例需有根据RANO 2.0标准记录的疾病进展,并在至少两个时间点(疑似进展时及此前6个月窗口内)进行连续FET PET检查。根据PET RANO 1.0标准评估了静态PET参数,即肿瘤脑比值(TBRmean、TBRmax)和代谢肿瘤体积(MTV),及其纵向变化,同时还包括额外的动态PET参数(达峰时间)。在摄取处于临界值的病例中比较了单次扫描指标和连续变化。90名患者共102例确认的进展事件符合所有选择标准(扫描间期中位数2.7个月)。在进展时,TBRmean、TBRmax和MTV显著增加(P < .001)。TBRmean(+4%)和TBRmax(+17%)的中位数百分比增加幅度较小,而MTV表现出显著扩张(+182%)。在摄取处于临界值的病例中,应用PET RANO 1.0标准的纵向MTV增加≥40%的标准将进展检测率大幅提高至89%,与单次扫描阈值相比诊断检测率高出14%。在有记录的RANO 2.0进展的胶质母细胞瘤中,整合纵向MTV变化显著提高了诊断确定性,优于单次扫描摄取指标,特别是在摄取处于临界值的挑战性病例中。
Glioblastoma is the most common malignant brain tumor in adults. Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter is the only clinically used biomarker predicting response to alkylating agents such as temozolomide and is associated with improved survival. However, its predictive accuracy is limited by an intermediate gray zone and variability in assessment methods. To reduce overtreatment of patients, improved stratification strategies are needed, potentially through integration of additional biomarkers such as MGMT protein expression. We performed a systematic review to evaluate studies comparing the prognostic value for progression-free survival and overall survival of MGMT promoter methylation and MGMT protein expression in glioblastoma patients treated with temozolomide, including 33 independent cohorts with a total of 4,691 patients. We searched three databases up to May 2025. Risk of bias was assessed with a modified Quips tool. Methylation-specific PCR and pyrosequencing indicated stronger prognostic value than immunohistochemical assessment of MGMT protein expression with hazard ratios (HRs) of 2.07 (95%CI 1.61-2.66), 2.13 (95%CI 1.64-2.75), and 1.50 (95%CI 1.26-1.79), respectively. An inverse correlation between MGMT promoter methylation and protein expression was observed in only 52% of assessed studies, suggesting that promoter methylation and protein expression may contribute independently to prognosis. Substantial variability in methylation assays and protein cut-offs underscores the need for methodological harmonization in future studies and clinical practice. Integration of MGMT protein expression with promoter methylation refines identification of primary temozolomide-resistant tumors and supports the debate of withholding temozolomide in patients unlikely to benefit.
中文摘要:胶质母细胞瘤是成人中最常见的恶性脑肿瘤。O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)启动子甲基化是唯一用于预测替莫唑胺等烷化剂反应性的临床生物标志物,且与生存改善相关。然而,其预测准确性受限于中间灰区及评估方法的变异性。为减少患者过度治疗,需要改进分层策略,可能通过整合MGMT蛋白表达等其他生物标志物实现。我们进行了系统评价,以评估替莫唑胺治疗的胶质母细胞瘤患者中MGMT启动子甲基化与MGMT蛋白表达对无进展生存期和总生存的预后价值,纳入33个独立队列共4,691名患者。检索了截至2025年5月的三个数据库。使用改良的Quips工具评估偏倚风险。甲基化特异性PCR和焦磷酸测序显示出比免疫组化检测MGMT蛋白表达更强的预后价值,其风险比(HR)分别为2.07(95%CI 1.61-2.66)、2.13(95%CI 1.64-2.75)和1.50(95%CI 1.26-1.79)。仅在52%的研究中观察到MGMT启动子甲基化与蛋白表达之间的负相关,表明启动子甲基化和蛋白表达可能独立影响预后。甲基化检测和蛋白截断值的显著变异性强调了未来研究和临床实践中方法学标准化的必要性。整合MGMT蛋白表达与启动子甲基化有助于更精准地识别原发替莫唑胺耐药肿瘤,并支持对不太可能受益的患者暂停使用替莫唑胺的讨论。
Accurate visualization of glioblastoma is essential for guiding biopsy, resection and radiotherapy. Contrast-enhanced MRI is routine in clinical practice, yet it can miss metabolically active tumor outside areas of blood-brain barrier disruption. In a histopathology-validated cohort with 472 tissue samples of 61 patients with IDH-wildtype glioblastoma, we show that O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET ([18F]FET PET) depicts tumor tissue significantly better than contrast-enhanced MRI (CE-MRI), especially in regions that show no enhancement on MRI. [18F]FET PET achieves substantially higher sensitivity for tumor detection (91.2% vs 52.6%) and maintains high reliability in non-enhancing tissue (positive predictive value 98.3%), findings that are consistent across newly diagnosed and recurrent disease and in both cohorts undergoing either resection or biopsy. These results indicate that [18F]FET PET complements MRI by revealing MRI-occult tumor burden. Incorporating amino acid PET into routine planning may therefore improve the accuracy of tumor visualization and, ultimately, patient management.
中文摘要:准确可视化胶质母细胞瘤对于指导活检、切除和放疗至关重要。对比增强MRI是临床常规手段,但可能遗漏血脑屏障破坏区域外代谢活跃的肿瘤组织。在一项包含61例IDH野生型胶质母细胞瘤患者472个组织样本的组织病理学验证队列中,我们表明O-(2-[18F]氟乙基)-L-酪氨酸PET([18F]FET PET)描绘肿瘤组织的效果显著优于对比增强MRI(CE-MRI),尤其是在MRI无强化的区域。[18F]FET PET实现了对肿瘤检测的显著更高敏感性(91.2% vs 52.6%),并在非强化组织中保持高可靠性(阳性预测值98.3%),这些结果在新诊断和复发性疾病队列以及接受切除或活检的患者中均一致。这些结果表明[18F]FET PET通过揭示MRI隐匿的肿瘤负荷来补充MRI。因此,将氨基酸PET纳入常规规划可能提高肿瘤可视化的准确性并最终改善患者管理。
基础研究 (10篇)
Glioma is a highly malignant tumor characterized by pronounced intratumoral heterogeneity. By integrating multi-omics analyses, we identified radial glial stem-like (RG-like) cells as a putative upstream developmental-like state in inferred glioma differentiation trajectories. Integrated spatial transcriptomic and histopathological analyses further linked the molecular features of RG-like cells to their spatial distribution and associated tissue morphology. A CRISPR-based knockout screen highlighted heat shock protein beta-1 (HSPB1) as a potential molecular target associated with RG-like cell functions. We subsequently investigated quercetin (QUE) and found that it inhibited glioma cell growth and suppressed mitotic somal translocation (MST), a characteristic RG-like cellular behavior. Mechanistic analyses showed that QUE reduced HSPB1 protein expression and was associated with a reduced detectable interaction between HSPB1 and vimentin (VIM). Together, these findings characterize RG-like cells at the molecular and histopathological levels and suggest that QUE may represent a potential pharmacological approach for modulating their associated functions in glioma.
中文摘要:胶质瘤是一种具有显著瘤内异质性的高度恶性肿瘤。通过整合多组学分析,我们将径向神经胶质干细胞样(RG-like)细胞确定为推断的胶质瘤分化轨迹中潜在的上游发育样状态。整合空间转录组学和组织病理学分析进一步将RG样细胞的分子特征与其空间分布及相关组织形态联系起来。基于CRISPR的敲除筛选突出了热休克蛋白β-1(HSPB1)作为与RG样细胞功能相关的潜在分子靶点。我们随后研究了槲皮素(QUE),发现其抑制胶质瘤细胞生长并抑制有丝分裂体胞转位(MST),这是一种典型的RG样细胞行为。机制分析显示,QUE降低了HSPB1蛋白表达,并与HSPB1和波形蛋白(VIM)之间可检测到的相互作用减少相关。综上所述,这些发现从分子和组织病理学水平表征了RG样细胞,并表明QUE可能代表一种调节胶质瘤中相关功能的潜在药理学方法。
Automated classification of glioblastoma (IDH-wt, WHO CNS Gr.4) histopathologic sub-regions in whole slide images (WSI) is essential for quantitative tumor characterization, but faces substantial challenges from intra-tumoral heterogeneity and inter-observer annotation variability. The AI-RANO & RANO-Pathology working groups organized BraTS-Path 2024, representing the first international benchmarking environment and publicly available spatially annotated dataset, towards promoting the development and fair evaluation of Artificial Intelligence (AI) models to classify specific sub-regions: cellular tumor, pseudopalisading necrosis (PN), microvascular proliferation, geographic necrosis, infiltration into the cortex, and white matter penetration (WM). Multi-institutional H&E-stained WSIs had reference standard samples generated by eight expert neuropathologists, following a rigorous peer review protocol, resulting in 309,118 data samples (training/validation/hold-out testing: 96,485/62,387/150,246). Quantitative performance evaluation of six AI approaches was conducted based on multiple metrics, including Accuracy and Matthew's correlation coefficient (MCC). A robust statistically-aware ranking strategy offered statistical significance of the final rankings. Top-performing approaches employed common strategies, including large pre-trained models, ensembling, and extensive data augmentation, reporting Accuracy=0.69 and MCC=0.58. Key challenges included severe class imbalance, hampering minority class performance, and inter-annotator variability, especially for ambiguous sub-regions such as PN or WM. BraTS-Path represents a valuable public resource for glioblastoma histopathologic sub-region assessment. Our findings indicate the specific task remaining an open research problem, highlighting the influence of rare sub-regions, the absence of a consistent "gold standard" annotation protocol, and the potential of foundation models to improve generalization, guiding future research toward developing more reliable AI tools for quantitative neuropathology.
中文摘要:胶质母细胞瘤(IDH野生型,WHO中枢神经系统4级)组织病理学亚区在全切片图像中的自动分类对于定量肿瘤表征至关重要,但面临肿瘤内异质性和观察者间注释变异性带来的重大挑战。AI-RANO与RANO-Pathology工作组组织了BraTS-Path 2024挑战赛,这是首个国际基准测试环境和公开的空间注释数据集,旨在促进人工智能模型的开发及公平评估,以分类特定亚区:细胞性肿瘤、假栅栏状坏死、微血管增生、地理性坏死、皮质浸润和白质穿透。多机构苏木精-伊红染色全切片图像由八位专家神经病理学家生成参考标准样本,遵循严格的同行评审协议,最终产生309,118个数据样本(训练/验证/保留测试集分别为96,485/62,387/150,246)。基于准确率等指标对六种人工智能方法进行了定量性能评估。一种稳健的统计感知排名策略提供了最终排名的统计显著性。表现最佳的方法采用了常见策略,包括大型预训练模型、集成学习和广泛的数据增强,报告准确率为0.69,马修斯相关系数为0.58。关键挑战包括严重的类别不平衡,阻碍了少数类的性能,以及注释者间的变异性,特别是在假栅栏状坏死或白质穿透等模糊亚区中。BraTS-Path代表了胶质母细胞瘤组织病理学亚区评估的宝贵公共资源。研究结果表明该特定任务仍是一个开放的研究问题,强调了罕见亚区的影响、缺乏一致的黄金标准注释协议,以及基础模型在提高泛化能力方面的潜力,从而指导未来研究开发更可靠的人工智能工具用于定量神经病理学。
Dysregulated epidermal growth factor receptor variant III (EGFRvIII) contributes to tumor progression in several human cancers, including oral squamous cell carcinoma (OSCC) and glioblastoma multiforme. Although genomic alterations are frequently associated with EGFRvIII expression, the contribution of environmental carcinogens and RNA-based regulatory mechanisms to its expression remains poorly understood and was investigated in this study. Chronic exposure models of the tobacco-specific nitrosamine nicotine-derived nitrosamine ketone (NNK) and the areca nut alkaloid arecoline were established in dysplastic oral keratinocytes. Expression and splicing patterns of EGFR isoforms were analyzed using molecular assays and long-read sequencing. Functional assays, RNA pull-down, AGO2 immunoprecipitation, MS2-based RNA affinity purification, and reporter assays were performed to investigate the roles of splicing factors, long noncoding RNAs (lncRNAs), and microRNAs in EGFRvIII regulation. Carcinogen exposure induced sustained EGFR and EGFRvIII expression, increased the levels of exon 1-8 junction-containing transcripts, and expanded EGFR isoform diversity. These changes were accompanied by upregulation of splicing regulators, particularly SRSF1. Transcriptomic and functional analyses identified the lncRNA RP11-30P6.6 as a carcinogen-responsive factor that promoted cell proliferation and migration and sustained increased EGFRvIII expression. RNA affinity-based assays showed preferential recovery of SRSF1 and EGFRvIII-related RNA in RP11-30P6.6 pull-down fractions, consistent with its involvement in EGFRvIII-associated RNA regulation. Functional and AGO2 immunoprecipitation analyses were consistent with a competing endogenous RNA (ceRNA)-like relationship in which RP11-30P6.6 may attenuate repression by candidate microRNAs that showed differential regulatory effects on EGFRvIII relative to WT-EGFR under the conditions tested. Perturbation of SRSF1, RP11-30P6.6, or candidate microRNAs attenuated EGFRvIII expression, while functional modulation of these regulatory components was associated with altered tumor cell growth and migration. The study findings support a model in which environmental carcinogens reprogram RNA splicing and noncoding RNA networks to sustain EGFRvIII expression. SRSF1, RP11-30P6.6, and microRNAs may contribute to the post-transcriptional regulation of EGFRvIII expression and may provide potential targets for EGFRvIII-associated cancers.
中文摘要:表皮生长因子受体变异体III(EGFRvIII)的失调参与了包括口腔鳞状细胞癌(OSCC)和胶质母细胞瘤在内的多种人类癌症的肿瘤进展。尽管基因组改变常与EGFRvIII表达相关,但环境致癌物和基于RNA的调控机制对其表达的贡献尚不清楚,本研究对此进行了调查。在发育不良的口腔角质形成细胞中建立了烟草特异性亚硝胺烟碱衍生的亚硝胺酮(NNK)和槟榔碱生物碱arecoline的慢性暴露模型。利用分子测定和长读长测序分析了EGFR异构体的表达和剪接模式。通过功能实验、RNA pull-down、AGO2免疫沉淀、基于MS2的RNA亲和纯化及报告基因实验,探究了剪接因子、长链非编码RNA(lncRNAs)和microRNAs在EGFRvIII调控中的作用。致癌物暴露诱导了持续的EGFR和EGFRvIII表达,增加了含外显子1-8连接区的转录本水平,并扩大了EGFR异构体的多样性。这些变化伴随着剪接调节因子特别是SRSF1的上调。转录组学和功能分析鉴定出lncRNA RP11-30P6.6为致癌物响应因子,其促进细胞增殖和迁移并维持EGFRvIII表达的增加。基于RNA亲和的实验显示在RP11-30P6.6 pull-down组分中优先回收SRSF1和EGFRvIII相关RNA,与其参与EGFRvIII相关RNA调控一致。功能性和AGO2免疫沉淀分析与竞争性内源RNA(ceRNA)样关系一致,其中RP11-30P6.6可能减弱候选microRNAs的抑制作用,这些microRNAs在测试条件下对EGFRvIII相对于野生型EGFR表现出差异化的调控效应。干扰SRSF1、RP11-30P6.6或候选microRNAs可减弱EGFRvIII表达,而这些调控组件的功能调节与肿瘤细胞生长和迁移的改变相关。研究结果支持一种模型,即环境致癌物重编程RNA剪接和非编码RNA网络以维持EGFRvIII表达。SRSF1、RP11-30P6.6和microRNAs可能参与EGFRvIII表达的转录后调控,并为EGFRvIII相关癌症提供潜在靶点。
Oncofetal reprogramming in glioblastoma (GBM) relies on the co-option of still poorly defined pathways that are transiently active during brain development, thereby exposing therapeutically actionable vulnerabilities. To better characterize GBM biology in the context of neurodevelopment, we create an expanded human spatiotemporal multi-omic dataset that resolves both gliogenic and neurogenic lineage fate and assess oncofetal reprogramming at the tumor core and infiltrative margin in both primary and recurrent disease. Analyses reveal the preferential enrichment of a glial intermediate progenitor cell (gIPC)-like state, which is most reminiscent of third-trimester germinal matrix gIPCs, across tumor regions and in recurrence. We uncover EGFR and the long non-coding RNA (lncRNA) NRXN1-DT as co-opted gIPC-specific markers, demonstrate NRXN1-DT's clinical utility in GBM diagnostics, and prioritize POU3F3 as a gIPC-like oncofetal driver, confirming its regulatory role in NRXN1-DT enhancer activity, EGFR expression, and maintenance of GBM stem/progenitor-like properties. This study lays the groundwork for future investigations into targeting POU3F3 and other co-opted gliogenic drivers as GBM therapeutics.
中文摘要:胶质母细胞瘤的胚胎性重编程依赖于在脑发育过程中短暂激活但定义尚不明确的通路,从而暴露出具有治疗潜力的脆弱环节。为了在神经发育背景下更好地表征胶质母细胞瘤生物学特征,我们构建了一个扩展的人类时空多组学数据集,该数据集能够区分胶质生成和神经生成谱系命运,并评估原发性和复发性疾病中肿瘤核心及浸润边缘的胚胎性重编程情况。分析显示,胶质中间祖细胞样状态在肿瘤区域和复发中均优先富集,其特征最接近于孕晚期胚基质中的胶质中间祖细胞。我们发现表皮生长因子受体和长链非编码RNA NRXN1-DT是被共选的胶质中间祖细胞特异性标志物,证明了NRXN1-DT在胶质母细胞瘤诊断中的临床效用,并将POU3F3确定为胶质中间祖细胞样胚胎性驱动因子,确认了其在NRXN1-DT增强子活性、表皮生长因子受体表达以及维持胶质母细胞瘤干细胞/祖细胞样特性中的调控作用。本研究为未来将靶向POU3F3和其他共选的胶质生成驱动因子作为胶质母细胞瘤治疗手段奠定了基础。
High-performance fluorescence imaging in the second near-infrared (NIR-II, 1000-1700 nm) window holds promise for deep-tissue optical diagnostics. However, simultaneously achieving high fluorescence quantum yields (QYs) and ultrasmall dimensions in physiological aqueous environments remains a fundamental challenge. Here, we report a de novo core-cap synthetic strategy to construct highly emissive, renal-clearable NIR-II fluorophores based on a unimolecular micelle architecture. By integrating a rigid, donor-acceptor-donor (D-A-D) hydrophobic core containing orthogonal axial and lateral steric shielding networks with a hydrophilic polyethylene glycol (PEG) outer cap, we successfully suppress water-induced nonradiative decay and intermolecular aggregation-induced quenching without compromising lateral conjugation. Molecular dynamics simulations and experimental characterizations reveal that these amphiphilic structures self-assemble into highly monodisperse unimolecular micelles featuring an ultrasmall hydrodynamic diameter of ∼5 nm. The optimized fluorophore exhibits a peak NIR-II emission centered at 1034 nm with a high aqueous QY of 4.6%. Owing to their sub-5 nm dimensions, unimolecular micelles undergo dual renal and hepatic clearance pathways, circumventing the biosafety concerns of prolonged tissue retention typical of conventional nanoparticles. Capitalizing on their high brightness, we demonstrate high-resolution, contrast-enhanced in vivo imaging of systemic and cerebral vasculatures, allowing the quantitative morphometric visualization of structural abnormalities in transgenic brain tumors. Furthermore, these fluorophores enable high-contrast, intraoperative fluorescence-guided tumor resection with clearly defined margins. This work provides a promising strategy for the rational design of bright, fast-clearing organic NIR-II probes for advanced biomedical diagnostics.
中文摘要:第二近红外(NIR-II,1000-1700 nm)窗口的高性能荧光成像在深层组织光学诊断方面具有广阔前景。然而,在生理水环境中同时实现高荧光量子产率(QYs)和超小尺寸仍是一个根本性挑战。本研究报道了一种从头设计的核壳合成策略,用于构建基于单分子胶束架构的高发射、可经肾脏清除的NIR-II荧光团。通过将含有正交轴向和侧向空间屏蔽网络的刚性给体-受体-给体(D-A-D)疏水核心与亲水性聚乙二醇(PEG)外壳整合,我们成功抑制了水诱导的非辐射衰减和分子间聚集诱导的猝灭,同时未牺牲侧向共轭。分子动力学模拟和实验表征表明,这些两亲性结构自组装成高度单分散的单分子胶束,其流体动力学直径约为5 nm。优化的荧光团在1034 nm处表现出峰值NIR-II发射,水相量子产率高达4.6%。得益于亚5 nm的尺寸,单分子胶束通过双肾和肝清除途径代谢,避免了传统纳米颗粒因长期组织滞留而带来的生物安全问题。凭借高亮度,我们展示了全身及脑血管的高分辨率、对比增强体内成像,实现了对转基因脑肿瘤结构异常的定量形态可视化。此外,这些荧光团实现了高对比度的术中荧光引导肿瘤切除,边界清晰。这项工作为设计明亮、快速清除的有机NIR-II探针以用于先进生物医学诊断提供了一种有前景的策略。
Glioblastoma is orchestrated by pacemaker cancer cells, a rare population preferentially residing at the hubs of tumor cell networks. These cells autonomously generate periodic Ca2+ oscillations that drive glioblastoma network function, resilience, and disease progression. To date, the Ca2+-activated K+ channel KCa3.1 is the only known driver of pacemaker function, calling for studies to identify additional factors - to better understand a key component of glioblastoma pathobiology, and uncover novel therapeutic targets. A molecular Ca2+ integrator technology enabled the transcriptional profiling of highly Ca2+-active glioblastoma cells, a population enriched for pacemaker cells. Putative regulators of pacemaker function were interrogated using genetic, pharmacological, and computational approaches across complementary glioblastoma models. We identified a distinct transcriptional program that captures highly Ca2+ active glioblastoma cells, including pacemaker cells, across preclinical models and human glioblastoma specimens. This program comprised upregulated cholesterol biosynthesis enzymes, TM-network markers (Aquaporin-4 and Cystatin C), and the Ca2+-activated K+ channels KCa1.1 and KCa2.3. Amongst these components, in silico modeling identified KCa2.3 as the only channel compatible with executing pacemaker function. Consistently, KCa2.3 expression was increased in pacemaker cells, and both genetic and pharmacological perturbation of KCa2.3 selectively disrupted pacemaker function, resulting in reduced network-wide Ca2+ activity. Ultimately, pharmacological inhibition of KCa2.3 with edelfosine reduced tumor burden in human brain spheroids. We present the first experimental approach to characterize molecular factors of glioblastoma pacemaker cells in a broad and unbiased manner, and identify KCa2.3 as a novel pacemaker gene and promising therapeutic target.
中文摘要:胶质母细胞瘤由起搏器癌细胞调控,这是一群罕见且优先位于肿瘤细胞网络枢纽的细胞。这些细胞自主产生周期性钙离子振荡,驱动胶质母细胞瘤的网络功能、韧性和疾病进展。迄今为止,钙激活钾通道KCa3.1是唯一已知的起搏器功能驱动因子,因此需要研究以识别其他因素,从而更好地理解胶质母细胞瘤病理生物学的关键组成部分并揭示新的治疗靶点。分子钙整合器技术实现了对高钙活性胶质母细胞瘤细胞的转录组分析,该群体富含起搏器细胞。利用遗传学、药理学和计算生物学方法在互补的胶质母细胞瘤模型中探究了起搏器功能的潜在调控因子。我们鉴定出一个独特的转录程序,该程序在临床前模型和人源胶质母细胞瘤标本中捕获了高钙活性的胶质母细胞瘤细胞包括起搏器细胞。该程序包含上调的胆固醇生物合成酶、TM网络标志物水通道蛋白4和半胱氨酸蛋白酶抑制剂C以及钙激活钾通道KCa1.1和KCa2.3。在这些成分中,计算机模拟识别出KCa2.3是唯一符合执行起搏器功能的通道。一致地,KCa2.3在起搏器细胞中的表达增加,且对KCa2.3进行遗传学和药理学扰动选择性地破坏了起搏器功能,导致全网络钙活性降低。最终,使用依德福辛药理学抑制KCa2.3降低了人脑类器官的肿瘤负荷。我们提出了第一种以广泛且无偏倚的方式表征胶质母细胞瘤起搏器癌细胞分子因素的实验方法,并将KCa2.3鉴定为一种新的起搏器基因和有前景的治疗靶点。
In this issue of Cancer Cell, Patel et al. integrate bulk and single-cell/single-nucleus RNA sequencing with spatial transcriptomics and spatial proteomics across neuroblastoma patient-derived xenografts and annotated tumors to reveal adrenergic and mesenchymal signatures, identify distinct tumor cell populations in vivo, and demonstrate associations with patient outcomes.
中文摘要:本期Cancer Cell杂志中Patel等人整合了来自神经母细胞瘤患者来源异种移植模型和注释肿瘤的大规模及单细胞单核RNA测序数据与空间转录组学及空间蛋白质组学数据揭示了肾上腺素能及间充质特征鉴定了体内不同的肿瘤细胞群并证明了这些特征与患者预后的关联
Neuroblastoma is a pediatric cancer arising from the developing sympathoadrenal lineage. Although cell lines derived from neuroblastoma patients have features of either adrenergic (ADRN) or mesenchymal (MES) cells, identifying MES cells in patient tumors is challenging and controversial. Here, to characterize intra- and inter-patient cellular heterogeneity, we analyze 54 neuroblastoma tumors spanning broad clinical, genetic, and histologic features using single-cell/single-nucleus RNA sequencing (sc/snRNA-seq), bulk RNA sequencing, spatial transcriptomics, and spatial proteomics. We show that tumor cells occupy distinct cellular neighborhoods separated from nonmalignant immune and stromal cells, yet established cell line-derived gene expression signatures fail to identify MES neuroblastoma cells. We therefore develop ADRN/MES signatures from early-passage orthotopic patient-derived xenografts, enabling the identification of MES tumor cells, validated by transcriptomic, epigenomic, proteomic, ultrastructural, and functional assays. In patients, high MES gene expression correlates with worse event-free and overall survival. Together, this study provides a framework for defining clinically relevant neuroblastoma cell states.
中文摘要:神经母细胞瘤是一种起源于发育中交感肾上腺谱系的儿童癌症。尽管源自神经母细胞瘤患者的细胞系具有肾上腺素能或间质细胞的特征,但在患者肿瘤中鉴定间质细胞既具挑战性又存在争议。为表征患者内和患者间的细胞异质性,我们利用单细胞及单核RNA测序、批量RNA测序、空间转录组学和空间蛋白质组学技术,分析了跨越广泛临床、遗传和组织学特征的54例神经母细胞瘤肿瘤。我们发现肿瘤细胞占据与良性免疫和基质细胞分离开的独特细胞微环境,但基于细胞系建立的基因表达特征无法识别间质神经母细胞瘤细胞。因此,我们利用早期传代原位患者来源异种移植物开发了肾上腺素能/间质特征,从而实现了对间质肿瘤细胞的鉴定,并通过转录组、表观基因组、蛋白质组、超微结构和功能测定进行了验证。在患者中,高间质基因表达与较差的事件无生存期和总生存期相关。综上所述,本研究为定义具有临床意义的神经母细胞瘤细胞状态提供了框架。
Glioblastoma (GBM) remains highly lethal despite early therapeutic responses, as resistance inevitably emerges. While clinical studies show improvements in progression-free survival (PFS) during the early response (ER) phase, the molecular trajectory bridging ER and recurrent resistance (RR)-and the adaptive resistance programs temporally engaged during this transition- remain poorly understood. To dissect the dynamic molecular evolution underlying therapy resistance, patient-derived xenograft (PDX) models were treated with anti-VEGF therapy. Longitudinal proteogenomic profiling across multiple time points was performed to capture time-resolved molecular changes associated with the tumor response to the therapy. Longitudinal analyses revealed a dynamic, temporally evolving response trajectory, with an initial response phase (IRP) marked by neuronal-like remodeling, and a late response phase (LRP) characterized by mesenchymal transdifferentiation and metabolic adaptation. Proteomic and phosphoproteomic analyses identified the CTNNB1-NRG3-ERBB4 signaling axis as a key driver of neuronal-like remodeling during the IRP. Mechanistically, β-catenin activation upregulated NRG3, promoting postsynaptic scaffold remodeling, while pharmacological inhibition of β-catenin/CBP with PRI-724 disrupted this neuronal program and significantly extended survival in vivo. These findings place neuronal-like remodeling within a time-resolved framework of tumor adaptation to anti-VEGF therapy in GBM and highlight the CTNNB1-NRG3-ERBB4 axis as a tractable therapeutic target, providing a rationale for combination strategies to overcome anti-VEGF therapy failure.
中文摘要:尽管早期治疗反应良好,胶质母细胞瘤(GBM)仍具有高致死率,因为耐药性不可避免。虽然临床研究显示在早期反应(ER)阶段无进展生存期(PFS)有所改善,但连接早期反应与复发耐药(RR)的分子轨迹以及在此过渡期间动态激活的适应性耐药程序仍不清楚。为了剖析治疗耐药背后的动态分子演变,研究者使用抗血管内皮生长因子(VEGF)药物治疗患者来源异种移植(PDX)模型。通过多个时间点的纵向蛋白质组学分析捕捉与肿瘤对治疗反应相关的时间分辨分子变化。纵向分析揭示了一个动态且随时间演变的反应轨迹,其中初始反应阶段(IRP)以神经元样重塑为特征,而晚期反应阶段(LRP)则以间质转化和代谢适应为特征。蛋白质组和磷酸化蛋白质组学分析鉴定出CTNNB1-NRG3-ERBB4信号轴是IRP期间神经元样重塑的关键驱动因素。在机制上,β-catenin激活上调NRG3,促进突触后支架重塑;而使用PRI-724药理学抑制β-catenin/CBP则破坏了这一神经元程序,并在体内显著延长生存期。这些发现将神经元样重塑置于GBM对抗VEGF治疗适应的时间分辨框架中,并突出CTNNB1-NRG3-ERBB4轴作为可行的治疗靶点,为克服抗VEGF治疗失败的联合策略提供了依据。
High-grade gliomas are the most aggressive brain tumors because of their invasive nature and resilience. Recent advances have shown that glioma cells form synapse-like contacts with neurons, responding to neuronal activity and promoting tumor growth. Glioma-neuron communication is initiated by the release of neurotrophic factors from tumors that exploit host neuronal plasticity mechanisms, subsequently inducing the formation and electrical activity of neuron-glioma synapses. Here, we review the evidence supporting functional neuron-glioma interactions and the molecular regulators underlying neuronal plasticity. Furthermore, we discuss the effects of cancer on neural circuits and the possible prognostic value of connectome studies. Finally, we outline therapeutic strategies and challenges in targeting the neuron-glioma interface to reduce brain cancer progression.
中文摘要:高级别胶质瘤因其侵袭性和韧性而成为最具侵袭性的脑肿瘤。最新进展表明,胶质瘤细胞与神经元形成突触样接触,响应神经元活动并促进肿瘤生长。胶质瘤与神经元之间的通讯始于肿瘤释放神经营养因子,这些因子利用宿主神经可塑性机制,随后诱导神经元-胶质瘤突触的形成和电活动。本文综述了支持功能性神经元-胶质瘤相互作用的证据以及潜在的分子调节因子。此外,我们讨论了癌症对神经回路的影响以及连接组研究的潜在预后价值。最后,我们概述了靶向神经元-胶质瘤界面以减少脑癌进展的治疗策略和挑战。
7肺癌 (12篇)
临床研究 (6篇)
Datopotamab deruxtecan (Dato-DXd)-a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate-has demonstrated efficacy in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) ± actionable genomic alterations. However, TROP2 expression by pathologist assessment using conventional immunohistochemistry with visual scoring does not predict response to TROP2-directed antibody-drug conjugates in NSCLC. We developed TROP2 quantitative continuous scoring (QCS)-a fully supervised computational pathology approach that quantifies TROP2 expression in individual NSCLC cells and subcellular components from immunohistochemistry-stained slides. Using QCS to determine TROP2 expression at the tumor cell membrane and cytoplasm, normalized membrane ratio (NMR) was developed (ratio of membrane relative to membrane + cytoplasmic TROP2) in the biomarker-evaluable population of patients with advanced NSCLC in the TROPION-PanTumor01 study (n = 115). The TROP2 NMR cut-point was optimized and validated in patients with nonsquamous NSCLC without actionable genomic alterations (primary intended-use population, n = 221) in the biomarker-evaluable population (n = 352) of the TROPION-Lung01 trial. Association with clinical outcomes was assessed. Progression-free survival was longer in Dato-DXd-treated (median 7.2 versus 4.0 months; hazard ratio 0.40, 95% confidence interval 0.25-0.64) but not docetaxel-treated (median 4.1 versus 4.4 months; hazard ratio 0.94, 95% confidence interval 0.59-1.49) patients with TROP2 NMR-positive versus TROP2 NMR-negative samples (treatment by biomarker status interaction P = 0.0098), indicating that TROP2 NMR may be a predictive biomarker for Dato-DXd.
中文摘要:德曲妥珠单抗维多坦(Dato-DXd)是一种靶向滋养层细胞表面抗原2(TROP2)的抗体偶联药物,在伴有或无明确基因组改变的晚期非鳞状非小细胞肺癌(NSCLC)患者中显示出疗效。然而,病理学家使用常规免疫组化进行视觉评分评估的TROP2表达并不能预测NSCLC患者对TROP2靶向抗体偶联药物的反应。我们开发了TROP2定量连续评分(QCS),这是一种完全监督的计算病理学方法,可从免疫组化染色切片中量化单个NSCLC细胞及其亚细胞成分的TROP2表达。利用QCS确定肿瘤细胞膜和细胞质中的TROP2表达,在TROPION-PanTumor01研究(n=115)的生物标志物可评估人群晚期NSCLC患者中开发了标准化膜比值(NMR),即膜TROP2相对于膜加细胞质TROP2的比值。在TROPION-Lung01试验生物标志物可评估人群(n=352)的非鳞状NSCLC且无明确基因组改变的初级预期使用人群(n=221)中优化并验证了TROP2 NMR截断值。评估了与临床结果的关联。在TROP2 NMR阳性样本患者中,接受Dato-DXd治疗的患者无进展生存期长于接受多西他赛治疗的患者(中位7.2个月对4.0个月;风险比0.40,95%置信区间0.25-0.64),而在TROP2 NMR阴性样本患者中则未观察到这种差异(中位4.1个月对4.4个月;风险比0.94,95%置信区间0.59-1.49)(治疗与生物标志物状态的交互作用P=0.0098),表明TROP2 NMR可能是Dato-DXd的预测性生物标志物。
Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk of transformation (TP53/RB1-deficient) and treated them with first-line osimertinib combined with platinum and etoposide. Despite the addition of SCLC-directed chemotherapy, nearly half of patients (5 of 11) underwent SCLC transformation, with median progression-free survival of 11 months and overall survival of 33 months. Genomic and single-cell transcriptomic profiling of patient samples revealed clinical and subclinical plasticity associated with TP53/RB1 comutations, including histological transformation to SCLC, as well as mesenchymal and squamous histologies. These changes in plasticity were linked to progressive disruption of the RB pathway, leading to altered chromatin accessibility and induction of neuronal differentiation and epithelial-to-mesenchymal transition transcriptional programs, further intensified by osimertinib treatment. These findings provide insights into the role of plasticity in mediating drug tolerance.
中文摘要:尽管EGFR抑制剂对治疗EGFR突变型肺腺癌(EGFR+ LUADs)高度有效,但耐药性不可避免,其中组织学转化为小细胞肺癌(SCLC)是一种特别具有侵袭性的机制。我们的前瞻性试验纳入了具有高转化风险(TP53/RB1缺陷)的EGFR+ LUAD患者,并采用一线奥希替尼联合铂类和依托泊苷进行治疗。尽管添加了针对SCLC的化疗药物,近半数患者(11例中的5例)仍发生了SCLC转化,中位无进展生存期为11个月,总生存期为33个月。对患者样本进行基因组学和单细胞转录组学分析揭示了与TP53/RB1共突变相关的临床和亚临床可塑性,包括向SCLC、间质性和鳞状组织学的转化。这些可塑性的变化与RB通路进行性破坏有关,导致染色质可及性改变,并诱导神经元分化和上皮间质转化转录程序,而奥希替尼治疗进一步加剧了这些过程。这些发现为理解可塑性在介导药物耐受中的作用提供了见解。
Systemic sclerosis (SSc) is associated with increased risk of cancer, but population-level data on cancer risk in morphea remain limited and conflicting. To compare the incidence and standardized incidence ratios (SIRs) of overall and site-specific cancers in patients with morphea and SSc compared with the general population, and to identify factors associated with incident cancer. This is a retrospective, population-based cohort study using linked administrative health databases (1996-2019) from Quebec, Canada, with follow-up through December 31, 2020. Patients were identified using published diagnostic algorithms requiring at least 2 billing claims with relevant International Classification of Diseases, Ninth Revision, and/or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes at least 2 months apart, with specialist diagnosis or hospitalization. Data were analyzed from June 2025 to June 2026. Diagnosis of morphea or SSc. Incident cancers were ascertained through linkage to the provincial cancer registry. SIRs were calculated with respect to the general population using Canadian Cancer Registry rates. Cumulative incidence was estimated using Fine-Gray competing risk methods; associated factors were evaluated with multivariable Cox regression. There were 6181 patients with morphea (median [IQR] age at diagnosis, 56 [40-68] years; 4605 female [74.50%]; 71 221.53 person-years of follow-up) and 8133 patients with SSc (median [IQR] age at diagnosis, 58 [48-69] years; 6530 female [80.29%]; 71 844.36 person-years of follow-up). During follow-up, 782 patients with morphea (12.65%) and 1104 with SSc (13.57%) developed cancer. Overall cancer incidence was increased in both the morphea (SIR, 1.24; 95% CI, 1.14-1.35) and SSc (SIR, 1.37; 95% CI, 1.27-1.48) cohorts. Solid tumor risk was elevated in both cohorts (morphea SIR, 1.17; 95% CI, 1.06-1.29; SSc SIR, 1.21; 95% CI 1.11-1.32). Hematologic cancer risk was markedly elevated in patients with SSc (SIR, 2.40; 95% CI, 1.92-2.96) but not statistically significant for those with morphea (SIR, 1.34; 95% CI, 0.97-1.81). Female reproductive and breast cancers predominated in the morphea group; lung cancer was most frequent among patients with SSc. Younger patients carried the highest relative risk. Immunosuppressant use was associated with lower cancer risk in patients with morphea (hazard ratio, 0.56; 95% CI, 0.46-0.68) and those with SSc (hazard ratio, 0.63; 95% CI, 0.55-0.70). This cohort study found that morphea and SSc were associated with increased cancer incidence compared with the general population, with distinct cancer profiles between the 2 conditions. These findings identify patients with morphea, like those with SSc, as a population warranting oncologic attention; whether disease-specific or intensified screening is beneficial requires further study.
中文摘要:系统性硬化症与癌症风险增加相关,但硬皮病人群水平的癌症风险数据仍然有限且存在争议。本研究旨在比较硬皮病和系统性硬化症患者与一般人群相比的整体及特定部位癌症的发病率和标准化发病率比,并识别与新发癌症相关的因素。这是一项基于加拿大魁北克省1996年至2019年链接行政健康数据库的回顾性队列研究,随访至2020年12月31日。患者通过已发表的诊断算法确定,要求至少2次账单索赔具有相关国际疾病分类第九版和国际统计分类疾病及相关健康问题第十版代码,且间隔至少2个月,伴有专科医生诊断或住院记录。数据于2025年6月至2026年6月进行分析。硬皮病或系统性硬化症的诊断通过链接省级癌症登记处确定新发癌症。使用加拿大癌症登记处率计算相对于一般人群的标准化发病率比。采用Fine-Gray竞争风险法估计累积发病率;多变量Cox回归评估相关因素。共有6181名硬皮病患者(诊断时中位年龄56岁,四分位距40至68岁;女性4605名占74.50%;71221.53人年随访)和8133名系统性硬化症患者(诊断时中位年龄58岁,四分位距48至69岁;女性6530名占80.29%;71844.36人年随访)。在随访期间,782名硬皮病患者和1104名系统性硬化症患者发展为癌症。硬皮病队列的整体癌症发病率增加(标准化发病率比1.24,95%置信区间1.14至1.35),系统性硬化症队列也增加(标准化发病率比1.37,95%置信区间1.27至1.48)。两个队列的实体瘤风险均升高。系统性硬化症患者的血液恶性肿瘤风险显著升高,而硬皮病患者未达到统计学显著性。女性生殖系统和乳腺癌在硬皮病组中占主导;肺癌在系统性硬化症患者中最常见。年轻患者具有最高的相对风险。免疫抑制剂的使用与硬皮病患者(危险比0.56)和系统性硬化症患者(危险比0.63)较低的癌症风险相关。这项队列研究发现,与一般人群相比,硬皮病和系统性硬化症均与癌症发病率增加相关,且两种疾病之间存在不同的癌症特征。这些发现表明硬皮病患者像系统性硬化症患者一样是需要肿瘤学关注的群体;特异性或强化筛查是否有益需要进一步研究。
Autoimmune cerebellar ataxias are debilitating neurological syndromes that need early detection and intervention. Antineural antibodies are a crucial diagnostic marker, however, lack of knowledge of specific autoantibodies in seronegative patients remains a significant challenge. To pair a cutting-edge, standardized, and rigorous autoantibody detection pathway with global clinical networks to identify novel autoantibody markers of autoimmune ataxia. This was a multicenter case series study that included samples of patients with uncharacterized central nervous system disorders, collected between 2015 and 2020 at the University of California, San Francisco (UCSF). A comprehensive screening for additional patients was conducted using a blinded cell-based and tissue-based assay in the French reference center on paraneoplastic neurological syndrome (PNS) and autoimmune encephalitis (AE). Analysis was completed in 2026. Referred participants included those with idiopathic neurological disease with suspicion of autoimmune etiology, controls with noninflammatory disease, and patients with known paraneoplastic autoantibody associations who served as positive controls. Sera and cerebrospinal fluid were collected for autoantibody screening and validation experiments. Autoantibody screening and candidate antibody validations. Detection of autoantibodies and characterization of their usefulness as biomarkers of autoimmune clinical symptoms. A total of 35 patients were referred, and 8 patients (median [IQR] age, 65 [47-74] years; 6 male [75%]) were identified to have IgG targeting the intracellular neural protein ribosomal modification protein RimK-like family member A (RIMKLA). Initially, cerebrospinal fluid (CSF) from a UCSF index patient with small cell lung cancer and inflammatory cerebellar ataxia showed a specific staining pattern in the deep nuclei of the cerebellum and brainstem but was seronegative on all known panels of PNS biomarkers. Subsequent screening identified 7 additional patients sharing a similar clinical profile characterized by progressive cerebellar ataxia, diplopia, cranial VI paresis, and sensory and motor abnormalities. The majority of patients (6 of 8 [75%]) had associated small cell lung cancer. All patients also exhibited inflammatory CSF and immunoglobulin synthesis. In this case series, novel PNS autoantibodies targeting the neural protein RIMKLA were identified in patients with small cell lung cancer and cerebellar ataxia. RIMKLA-IgG represents a new diagnostic biomarker for an intracellular-antigen PNS associated with cerebellar and hindbrain encephalitis with possible peripheral and motor involvement.
中文摘要:自身免疫性小脑共济失调是致残性神经综合征,需早期诊断与干预。抗神经抗体是关键诊断标志物,但血清阴性患者特异性自身抗体知识匮乏仍是重大挑战。本研究旨在将前沿、标准化且严谨的自身抗体检测路径与全球临床网络结合,以鉴定自身免疫性共济失调的新型自身抗体标志物。这是一项多中心病例系列研究,纳入了2015年至2020年间在加州大学旧金山分校(UCSF)收集的中枢神经系统疾病未明患者的样本。法国副肿瘤性神经综合征(PNS)和自身免疫性脑炎(AE)参考中心采用盲法细胞基和组织基检测对更多患者进行了全面筛查。分析工作于2026年完成。转诊参与者包括疑似自身免疫病因的特发性神经系统疾病患者、非炎症性疾病对照以及已知副肿瘤自身抗体关联的患者(作为阳性对照)。收集血清和脑脊液进行自身抗体筛查和验证实验,旨在检测自身抗体并评估其作为自身免疫性临床症状生物标志物的效用。共转诊35名患者,其中8名患者(中位年龄65岁,四分位距47-74岁;男性6名占75%)被鉴定出存在针对细胞内神经蛋白核糖体修饰蛋白RimK样家族成员A(RIMKLA)的IgG。最初,一名患有小细胞肺癌和炎症性小脑共济失调的UCSF索引患者的脑脊液在PNS生物标志物的所有已知面板中呈血清阴性,但在小脑深部核团和脑干显示出特异性染色模式。后续筛查确定了7名具有相似临床特征的患者,表现为进行性小脑共济失调、复视、第六对颅神经麻痹以及感觉和运动异常。大多数患者(8名中的6名占75%)伴有小细胞肺癌。所有患者均表现出炎症性脑脊液和免疫球蛋白合成。在该病例系列中,鉴定出患有小细胞肺癌和小脑共济失调的患者中存在针对神经蛋白RIMKLA的新型副肿瘤自身抗体。RIMKLA-IgG代表了一种新的诊断生物标志物,用于与小脑和后脑脑炎(可能伴有周围神经和运动受累)相关的细胞内抗原副肿瘤综合征。
P-loop and αC-helix compressing (PACC) mutations comprise a structurally distinct subgroup of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) with limited treatment options. Firmonertinib is a once-daily oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor with a unique trifluoroethoxy side chain. Firmonertinib had high anti-proliferative efficacy in EGFR PACC-mutant cells and xenografts. In the phase 1b FURTHER study (NCT05364073), patients with metastatic EGFR PACC-mutant NSCLC randomized to receive first-line firmonertinib 160 mg (n = 25) or 240 mg (n = 22) had confirmed objective response rates (ORRs) of 43% and 68%, median duration of response not reached and 14.6 months, and median progression-free survival of 11.1 and 16.0 months, respectively; treatment-related adverse events led to dose reductions (19% and 24%) and discontinuation (3% and 0%). Intracranial ORR among patients with brain metastases at baseline was 47% (8/17). Results support further study of first-line firmonertinib in patients with EGFR PACC-mutant NSCLC.
中文摘要:P-loop和αC螺旋压缩(PACC)突变是非小细胞肺癌(NSCLC)中表皮生长因子受体(EGFR)突变的结构独特亚组,治疗选择有限。Firmonertinib是一种每日一次口服、具有脑渗透性且对突变体选择性高的EGFR酪氨酸激酶抑制剂,拥有独特的三氟乙氧基侧链。Firmonertinib在EGFR PACC突变细胞和异种移植模型中表现出高抗增殖效力。在Ib期FURTHER研究(NCT05364073)中,接受一线firmonertinib 160 mg(n=25)或240 mg(n=22)治疗的转移性EGFR PACC突变NSCLC患者,其确认的客观缓解率(ORR)分别为43%和68%,中位缓解持续时间未达和14.6个月,中位无进展生存期分别为11.1和16.0个月;治疗相关不良事件导致剂量减少(19%和24%)和停药(3%和0%)。基线时存在脑转移患者的颅内ORR为47%(8/17)。结果支持进一步研究一线firmonertinib在EGFR PACC突变NSCLC患者中的应用。
China's oncology drug development ecosystem has shifted from rapid pipeline expansion toward clinical value-driven innovation. We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies. China's disease burden and enrollment capacity have enabled globally relevant advances in EGFR-mutant lung cancer, gastrointestinal malignancies, hepatocellular carcinoma, nasopharyngeal carcinoma, and CLDN18.2-directed therapies. We highlight persistent challenges in target and modality convergence, biomarker definition, therapeutic window optimization, manufacturing consistency, and globally interpretable evidence generation and discuss how artificial intelligence may connect target discovery, drug design, and clinical trial optimization more efficiently. China has become a major source of oncology trials and modality innovation, but scale alone will not ensure global impact. This review links regulatory reform, disease-specific opportunity, target biology, therapeutic format, and evidence quality across a decade of solid tumor development. It defines the conditions under which China-originated programs can generate globally practice-changing evidence. See related article by Shi, p. XX .
中文摘要:中国肿瘤药物开发生态系统已从快速管线扩张转向以临床价值为导向的创新。本文综述了监管改革以及2015年至2025年间小分子、单克隆抗体、双特异性抗体、抗体偶联药物和细胞及基因治疗在临床开发方面的演变。中国疾病负担与受试者招募能力推动了EGFR突变肺癌、胃肠道恶性肿瘤、肝细胞癌、鼻咽癌及CLDN18.2靶向疗法等领域具有全球相关性的进展。我们强调了靶点与模态趋同、生物标志物定义、治疗窗口优化、生产一致性以及生成全球可解释证据方面存在的持续挑战,并探讨了人工智能如何更高效地连接靶点发现、药物设计与临床试验优化。中国已成为肿瘤试验与模态创新的主要来源,但仅靠规模无法确保全球影响力。本综述将监管改革、疾病特异性机遇、靶点生物学、治疗形式及证据质量联系起来,涵盖了过去十年实体瘤开发的全过程。文章界定了中国起源项目能够产生改变全球临床实践的证据所需条件。参见Shi相关文章第XX页。
基础研究 (6篇)
Super-carbon-chain compounds (SCCCs), marine long-carbon-chain polyketides featuring numerous carbon stereocenters, fall into untapped chemical space in between drug-like small molecules and biopolymers. Due to mass-material unavailability and flexible-structure complexity, the reliable stereochemical assignment of SCCCs has long remained stagnant. In this work, a modern microalgal biomass production-platform is created for pilot-scale cultivation of marine dinoflagellates to produce over 100 milligrams of minor SCCCs. The modular fragment-based identification (MFBI) approach is successfully employed to establish the relative and absolute configurations of SCCCs. As an example, 157.7 mg of a minor SCCC, named amphidiketol A, featuring a highly-flexible C76-linear carbon backbone and thirty-three carbon stereocenters, is obtained from Amphidinium sp. in our platform. Its hybrid architecture contains eleven distinct modular fragments. Its relative and absolute configurations are successfully established by the MFBI approach. Collectively, an undescribed paradigm for stereochemical assignment of SCCCs is presented. Nine senescence-associated protein targets of amphidiketol A in lung cancer A549 cells are identified.
中文摘要:超级碳链化合物(SCCCs)是海洋长碳链聚酮类物质,具有众多碳手性中心,处于药物样小分子与生物大分子之间未被充分开发的化学空间。由于缺乏大量材料且结构柔性复杂,SCCCs的可靠立体化学构型鉴定长期停滞不前。本研究建立了一种现代微藻生物质生产平台,用于大规模培养海洋甲藻以生产超过100毫克的微量SCCCs。成功应用模块化片段基团鉴定(MFBI)方法确立了SCCCs的相对和绝对构型。作为示例,从我们平台中的Amphidinium sp.中获得了157.7毫克名为amphidiketol A的微量SCCC,其具有高度柔性的C76线性碳骨架和三十三个碳手性中心。其杂化架构包含十一个不同的模块化片段。通过MFBI方法成功确立了其相对和绝对构型。综上所述,提出了一种用于SCCCs立体化学鉴定的新范式。鉴定了amphidiketol A在肺癌A549细胞中的九个衰老相关蛋白靶点。
Acquired resistance to osimertinib mediated by the EGFR C797S mutation remains a major therapeutic challenge in EGFR-mutant non-small cell lung cancer (NSCLC), with limited effective treatment options. This study explored whether abemaciclib, an FDA-approved CDK4/6 inhibitor, can overcome C797S-mediated osimertinib resistance in EGFR-mutant NSCLC. A high-throughput screen of approximately 125,000 compounds was performed using Ba/F3 cells expressing EGFR triple mutations (L858R/T790M/C797S and Del19/T790M/C797S). The impact of abemaciclib on EGFR kinase activity was evaluated via in vitro kinase and Western blot assays. Apoptosis induction was assessed using flow cytometry. The activity of abemaciclib was evaluated using biochemical assays, cellular thermal shift assays (CETSA), molecular docking analyses, CRISPR-engineered isogenic models, xenografts, and patient-derived xenograft (PDX) models. Abemaciclib was identified as a potent inhibitor of EGFR triple-mutant cell growth and exhibited preferential activity toward mutant EGFR-dependent models. IL-3 rescue assays demonstrated that its antiproliferative effects were dependent on suppression of oncogenic EGFR signaling. Abemaciclib inhibited mutant EGFR kinase activity, reduced EGFR phosphorylation, and induced apoptotic cell death in osimertinib-resistant models while exhibiting substantially weaker activity toward wild-type EGFR. CETSA and molecular docking analyses supported direct engagement of mutant EGFR by abemaciclib. Importantly, abemaciclib significantly suppressed tumor growth in CRISPR-engineered isogenic xenografts and PDX models harboring EGFR C797S-mediated osimertinib resistance. Abemaciclib selectively suppresses C797S-mutant EGFR signaling and demonstrates robust antitumor activity in preclinical models of osimertinib-resistant EGFR-mutant NSCLC. This breakthrough not only overcomes the existing therapeutic barrier but also demonstrates minimal interference with WT EGFR, offering a transformative and precise therapeutic strategy with significant translational and clinical potential. These findings support the therapeutic repurposing of abemaciclib as a potential treatment strategy for EGFR C797S-mediated resistance and provide a translational strategy for overcoming resistance-associated EGFR alterations using clinically available targeted agents.
中文摘要:EGFR突变型非小细胞肺癌中由EGFR C797S突变介导的奥希替尼获得性耐药仍是主要治疗挑战,且有效治疗选择有限。本研究探讨了FDA批准的CDK4/6抑制剂阿贝西利能否克服EGFR突变型非小细胞肺癌中C797S介导的奥希替尼耐药。利用表达EGFR三重突变(L858R/T790M/C797S和Del19/T790M/C797S)的Ba/F3细胞进行了约12.5万种化合物的高通量筛选。通过体外激酶实验和Western blot评估阿贝西利对EGFR激酶活性的影响。使用流式细胞术评估凋亡诱导情况。通过生化实验、细胞热位移分析(CETSA)、分子对接分析、CRISPR工程同基因模型、异种移植模型及患者来源异种移植(PDX)模型评估阿贝西利的活性。鉴定出阿贝西利是EGFR三重突变细胞生长的强效抑制剂,并对突变型EGFR依赖的模型表现出偏好性活性。IL-3挽救实验表明其抗增殖作用依赖于对致癌EGFR信号的抑制。阿贝西利抑制突变型EGFR激酶活性,降低EGFR磷酸化,并在奥希替尼耐药模型中诱导凋亡细胞死亡,同时对野生型EGFR表现出显著较弱的活性。CETSA和分子对接分析支持阿贝西利与突变型EGFR的直接结合。重要的是,在携带EGFR C797S介导的奥希替尼耐药的CRISPR工程同基因异种移植模型和PDX模型中,阿贝西利显著抑制了肿瘤生长。阿贝西利选择性抑制C797S突变型EGFR信号传导,并在奥希替尼耐药的EGFR突变型非小细胞肺癌临床前模型中展现出强大的抗肿瘤活性。这一突破不仅克服了现有的治疗障碍,还证明了对野生型EGFR干扰极小,提供了一种变革性的精准治疗策略,具有显著的转化和临床潜力。这些发现支持阿贝西利的治疗再利用作为EGFR C797S介导耐药的一种潜在治疗策略,并为利用临床可用的靶向药物克服与耐药相关的EGFR改变提供了转化策略。
Non-small-cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, characterized by extensive cellular and molecular heterogeneity. Here, to capture this complexity, we present LuCaS+, a multicenter single-cell RNA sequencing atlas comprising over 2.5 million nuclei from 454 clinically annotated patients with NSCLC with long-term follow-up. LuCaS+ consists of a discovery dataset (Berlin and Cologne, 364 patients) and an independent validation dataset (Munich, 90 patients). Leveraging this dataset, we identified tumor subpopulations with high metastatic potential associated with oncogenic signaling, immune evasion and epithelial-mesenchymal transition. In early-stage adenocarcinoma (lung adenocarcinoma), these cells showed strong prognostic value. Integrating tumor and microenvironmental cell profiles improved survival prediction across all stages, identifying distinct tumor-immune-stromal interaction patterns. These included monocyte- and fibroblast-driven inflammation (lung adenocarcinoma), VEGF-TGFβ-mediated angiogenic feedback loops (lung squamous cell carcinoma) and immune-permissive niches promoting antitumor immunity. LuCaS+ offers a clinically anchored single-cell resource to enable personalized, biology-driven therapies in NSCLC.
中文摘要:非小细胞肺癌(NSCLC)仍是癌症相关死亡的主要原因,其特征是广泛的细胞和分子异质性。为了捕捉这种复杂性,我们提出了LuCaS+,这是一个多中心单细胞RNA测序图谱,包含来自454名有长期随访记录的NSCLC临床注释患者的超过250万个细胞核。LuCaS+由一个发现数据集(柏林和科隆,364名患者)和一个独立的验证数据集(慕尼黑,90名患者)组成。利用该数据集,我们鉴定了具有高转移潜力的肿瘤亚群,这些亚群与致癌信号、免疫逃逸和上皮间质转化相关。在早期腺癌(肺腺癌)中,这些细胞显示出强大的预后价值。整合肿瘤和微环境细胞谱提高了所有阶段的生存预测能力,识别出不同的肿瘤免疫基质相互作用模式。其中包括单核细胞和成纤维细胞驱动的炎症(肺腺癌)、VEGF-TGFβ介导的血管生成反馈环(肺鳞状细胞癌)以及促进抗肿瘤免疫的免疫许可生态位。LuCaS+提供了一个临床锚定的单细胞资源,以推动NSCLC中个性化、生物学驱动的治疗。
The APOBEC3 family of cytidine deaminases, originally evolved for antiviral defense, functions as a potent source of somatic mutations in human malignancies. Although the genomic footprints of APOBEC3 were deciphered over a decade ago with characteristic mutational signatures (single-base substitution [SBS]2 and SBS13), their clinical significance is only now becoming apparent, shifting from a descriptive hallmark of mutagenesis to a potential predictor of therapy outcomes. Emerging evidence from landmark studies reveals that apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)-associated mutational signatures are associated with acquired resistance to targeted therapies and are an emerging biomarker of response to immune checkpoint inhibitors (ICIs). Mechanistically, therapy-induced activation of APOBEC3A and APOBEC3B drives the evolution of drug-tolerant persister cells and generates genomic diversity from which resistant clones emerge-a phenomenon demonstrated across epidermal growth factor receptor inhibitor resistance in lung cancer, endocrine therapy resistance in breast cancer, and androgen receptor blockade resistance in prostate cancer. Concurrently, studies have shown that APOBEC mutational signatures are associated with ICI benefit, including in tumor mutational burden-adjusted analyses, most notably in urothelial carcinoma and non-small-cell lung cancer. In this study, we review this emerging paradigm, focusing on the newly established mechanisms and clinical findings. We further address the translational hurdles of detecting APOBEC mutational signatures in clinical practice and emerging therapeutic strategies, including oligonucleotide-based inhibitors and synthetic lethality. Finally, we discuss standardizing APOBEC mutational signature detection for clinical use, including developing liquid biopsy-based dynamic monitoring, and designing prospective trials with APOBEC mutational signature-based stratification.
中文摘要:APOBEC3家族胞苷脱氨酶最初进化用于抗病毒防御,是人类恶性肿瘤中体细胞突变的强效来源。尽管十余年前已破译了APOBEC3的基因组足迹及其特征性突变特征单碱基替换SBS2和SBS13但其临床意义如今才逐渐显现从描述性突变标志转变为治疗结果的潜在预测因子。来自标志性研究的新证据表明载脂蛋白B mRNA编辑酶催化多肽样APOBEC相关的突变特征与靶向治疗的获得性耐药相关且是免疫检查点抑制剂ICIs反应的 Emerging 生物标志物。在机制上治疗诱导的APOBEC3A和APOBEC3B激活驱动药物耐受持久细胞的进化并产生基因组多样性从而催生耐药克隆这一现象已在肺癌表皮生长因子受体抑制剂耐药乳腺癌内分泌治疗耐药以及前列腺癌雄激素受体阻断剂耐药中得到证实。同时研究表明APOBEC突变特征与ICIs获益相关包括在肿瘤突变负荷调整后的分析中这一点在尿路上皮癌和非小细胞肺癌中尤为显著。本研究综述了这一新兴范式重点关注新确立的机制和临床发现。我们进一步探讨了在临床实践中检测APOBEC突变特征的转化障碍以及新兴的治疗策略包括寡核苷酸抑制剂和合成致死性。最后我们讨论了标准化APOBEC突变特征检测以用于临床包括开发基于液体活检的动态监测设计基于APOBEC突变特征分层的前瞻性试验。
Tarlatamab, a delta-like protein 3 (DLL3) × CD3-directed T cell engager (TCE), provides clinical efficacy against small cell lung cancers (SCLCs), although its efficacy remains limited, indicating the importance of clarifying the resistance mechanisms. We show that serotonin (5-HT) produced by DLL3high neuroendocrine cancers (NECs) induces immunosuppressive tumor-associated macrophages (TAMs), resulting in impaired CD8+ T cell function and TCE resistance. Using SCLC and large cell neuroendocrine carcinoma cohorts, we find that DLL3high SCLCs induce immunosuppressive TAMs in the tumor microenvironment and become resistant to tarlatamab. DLL3high NECs increase 5-HT production via TPH1 upregulation. NEC-derived 5-HT augments the immunosuppressive activity of 5-HT receptor 7 (HTR7)-expressing TAMs. Genetic ablation of HTR7 in TAMs or TPH1 in NECs restores CD8+ T cell function and improves the efficacy of TCEs and programmed cell death protein 1 (PD-1) blockade. We propose that NEC-derived 5-HT-HTR7 axis drives immunosuppressive TAM activation and TCE resistance, making it a key target to increase TCE efficacy.
中文摘要:DLL3×CD3靶向T细胞衔接剂tarlatamab对小细胞肺癌具有临床疗效,但其疗效有限,阐明耐药机制至关重要。我们表明由DLL3高表达神经内分泌癌产生的血清素诱导免疫抑制性肿瘤相关巨噬细胞,导致CD8+ T细胞功能受损及TCE耐药。利用SCLC和大细胞神经内分泌癌队列发现,DLL3高表达SCLC在肿瘤微环境中诱导免疫抑制性巨噬细胞并对tarlatamab产生耐药。NECs通过上调TPH1增加血清素产生。NEC来源的血清素增强表达5-HT受体7的巨噬细胞的免疫抑制活性。敲除巨噬细胞中的HTR7或NEC中的TPH1可恢复CD8+ T细胞功能并提高TCE和PD-1阻断疗法的疗效。我们提出NEC来源的血清素-HTR7轴驱动免疫抑制性巨噬细胞活化和TCE耐药,使其成为提高TCE疗效的关键靶点。
EGFR PACC-mutant non-small cell lung cancer (NSCLC) has limited treatment options. In this issue of Cancer Cell, Le et al. report preclinical profiles and promising systemic and intracranial efficacy of the broad-spectrum CNS-penetrant tyrosine kinase inhibitor firmonertinib in PACC-mutant NSCLC, supporting its further clinical development in this challenging mutation class.
中文摘要:EGFR PACC突变型非小细胞肺癌(NSCLC)的治疗选择有限。本期《癌症细胞》杂志中,Le等人报道了广谱中枢神经系统穿透性酪氨酸激酶抑制剂firmonertinib在PACC突变型NSCLC中的临床前特征以及令人鼓舞的全身和颅内疗效,支持其在这一具有挑战性的突变类别中进一步开展临床研究。
8泌尿生殖肿瘤 (11篇)
临床研究 (5篇)
Risk-adapted prostate cancer screening is endorsed by international healthcare organizations. However, oncological safety and harm minimization in magnetic resonance imaging (MRI)-informed screening lack validation. The purpose of this study was to evaluate the diagnostic utility of an MRI-first screening strategy for detecting grade group (GG) ≥ 2 prostate cancer. This prospective, multi-site study recruited men between the ages of 50 and 69 from three public service providers in Berlin. Eligible participants underwent MRI and serum prostate-specific antigen (PSA) testing at two imaging centers. Prostate biopsy was recommended following MRI positivity (score 4-5) or serum PSA ≥ 4 ng/mL (high-risk). MRI-negative men (score 1-2) with PSA < 3 ng/mL were discharged (low-risk), while men with an MRI score of 3 or a PSA of 3-4 ng/mL were actively followed and invited to repeat screening after 1 year (indeterminate-risk). The primary outcome was the proportion of risk groups and GG ≥ 2 prostate cancer detected using MRI alone or combined with PSA. Of 587 screened men, 566 (mean age, 57.2 ± 4.7 years [SD]; range: 50-69 years) were eligible, and 552 underwent both screening tests. Of these, 78/552 (14.1%; 95% CI: 11.5-17.3), 51/552 (9.2%; 95% CI: 7.1-11.9), and 423/552 (76.6%; 95% CI: 72.9-80.0) were classified as high-, indeterminate-, and low-risk, respectively. PSA testing alone would have missed 9/18 (50.0%) and 7/18 (38.9%) of screen-detected GG ≥ 2 prostate cancers at ≥ 4 and ≥ 3 ng/mL thresholds. Biopsying MRI-positive men detected 17/18 (94.4%) of GG ≥ 2 prostate cancers. A PSA-gated (≥ 3 ng/mL) MRI-informed strategy demonstrated excellent strategy compliance (13/13 [100.0%]), could protect 24/27 (88.9%) from unproductive biopsies and GG1 overdiagnosis, and detect 10/18 (55.6%) of GG ≥ 2 prostate cancers. MRI-first screening demonstrates high oncological safety for GG ≥ 2 prostate cancer but increases overdiagnosis and biopsy rates. PSA-gated MRI-informed strategies may reduce harm while maintaining acceptable detection rates.
中文摘要:国际医疗保健组织推荐风险适应的前列腺癌筛查,但磁共振成像(MRI)指导下的筛查在肿瘤学安全性和危害最小化方面缺乏验证。本研究旨在评估MRI优先筛查策略在检测2级及以上(GG≥2)前列腺癌方面的诊断效用。这项前瞻性多中心研究招募了来自柏林三家公共服务机构的50至69岁男性。符合条件的参与者在两个影像中心接受了MRI和血清前列腺特异性抗原(PSA)检测。MRI阳性(评分4-5)或血清PSA≥4 ng/mL(高风险)者建议进行前列腺活检。MRI阴性(评分1-2)且PSA<3 ng/mL(低风险)者出院,而MRI评分为3或PSA为3-4 ng/mL(不确定风险)者接受主动随访并在1年后邀请重复筛查。主要结局是使用MRI单独或联合PSA检测出的风险组比例和GG≥2前列腺癌的比例。在587名接受筛查的男性中,566名(平均年龄57.2±4.7岁;范围50-69岁)符合条件,其中552人接受了两种筛查测试。在这552人中,78/552(14.1%;95% CI: 11.5-17.3)、51/552(9.2%;95% CI: 7.1-11.9)和423/552(76.6%;95% CI: 72.9-80.0)分别被归类为高风险、不确定风险和低风险。单独使用PSA检测会在≥4 ng/mL和≥3 ng/mL阈值下分别漏检18例GG≥2前列腺癌中的9例(50.0%)和7例(38.9%)。对MRI阳性者进行活检可检出18例GG≥2前列腺癌中的17例(94.4%)。PSA门控(≥3 ng/mL)的MRI指导策略显示出极佳依从性(13/13 [100.0%]),可使27人中的24人(88.9%)免于无效活检和GG1过度诊断,并检出18例GG≥2前列腺癌中的10例(55.6%)。MRI优先筛查对GG≥2前列腺癌显示出较高的肿瘤学安全性,但会增加过度诊断和活检率。PSA门控的MRI指导策略可能在保持可接受检测率的同时减少危害。
Flower-Win/Lose signaling underlies a tumor-host fitness conflict in ovarian cancer, in which tumor-derived exosomal Tu-stroma reduces the fitness of surrounding host cells, favoring tumor expansion within host tissues. High-grade serous carcinoma (HGSC), the most prevalent histotype of epithelial ovarian cancer and leading cause of ovarian-cancer-related mortality, arises from serous tubal intraepithelial carcinoma (STIC), a noninvasive precursor typically identifiable only by histopathologic examination of excised fallopian tube tissue. Here we evaluated Tu-stroma, a tumor-associated long noncoding RNA enriched in serum extracellular vesicles (EVs), as a circulating biomarker in STIC and early-stage HGSC, representing the earliest histopathologically defined phases of disease. Tu-stroma was quantified in serum EVs from 506 individuals with histologically normal adnexa, benign-adnexal lesions, isolated STIC and HGSC across International Federation of Gynecology and Obstetrics (FIGO) stages I-IV. Normalized EV Tu-stroma ΔCT values were elevated in STIC (n = 43) and HGSC (n = 232) versus controls (n = 143) and benign-adnexal lesions (n = 88), including premenopausal women (controls = 57, benign = 34, STIC = 32, HGSC = 88). In paired receiver operating characteristic analyses, Tu-stroma showed higher discrimination than cancer antigen 125 (CA125) for STIC versus controls (area under the curve (AUC) = 0.99 versus 0.59, P < 0.001) and benign-adnexal masses (0.99 versus 0.31, P < 0.001), and for HGSC versus controls (AUC = 0.99 versus 0.96, P = 0.001) and benign-adnexal masses (0.98 versus 0.84, P < 0.001). Tu-stroma showed no systematic elevation across inflammatory or physiologic comparators (n = 116) or nonovarian malignancies (n = 160), each assessed against healthy controls (n = 100), supporting disease-context specificity. Modeled risk-enriched contexts yielded predictive values compatible with intended-use populations. These findings identify Tu-stroma as a candidate EV-RNA marker associated with pre-invasive and early HGSC biology. Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility.
中文摘要:Flower-Win/Lose信号通路是卵巢癌中肿瘤与宿主适应性冲突的基础,其中肿瘤来源的外泌体Tu-stroma降低周围宿主细胞的适应性,从而促进肿瘤在宿主组织内的扩张。高级别浆液性癌(HGSC)是最常见的上皮性卵巢癌组织学类型,也是导致卵巢癌相关死亡的主要原因,它起源于浆液性输卵管原位癌(STIC),这是一种非侵袭性前驱病变,通常只能通过切除的输卵管组织的组织病理学检查来识别。本研究评估了富集于血清细胞外囊泡(EVs)中的肿瘤相关长链非编码RNA Tu-stroma作为STIC和早期HGSC循环生物标志物的潜力,这两种情况代表了疾病最早的组织病理学定义阶段。我们在506名具有组织学正常附件、良性附件病变、孤立性STIC以及FIGO I-IV期HGSC患者的血清EVs中定量了Tu-stroma。与对照组(n=143)和良性附件病变(n=88,包括绝经前女性:对照=57,良性=34,STIC=32,HGSC=88)相比,STIC(n=43)和HGSC(n=232)患者的标准化EV Tu-stroma ΔCT值升高。在配对受试者工作特征分析中,Tu-stroma对STIC与对照(曲线下面积AUC=0.99 vs 0.59,P<0.001)及良性附件肿块(AUC=0.99 vs 0.31,P<0.001)的区分能力优于癌症抗原125(CA125),对HGSC与对照(AUC=0.99 vs 0.96,P=0.001)及良性附件肿块(AUC=0.98 vs 0.84,P<0.001)的区分能力也优于CA125。Tu-stroma在炎症或生理比较组(n=116)或非卵巢恶性肿瘤(n=160)中未显示系统性升高,这些组均与健康对照组(n=100)进行比较,支持了疾病背景特异性。建模的风险富集上下文产生了与预期使用人群兼容的预测值。这些发现确定Tu-stroma是与前侵袭性和早期HGSC生物学相关的候选EV-RNA标志物。需要在连续入组的真实世界队列中进行前瞻性评估,以验证其诊断性能、预测价值和临床效用。
Tumour-promoting inflammation and immune evasion are key features of cancer, but prospective evidence linking specific immune pathways to prostate cancer risk remains limited. Here we show that circulating proteins involved in immune regulation may influence prostate cancer development. We analyse 368 immune- and inflammation-related proteins measured in blood samples from men in the European Prospective Investigation into Cancer and Nutrition (EPIC), including 1434 cases and matched controls, and combine these results with data from UK Biobank. While no proteins are associated with risk in EPIC alone after multiple testing correction, meta-analysis identifies several proteins linked to prostate cancer risk, including IL15 and FLT3LG, in particular, in blood taken long before diagnosis. Higher levels of immune surveillance-related proteins, particularly those involved in natural killer and T cell activity, are associated with lower prostate cancer risk, whereas genetic evidence implicates PARP1, SPINT2 and NME3 in increased risk. These findings suggest that immune pathways play a role in prostate cancer development and highlight potential targets for prevention.
中文摘要:肿瘤促进性炎症和免疫逃逸是癌症的关键特征,但将特定免疫通路与前列腺癌风险联系起来的前瞻性证据仍然有限。本研究显示,参与免疫调节的循环蛋白可能影响前列腺癌的发展。我们分析了欧洲癌症与营养前瞻性调查(EPIC)中男性血液样本测得的368种免疫和炎症相关蛋白,其中包括1434例病例及匹配对照,并将这些结果与英国生物银行的数据相结合。在EPIC单独分析中,经多重检验校正后未发现任何蛋白与风险相关,但荟萃分析确定了多种与前列腺癌风险相关的蛋白,特别是IL15和FLT3LG,尤其是在诊断前很久采集的血液中。较高水平的免疫监视相关蛋白,特别是那些参与自然杀伤细胞和T细胞活动的蛋白,与较低的前列腺癌风险相关,而遗传证据则表明PARP1、SPINT2和NME3会增加风险。这些发现表明免疫通路与前列腺癌的发展有关,并突出了潜在的预防靶点。
Preoperative discrimination of ovarian cancer from benign masses poses significant challenges, particularly in cases where serum biomarkers yield negative or nonspecific results. This multicenter observational diagnostic modeling study analyzed plasma cell-free DNA (cfDNA) from 743 participants across training, internal test, external test, and two exploratory cohorts using low-pass whole-genome sequencing. Four fragmentomic feature classes-fragment size patterns, nucleosome footprint-related features, copy-number variations, and repeat element patterns-were incorporated into a stacked machine-learning model. Model development and cutoff selection were limited to the training cohort, followed by evaluation in the internal-test and external-test cohorts. The cfDNA model achieved areas under the receiver operating characteristic curve (AUCs) of 0.930 (95% confidence interval [CI], 0.894-0.966) and 0.932 (95% CI, 0.891-0.972) in the internal-test and external-test cohorts, respectively. Incorporation of cfDNA with cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) increased AUCs to 0.964 (95% CI, 0.938-0.990) and 0.964 (95% CI, 0.938-0.991). At cutoffs derived from the training cohort, the combined model maintained sensitivities of 88.4% and 89.2% while enhancing specificity from 77.9% to 88.4% and from 78.9% to 91.5%, respectively. The cfDNA model also effectively detected cancers with CA125 and/or HE4 levels below conventional thresholds, and post hoc analyses demonstrated complementary discrimination when cfDNA was added to the Risk of Ovarian Malignancy Algorithm. These findings advocate for prospective evaluation of integrated cfDNA fragmentomics as an adjunct for preoperative risk stratification of ovarian masses.
中文摘要:术前鉴别卵巢癌与良性肿块存在显著挑战,尤其是在血清生物标志物结果为阴性或非特异性的情况下。这项多中心观察性诊断建模研究利用低通全基因组测序技术,分析了来自训练队列、内部测试队列、外部测试队列以及两个探索性队列中743名参与者的血浆游离DNA(cfDNA)。研究将四类片段组学特征——片段大小模式、核小体足迹相关特征、拷贝数变异和重复元件模式——纳入堆叠机器学习模型。模型开发与临界值筛选仅限于训练队列,随后在内部测试和外部测试队列中进行评估。cfDNA模型在内部测试和外部测试队列中获得的受试者工作特征曲线下面积(AUC)分别为0.930(95%置信区间[CI],0.894-0.966)和0.932(95% CI,0.891-0.972)。将cfDNA与癌症抗原125(CA125)和人附睾蛋白4(HE4)结合后,AUC分别提高至0.964(95% CI,0.938-0.990)和0.964(95% CI,0.938-0.991)。在基于训练队列确定的临界值下,联合模型将敏感性维持在88.4%和89.2%,同时将特异性从77.9%提升至88.4%,从78.9%提升至91.5%。cfDNA模型还有效检测出CA125和/或HE4水平低于传统阈值的癌症病例,事后分析表明,将cfDNA添加到卵巢恶性肿瘤风险算法(ROMA)中时具有互补的鉴别能力。这些发现支持对整合的cfDNA片段组学作为术前卵巢肿块风险分层的辅助手段进行前瞻性评估。
AI is reshaping the landscape of medical education, yet the widespread adoption of general-purpose AI tools in student learning raises substantial concerns about curricular alignment, information accuracy, and the absence of pedagogical scaffolding. This crossover pilot study evaluated a curriculum-aligned custom GPT that was developed to support AI-scaffolded self-directed learning (SDL), preparation that remains student-initiated but is supported by structured Socratic prompting, compared with fully unguided traditional preparation in second-year medical students at the University of South Carolina, Floyd School of Medicine (USC Floyd SoM). Forty-four second-year medical students voluntarily participated in the 2 faculty-led pathology small group discussions (Cushing disease and prostate cancer), using the custom GPT for one case and conventional resources for the other. Faculty assessed SDL documentation forms and small group discussion performance using standardized rubrics. Students using the curriculum-aligned custom GPT achieved significantly higher SDL rubric scores (10.3 vs 9.4 out of 12; mean difference 0.9, 95% CI 0.5-1.3; P<.001; Cohen d=0.71) and small group discussion scores (14.9 vs 13.7 out of 16; mean difference 1.2, 95% CI 0.7-1.7; P<.001; Cohen d=0.78), with moderate-to-large effect sizes. Delayed retention (end-of-block examination items) did not differ significantly (Wilcoxon signed-rank P=.052). Students also reported significantly greater gains in understanding and pathophysiological reasoning. A total of 34 out of 44 (77%) reported improved reasoning clarity, and 31 out of 44 (70%) improved conceptual understanding. Assessment of 5 prespecified AI-related concern domains did not identify major concerns. In this crossover pilot study, use of a curriculum-aligned custom GPT was associated with higher faculty-assessed SDL documentation and small group discussion performance. Delayed knowledge retention did not differ significantly in the primary analysis. These findings support further investigation of curriculum-aligned AI tools in larger, multisite studies.
中文摘要:人工智能正在重塑医学教育格局,然而通用人工智能工具在学生中的广泛使用引发了关于课程对齐、信息准确性以及缺乏教学支架的诸多担忧。本研究是一项交叉试点研究,评估了一款为支持AI支架式自主学习而开发的课程定制GPT模型。该模型旨在为学生主导但受结构化苏格拉底式提示支持的准备过程提供辅助,并与传统无指导的准备方式进行对比。研究对象为南卡罗来纳大学弗洛伊德医学院二年级医学生。共有44名二年级医学生自愿参与了2次由教师主导的病理学小组讨论(分别涉及库欣病和前列腺癌),其中一种病例使用定制GPT,另一种病例使用常规资源。教师使用标准化评分量表对自主学习文档和小组讨论表现进行评估。使用课程定制GPT的学生在自主学习评分量表得分上显著更高(10.3分 vs 9.4分,满分12分;均值差0.9,95%置信区间0.5-1.3;P<.001;Cohen d=0.71),小组讨论得分也显著更高(14.9分 vs 13.7分,满分16分;均值差1.2,95%置信区间0.7-1.7;P<.001;Cohen d=0.78),效应量为中等至大。延迟保留效果(期末考试的题目得分)在主要分析中未见显著差异(Wilcoxon符号秩检验P=.052)。学生报告的理解力和病理生理推理能力有显著提升。44名学生中有34名(77%)表示推理清晰度有所提高,31名(70%)表示概念理解有所改善。对5个预设的人工智能相关担忧领域的评估未发现主要问题。在这项交叉试点研究中,使用课程定制GPT与更高的教师评估的自主学习文档质量和小组讨论表现相关。延迟知识保留在主要分析中未见显著差异。这些发现支持在更大规模的多中心研究中进一步调查课程对齐的人工智能工具。
基础研究 (6篇)
Transcriptional addiction to the androgen receptor (AR) underlies metastatic castration-resistant prostate cancer1, in which AR maintains oncogenic programs through domain-specific interactions with the acetyltransferases p300 and CBP (collectively p300/CBP)2. Here we describe a novel therapeutic modality, domain-alteration chimeras (DALTACs), that rewire endogenous protein complexes by enforcing non-native domain-domain interactions. Our first-in-class AR-p300/CBP DALTAC-1 induces synthetic proximity between the ligand-binding domain of AR and the bromodomain of p300/CBP, misconfiguring their native interface and locking the complex in a non-productive state. DALTAC-1 triggers a 'super-inhibitory' effect, suppressing AR-driven transcription and proliferation more potently than combined AR and p300/CBP inhibition. Mechanistically, DALTAC-1 reprograms p300/CBP substrate engagement, abolishing the histone mark H2B N-terminal acetylation and inducing neomorphic acetylation of AR and coactivators, ultimately collapsing the AR neo-enhanceosome. Chromatin profiling revealed redistribution of AR and p300/CBP towards palindromic androgen response elements, accompanied by disruption of cofactor and transcriptional machinery recruitment at oncogenic AR and ERG neo-enhancers. DALTAC-1 exhibits exquisite lineage selectivity, displaying potent activity in AR-p300/CBP dual-dependent cells and sparing AR-negative cells. In multiple in vivo models, DALTAC-1 induces deep and durable tumour regressions. Together, these findings establish DALTACs as a broadly applicable strategy to rewire disease-defining complexes through domain-topology alteration, expanding induced-proximity therapies, and the precise lineage selectivity of DALTAC-1 supports its translational potential in AR-driven prostate cancer.
中文摘要:转录对雄激素受体(AR)的依赖是转移性去势抵抗性前列腺癌的病理基础,其中AR通过与乙酰转移酶p300和CBP(统称p300/CBP)进行结构域特异性相互作用来维持致癌程序。本研究描述了一种新型治疗方式——结构域改变嵌合体(DALTACs),通过强制非天然的结构域-结构域相互作用来重排内源性蛋白复合物。我们开发的AR-p300/CBP DALTAC-1诱导了AR配体结合域与p300/CBP溴结构域之间的合成邻近性,错配其天然界面并将复锁定在非生产状态。DALTAC-1触发“超级抑制”效应,比联合抑制AR和p300/CBP更有效地抑制AR驱动的转录和增殖。机制上,DALTAC-1重编程了p300/CBP的底物结合,消除了组蛋白标记H2B N端乙酰化并诱导AR及共激活因子的新形态乙酰化,最终导致AR新增强体崩溃。染色质谱分析显示AR和p300/CBP向回文雄激素反应元件重新分布,同时破坏了致癌性AR和ERG新增强子上辅因子及转录机制的招募。DALTAC-1表现出精确的谱系选择性,在依赖AR-p300/CBP的双依赖细胞中显示强效活性并保留AR阴性细胞。在多种体内模型中,DALTAC-1诱导了深度且持久的肿瘤消退。这些发现确立了DALTACs作为通过结构域拓扑改变重排疾病定义性复合物的广泛适用策略,拓展了诱导邻近疗法的应用,而DALTAC-1精确的谱系选择性支持其在AR驱动的前列腺癌中的转化潜力。
Germline pathogenic BRCA1 variants predispose women to breast and ovarian cancer. Despite accumulation of functional evidence, over half of reported single-nucleotide variants in BRCA1 lack a definitive clinical interpretation. Furthermore, the consistency of variant effects across cell types remains largely unexplored. Here we performed saturation genome editing (SGE) of BRCA1 in HAP1 cells to score 4,113 previously unassayed variants. Additionally, we developed an SGE assay in human mammary epithelial cells (HMECs), allowing comparison of effects across cell lines, drug treatments and genetic backgrounds. We identified 538 variants impacting gene function through distinct mechanisms. HAP1 function scores discriminate between known pathogenic and benign variants with near-perfect accuracy. Intriguingly, however, nearly half of HAP1 loss-of-function variants scored neutrally in HMECs. We show that discordantly scored variants are hypomorphic and confer intermediate cancer risk. Overall, this work demonstrates how performing SGE across cell models improves the functional interpretation of rare variants.
中文摘要:生殖系致病性BRCA1变异使女性易患乳腺癌和卵巢癌。尽管功能证据不断积累,但报告的BRCA1单核苷酸变异中超过一半缺乏明确的临床解读。此外,不同细胞类型间变异效应的一致性仍未得到充分探索。本研究在HAP1细胞中对BRCA1进行饱和基因组编辑(SGE),对4,113个此前未检测的变异进行评分。此外,我们开发了人乳腺上皮细胞(HMECs)中的SGE检测方法,从而能够比较不同细胞系、药物处理和遗传背景下的效应差异。我们鉴定出538种通过不同机制影响基因功能的变异。HAP1功能评分以近乎完美的准确性区分已知的致病性和良性变异。然而有趣的是,近一半在HAP1中表现为功能缺失的变异在HMECs中被评定为中性。研究表明,评分不一致的变异属于亚效型变异并赋予中等癌症风险。总体而言,这项工作展示了跨细胞模型进行SGE如何改善对罕见变异的功能性解读。
In prostate cancer (PCa), epigenomic mechanisms drive resistance to androgen receptor (AR) signaling inhibitors, such as enzalutamide (enza). We tested whether retinoic acid receptor gamma (RARγ) shapes the epigenome to direct AR transcription, promote luminal identity, and limit enza resistance. RARγ restoration in enza-resistant 22Rv1 cells induced a large RARγ complex containing its coactivator TACC1 and the chromatin remodeler ISWI ATPase SMARCA5. RARγ restoration expanded and redistributed the AR cistrome toward active promoters, enhancers, and unique super-enhancers and increased the overlap with H3K27ac. RARγ restoration also increased SMARCA5 promoter-proximal binding that overlapped with G2/M-enriched AR cistrome, linking AR redistribution to cell cycle-associated chromatin engagement, including at luminal genes. In 22Rv1 and LNCaP C4-2 (also enza-resistant), RARγ restoration directed the AR transcriptome toward luminal differentiation. A miR-96 antagomir (targeting RARγ) mirrored the impact of RARγ restoration. RARγ antagonized the actions of the master lineage regulator ONECUT2 at the cistrome and transcriptome level and these antagonized genes were significantly associated with alternative lineages in murine PCa models of lineage plasticity and enza responsiveness and lineage plasticity in human PCa cohorts. These findings identify RARγ as a regulator of a chromatin remodeling mechanism that sustains luminal AR programs and opposes therapeutic resistance.
中文摘要:在前列腺癌中,表观基因组机制驱动对雄激素受体信号抑制剂如恩杂胺的耐药性。我们测试了视黄酸受体γ是否通过塑造表观基因组来指导雄激素受体转录、促进腔表型并限制恩杂胺耐药性。在恩杂胺耐药的22Rv1细胞中恢复RARγ诱导了一个包含其共激活因子TACC1和染色质重塑酶ISWI ATP酶SMARCA5的大型RARγ复合物。RARγ的恢复扩大了雄激素受体的结合位点并重新分布至活性启动子、增强子和独特的超级增强子,同时增加了与H3K27ac的重叠。RARγ的恢复还增加了SMARCA5在启动子近端的结合,该结合与G2/M期富集的雄激素受体转录组重叠,将雄激素受体的重新分布与细胞周期相关的染色质相互作用联系起来,包括在腔基因处。在22Rv1和LNCaP C4-2(同样对恩杂胺耐药)中,RARγ的恢复指导雄激素受体转录组向腔分化方向转变。靶向RARγ的miR-96反义寡核苷酸模拟了RARγ恢复的影响。RARγ在染色质结合位点和转录组水平上拮抗了主要谱系调节因子ONECUT2的作用,这些被拮抗的基因在小鼠前列腺癌谱系可塑性模型和恩杂胺反应性以及人类前列腺癌队列中的谱系可塑性中与替代谱系显著相关。这些发现确定了RARγ作为维持腔雄激素受体程序并拮抗治疗耐药性的染色质重塑机制调节因子。
Colorectal and prostate cancer incidence has risen rapidly in several industrializing Asian populations. Dietary-pattern explanations focus on macronutrients, but cooking method is rarely examined. We discuss a "carcinogenic transition" hypothesis, in which a shift from moist-heat cooking (≤100 °C) toward dry-heat techniques (≥150 °C) increases formation of heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs) in food. We examine three components (the "Triple Threat" framework) that may be relevant to some populations: (1) dietary HCA/PAH exposure; (2) host variation in xenobiotic metabolism, including N-acetyltransferase 2 (NAT2), cytochrome P450 1A2 (CYP1A2), and aldehyde dehydrogenase 2 (ALDH2) variants, which may alter bioactivation or clearance; and (3) diet-associated gut microbiome activity, including β-glucuronidase (GUS)-mediated deconjugation of excreted metabolites, supported by in vitro data with unquantified human magnitude. The framework rests on epidemiological associations and experimental mechanisms, not established causation. Confounding by obesity, alcohol, screening, and acculturation cannot be excluded, and trials isolating cooking method are needed. We also discuss practical food-preparation strategies, including lower-temperature cooking and antioxidant-rich marinades. Support comes from food-chemistry experiments and small urinary biomarker studies; effects on cancer incidence remain untested.
中文摘要:多个工业化亚洲人群中结直肠癌和前列腺癌的发病率迅速上升。饮食模式解释主要关注宏量营养素,但很少考察烹饪方法。我们讨论了“致癌转变”假说,即从湿法烹饪(≤100°C)转向干法技术(≥150°C)会增加食物中杂环胺(HCAs)和多环芳烃(PAHs)的形成。我们检查了可能与某些人群相关的三个组成部分(“三重威胁”框架):(1)饮食中的HCA/PAH暴露;(2)宿主在异源代谢方面的变异,包括N-乙酰转移酶2(NAT2)、细胞色素P450 1A2(CYP1A2)和醛脱氢酶2(ALDH2)变异体,这些可能改变生物活化或清除;(3)与饮食相关的肠道微生物组活性,包括由β-葡萄糖醛酸酶(GUS)介导的排泄代谢物去结合,得到了体外数据的支持,但人类规模未量化。该框架基于流行病学关联和实验机制,而非既定因果关系。肥胖、酒精、筛查和文化适应带来的混杂因素无法排除,需要隔离烹饪方法的试验。我们还讨论了实用的食物制备策略,包括低温烹饪和富含抗氧化剂的腌料。支持来自食品化学实验和小规模的尿液生物标志物研究;对癌症发病率的影响仍未得到测试。
High-grade serous ovarian carcinoma (HGSOC), the most lethal subtype of ovarian cancer, is often diagnosed at advanced stages and remains associated with poor clinical outcome. In this study, we identify a critical oncogenic role of the RNA methyltransferase METTL3 and the N6-methyladenosine (m6A) RNA modification pathway in HGSOC. Suppression of METTL3, either genetically or pharmacologically, and depletion of its binding partner METTL14 impair ovarian cancer proliferation and tumor progression. Mechanistically, we show that METTL3-mediated m6A deposition enhances the translation of DNA methyltransferase 1 (DNMT1), the primary maintenance DNA methyltransferase responsible for preserving genome-wide methylation patterns and silencing tumor suppressor genes. Pharmacological inhibition of DNMT1 induces widespread DNA hypomethylation and up-regulation of the tumor suppressors TNFAIP3 and FBXO32. Consistently, METTL3 suppression reduces DNMT1 abundance and derepresses TNFAIP3 and FBXO32 expression. Knockdown and rescue studies further reveal that DNMT1 primarily mediates METTL3-dependent regulation of cell migration, whereas the antiproliferative effects of METTL3 suppression are likely driven by additional downstream targets. Collectively, these findings identify the m6A-METTL3-DNMT1 axis as a mechanistic link between RNA and DNA methylation pathways and a potential therapeutic vulnerability in HGSOC.
中文摘要:高级别浆液性卵巢癌(HGSOC)是致死率最高的卵巢癌亚型,常在晚期确诊且临床预后不良。本研究鉴定出RNA甲基转移酶METTL3及N6-甲基腺苷(m6A)RNA修饰通路在HGSOC中的关键致癌作用。无论是基因敲除还是药理学抑制METTL3,以及耗竭其结合伙伴METTL14,均会损害卵巢癌细胞的增殖和肿瘤进展。机制研究表明,METTL3介导的m6A沉积增强了DNA甲基转移酶1(DNMT1)的翻译,DNMT1是负责维持全基因组甲基化模式并沉默抑癌基因的主要维持型DNA甲基转移酶。药理学抑制DNMT1可诱导广泛的DNA低甲基化及抑癌因子TNFAIP3和FBXO32的上调。一致地,METTL3抑制降低了DNMT1丰度并去抑制了TNFAIP3和FBXO32的表达。敲除与回补实验进一步揭示,DNMT1主要介导METTL3依赖性调控的细胞迁移,而METTL3抑制的抗增殖效应可能由其他下游靶点驱动。综上所述,这些发现确立了m6A-METTL3-DNMT1轴作为RNA和DNA甲基化通路之间的机制联系,并指出了HGSOC中潜在的 therapeutic vulnerability(治疗弱点)。
Enzalutamide (Enz)-resistant prostate cancer (PCa) is a lethal disease that affects a broad population of elderly men. Experimental and clinical evidence has demonstrated that androgen receptor variant 7 (ARv7) plays a critical role in Enz-resistant (EnzR) PCa by functioning as a constitutively active transcription factor driving disease progression. However, the predictive value of the ARv7 transcript has not been fully recognized due to its low frequency in castration-resistant PCa. In this study, we identified ARv7 mRNA as an N6-methyladenosine (m6A)-modified transcript. Enz treatment increases METTL3-dependent m6A methylation of ARv7 mRNA at the A1177 site, which is subsequently recognized by the reader protein YTHDC2, leading to enhanced translation efficiency of ARv7. Furthermore, EnzR PCa exhibited elevated lactate metabolism, which regulated AR transcription through promoter-mediated epigenetic modifications at H3K9 and H3K14. Reactivated AR exhibited enhanced phase separation to transcriptionally up-regulate YTHDC2 expression. In vivo experiments demonstrated that targeting the METTL3-YTHDC2-ARv7 axis represents a promising therapeutic strategy to suppress EnzR PCa progression. Moreover, the METTL3 inhibitor STM2457 synergized with Enz to inhibit tumor growth without observable toxicity. Collectively, our findings suggest that the clinical utility of ARv7 may need to be reconsidered in light of its m6A-dependent translational regulation.
中文摘要:恩杂鲁胺(Enz)耐药前列腺癌(PCa)是一种影响广泛老年男性群体的致命性疾病。实验与临床证据表明,雄激素受体变体7(ARv7)作为组成型活性转录因子驱动疾病进展,在恩杂鲁胺耐药(EnzR)PCa中发挥关键作用。然而,由于其在去势抵抗性前列腺癌中的频率较低,ARv7转录本的预测价值尚未得到充分认可。本研究鉴定出ARv7 mRNA是一种N6-甲基腺苷(m6A)修饰的转录本。恩杂鲁胺处理增加了METTL3依赖性的ARv7 mRNA在A1177位点的m6A甲基化,该修饰随后被阅读器蛋白YTHDC2识别,从而提高了ARv7的翻译效率。此外,EnzR PCa表现出升高的乳酸代谢,通过H3K9和H3K14上的启动子介导表观遗传修饰调节雄激素受体(AR)转录。重新激活的AR增强了相分离,以转录方式上调YTHDC2表达。体内实验表明,靶向METTL3-YTHDC2-ARv7轴是抑制EnzR PCa进展的一种有前景的治疗策略。此外,METTL3抑制剂STM2457与恩杂鲁胺协同作用抑制肿瘤生长且未观察到明显毒性。综上所述,我们的发现表明,鉴于其m6A依赖性的翻译调控,ARv7的临床效用可能需要重新评估。
9肿瘤基础/转化 (10篇)
基础研究 (10篇)
Plasma membrane rupture (PMR) is the terminal step of lytic cell death pathways and is implicated in inflammatory diseases, infections, and cancer. Recent work has identified two proteins-ninjurin-1 (NINJ1) and sialic acid-binding immunoglobulin-like lectin 12 (SIGLEC12)-as mediators of PMR. NINJ1 executes PMR during pyroptosis, ferroptosis, and secondary necrosis following apoptosis, but not necroptosis. SIGLEC12 is an effector of necroptotic PMR downstream of transmembrane serine protease 4-mediated cleavage. This review summarizes the molecular mechanisms underlying NINJ1- and SIGLEC12-dependent PMR, their biological functions, and their roles in physiological and pathological contexts. Understanding how these mechanisms are dysregulated in human diseases and co-opted by pathogens will open avenues for developing therapies that target PMR in lytic cell death.
中文摘要:细胞膜破裂是裂解性细胞死亡通路的终末步骤,与炎症性疾病、感染和癌症有关。近期研究鉴定出ninjurin-1(NINJ1)和sialic acid-binding immunoglobulin-like lectin 12(SIGLEC12)为细胞膜破裂的介导蛋白。NINJ1在细胞焦亡、铁死亡以及凋亡后的继发性坏死中执行细胞膜破裂,但不参与坏死性凋亡。SIGLEC12是跨膜丝氨酸蛋白酶4介导切割下游的坏死性凋亡细胞膜破裂效应因子。本综述总结了NINJ1和SIGLEC12依赖性细胞膜破裂的分子机制、生物学功能及其在生理和病理背景中的作用。理解这些机制在人类疾病中的失调以及被病原体利用的方式,将为开发靶向裂解性细胞死亡中细胞膜破裂的治疗策略开辟途径。
Human apurinic/apyrimidinic endonuclease 1 (APE1) exhibits aberrant expression and distribution as cells acquire metastatic potential. However, the complex intracellular environment often limits the recognition accuracy of probes based on a single target. Leveraging pathophysiology-associated microenvironmental conditions as endogenous triggers enables the spatial control of molecular imaging signals, thereby enhancing the differentiation between cancerous and non-cancerous cells. Herein, we developed a pH-responsive, cofactor-self-sufficient probe for APE1 activity imaging based on the acid-responsiveness of zeolitic imidazolate framework-8 (ZIF-8) and Zn2+-dependent deoxyribozyme (DNAzyme) signal amplification. ZIF-8 not only effectively delivers DNA probes into cancer cells but also provides the essential cofactor (Zn2+) for signal amplification. This probe distinguishes cancer cells from normal cells in both cell lysates and living cells, demonstrating its potential application in the precision diagnosis of malignant tumors. Further investigations revealed that APE1 promoted the epithelial-mesenchymal transition in the TGF-β-induced model. In the hydrogen peroxide-induced oxidative stress model, moderate oxidative stress elevated APE1 activity and enhanced cell proliferation and migration, while excessive stress showed the opposite effect. These results establish the relationship between APE1 activity and cell behaviors in tumor metastasis and under oxidative stress and suggest that oxidative stress plays a complex role in the regulation of tumor metastasis.
中文摘要:人AP内切核酸酶1(APE1)在细胞获得转移潜能时表现出异常的表达和分布。然而,复杂的细胞内环境往往限制了基于单一靶点的探针的识别准确性。利用与病理生理学相关的微环境条件作为内源性触发器,可以实现分子成像信号的空间控制,从而增强癌细胞与非癌细胞之间的区分度。在此,我们开发了一种基于沸石咪唑酯骨架8(ZIF-8)的酸响应性和锌离子依赖性脱氧核酶(DNAzyme)信号扩增机制的pH响应性、辅因子自给型探针,用于APE1活性成像。ZIF-8不仅有效地将DNA探针递送至癌细胞内,还为信号扩增提供了必需的辅因子(Zn2+)。该探针在细胞裂解液和活细胞中均能区分癌细胞与正常细胞,展示了其在恶性肿瘤精准诊断中的应用潜力。进一步研究表明,APE1促进了TGF-β诱导模型中的上皮间质转化。在过氧化氢诱导的氧化应激模型中,中度氧化应激提高了APE1活性并增强了细胞增殖和迁移能力,而过度应激则表现出相反的效果。这些结果确立了APE1活性与肿瘤转移及氧化应激状态下细胞行为之间的关系,并表明氧化应激在调节肿瘤转移中发挥着复杂的作用。
Aberrant endocytosis has long been associated with epithelial plasticity and tumorigenesis, but direct in vivo evidence of its causal role in tumor progression and metastasis has been lacking. Here, we identify and molecularly characterize a previously unrecognized form of E-cadherin (ECAD) internalization in mammary epithelial cells. This process is n mediated by the endocytic adapter Epsin 3 (EPN3) through glycolipid-lectin (GL-Lect)-driven endocytosis requiring galectin-3 and Eps15-family adapters. We further define the molecular basis of this pathway, identifying EPN3-specific interaction surfaces that promote ECAD clustering and galectin-3 recruitment, thereby driving clathrin-independent ECAD internalization. Leveraging an EPN3 knock-in mouse model, we show that dysregulation of GL-Lect-driven endocytosis disrupts mammary gland morphogenesis, induces epithelial-to-mesenchymal plasticity (EMP), and activates transcriptional programs associated with tissue remodeling and alveologenesis. These alterations synergize with the ERBB2/Neu breast oncogene to accelerate tumor onset and promote lung metastasis. Importantly, enhanced ECAD endocytosis was directly demonstrated in the intact mammary epithelium and shown to underlie the morphogenetic and invasive phenotypes. Pharmacologic inhibition of the GL-Lect mechanism suppressed ECAD internalization and reversed morphogenetic, polarity, and invasive phenotypes ex vivo, providing proof-of-concept for therapeutic targeting. These findings establish GL-Lect-driven endocytosis as a physiological regulator of mammary epithelial plasticity. When dysregulated, it drives metastatic progression and uncovers a tractable therapeutic vulnerability in breast cancer.
中文摘要:异常内吞作用长期以来被认为与上皮可塑性和肿瘤发生有关,但其在肿瘤进展和转移中因果作用的直接体内证据一直缺乏。在此,我们鉴定并分子表征了乳腺上皮细胞中一种先前未被认识的E-钙黏蛋白(ECAD)内化形式。该过程由Epsin 3(EPN3)介导,通过依赖半乳糖凝集素-3和Eps15家族适配体的糖脂凝集素驱动的GL-Lect内吞作用进行。我们进一步定义了该通路的分子基础,鉴定出促进ECAD聚集和半乳糖凝集素-3招募的EPN3特异性相互作用表面,从而驱动非网格蛋白依赖性的ECAD内化。利用EPN3敲入小鼠模型,我们表明GL-Lect驱动的异常内吞作用会破坏乳腺腺管形态发生,诱导上皮间质可塑性(EMP),并激活与组织重塑和肺泡发生相关的转录程序。这些改变与ERBB2/Neu乳腺癌癌基因协同作用,加速肿瘤起始并促进肺转移。重要的是,在完整的乳腺上皮中直接证明了ECAD内吞作用的增强,并显示其构成了形态发生和侵袭表型的基础。药理学抑制GL-Lect机制可抑制ECAD内化,并在体外逆转形态发生、极性和侵袭表型,为治疗靶向提供了概念验证。这些发现确立了GL-Lect驱动的內吞作用作为乳腺上皮可塑性的生理调节因子。当其失调时,它会驱动转移性进展并揭示乳腺癌中一种可行的治疗脆弱性。
Mitochondria play a crucial role in the energy metabolism, redox balance, and cell death regulation of tumor cells, making them potential targets for precise cancer treatment. Metal-based nanoparticles (MNPs) can precisely target mitochondria and directly interfere with mitochondrial functions, providing a unique opportunity for mitochondrial-directed tumor therapy. However, there is no comprehensive analysis of the mechanisms for interfering with mitochondrial functions, and questions regarding the cross-regulation of mitochondrial functions and the feasibility of clinical translation have not been answered. This review proposes a unified conceptual framework for MNP-based mitochondrial targeting, focusing on the crosstalk and synergistic interactions among ferroptosis, cuproptosis, metabolic intervention, mitophagy regulation, and immune activation. We also discuss current clinical translation challenges and the future development prospects of MNPs treatment. This review provides an important reference for the innovative design of mitochondrial-targeted nanomedicines for precise tumor treatment. STATEMENT OF SIGNIFICANCE: Current research on metal-based nanoparticles-mediated mitochondrial therapy is developing rapidly, and the research directions are rather scattered. Previous reviews have often focused on individual mitochondria-related therapeutic mechanism such as ferroptosis, cuproptosis, metabolic intervention, mitochondrial autophagy regulation, or immune activation. However, the mitochondrial regulatory system operates as an interconnected network in which various mechanisms interact and influence one another. Hence, we integrate these mechanisms under a unified conceptual framework and highlight their crosstalk and synergistic interaction. We further discuss the current clinical translation challenges and the future development prospects of MNPs treatment. This review provides an important reference for the innovative design of mitochondrial-targeted nanomedicines for precise tumor treatment.
中文摘要:线粒体在肿瘤细胞的能量代谢、氧化还原平衡及细胞死亡调控中发挥关键作用,使其成为精准癌症治疗的潜在靶点。金属基纳米颗粒可精准靶向线粒体并直接干扰其功能,为线粒体导向的肿瘤治疗提供了独特机遇。然而,目前尚缺乏对干扰线粒体功能机制的全面分析,且关于线粒体功能交叉调控及临床转化可行性的问题仍未得到解答。本综述提出了基于金属基纳米颗粒靶向线粒体的统一概念框架,重点探讨铁死亡、铜死亡、代谢干预、线粒体自噬调控及免疫激活之间的交叉对话与协同相互作用。我们还讨论了当前临床转化的挑战及金属基纳米颗粒治疗的未来发展前景。本综述为精准肿瘤治疗中靶向线粒体纳米药物的创新设计提供了重要参考。当前基于金属基纳米颗粒介导的线粒体治疗研究发展迅速且方向较为分散,既往综述多聚焦于铁死亡、铜死亡、代谢干预、线粒体自噬调控或免疫激活等单一机制。然而,线粒体调控系统作为一个相互关联的网络,各机制间存在相互作用与影响。因此,我们将这些机制整合至统一概念框架下,强调其交叉对话与协同作用,并进一步讨论临床转化挑战及未来前景,为靶向线粒体纳米药物的创新设计提供重要参考。
Piezocatalysis has emerged as a promising tumor therapeutic strategy because it enables oxygen-independent generation of multiple reactive oxygen species (ROS) with deep tissue penetration. However, the piezocatalytic efficiency of piezoelectric nanomaterials remains constrained by limited lattice distortion, low carrier separation efficiency, and insufficient catalytic active sites. Herein, we report the centrosymmetry breaking of cobalt-vanadium-layered double hydroxide (CoV-LDH) nanosheets via nitrogen doping for efficient ultrasound (US)-mediated piezocatalytic tumor therapy. Owing to the nitrogen doping-induced disruption of the centrosymmetric structure and lattice distortion in CoV-LDH, nitrogen-doped CoV-LDH (N-CoV-LDH) achieves an ultrahigh piezoelectric coefficient of 89.4 pm·V-1, which is superior to that of previously reported piezocatalytic nanomaterials. Moreover, nitrogen doping introduces an unsaturated coordination environment, significantly promoting the adsorption and activation of O2 (Eads = -2.63 eV) and H2O (Eads = -2.37 eV), thereby enhancing piezocatalytic redox reaction kinetics (k > 1.1 × 103 min-1·g-1). Consequently, under low-power US stimulation (0.15 W·cm-2), N-CoV-LDH nanosheets exhibit markedly enhanced ROS generation efficiency, including that of hydroxyl radicals (·OH), superoxide anions (·O2-), and singlet oxygen (1O2). This robust piezocatalytic ROS generation induces tumor cell apoptosis and immunogenic cell death, thereby activating an antitumor immune response characterized by dendritic cell maturation, M1 macrophage polarization, and T cell activation. Ultimately, N-CoV-LDH-mediated piezocatalytic therapy achieves suppression rates of 97.78% for primary tumors and 87.67% for metastatic tumors, establishing an efficient therapeutic paradigm for suppressing tumor metastasis and recurrence.
中文摘要:压电催化因能实现氧依赖的多活性氧生成并具备深层组织穿透能力,已成为一种极具前景的肿瘤治疗策略。然而,压电纳米材料的压电催化效率仍受限于晶格畸变有限、载流子分离效率低及催化活性位点不足。本研究报道了通过氮掺杂破坏钴钒层状双氢氧化物纳米片的中心对称性,以实现高效的超声介导压电催化肿瘤治疗。由于氮掺杂诱导的CoV-LDH中心对称结构破坏和晶格畸变,氮掺杂CoV-LDH实现了89.4 pm·V-1的超高压电系数,优于此前报道的压电催化纳米材料。此外,氮掺杂引入了不饱和配位环境,显著促进了O2(Eads = -2.63 eV)和H2O(Eads = -2.37 eV)的吸附与活化,从而增强了压电催化氧化还原反应动力学(k > 1.1 × 103 min-1·g-1)。因此,在低功率超声刺激下,N-CoV-LDH纳米片表现出显著增强的羟基自由基、超氧阴离子和单线态氧生成效率。这种强大的压电催化活性氧生成诱导了肿瘤细胞凋亡和免疫原性细胞死亡,从而激活了以树突状细胞成熟、M1巨噬细胞极化和T细胞活化为特征的抗肿瘤免疫反应。最终,N-CoV-LDH介导的压电催化治疗实现了97.78的原发肿瘤抑制率和87.67的转移性肿瘤抑制率,确立了抑制肿瘤转移和复发的有效治疗范式。
Ferroptosis, a type of regulated cell death characterized by lipid peroxide accumulation, has emerged as a promising subroutine of cell death capable of sensitizing chemoresistant cancer cells. To identify novel ferroptosis inducers, a natural product library of 1023 compounds was screened, leading to the identification of Hdj-15. Hdj-15 elicited oxidative stress, the unfolded protein response (UPR), lysosomal biogenesis, and massive lipid peroxidation to trigger ferroptosis. Mechanistically, Hdj-15 directly targeted TrxR1, leading to oxidative stress and ER stress. Knockdown of TXNRD1 (which encodes TrxR1) further sensitized cells to Hdj-15, and reconstitution with wild-type, but not U498C mutant, TXNRD1 reversed this effect. The IRE1α branch of the UPR was activated upon Hdj-15 treatment, which in turn enabled X-box binding protein 1 (XBP1) to directly transactivate transcription factor E3 (TFE3) and transcription factor EB (TFEB), thereby triggering lysosomal biogenesis. Chromatin immunoprecipitation (ChIP) revealed that XBP1s directly occupied the -735 to -631 and the -493 to -365 sites of the TFE3 and TFEB promoters. Hdj-15-induced lysosomal biogenesis further facilitated lysosomal GPX4 degradation via chaperone-mediated autophagy (CMA), sensitizing cancer cells to ferroptosis. Furthermore, drug-resistant cancer cells (Taxol-resistant A549 cells and gefitinib-resistant PC9 cells), including both p53-proficient and p53-deficient cells, were vulnerable to Hdj-15-mediated GPX4 inhibition. In xenograft tumor models, Hdj-15 suppressed tumor growth in vivo. In summary, elucidating the molecular mechanisms of the novel ferroptosis inducer Hdj-15 demonstrated that the interplay between the ER and lysosomes plays a critical role in shaping ferroptotic cell death, which in turn sensitizes drug-resistant cancer cells.
中文摘要:铁死亡是一种以脂质过氧化物积累为特征的调节性细胞死亡,已成为能够敏化化疗耐药癌细胞的有效细胞死亡亚型。为鉴定新型铁死亡诱导剂,研究人员对包含1023种化合物的天然产物库进行了筛选,最终确定了Hdj-15。Hdj-15通过引发氧化应激、未折叠蛋白反应(UPR)、溶酶体生物发生及大量脂质过氧化来触发铁死亡。在机制上,Hdj-15直接靶向TrxR1,导致氧化应激和内质网(ER)应激。敲低编码TrxR1的TXNRD1基因进一步使细胞对Hdj-15敏感,而用野生型而非U498C突变型的TXNRD1进行回复表达则逆转了这一效应。Hdj-15处理激活了UPR的IRE1α分支,进而使X盒结合蛋白1(XBP1)直接反式激活转录因子E3(TFE3)和转录因子EB(TFEB),从而触发溶酶体生物发生。染色质免疫沉淀(ChIP)显示,剪接形式的XBP1(XBP1s)直接占据TFE3和TFEB启动子的-735至-631及-493至-365位点。Hdj-15诱导的溶酶体生物发生通过伴侣介导的自噬(CMA)进一步促进溶酶体GPX4降解,使癌细胞对铁死亡敏感。此外,包括p53野生型和p53缺陷型在内的耐药癌细胞(紫杉醇耐药的A549细胞和吉非替尼耐药的PC9细胞)均易受Hdj-15介导的GPX4抑制作用影响。在异种移植肿瘤模型中,Hdj-15在体内抑制了肿瘤生长。综上所述,阐明新型铁死亡诱导剂Hdj-15的分子机制表明,内质网与溶酶体之间的相互作用在塑造铁死亡细胞死亡过程中起关键作用,从而敏化耐药癌细胞。
Radiotherapy for head and neck cancers is frequently complicated by radiation-induced oral mucositis (RIOM), which can compromise treatment tolerance and negatively affect patients' quality of life. Current preventive and therapeutic options remain limited, highlighting the need for safer and more effective interventions. The development of RIOM involves a cascade of radiation-triggered oxidative stress, epithelial injury, and sustained inflammatory responses. Given the reported antioxidant and anti-inflammatory activities of sitagliptin, a widely used dipeptidyl peptidase - 4 inhibitor, we investigated its potential protective effects against RIOM. Here we show that oral sitagliptin markedly reduces mucosal ulceration and radiation-associated weight loss in mouse models of localized head-and-neck irradiation, while preserving mucosal thickness and basal epithelial stem cells and sustaining proliferative activity after irradiation. Sitagliptin limits reactive oxygen species accumulation and lipid peroxidation, restores glutathione levels and superoxide dismutase activity, and reduces DNA damage, apoptosis, inflammatory cytokine expression, and inflammatory-cell infiltration. Mechanistically, sitagliptin inhibits TLR2/MyD88/NF-κB signaling, whereas pharmacological activation of TLR2 partially reverses its protective effects in vitro, providing further evidence that this pathway contributes to sitagliptin-mediated protection. Sitagliptin is well tolerated in healthy mice, causes no detectable hypoglycemia or organ toxicity, and does not measurably impair radiotherapy-mediated tumor control or tumor radiosensitivity. Collectively, these results demonstrate that sitagliptin protects against RIOM through coordinated antioxidant, anti-apoptotic, and anti-inflammatory actions involving suppression of TLR2/MyD88/NF-κB signaling, while maintaining tumor radiosensitivity. Its established clinical use and the efficacy and tolerability observed in our preclinical models support further evaluation of sitagliptin for RIOM.
中文摘要:头颈部癌症的放疗常并发放射性口腔黏膜炎,影响治疗耐受性和患者生活质量。目前预防和治疗手段有限,亟需更安全有效的干预措施。放射性口腔黏膜炎的发生涉及辐射触发的氧化应激、上皮损伤和持续性炎症反应。鉴于西格列他汀具有抗氧化和抗炎活性,我们探究了其对抗放射性口腔黏膜炎的潜在保护作用。结果显示,在局部头颈部照射的小鼠模型中,口服西格列他汀显著减少黏膜溃疡和放疗相关体重减轻,维持黏膜厚度和基底上皮干细胞数量及增殖活性。西格列他汀限制活性氧积累和脂质过氧化,恢复谷胱甘肽水平和超氧化物歧化酶活性,减少DNA损伤、凋亡、炎症因子表达及炎性细胞浸润。机制上,西格列他汀抑制TLR2/MyD88/NF-κB信号通路,而药理学激活TLR2在体外部分逆转其保护作用,证实该通路参与保护机制。西格列他汀在健康小鼠中耐受良好,无低血糖或器官毒性,且不损害放疗介导的肿瘤控制或肿瘤放射敏感性。结果表明西格列他汀通过抑制TLR2/MyD88/NF-κB信号通路发挥抗氧化、抗凋亡和抗炎作用保护黏膜,同时维持肿瘤放射敏感性。其临床应用基础及前临床模型中的疗效和耐受性支持进一步评估其用于放射性口腔黏膜炎治疗。
Breast cancer therapy remains constrained by poor tumor selectivity, adaptive drug resistance, and a narrow therapeutic window. Existing small-molecule inhibitors and targeted protein degradation strategies often suffer from insufficient tumor specificity, whereas photodynamic therapy (PDT) is compromised in hypoxic, glutathione (GSH)-rich tumors. Herein, Ir-F-GSH-JQ1 is developed as a GSH-gated iridium(III) theranostic agent that couples activation-reported phosphorescence imaging with redox-epigenetic synergistic therapy (REST) by integrating a GSH-activatable photosensitizer and a bromodomain-containing protein 4 (BRD4)-targeting JQ1 ligand. A 2-fluoro-4-nitrophenylsulfonyl trigger remains largely inert at physiological GSH concentrations (0.1-0.5 mM) but undergoes selective cleavage in GSH-rich tumors (∼10 mM), enabling tumor-specific activation and intracellular GSH depletion. The activated iridium(III) complex generates reactive oxygen species through a hypoxia-tolerant Type I pathway, disrupts redox homeostasis, promotes lipid peroxidation, downregulates glutathione peroxidase 4 (GPX4), and induces ferroptosis. Meanwhile, JQ1 ligand promotes nuclear accumulation and BRD4-targeted epigenetic intervention, which cooperates with oxidative stress to drive tumor cell killing and senescence. In breast tumor models, Ir-F-GSH-JQ1 enables GSH-activated luminescence imaging for tumor diagnosis while markedly suppressing tumor growth under light irradiation with limited systemic toxicity. This work establishes an activation-reported molecular theranostic strategy that integrates tumor diagnosis and multimodal therapy through a shared GSH-triggered mechanism.
中文摘要:乳腺癌治疗仍受限于肿瘤选择性差、适应性耐药及治疗窗口狭窄。现有小分子抑制剂和靶向蛋白降解策略常因肿瘤特异性不足而受限,而光动力疗法在缺氧且富含谷胱甘肽的肿瘤中效果不佳。本研究开发了Ir-F-GSH-JQ1作为谷胱甘肽门控的铱(III)诊疗一体化制剂,该制剂整合了谷胱甘肽激活型光敏剂和溴结构域蛋白4靶向JQ1配体,实现了激活报告型磷光成像与氧化还原表观遗传协同治疗的耦合。2-氟-4-硝基苯磺酰基触发剂在生理谷胱甘肽浓度下基本惰性,但在富含谷胱甘肽的肿瘤中发生选择性裂解,从而实现肿瘤特异性激活并消耗细胞内谷胱甘肽。激活后的铱(III)复合物通过缺氧耐受型I型途径产生活性氧,破坏氧化还原稳态,促进脂质过氧化,下调谷胱甘肽过氧化物酶4并诱导铁死亡。同时JQ1配体促进核积累及BRD4靶向表观遗传干预,与氧化应激协同驱动肿瘤细胞杀伤和衰老。在乳腺癌模型中Ir-F-GSH-JQ1实现了谷胱甘肽激活的发光成像用于肿瘤诊断并在光照下显著抑制肿瘤生长且全身毒性有限。本研究建立了一种通过共享谷胱甘肽触发机制整合肿瘤诊断和多模态治疗的激活报告型分子诊疗策略。
Genomic instability and dysregulated RNA processing are each recognized as core hallmarks of cancer, but accumulating evidence indicates that they are mechanistically intertwined rather than independent features. Chromosomal instability, mismatch-repair deficiency, and homologous recombination deficiency can reshape RNA splicing, 3' end formation, and RNA surveillance through changes in gene dosage, DNA damage signaling, and alterations in regulatory elements. Conversely, aberrant splicing, polyadenylation, and RNA modifications can impair DNA repair, perturb mitotic control, and promote replication stress, thereby reinforcing genomic instability. This bidirectional circuit drives clinically relevant phenotypes, including therapeutic resistance, immune modulation, and emergent vulnerabilities that are not captured by DNA-centric biomarkers alone. Here, we present a unified framework for the genome instability-RNA processing axis and its direct clinical implications for cancer diagnosis, treatment stratification, and therapeutic exploitation, highlighting the most actionable mechanistic interfaces and discussing how integrated DNA-RNA biomarkers and rational combination strategies could extend precision oncology beyond static genomic lesions.
中文摘要:基因组不稳定性和RNA加工失调均被视为癌症的核心特征,但越来越多的证据表明它们在机制上是相互交织的而非独立存在的。染色体不稳定性、错配修复缺陷和同源重组缺陷可通过改变基因剂量、DNA损伤信号及调控元件的改变来重塑RNA剪接、3'末端形成和RNA监视过程。相反,异常的剪接、多聚腺苷酸化及RNA修饰可损害DNA修复、扰乱有丝分裂控制并促进复制压力,从而进一步加剧基因组不稳定性。这种双向循环驱动了具有临床意义的表型,包括治疗耐药性、免疫调节以及仅靠以DNA为中心的生物标志物无法捕捉的新兴脆弱性。本文提出了一个关于基因组不稳定性与RNA加工轴的统一框架及其对癌症诊断、治疗分层和治疗利用的直接临床意义,重点阐述了最具可行性的机制界面,并探讨了整合的DNA-RNA生物标志物和合理的联合策略如何将精准肿瘤学拓展至超越静态基因组病变的层面。
Transcriptional regulation is fundamental to vascular homeostasis, ensuring vessel stability and function. Disruption of this regulation underlies pathological angiogenesis in cancer and vascular malformations. While RUNX3 (Runt-related transcription factor 3), a Runt-domain transcription factor, is established as a tumor suppressor and regulator of lymphocyte development, its role in endothelial cells has remained unknown. To define the vascular function of RUNX3, we generated endothelial-specific RUNX3 knockout mice and analyzed postnatal retinal angiogenesis and oxygen-induced retinopathy. Mechanistic insights were obtained through assay for transposase-accessible chromatin with high-throughput sequencing data analysis, coimmunoprecipitation, proximity ligation assay, electrophoretic mobility shift assay, and chromatin immunoprecipitation followed by quantitative real-time polymerase chain reaction (ChIP-qPCR). Loss of endothelial RUNX3 induced hypersprouting angiogenesis with excessive tip cell formation and reduced DLL4 (delta-like ligand 4) expression. RUNX3 deficiency disrupted vascular integrity by lowering VE-cadherin (vascular endothelial cadherin) and claudin-5 levels, while increasing ICAM1 (intercellular adhesion molecule 1) expression, retinal hemorrhage, and leukocyte infiltration. In the oxygen-induced retinopathy model, endothelial RUNX3 deletion aggravated pathological neovascularization. Mechanistically, RUNX3 cooperated with ERG (ETS-related gene) at ETS:RUNX motifs to regulate genes controlling sprouting (DLL4), junctional stability (CDH5, CLDN5), and leukocyte adhesion (ICAM1). RUNX3 formed complexes with ERG, p300, and HDAC3 (histone deacetylase 3), and proximity ligation assays showed that these interactions were enriched in the nucleus upon VEGF-A (vascular endothelial growth factor-A) stimulation. ChIP-qPCR further demonstrated that RUNX3 was required for the recruitment of these coregulators to target loci. Through differential coregulator engagement, RUNX3 functioned bidirectionally, acting as a transcriptional activator of CDH5, CLDN5, and DLL4 while serving as a repressor of ICAM1. Consistently, single-cell transcriptome analysis of human arteriovenous malformations revealed dysregulated RUNX3 and target gene expression, underscoring translational relevance. This study provides the first evidence that RUNX3 is a pivotal transcriptional coordinator in endothelial cells. By integrating ERG and chromatin regulators at ETS:RUNX motifs, RUNX3 safeguards the balance between angiogenic activation and vascular stability. These findings establish RUNX3 as a gatekeeper of endothelial transcriptional identity and highlight its potential as a therapeutic target in pathological angiogenesis.
中文摘要:转录调控对于维持血管稳态至关重要,确保血管的稳定性和功能。该调控机制的破坏是癌症和血管畸形中病理性血管生成的基础。尽管RUNX3(Runt相关转录因子3)作为Runt结构域转录因子已被确立为肿瘤抑制因子和淋巴细胞发育的调节因子,但其在内皮细胞中的作用尚不明确。为了明确RUNX3的血管功能,我们构建了内皮特异性RUNX3敲除小鼠模型,并分析了出生后视网膜血管生成和氧诱导性视网膜病变。通过高通量测序数据分析、共免疫沉淀、邻近连接实验、电泳迁移率变动分析以及染色质免疫沉淀结合定量实时聚合酶链反应(ChIP-qPCR)获得了机制见解。内皮细胞RUNX3的缺失导致过度出芽血管生成,表现为tip细胞形成过多和DLL4(delta样配体4)表达降低。RUNX3缺陷通过降低VE-cadherin(血管内皮钙黏蛋白)和claudin-5水平,同时增加ICAM1(细胞间黏附分子1)表达、视网膜出血和白细胞浸润,破坏了血管完整性。在氧诱导性视网膜病变模型中,内皮细胞RUNX3缺失加重了病理性新生血管形成。机制上,RUNX3与ERG(ETS相关基因)在ETS:RUNX基序处协同作用,调控控制出芽(DLL4)、连接稳定性(CDH5, CLDN5)和白细胞黏附(ICAM1)的基因。RUNX3与ERG、p300和HDAC3(组蛋白去乙酰化酶3)形成复合物,邻近连接实验显示这些相互作用在VEGF-A刺激后富集于细胞核内。ChIP-qPCR进一步证明RUNX3对于招募这些共调节因子至靶位点是必需的。通过差异性的共调节因子参与,RUNX3发挥双向功能,作为CDH5、CLDN5和DLL4的转录激活剂,同时作为ICAM1的抑制因子。一致地,对人动静脉畸形单细胞转录组分析显示RUNX3及其靶基因表达失调,强调了其转化意义。本研究提供了首个证据表明RUNX3是内皮细胞中关键的转录协调因子。通过在ETS:RUNX基序处整合ERG和染色质调节因子,RUNX3保障了血管生成激活与血管稳定性之间的平衡。这些发现确立了RUNX3作为内皮转录身份守门人的地位,并突显了其在病理性血管生成中的潜在治疗靶点价值。
10其他 (14篇)
临床研究 (2篇)
Over the past decade, oncology has consistently ranked among the top in National Natural Science Foundation of China (NSFC) grant applications and funded projects across all research fields. Chinese researchers' preferences across cancer types and the evolutionary trends of oncology research areas point to key challenges and future potential funding trends in China.
中文摘要:在过去十年中,肿瘤学在中国国家自然科学基金(NSFC)所有研究领域的资助申请和获批项目中始终名列前茅。中国研究人员在不同癌种上的偏好以及肿瘤学研究领域的演变趋势,揭示了中国面临的关键挑战及未来潜在的资助趋势。
To describe lower anterior access single-port robotic radical nephroureterectomy (LAA-SP RNU), including bladder cuff excision (BCE) and lymph node dissection (LND), without repositioning or redocking. We present a multicenter retrospective series of 47 patients with upper tract urothelial carcinoma who underwent LAA-SP RNU at five referral centers (May 2024-July 2025). A single 4-cm extraperitoneal incision enabled nephroureterectomy, BCE, and selective hilar/pelvic LND without repositioning or redocking. Data were evaluated using descriptive analyses, and pentafecta achievement for the full cohort was estimated through Kaplan-Meier analysis. Median age of the patients was 72 yr; 95% had high-risk disease. LND was performed in 20 patients (43%). Median docking and operative times were 20 and 220 min, respectively; one procedure was converted to open surgery. Grade ≥3 complications occurred in three patients (6%); median hospital stay was 5 d. Pathology showed pT2 and pT3 disease in 15% and 36%, respectively. At median follow-up of 12.3 mo, seven patients (14.9%) experienced recurrence, including five intravesical recurrences; two died from metastatic disease. The 12-mo Kaplan-Meier estimate of pentafecta achievement was 76.7% (95% confidence interval, 62.8-90.5%). This study is limited by potential referral-center and patient-selection bias, heterogeneity in LND and postoperative management, limited follow-up, and the absence of cost-effectiveness data. LAA-SP RNU appears feasible and associated with acceptable perioperative and early oncological outcomes in experienced centers. Comparative prospective studies with longer follow-up are needed to establish oncological durability, patient benefit, and cost-effectiveness.
中文摘要:旨在描述无需重新定位或重新 docking 的下前入路单孔机器人根治性肾输尿管切除术(LAA-SP RNU),包括膀胱袖状切除(BCE)和淋巴结清扫(LND)。我们报告了来自五个转诊中心的多中心回顾性系列研究,共纳入47例接受 LAA-SP RNU 的上尿路尿路上皮癌患者(2024年5月至2025年7月)。通过一个4厘米的腹膜外切口即可完成肾输尿管切除、BCE 和选择性 hilar/盆腔 LND,无需重新定位或重新 docking。采用描述性分析评估数据,并通过 Kaplan-Meier 分析估算全队列的五重终点(pentafecta)达成率。患者中位年龄为72岁;95%为高危疾病。20例患者(43%)接受了 LND。中位 dock 时间和手术时间分别为20分钟和220分钟;1例转为开放手术。3例患者(6%)出现≥3级并发症;中位住院时间为5天。病理显示15%为pT2期,36%为pT3期。在中位随访12.3个月时,7例患者(14.9%)出现复发,包括5例膀胱内复发;2例死于转移性疾病。12个月的 Kaplan-Meier 五重终点达成率估计为76.7%(95%置信区间,62.8-90.5%)。本研究存在潜在转诊中心和患者选择偏倚、LND和术后管理的异质性、随访时间有限以及缺乏成本效益数据等局限性。在经验丰富的中心,LAA-SP RNU 似乎是可行的,并与可接受的围手术期和早期肿瘤学结果相关。需要开展具有更长随访时间的比较性前瞻性研究,以确立其肿瘤学持久性、患者获益和成本效益。
基础研究 (12篇)
Perturbed glucose homeostasis is a hallmark of metabolic disease and cancer, and cellular responses to excess glucose are tightly controlled. We report here a lysosomal glucose sensing axis linking the transporter GLUT1 with the lysosomal protein DRAM1. Pathophysiological glucose induces DRAM1 via the MLX/ChREBP transcriptional complex. DRAM1 then binds newly synthesized GLUT1 and promotes its traffic to lysosomes without degradation, reducing surface GLUT1 and acting as a reversible brake on glucose entry. Hexokinase or glucose-6-phosphate (G6P) dehydrogenase disruption weakens DRAM1-GLUT1 complex formation, whereas nicotinamide adenine dinucleotide phosphate(NADPH) oxidase (NOX) inhibition enhances assembly, implicating NADPH as a key metabolic signal downstream of elevated glucose. Sequestration of GLUT1 suppresses glucose uptake and glycolysis and rewires metabolism toward glutamine anaplerosis, creating vulnerability to glutaminase (GLS) inhibition. In vivo, Dram1-/- tumors display a glycolytic metabolite profile, consistent with loss of this brake. Together, these data define an mTORC1- and AMPK-independent lysosomal mechanism that protects metabolic homeostasis under hyperglycemic conditions.
中文摘要:葡萄糖稳态失衡是代谢性疾病和癌症的特征之一,细胞对过量葡萄糖的反应受到严格控制。我们在此报道了一个连接转运蛋白GLUT1与溶酶体蛋白DRAM1的溶酶体葡萄糖感知轴。病理生理性葡萄糖通过MLX/ChREBP转录复合物诱导DRAM1表达。随后DRAM1结合新合成的GLUT1并促进其向溶酶体运输而不发生降解,从而减少细胞表面的GLUT1数量,作为葡萄糖进入的可逆刹车机制。己糖激酶或葡萄糖-6-磷酸脱氢酶的破坏削弱了DRAM1-GLUT1复合物的形成,而烟酰胺腺嘌呤二核苷酸磷酸氧化酶抑制则促进其组装,表明NADPH是升高葡萄糖下游的关键代谢信号。GLUT1的隔离抑制了葡萄糖摄取和糖酵解,并将代谢重定向至谷氨酰胺回补途径,从而产生对谷氨酰胺酶抑制的易感性。在体内,Dram1缺失肿瘤表现出糖酵解代谢物特征,符合该刹车机制丧失的情况。综上所述,这些数据定义了一种独立于mTORC1和AMPK的溶酶体机制,该机制在高血糖条件下保护代谢稳态。
Interactive foundation models such as SAM struggle to generalize across clinical deployment sites. Among existing adaptation strategies, test-time adaptation (TTA) is the most promising, yet current TTA methods trade one problem for another: removing the physician eliminates clinical grounding, while retaining the physician reintroduces a costly annotation burden. In this work, we propose Clinical-SAM, a two-phase agentic physician-in-the-loop TTA framework that teaches a frozen SAM to approximate what a physician would accept - directly and continuously, without requiring spatial annotations. In Phase I (pre-deployment), a self-prompting agent trained via reinforcement learning generates prompts autonomously, eliminating per-case expert spatial input at inference. In Phase II (deployment), the agent policy is refined online by the one signal physicians already produce: a binary accept/reject feedback on each proposed mask. As the binary feedback accumulates across deployed cases, the agent converges toward a policy that produces masks meeting a reference acceptance standard designed to approximate physician judgment, with progressively fewer interactions. We evaluate Clinical-SAM in a pre-clinical setting on six oncological benchmarks spanning CT (colon, pancreas, liver, kidney) and PET (head & neck, lung) tumor segmentation, using agreement with reference-standard segmentations as a proxy for physician acceptance. Clinical-SAM achieves state-of-the-art performance on all six datasets, outperforming fine-tuning, interactive, TTA, and online-learning baselines, while requiring only 3.3 binary judgments per case on average across the six datasets. Our code is available here.
中文摘要:交互式基础模型如SAM在临床部署中难以实现跨站点泛化。在现有的适应策略中,测试时适应(TTA)最具前景,但现有TTA方法往往顾此失彼:移除医师会丧失临床依据,而保留医师则会重新引入高昂的标注负担。本研究提出Clinical-SAM,这是一种两阶段的代理式人机协同TTA框架,旨在无需空间标注的情况下直接且持续地教导冻结的SAM模型逼近医师可接受的分割结果。在第一阶段(部署前),通过强化学习训练的自提示代理自主生成提示,消除了推理过程中对专家空间输入的需求。在第二阶段(部署中),基于医师已提供的单一信号即对每个建议掩码的二元接受或拒绝反馈在线优化代理策略。随着二元反馈在部署病例中的积累,代理逐渐收敛至一种产生符合参考接受标准掩码的策略,该标准旨在逼近医师判断,且交互次数逐步减少。我们在涵盖CT(结肠、胰腺、肝脏、肾脏)和PET(头颈、肺部)肿瘤分割的六个肿瘤学基准数据集上,在临床前环境中评估了Clinical-SAM的性能,并以与参考标准分割的一致性作为医师接受的代理指标。Clinical-SAM在所有六个数据集上均取得了最先进性能,优于微调、交互式、TTA及在线学习基线方法,且在六个数据集上平均每个病例仅需3.3次二元判断。代码已公开。
Metastatic dormancy reflects a dynamic immune-tumor equilibrium in which disseminated tumor cells, either as individual cells or multicellular ecosystems, may persist for years before relapse. Recent studies show that dormant cells evade elimination through spatial and numerical rarity, insufficient immune effectors, suppression of innate immune signaling and inflammasome pathways, and adaptation to local immune niches. Inflammatory stress leading to tissue remodeling dampens immune restraint and promotes metastatic outgrowth. Emerging spatial and single-cell genomic and evolutionary profiling approaches now offer a potential path toward defining dormant disseminated tumor cell states and niches directly in patients. Here, we review mechanisms of tumor-immune interactions in dormant cells or incipient metastases and discuss how these could be leveraged to develop strategies to eradicate minimal residual disease, restore immune surveillance, and prevent inflammatory reawakening. We also provide a perspective on how predominantly murine studies in this field may be extended to studying the dormancy paradigm directly in patients.
中文摘要:转移性休眠反映了动态的免疫肿瘤平衡,在此过程中,播散的肿瘤细胞以单个细胞或多细胞生态系统的形式存在,可能在复发前持续数年。最近的研究表明,休眠细胞通过空间上和数量上的稀有性、免疫效应细胞不足、抑制先天免疫信号和炎症小体通路以及适应局部免疫微环境来逃避清除。导致组织重塑的炎症应激削弱了免疫约束并促进了转移灶的生长。新兴的空间单细胞基因组学和进化谱分析技术为直接在患者中定义休眠播散肿瘤细胞的状态和微环境提供了潜在途径。本文综述了休眠细胞或早期转移灶中肿瘤免疫相互作用的机制,并讨论了如何利用这些机制开发根除微小残留病灶、恢复免疫监视以及防止炎症再激活的策略。我们还就如何将目前该领域主要基于小鼠模型的研究扩展到直接在患者中研究休眠范式提出了展望。
To determine the cancer-initiating activity of oncoprotein CIP2A, which is overexpressed in a majority of cancers and promotes cell growth by stabilizing MYC, we established an alveolar type 2 cell-specific CIP2A transgenic mouse line. Among 114 transgenic mice aged 12 months or older, 23 (20.2%) developed lung adenocarcinoma (LUAD)-like disease, significantly higher than in the control mice (3/63, 4.8%). Multi-omic studies revealed enrichment of the oxidative phosphorylation (OXPHOS) pathway in tumor tissues from transgenic mice. CIP2A upregulated phosphorylation of FOXO3A (p-FOXO3A S253) by inhibiting phosphatase PP2A-B56α and promoted FOXO3A mitochondrial translocation. CIP2A-FOXO3A reshaped mitochondrial morphology, activated mitochondrial DNA transcription, and enhanced complexes IV/V activities. OXPHOS inhibitor repressed CIP2A-induced cell proliferation and tumor growth. Moreover, tobacco carcinogens upregulated CIP2A and p-FOXO3A S253 and significantly increased cancer incidence in CIP2A-transgenic mice. These data indicate that CIP2A plays a critical role in mitochondrial regulation and represents a promising therapeutic target for LUADs lacking actionable driver mutations.
中文摘要:为确定在多数癌症中过表达并通过稳定MYC促进细胞生长的癌蛋白CIP2A的致癌活性,我们构建了肺泡II型细胞特异性CIP2A转基因小鼠模型。在114只年龄大于等于12个月的转基因小鼠中,23只(20.2%)发展为类似肺腺癌的病变,显著高于对照组小鼠(63只中的3只,4.8%)。多组学研究显示,转基因小鼠肿瘤组织中氧化磷酸化通路富集。CIP2A通过抑制磷酸酶PP2A-B56α上调FOXO3A磷酸化水平(p-FOXO3A S253),并促进FOXO3A线粒体转位。CIP2A-FOXO3A重塑了线粒体形态,激活了线粒体DNA转录,并增强了复合物IV和V的活性。氧化磷酸化抑制剂抑制了CIP2A诱导的细胞增殖和肿瘤生长。此外,烟草致癌物上调了CIP2A和p-FOXO3A S253,并显著增加了CIP2A转基因小鼠的癌症发病率。这些数据表明CIP2A在线粒体调控中发挥关键作用,是缺乏可操作驱动突变肺腺癌的潜在治疗靶点。
Selective drug activation in living systems remains a central challenge in targeted cancer therapy. Bioorthogonal catalysis addresses this by using abiotic transition-metal catalysts to unmask prodrugs at the tumor site, but the repertoire of suitable reactions remains limited. Here, we exploit the Buchner ring-expansion as a new uncaging strategy, in which a metal-carbene catalyzes a regioselective intramolecular ring-expansion followed by spontaneous 1,6-elimination to release a caged payload─a cascade with no biological equivalent. The iridium porphyrin complex [Ir(mPIX)Me] catalyzes this reaction at nanomolar concentrations, and the platform can accommodate structurally diverse payloads. As a proof of concept, functionalization with a bivalent human carbonic anhydrase IX (hCA IX) inhibitor enabled tumor-selective release of epirubicin (Epi) in a cancer cell model. This work thus delineates a new reaction class to the growing toolkit of transition-metal-mediated bioorthogonal chemistry.
中文摘要:在活体系统中实现药物的选择性激活仍是靶向癌症治疗的核心挑战。生物正交催化通过利用非生物过渡金属催化剂在肿瘤部位解掩前药来解决这一问题,但适用的反应种类仍然有限。本研究利用布希纳环扩张作为新的解掩策略,其中金属卡宾催化区域选择性分子内环扩张,随后发生自发的1,6-消除以释放被笼蔽的有效载荷,该级联反应在生物学中无对应物。吡咯卟啉铱络合物[Ir(mPIX)Me]在纳摩尔浓度下即可催化此反应,且该平台可容纳结构多样的有效载荷。作为概念验证,通过与双价人碳酸酐酶IX(hCA IX)抑制剂功能化,实现了在癌症细胞模型中肿瘤选择性释放表柔比星(Epi)。这项工作因此为日益增多的过渡金属介导的生物正交化学工具包描绘了一种新的反应类别。
Metabolites can regulate T cell gene expression and effector function, but how changes in mitochondrial ATP production influence chromatin remodeling remains unclear. In a recent issue of Cell, Ng et al. demonstrate that D-α-hydroxybutyrate (DAHB) increases oxidative phosphorylation and phosphocreatine production, promoting chromatin accessibility and CD8+ T cell effector function to limit tumor growth.
中文摘要:代谢物可调节T细胞基因表达和效应功能,但线粒体ATP生成变化如何影响染色质重塑仍不清楚。Ng等人在最新一期Cell杂志上证明,D-α-羟基丁酸(DAHB)可增加氧化磷酸化和磷酸肌酸的产生,促进染色质可及性和CD8+ T细胞的效应功能,从而限制肿瘤生长。
The efficacy of peptide-based tumor vaccines is often constrained by the size-exclusion barrier of the subcapsular sinus (SCS), which restricts infiltration of macromolecules into the lymph node (LN) parenchyma essential for T-cell priming. Here, inspired by the clinical contrast agent Sonazoid, we developed an ultrasound-assisted vaccine platform with tunable phase-transition behavior for the active modulation of the LN microenvironment. The system integrates phosphoserine-decorated lipid chemistry to promote cell-mediated LN trafficking, a covalently conjugated adjuvant-antigen construct for synchronized immunostimulation, and liquid-state perfluorocarbon nanodomains programmed for ultrasound-triggered liquid-gas transition. Upon localized ultrasound irradiation, the chemically programmed phase transition triggers cargo release, while the resultant acoustic cavitation generates transient openings in the SCS endothelium. This process enables deep parenchymal infiltration of vaccine components that would otherwise be excluded. Beyond the physical barrier disruption, RNA sequencing reveals that acoustic stimulation drives both structural and immunological reprogramming of LN into an immune-permissive niche. By synergizing mechanical stimulation with biological modulation, this strategy induces benign and persistent LN expansion, amplifies antitumor T-cell responses, and establishes durable immunological memory, resulting in both prophylactic and therapeutic outcomes. This approach is versatile across both model antigens and neoantigens, offering a bioinspired, two-stage LN-targeted delivery strategy that serves as a framework for designing more effective therapeutic vaccines.
中文摘要:基于肽类的肿瘤疫苗疗效常受限于被膜窦的尺寸排斥屏障,该屏障限制了进入淋巴结实质以启动T细胞免疫所需的生物大分子渗透。受临床造影剂Sonazoid启发,我们开发了一种具有可调相变行为的超声辅助疫苗平台,用于主动调控淋巴结微环境。该系统整合了促进细胞介导的淋巴结运输的磷酰丝氨酸修饰脂质化学、用于同步免疫刺激的共轭佐剂抗原构建体,以及编程为超声触发液气相变的液态全氟碳纳米结构域。在局部超声照射下,化学编程的相变触发货物释放,同时产生的声空化在被膜窦内皮中产生瞬时开口。这一过程使得疫苗成分能够深入渗透原本会被排除的实质组织。除了物理屏障的破坏外,RNA测序显示声学刺激驱动淋巴结向免疫许可生态位进行结构和免疫重编程。通过机械刺激与生物调节的协同作用,该策略诱导良性且持久的淋巴结扩张,放大抗肿瘤T细胞反应并建立持久的免疫记忆,从而产生预防性和治疗性效果。该方法在模型抗原和新抗原中均表现出通用性,提供了一种仿生、两阶段的淋巴结靶向递送策略,为设计更有效的治疗性疫苗提供了框架。
Regulatory T cells (Tregs) are central guardians of immune tolerance and tissue homeostasis. Initially defined as suppressors of excessive immune responses, Tregs are now recognized as adaptable cells that integrate antigenic, cytokine, metabolic, and tissue-derived signals to coordinate immune regulation, inflammation resolution, and tissue repair. However, these dimensions are often considered separately, and their interrelationships across physiological and pathological contexts remain insufficiently integrated. Here, we summarize the developmental origin, lineage stability, plasticity, and tissue adaptation of Tregs, and examine how these features shape their context-dependent functions. In lymphoid organs, Tregs maintain systemic tolerance by limiting antigen-presenting cell activation, restraining IL-2 availability, and setting the threshold for T- and B-cell responses, whereas in non-lymphoid tissues, they acquire organ-specific transcriptional, metabolic, and migratory programs that support barrier integrity, metabolic fitness, and regenerative repair. Chronic inflammation, persistent antigenic stimulation, oxidative stress, and metabolic disturbance can in turn disrupt these programs, promoting functional reprogramming or lineage instability, while excessive Treg-mediated suppression may favor pathogen persistence and tumor immune escape. We further discuss Treg alterations across major disease settings and emerging Treg-targeted therapies, providing an integrated framework that links developmental origin, tissue context, and functional state to more precise therapeutic strategies.
中文摘要:调节性T细胞(Tregs)是免疫耐受和组织稳态的核心守护者。最初被定义为过度免疫反应的抑制者,如今Tregs被视为能够整合抗原、细胞因子、代谢和组织来源信号的可适应细胞,以协调免疫调节、炎症消退和组织修复。然而,这些维度通常被单独考虑,其在生理和病理背景下的相互关系尚未得到充分整合。本文总结了Tregs的发育起源、谱系稳定性、可塑性和组织适应性,并考察了这些特征如何塑造其情境依赖性功能。在淋巴器官中,Tregs通过限制抗原呈递细胞活化、限制IL-2可用性以及设定T细胞和B细胞反应的阈值来维持全身耐受性;而在非淋巴组织中,它们获得支持屏障完整性、代谢适应性和再生修复的器官特异性转录、代谢和迁移程序。慢性炎症、持续性抗原刺激、氧化应激和代谢紊乱反过来可能破坏这些程序,促进功能重编程或谱系不稳定性,而过度的Treg介导的抑制作用可能有利于病原体持续存在和肿瘤免疫逃逸。我们进一步讨论了主要疾病状态下Tregs的改变以及新兴的Treg靶向疗法,提供了一个将发育起源、组织背景和功能状态联系起来以制定更精准治疗策略的综合框架。
In this issue of Cancer Cell, Zhang et al. perform multi-omics profiling on a large collection of patient-derived pancreatic ductal adenocarcinoma organoids to elucidate the mechanisms underlying intrinsic resistance to KRAS inhibition. This work identifies suppression of innate immune signaling through sustained MYC activity as the principal driver of intrinsic resistance.
中文摘要:本期《癌症细胞》杂志中,Zhang等人对大量患者来源的胰腺导管腺癌类器官进行多组学分析,以阐明KRAS抑制内在耐药性的机制。该研究确定持续MYC活性导致的先天免疫信号抑制是内在耐药性的主要驱动因素。
Beyond identifying individual malignant hallmarks, the central challenge in cancer biology is to uncover the fundamental organizing principles that underlie the interactive nature of cancer cell behavior. Here, we transform the ancient Wuxing theory into a mechanistically grounded, hypothesis-generating biological framework that conceptualizes cancer cell biology around five mutually interacting processes: Pliability, Hybridity, Aggressivity, Sociability, and Evolutivity (PHASE). By engaging in the circuit of mutual promotion and restriction, these phases form an integrated regulatory system that provides a rationale for organizing diverse malignant properties. Within this framework, cancer traits emerge as context-dependent manifestations of the proposed core interactions. Collectively, PHASE offers a complementary perspective for understanding disease progression that could advance interaction-guided therapeutic strategies to target human cancers.
中文摘要:超越识别单个恶性特征,癌症生物学中的核心挑战是揭示支撑癌细胞行为互动性质的基本组织原则。在此,我们将古代五行理论转化为具有机制基础且能生成假设的生物学框架,围绕五个相互作用的进程:可塑性、混合性、侵袭性、社会性和进化性(PHASE)来概念化癌细胞生物学。通过这些促进与限制循环,这些阶段形成一个整合的调节系统,为组织多样的恶性特征提供依据。在此框架内,癌症特征表现为所提出的核心互作的语境依赖性表现。总体而言,PHASE为理解疾病进展提供了补充视角,可能推动以互动为导向的治疗策略以针对人类癌症。
Eosinophils are highly adaptable immune cells whose phenotype and function are shaped by developmental, spatial, temporal, and inflammatory cues. Beyond their classical roles in type 2 immunity, eosinophils participate in chronic inflammation, fibrosis, metabolic disease, infection, and cancer. Here, we review how disease-associated eosinophil states emerge through perturbation of four interconnected determinants: eosinophil development, local tissue environment, tissue residency time, and inflammatory context. We discuss how disease can alter eosinophil development before tissue entry and reshape eosinophil adaptation within tissues, and how these processes may influence therapeutic responses. Together, these observations provide a framework for understanding disease-associated eosinophil diversity and for considering therapeutic strategies that preserve beneficial tissue-associated functions.
中文摘要:嗜酸性粒细胞是具有高度适应性的免疫细胞,其表型和功能受发育、空间、时间以及炎症信号的影响。除了参与2型免疫反应外,嗜酸性粒细胞还参与慢性炎症、纤维化、代谢性疾病、感染和癌症的发生发展。本文综述了疾病相关的嗜酸性粒细胞状态如何通过四个相互关联的决定因素的改变而出现:嗜酸性粒细胞的发育、局部组织环境、组织驻留时间以及炎症背景。我们讨论了疾病如何在细胞进入组织前改变其发育过程,并在组织内重塑其适应性,以及这些过程如何影响治疗反应。这些观察结果提供了一个理解疾病相关嗜酸性粒细胞多样性的框架,并为制定保留有益组织相关功能的治疗策略提供了思路。
In vivo cell engineering enables the direct programming of immune cells inside patients. Instead of isolating, modifying, and reinfusing cells, therapeutic instructions are delivered directly to selected immune cells through lipid nanoparticles or viral vectors. This approach could facilitate rapid and scalable deployment of varied immune cell therapies across disease contexts. Early clinical studies in oncology and autoimmunity demonstrate increasing technical and clinical feasibility. The next challenge lies in enhancing precision to ensure that vectors reach the target cell type and tissue, deliver the appropriate payload, and produce desired transient or durable activity. Progress in targeting ligands, vector design, biodistribution control, and genome editing is beginning to address these barriers. Ensuring safety against immunogenicity, inflammatory toxicity, off-target editing, and uncontrolled persistence remains a central priority. By mastering these constraints, in vivo engineering could turn endogenous immune cells into therapeutic agents generated directly in the body, expanding cell therapy to diseases refractory to current modalities.
中文摘要:体内细胞工程能够直接在患者体内对免疫细胞进行编程。与分离、修饰和回输细胞不同,治疗指令通过脂质纳米颗粒或病毒载体直接递送至选定的免疫细胞。该方法有助于在不同疾病背景下快速且可扩展地部署多种免疫细胞疗法。肿瘤学和自身免疫病领域的早期临床研究显示出日益增强的技术和临床可行性。下一个挑战在于提高精准度,确保载体到达目标细胞类型和组织,递送适当的载荷,并产生所需的瞬时或持久活性。靶向配体、载体设计、生物分布控制和基因编辑方面的进展开始解决这些障碍。确保安全以对抗免疫原性、炎症毒性、脱靶编辑和不可控的持续性仍是核心优先事项。通过掌握这些限制条件,体内工程可能将内源性免疫细胞转化为直接在体内生成的治疗剂,从而将细胞疗法扩展至对当前疗法难治的疾病。